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Abstract  
Mycoplasma bovis can be a commensal bacterial inhabitant of the upper respiratory tract of healthy 
bovines. However, under certain circumstances and conditions that are incompletely understood, 
M. bovis can be associated with a number of clinical syndromes, one of which is bovine respiratory 
disease (BRD). In Australia, there is little information on the prevalence and epidemiology M. bovis 
in beef production systems. The overall aim of this thesis was to help close this knowledge gap.  
Commercially available serological diagnostic methods for the detection of M. bovis-specific antibody 
have not been validated in the Australian cattle population. Arguably, more importantly, however is the 
fact that diagnostic sensitivity (Se) and specificity (Sp) and / or analytical sensitivity (ASe) and 
specificity (ASp) estimates for commercially available M. bovis sero-diagnostic tests are not available.  
The diagnostic Se and Sp were estimated for two currently available commercial M. bovis enzyme-
linked immunosorbent assays (ELISAs), the BioK302 and BioK260 (Bio-X Diagnostics
®
, 2013a) from 
Bio-X Diagnostics
®
 (Belgium), in addition to western blot analyses using a novel recombinant 
M. bovis protein. This was performed using a panel of reference sera from animals of known M. bovis 
infection status. Western blotting was found to have improved Se at 74% (95% CI: 16 – 98%), 
compared to the commercial ELISAs; BioK302: 47% (95% CI: 10% – 89%) and BioK260: 
28% (95% CI: 1% – 92%). However, in terms of Sp the commercial ELISAs out performed western 
blotting; BioK302: 96% (95% CI: 87% – 99%); BioK260:100% (95% CI: 93% – 100%) and western 
blotting: 88% (95% CI: 56% – 98%) respectively. In terms of both Se and Sp combined, none of the 
methods assessed here performed well. As such, when interpreting the results obtained from these 
ELISAs, the potential impact imperfect Se and / or Sp can have needs to be considered. 
Despite the poor performance of the BioK302 and BioK260 ELISAs particularly in terms of Se, these 
tests were used to determine the sero-prevalence of M. bovis antibody in Australian feeder cattle at 
feedlot induction and draft (approximately 42 days on feed). Paired bovine sera from 1,354 randomly 
selected animals were sourced from a bovine serum bank (n = 35,160) collected as part of another 
study, The National Bovine Respiratory Disease Initiative. As the classification of the result of a single 
serum sample could differ between the BioK302 and BioK260, sero-prevalence estimates were 
obtained using the individual ELISA results in addition to series and parallel interpretation of the two 
ELISA kit results. The apparent sero-prevalence of M. bovis-specific antibody at feedlot induction 
estimates ranged from 2.4% – 6.8% (95% CI: 1.3% – 8.6%) and the apparent sero-prevalence 
estimates at draft ranged from 22.4% – 44.2% (95% CI: 19.1% – 48.6%). The level of sero-conversion 
to M. bovis between induction and draft was also determined. Only animals that were classified as 
sero-negative at induction were included in sero-conversion analyses. In the current study, 24.3% (95% 
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CI: 20.8% – 27.7%) and 19.5% (95% CI: 17.3% – 21.7%) of animals sero-converted to M. bovis 
between induction and draft based on the BioK302 and dichotomised BioK260 ELISA results 
respectively.  
Using these ELISA results, an assessment of putative risk factors associated with sero-positivity at 
feedlot induction or sero-conversion between induction and draft was performed. An increased risk of 
sero-positivity at feedlot induction was found to be associated with; (i) history of exposure to a 
saleyard at least 27 days prior to induction, (ii) mixing with animals from another property at least 27 
days prior to induction and; (iii) the size of the group of animals an animal was with 13 days prior to 
induction. While the region from which animals were sourced 28 days prior to induction was 
associated with a reduced risk of sero-positivity at feedlot induction. Risk factors that were found to be 
associated with a decreased risk of sero-conversion between induction and draft included; (i) breed; (ii) 
source region; and (iii) group size, while access to water shared with another pen of animals was 
associated with increased risk. Sero-conversion to M. bovis between induction and draft was strongly 
associated with the development of BRD with an odds ratio of 2.1 – 3.1 (95% CI: 1.4 – 4.7) during the 
early feeding period. 
This is the first Australian study that has investigated M. bovis in the feeder cattle population. The 
findings reported herein have improved the understanding of the currently available sero-detection 
methods in addition to providing sero-prevalence information which is essential for future studies 
when trying to determine sample size estimate. In addition, the identification of potential risk 
factors associated with sero-positivity to M. bovis and those associated with sero-conversion 
between induction and draft will inform future M. bovis epidemiological investigations. Improving 
the overall knowledge of the epidemiology of M. bovis in Australia will in turn, assist the 
development of targeted control measures and help reduce the economic impact of M. bovis-
associated disease including BRD.  
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CHAPTER 1   Mycoplasma bovis: A review of the literature 
1.1  Introduction 
Mycoplasma bovis is an important bovine bacterial pathogen of cattle. In Europe, Canada and North 
America it is widely accepted that M. bovis is a significant contributing factor and aetiological agent 
in the development of bovine respiratory disease (BRD) in calves and lightweight stocker cattle 
(Apley, 2006). Like a number of other bovine bacterial pathogens involved in the development of 
BRD, M. bovis it is often regarded as a commensal inhabitant of the upper respiratory tract (URT) 
in healthy animals. It is not until tissues of the lower respiratory tract (LRT) are invaded or mucosal 
surface barriers in other body sites are crossed, that disease occurs.  
It has been suggested that antibodies specific to M. bovis do not develop unless LRT infection 
occurs, or an infection has become invasive. If this is the case, than it can be expected that animals 
where M. bovis is commensally associated with the URT would not develop antibodies; and in the 
case of serology, would return sero-negative results. Thus serology provides a useful tool for the 
indirect diagnosis of M. bovis infection (Boothby et al., 1981, Boothby et al., 1983, Burnens et al., 
1999). Interpretation of serological detection methods for M. bovis antibody is hampered by a 
number of factors. Mycoplasma bovis is highly variable in terms of antigenic expression and the 
processes of this antigenic variation are incompletely understood. This has made identification of a 
single antigen that is both highly specific and sensitive for the detection of M. bovis antibody a 
troublesome process. In the absence of such an antigen, the performance of serological detection 
methods in terms of Se and Sp is not known.  
Another factor that hinders interpretation of serological diagnostic methods is that the immune 
response of individual animals to infection is also incompletely understood. Although the 
development of antibody is thought to be associated with an invasive infection of the LRT tissue, 
not all animals experimentally infected with M. bovis develop antibody. This suggests that the 
individual immune response of the animal needs to be considered when interpreting results of 
serology. Consequently, the usefulness of serology at an individual animal level is likely to have its 
limitations.  
Limited therapeutic options exist for the control of M. bovis associated diseases (MbAD) (Nicholas, 
2011). This factor combined with the absence of effective control measures means that M. bovis 
should be considered as a serious bovine pathogen (Caswell and Archambault, 2007) in Australia. 
Yet, to date the prevalence of M. bovis among beef cattle herds or in cattle entering Australian 
feedlots is not known. Because of this, research on the epidemiology, including prevalence and risk 
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factors associated with infection is highly warranted (Caswell and Archambault, 2007, Nicholas and 
Ayling, 2003, Pfutzner and Sachse, 1996, Thomas et al., 2002b). The overall aim of this thesis is to 
provide a greater understanding of the epidemiology and to gain a better understanding of the 
importance of M. bovis in Australian feedlot cattle. 
1.2  The history of M. bovis 
Mycoplasma bovis was first isolated by Hale et al. (1962) from a dairy herd in Connecticut in the 
United States of America (USA) during an outbreak of severe mastitis in 1961. At the time, the 
organism was tentatively given the name Mycoplasma agalactiae var. bovis due to clinical 
similarities to contagious agalactia of goats and sheep caused by Mycoplasma agalactiae (Hale et 
al., 1962). An alternative name, Mycoplasma bovimastitidis, was proposed some five years later by 
Jain et al. (1967), but was rejected due to the lack of evidence to support the organism as a separate 
species from M. agalactiae using serological growth-inhibitory antibody and gel-diffusion 
precipitation methods (Freundt, 1971). For the following decade the organism was recognised as a 
subspecies of M. agalactiae and given the name M. agalactiae subsp. bovis (Freundt, 1971). It was 
not until 1976 that experiments by Askaa and Erno (1976) showed a total DNA-DNA hybridization 
value of 38 - 40% between the type strain of M. agalactiae (PG2) and the proposed type strain of 
M. agalactiae subsp. bovis (Donetta or PG45). This finding was sufficient to warrant full species 
status and officially give M. bovis its current name. 
1.3  Taxonomic classification  
Mycoplasma bovis belongs to the bacterial class Mollicute, within the family Mycoplasmataceae. 
This family encompasses the vast majority of animal and human organisms and can be further 
subdivided into the Mycoplasma and Ureaplasma genera (Citti et al., 2010). By definition, the 
Mycoplasma genus contains the bacterial species that are sensitive to digitonin and are restricted to 
vertebrate animal hosts (Quinn et al., 2011). Organisms within the Mycoplasma genus are often 
portrayed as the simplest self-replicating life forms due to their minute size, total lack of a cell wall, 
paucity of metabolic pathways meaning that they are often dependent on host cells for much of their 
nutritional requirements; and a reduced genome size which has a low guanine (G) and cytosine (C) 
content (Bove, 1993, Chazel et al., 2010, Citti et al., 2010, Miles and Nicholas, 1998, Pitcher and 
Nicholas, 2005).  
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1.4  Epidemiology 
1.4.1  Distribution  
Found worldwide, M. bovis is the most widely occurring bovine mycoplasma species (Nicholas, 
2011, Ball and Nicholas, 2010, Nicholas, 2004). In enzootically infected regions, M. bovis is not 
ubiquitous, but common (Pfutzner and Sachse, 1996). Globally, M. bovis was first reported in the 
USA (1961) and isolation in other countries after this time followed (Nicholas et al., 2002). It 
remains unclear whether the detection of M. bovis in other countries after its first isolation in the 
USA was a result of its spread through animal movements or simply through increased awareness 
and ability to detect it. 
1.4.2  Host specificity  
There are a number of known bovine mycoplasma species, many of which are considered 
commensal’s of the respiratory or urogenital tracts. However, under the right conditions, most can 
be found associated with disease conditions of varying severity. Despite most mycoplasmas often 
regarded as highly adapted to a specific host species, isolations of M. bovis from animals other than 
the bovine have been reported. Studies have isolated M. bovis from goats, chickens, humans and 
pigs, but often in these situations there is an association with another underlying condition 
(Bashiruddin et al., 2005, Ongor et al., 2008, Pitcher and Nicholas, 2005, Spergser et al., 2013). In 
other cases, M. bovis has been isolated as the sole pathogen. For example, in the Austrian Alps, pigs 
kept on the same pasture as dairy cattle and fed a diet which contained whey from a cow with 
M. bovis mastitis developed severe conjunctivitis, nasal discharge and coughing (Spergser et al., 
2013).  
1.4.3  Reservoir and transmission 
Following exposure, M. bovis is well adapted to colonisation of mucosal surfaces where it is able to 
persist within the URT of the bovine in the absence of clinical disease (Maunsell et al., 2011). The 
URT mucosa and mammary gland have been suggested as the most important sites for persistence 
and shedding of M. bovis (Bennett and Jasper, 1977a, Pfutzner and Sachse, 1996, 
Punyapornwithaya et al., 2010, Thomas et al., 2002a). Cattle exposed to M. bovis in most cases do 
not develop M. bovis-associated disease (MbAD). As such the relative importance of asymptomatic 
vs. diseased animals in terms of transmission is not fully understood. It is thought that animals with 
MbAD shed higher numbers of pathogens in mucosal secretions in comparison to asymptomatic 
animals (Bennett and Jasper, 1977b). Shedding of M. bovis in nasal or mucosal secretions is thought 
to occur from asymptomatic animals for a few months or less (Bennett and Jasper, 1977a, 
Punyapornwithaya et al., 2010), however some cattle have been found to continue to shed M. bovis 
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intermittently for many months or even years (Bennett and Jasper, 1977a, Biddle et al., 2003, 
Punyapornwithaya et al., 2010). The specific factors responsible for intermittent shedding are 
currently not completely understood however stressful events such as transportation, co-mingling, 
cold stress and entry into a feedlot, have all been associated with increased rates of nasal shedding 
(Boothby et al., 1983, Woldehiwet et al., 1990). Because asymptomatically infected animals lack 
clinical signs of infection, they are believed to be the primary means by which M. bovis-free herds 
become infected (Gonzalez et al., 1992, Maunsell et al., 2011, Nicholas et al., 2008). This situation 
can make identification of the source difficult, especially if shedding is delayed with MbAD 
outbreaks possible some months to years after the introduction of an asymptomatic infected animal 
to what may seem a ‘closed’ herd (Wilson et al., 2007). In addition, eradication of M. bovis once 
established on multi-age sites becomes extremely difficult if not impossible (Maunsell et al., 2011, 
Pfutzner and Sachse, 1996). 
Transmission of M. bovis between animals can occur directly through nose-to-nose contact of naive 
animals with an animal shedding the organism or via aerosolisation of respiratory secretions 
(Nicholas, 2011, Maunsell et al., 2011). Indirect transmission is possible through ingestion of 
contaminated milk, feed or water, or contact with contaminated bedding or fomites (Maunsell et al., 
2011). Additional sources of infectious material are mucosal surface secretions from the teat canal 
or genital tract of adult cattle, as well as contaminated frozen semen (Nicholas et al., 2008, Nicholas 
and Ayling, 2003, Pitcher and Nicholas, 2005, Sachse et al., 2010).  
The primary site of colonisation is somewhat dependent on the route of exposure with the URT 
mucosa the primary site of colonisation following URT exposure (Nicholas et al., 2002). Similarly 
the mammary gland appears to be the major site of colonisation following intra-mammary exposure 
(Bennett and Jasper, 1977a). Regardless of the route of exposure, M. bovis can be isolated from 
multiple body sites during early infection particularly the URT, mammary gland, conjunctiva and 
urogenital tract (Bennett and Jasper, 1977a, Pfutzner and Sachse, 1996, Punyapornwithaya et al., 
2010, Thomas et al., 2002a). In addition to colonisation of mucosal surfaces, bacteraemia can occur 
(Nicholas et al., 2002) and it is via this haematogenous route in which infection of joints, the ear 
canal and in some situations the mammary gland can occur (Fox et al., 2005).  
Lacking a protective cell wall, M. bovis is susceptible to high temperatures and desiccation outside 
its host (Pfutzner and Sachse, 1996). As such the environment has not been considered a significant 
source of infection for naive animals. Research by McAuliffe et al. (2006) showed that some 
mycoplasmas including M. bovis possess the ability to produce an extracellular polysaccharide 
matrix, or ‘biofilm’. This biofilm was shown to provide some protection against the environmental 
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elements and helps explain the improved survivability of M. bovis on moist, protected fomites at 
lower temperatures (Maunsell et al., 2011, Pfutzner and Sachse, 1996). It has been reported that 
M. bovis is able to remain viable at 4°C for nearly two months in sponges and milk, and in water for 
over two weeks (Maunsell et al., 2011, Pfutzner and Sachse, 1996). Justice-Allen et al. (2010) has 
also reported that M. bovis is able to persist for months in recycled sand bedding again with 
survivability of the organism strongly associated with cool temperatures and moist environments. 
With this in mind, the environment should not be completely disregarded as a potential source of 
infection for animals naive to M. bovis (Pfutzner and Sachse, 1996) especially if the environmental 
load is high and environmental conditions are ideal. To fully determine the role environmental 
reservoirs have in M. bovis epidemiology, further studies in this area are required (Maunsell et al., 
2011) and could provide valuable information on management factors that could limit the spread of 
the pathogen. 
1.4.4  Risk factors  
There has been limited research on specific risk-factors for M. bovis infection. Some studies have 
defined certain cattle management practices that are often associated with an increased sero-
prevalence of M. bovis-specific antibody among cattle herds. Bednarek et al. (2012), found that 
M. bovis sero-positivity was associated with more intensive levels of cattle breeding and 
production. Tschopp et al. (2001) reported mixing of calves from different age groups and contact 
of naive animals with sero-positive animals was associated with sero-conversion. While Boothby et 
al. (1983) had similar findings to Tschopp et al. (2001) in that the nasal prevalence of mollicutes 
was increased when groups of cattle from different sources were co-mingled or transported over 
long distances.  
The difficulties associated with detecting infection, the ability to culture M. bovis from the URT 
secretions from both healthy and pneumonic cattle, the presence of maternal antibodies in calves 
which are often the most susceptible to MbAD and the often high sero-prevalence of M. bovis 
antibody in herds where M. bovis is endemic are likely to have contributed to the methodological 
difficulties in defining particular risk factors associated with infection.  
1.5  Mycoplasma bovis-associated disease 
M. bovis is known to be a contributing factor in a number of clinical conditions in the bovine 
including; mastitis, chronic pneumonia, arthritis, conjunctivitis, otitis, abscesses, genital disorders, 
abortions, and meningitis (Kinde et al., 1993, Kirby and Nicholas, 1996, Pfutzner and Sachse, 1996, 
Stipkovits et al., 1993, Walz et al., 1997). Although M. dispar, M. leachii and M. bovirhinis have 
been isolated from the lungs of pneumonic cattle they are not believed to be primary causes of 
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pneumonia (Nicholas and Ayling, 2003). Diseases associated with M. bovis tend to be chronic in 
nature and respond poorly to treatment with many of the commonly used antimicrobials (Caswell et 
al., 2010). They are also often associated with intensive production systems (Pfutzner and Sachse, 
1996, ter Laak et al., 1992).  
1.5.1  Mycoplasma bovis associated pneumonia  
Pneumonia associated with M. bovis can occur in cattle of any age including dairy and beef calves, 
beef cattle after arrival at a feedlot and adults (Maunsell et al., 2011). Clinical signs are non-specific 
and include fever, tachypnoea, dyspnoea, decreased appetite, poor weight gain, with or without 
nasal discharge and coughing (Caswell and Archambault, 2007, Maunsell et al., 2011, Pfutzner and 
Sachse, 1996, Stipkovits et al., 2000). Otitis media and or arthritis may accompany M. bovis-
pneumonia in an individual or occur in other animals in the herd (Maunsell et al., 2011). Animals 
suffering chronic M. bovis-pneumonia may also develop polyarthritis several weeks after feedlot 
entry (Maunsell et al., 2011, Stipkovits et al., 2000). This condition is often referred to as chronic 
pneumonia and polyarthritis syndrome (Maunsell et al., 2011). 
In recent years, increased interest in the involvement of M. bovis in BRD combined with 
improvements in the isolation and detection of this organism have provided evidence to support 
M. bovis infections in cattle are major primary and contributory causes to the development of BRD 
(Caswell et al., 2010, Nicholas et al., 2008). In fact Gerchman et al. (2009) suggests that M. bovis is 
the most common bacterium identified in feedlot cattle affected by chronic pneumonia and in veal 
calves with fatal bronchopneumonia. However the causative nature, of M. bovis in cattle older than 
6 months of age is still not well understood. Evidence to support M. bovis as a predisposing factor 
in the infectious process for the development of BRD in cattle older than 6 months of age has been 
provided by Divers (2008), Poumarat et al. (2001) and Tenk (2004). They suggest that the presence 
of M. bovis in an animal under the correct conditions can further compromise the animal’s immune 
defences, thereby enhancing the ability of other bacteria to invade the LRT. 
Natural LRT infections involving M. bovis frequently produce lung lesions characterised by 
caseonecrotic bronchopneumonia while experimental infections often produce milder lesions 
(Castillo-Alcala et al., 2012, Caswell and Archambault, 2007). Lung lesions typically have a 
cranioventral distribution which differs from other forms of bronchopneumonia by the presence of 
unique multiple coalescing round friable foci of caseous necrosis within the consolidated areas 
(Caswell et al., 2010). As animals in experimental infection trials are often slaughtered or 
euthanased within two weeks of infection, the time frame for lung lesions to develop is limited and 
may explain the reason for this difference (Quinn et al., 2011). The importance of M. bovis as a 
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cause of other forms of bronchopneumonia in feedlot cattle remains uncertain, but its role in 
caseonecrotic bronchopneumonia is compelling (Castillo-Alcala et al., 2012). 
Many naturally occurring cases of M. bovis pneumonia are associated with other bovine viral and 
bacterial pathogens commonly implicated in BRD. An association between bovine viral diarrhoea 
virus (BVDV) infection and M. bovis has been observed (Shahriar et al., 2002), however others 
found no association (Fulton et al., 2009). Bacterial co-infections involving 
Mannheimia haemolytica, Histophilus somni and Pasteurella multocida are extremely common in 
cases of M. bovis-associated pneumonia (Fulton et al., 2009, Gagea et al., 2006a, Stipkovits et al., 
2000). In addition, a number of studies have reported that co-infections involving M. bovis and 
Histophilus somni, Mannheimia haemolytica, BVDV, bovine respiratory syncytial virus (BRSV) 
and bovine parainfluenza virus type 3 (BPIV-3) exacerbates BRD (Booker et al., 1999, Booker et 
al., 2008, Gourlay et al., 1989, Martin et al., 1989, Perez-Casal and Prysliak, 2007). These findings 
suggest an important synergism in the development of disease during co-infection of animals 
involving M. bovis and other BRD pathogens (van der Merwe et al., 2010). 
1.5.2  The cost of M. bovis-associated disease 
In the US, costs associated solely with M. bovis infections to the feeder cattle industry have been 
estimated to exceed an annual US$32 million; mainly due to reduction of body weight gain and 
lower carcase values (Maunsell et al., 2011, Nicholas and Ayling, 2003). In Europe, M. bovis is 
estimated to be a causative agent in 25 – 30% of respiratory disease outbreaks in feeder calves 
equating to total economic losses estimated at 600 million euros per year (Nicholas and Ayling, 
2003). In Poland, the direct cost of respiratory related morbidities without treatment has been 
estimated to be 10 million euros per year (Bednarek et al., 2012), while in the UK the total cost of 
BRD to the UK feeder cattle industry has been estimated at £54 million per year (Bednarek et al., 
2012). In Australia the direct cost of MbAD is unknown, however using data from 2001, Meat and 
Livestock Australia (MLA) found that BRD accounted for an alarming 60 – 70% of all feedlot 
morbidity and mortality equating to an estimated national economic loss of AS$40 million to the 
Australian feedlot industry each year (Sackett, 2006). Irrespective of the country concerned, 
production losses associated with BRD are attributed to decreased animal performance and health, 
reduced carcass quality, costs associated with treatment of morbid animals, increased labour and the 
inherent cost of mortalities (Smith, 1998). 
1.6  Mycoplasma bovis pathogenicity and virulence factors  
There are a number of factors that appear to play an important role in the virulence of M. bovis and 
the development of disease following infection. The specific mechanisms involved in these 
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processes is still incompletely understood (van der Merwe et al., 2010). The pathogenicity of 
M. bovis is highly dependent on its cytoplasmic membrane, and in particular the proteins within or 
tethered to the outer surface of it (Adamu et al., 2013). Variation in mycoplasma membrane 
proteins affords M. bovis antigenic plasticity and assists in evasion of the host immune response to 
infection. This combined with the production of a biofilm, immunomodulation and the production 
of toxic metabolites all appear important in the pathogenesis of MbAD (Maunsell et al., 2011).  
1.6.1  Antigenic variation of membrane proteins 
Exposed mycoplasmal membrane proteins form the primary interface with the host and facilitate 
adherence to mucosal surfaces (Maunsell et al., 2011). Variation in surface proteins is a virulence 
attribute that allows M. bovis to rapidly adapt to the host environment and evade the developing 
host immune response (Quinn et al., 2011). Mycoplasma membrane proteins influence cell shape, 
cell division, motility and adhesion to host cells and are thought to be integrally involved in the 
pathogenesis of MbAD (Adamu et al., 2013).  
Studies have shown that populations of M. bovis spontaneously and randomly generate distinct 
progenies with varied antigenic phenotypes by changing the expression of membrane proteins 
(Lysnyansky et al., 1999). This antigenic variation has been suggested as a mechanism for the often 
chronic nature of MbAD as the host immune response is continually evaded (Le Grand et al., 1996). 
In M. bovis the importance of diversifying the antigenic repertoire of their cell surface is reflected 
by the fact that despite their limited genetic material, the number of genes that are extensively 
dedicated to this purpose is unexpectedly large (Razin et al., 1998). It is not known if the antigenic 
variation which occurs in these surface proteins is a regulated event or whether it is a random 
response due to selection pressure by the host immune response to surface antigens (Quinn et al., 
2011). Separate studies by Poumarat et al. (1994), Rosengarten et al. (1994) and Behrens et al. 
(1994) demonstrated that M. bovis employs two surface antigenic systems which each have the 
potential to act independently and facilitate immune evasion. The first represents a family of major 
lipoprotein antigens designated variable surface proteins (Vsps). The second, unrelated surface 
protein designated pMB67 (Behrens et al., 1996) proved to be as highly variable as the Vsps but 
lacked the typical repetitive vsp-DNA sequence nature (Le Grand et al., 1996). 
1.6.1.1  Variable surface proteins 
The variable surface proteins (Vsps) are the most extensively studied of the M. bovis membrane 
proteins. They comprise a large family of lipoprotein antigens located on the surface of M. bovis 
and have been suggested as playing a critical role in the attachment of M. bovis cells to host cells 
(Beier et al., 1998, Le Grand et al., 1996, Lysnyansky et al., 1999, Nussbaum et al., 2002, van der 
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Merwe et al., 2010). Within the M. bovis PG45 type strain genome, a total of 13 single-copy vsp 
genes organised in a chromosomal cluster have been identified and characterised (Lysnyansky et 
al., 1999). These Vsp proteins have been shown to spontaneously undergo non-coordinate phase 
variation, between on- and off- expression states, with high frequency both in vivo and in vitro 
(Beier et al., 1998, Buchenau et al., 2010, Lysnyansky et al., 1996, Lysnyansky et al., 1999).  
Approximately 80% of each vsp-coding region is composed of reiterated, highly repetitive coding 
sequences that create a periodic polypeptide structure (Lysnyansky et al., 1999). These reiterated 
sequences are highly mutable and are subject to frequent contraction or expansion of the intragenic 
repetitive units resulting in expression of phase and size variants of the corresponding protein in 
vitro (Lysnyansky et al., 1996). Despite their variability, all vsp genes identified thus far have been 
found to encode highly conserved N-terminal domains for membrane insertion and lipoprotein 
processing (Lysnyansky et al., 1999). The first 29 amino acids appear conserved across all Vsps 
even though the mature Vsp proteins vary (Lysnyansky et al., 1999). 
A study by Brank et al. (1999) suggested that the Vsps or at least some members of the Vsp family 
are persistently expressed by M. bovis in the bovine host during infection and that immunodominant 
epitopes are highly conserved among M. bovis strains and isolates. In another study involving 
250 European M. bovis field isolates it was found that although the number of vsp genes among the 
isolates in the study varied, they all contained multiple copies of the same sequence encoding the 
RA1 motif of the mature Vsp protein (Poumarat et al., 1999). These findings suggest that the RA1 
motif may encode an immunodominant epitope that is highly conserved among M. bovis field 
strains and isolates.  
1.6.1.2  Membrane protein pMB67 
Aside from the Vsps, there are few other M. bovis membrane proteins that have been identified and 
as extensively characterised (Adamu et al., 2013). The M. bovis type strain PG45 membrane protein 
pMB67 was first described by Behrens et al. (1996). This membrane protein was found to contain a 
specific epitope, did not contain a Vsp-like repetitive periodic protein structure and was not lipid 
modified. However like the Vsps; it did undergo a high rate of phase and size variation in vitro and 
was found by the authors to be a predominant antigen recognised during M. bovis infections.  
1.6.1.3  Other membrane proteins 
1.6.1.3.1 Lipoprotein P48 
The structurally and antigenically conserved 48 kDa membrane lipoprotein P48 is an invariable 
immunodominant lipoprotein that is homologous to the macrophage activating lipoprotein (MALP) 
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of M. fermentans (Robino et al., 2005). A homologue of P48 has proven to be a specific marker of 
M. agalactiae infection and has been used for the development of recombinant immuno-diagnostic 
methods for contagious agalactia (Rosati et al., 2000). With M. bovis and M. agalactiae being 
phylogenetically closely related, lipoprotein P48 has been investigated for the use in serologic 
diagnostic tests for M. bovis (Robino et al., 2005).  
1.6.1.3.2 Lipoprotein P68 
A 68 kDa protein designated P68 was identified in a clonal variant of M. bovis type strain PG45 
(Lysnyansky et al., 2008). The protein was found to share the conserved selective lipoprotein-
associated motifs of the MALP-related lipoproteins (Lysnyansky et al., 2008). The associated P68 
gene was only detected in some strains of M. bovis, all of which also contained the P48 gene 
(Adamu et al., 2013). 
1.6.1.3.3 Protein milA 
More recently, a novel 226 kDa protein encoded by the milA gene (MBOVPG45_0710) was 
characterised from the M. bovis field strain 3683 and investigated for use in the sero-diagnosis of 
experimental M. bovis infections in calves in Australia (Wawegama et al., 2014). Analysis by the 
authors revealed that the milA protein contained a membrane spanning region at its amino terminal 
end, with the remainder of the protein predicted to be located extracellularly (Wawegama et al., 
2014). Homologues were found in both Hubei-1 and HB0801 M. bovis strains for which complete 
genome sequences are available, as well as M. agalactiae strains 5632 and PG2 (Wawegama et al., 
2014). This high molecular weight protein was reported by the authors to be immuno-reactive by 
western blotting to M. bovis-specific calf sera and unlike the Vsps, the milA protein did not appear 
to undergo phase or antigenic variation (Wawegama et al., 2014). However, how conserved this 
protein is across multiple M. bovis field isolates remains to be elucidated. In addition, the immuno-
reactivity of this protein with sera obtained from naturally acquired M. bovis infections is needed 
before conclusions on the usefulness of the milA protein in the sero-diagnosis of M. bovis can be 
made. 
1.6.2  Biofilm formation 
Biofilms have been defined by McAuliffe et al. (2006) as sessile bacteria attached to a substratum, 
or each other, often surrounded by an extracellular polysaccharide matrix. Some M. bovis strains 
possess the ability to form a biofilm and this may provide some protection from heat and 
desiccation in the environment (McAuliffe et al., 2006). Within the host, the formation of a biofilm 
is thought to assist and play a part in the chronic nature of MbAD. Cells adherent to the biofilm 
possess increased resistance to host antibodies and phagocytes in comparison to individual cells 
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(McAuliffe et al., 2006). Within the host, M. bovis infection is often exacerbated by host cell 
damage caused by the release of phagocytic enzymes from frustrated phagocytes in areas where 
colonisation and biofilm production occur (McAuliffe et al., 2006). The periodic release of 
individual M. bovis cells from the biofilm may also be associated with bouts of acute infection in 
chronically infected animals (McAuliffe et al., 2006). 
The most comprehensive study on biofilm formation in mycoplasmas including M. bovis was 
conducted by McAuliffe et al. (2006). The authors found that M. bovis strains varied widely in their 
ability to form a biofilm and when compared to Vsp profiles, there was a strong correlation between 
the expression of certain Vsps and biofilm formation (McAuliffe et al., 2006).  
1.6.3  Toxic metabolite production 
The generation of toxic metabolites enhances the pathogenesis of M. bovis during the infectious 
process (Khan et al., 2005b, Maunsell et al., 2011, Nicholas et al., 2008). The production of 
phospholipases, hydrogen peroxide and superoxide radicals can induce toxic damage to the host 
cells (Khan et al., 2005b, Maunsell et al., 2011, Quinn et al., 2011, Schott et al., 2014). Khan et al. 
(2005a) showed that the ability of 16 M. bovis strains from the UK (14 bovine field isolates, one 
human isolate and the type strain NCTC 10131), varied widely in their ability to produce hydrogen 
peroxide. They also found that a large reduction in hydrogen peroxide production occurred in one 
particular high-producing strain (M. bovis strain 119B96) after in vitro subculturing. After the 50
th
 
passage in broth medium hydrogen peroxide production reduced by 50% and was associated with 
the loss of a 35 kDa protein band using sodium dodecylsulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) separation of whole-cell protein (20 µg). 
1.6.4  Immunomodulation  
Mycoplasma bovis itself may cause suppression or alteration of immune cell function, leading to 
invasion by other bacterial and viral pathogens (Nicholas et al., 2008). In vitro studies by Vanden 
Bush and Rosenbusch (2002, 2004) found that M. bovis was able to inhibit the proliferation of 
bovine lymphocytes through the activation of the apoptotic cascade in activated bovine 
lymphocytes. This process is thought to occur via the production of a specific lympho-inhibitor 
peptide (Mb-LIP-M. bovis inhibitory peptide). This 26-amino-acid peptide was found to be 84% 
homologous to the C-terminus of VspL and a suggested new function of a vsp family member 
(Vanden Bush and Rosenbusch, 2002). This peptide appears to take part in the down regulation of 
lymphocyte proliferation which in turn affects an appropriate immune response by the host to 
M. bovis infection (van der Merwe et al., 2010). 
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Mycoplasmas also have the ability to adhere to neutrophils and macrophages which in turn impairs 
the phagocytic functions of these immune system cells (Quinn et al., 2011). Other experiments by 
van der Merwe et al. (2010) have shown that M. bovis is capable of invading some peripheral blood 
mononuclear cells (PBMC) populations. They found that the majority of PBMC populations studied 
had M. bovis cells associated with their cell surface within two hrs of infection, while at 24 hrs post-
infection 100% contained intracellular M. bovis. 
1.7  Diagnosis of infection 
1.7.1  Culture 
Clinical and pathological signs of MbAD in an individual animal are non-specific. Consequently 
laboratory diagnosis of MbAD is still required with culture remaining the ‘gold standard’ for the 
detection of M. bovis from clinical samples (Pitcher and Nicholas, 2005). Culture allows isolation 
of an isolate from the affected tissue sample making it a useful tool for single-animal diagnosis 
(Sachse et al., 1993). Due to the commensal nature of M. bovis however, successful culture alone 
does not confirm M. bovis as the cause of disease unless all other pathogens and potential causes 
have been eliminated. 
Successful culture depends highly on an external supply of a wide variety of nutrients within the 
culture medium (Windsor and Windsor, 1998). Even though the exact requirements of most 
mycoplasma species are still incompletely defined, most mycoplasmal species including M. bovis 
can be grown in the laboratory in both liquid and solid media (Windsor and Windsor, 1998). As a 
minimum these media should comprise: a broth base, yeast extract, serum source, and solutions of 
pure chemicals (Windsor and Windsor, 1998) required for cellular growth and repair. Most of the 
general purpose media such as Eaton’s, Friis, modified Chanock’s, or Hayflick’s, contain such 
ingredients and have been reported as generally being suitable for the culture of M. bovis (Nicholas 
and Baker, 1998). The inclusion of non-mycoplasmastatic antimicrobial agents and thallium acetate 
to the media helps prevent overgrowth of contaminating bacteria and the less important but rapidly 
growing mollicutes, such as the acholeplasmas (Nicholas and Baker, 1998). Broths and solid media 
plates are generally incubated at 37°C in a humidified atmosphere with 5% CO2 (Nicholas and 
Baker, 1998). Daily examination of broths for signs of growth which is indicated by a colour 
change of the broth media as a result of a change in pH is recommended (Nicholas and Baker, 1998, 
Smith, 1971). Plates with solid media should be examined under 35 × magnification at two –
 three day intervals for the appearance of typical “fried egg” mycoplasma colonies (Nicholas and 
Baker, 1998, Smith, 1971). Growth of M. bovis from clinical samples on culture media is often 
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apparent by 48 hrs, but 5 – 10 days incubation is recommended before samples are called negative 
(Nicholas and Baker, 1998, Sachse et al., 1993, Maunsell et al., 2011). 
Few laboratories routinely monitor for mycoplasmas because of difficulties associated with routine 
culture and their fastidious nature (Nicholas and Ayling, 2003). This has led to other more 
commonly isolated bacteria being represented in clinical investigations involving culture, especially 
with regard to mastitis and BRD (Nicholas and Ayling, 2003). In these situations it is believed that 
an incorrect identification of the causative agent may occur because the easier to culture bacteria are 
often isolated earlier in comparison to the slower growing more fastidious bacteria (Nicholas et al., 
2008). When equipped and laboratory personnel have the necessary expertise in culturing 
mycoplasmas, culture has high Sp (Sachse et al., 1993). The Se of culture however is dependent on 
a number of factors. Firstly, the Se of culture is somewhat dependent on the laboratory and the 
submitted sample (Sachse et al., 1993). Castillo-Alcala et al. (2012) found that the culture of fluid 
samples is more likely to be positive if sediments rather than supernatants are used. The number of 
viable organisms present in the submitted sample can also affect the culture Se. Sachse et al. (1993) 
reported that in their laboratory, culture required 10
1
 – 102 colony forming units (CFU) / ml of 
sample to reliably detect the pathogen from a wide variety of clinical specimens. Intermittent and 
low level shedding of M. bovis in secretions, uneven distribution of the organism throughout the 
affected tissue or sample, suboptimal sample handling during storage and transport, suboptimal 
culture conditions and the presence of mycoplasma inhibitors in the sample along with prior 
treatment with antimicrobials can impact the number of viable M. bovis cells in the sample and in 
turn the Se of culture (Maunsell et al., 2011, Nicholas and Baker, 1998, Robino et al., 2005, Sachse 
et al., 1993). Finally, contamination of the sample with other bacteria that often grow faster and out-
compete M. bovis in culture media can also result in false negative culture results (Nicholas and 
Baker, 1998, Sachse et al., 1993).  
1.7.1.1  Specimen selection and submission  
There are a range of samples suitable for M. bovis culture provided normal bacteriological 
procedures for sample collection are adhered to (Nicholas and Baker, 1998). In the live animal, 
samples suitable for M. bovis isolation depend somewhat on the associated disease. Nasal or 
conjunctival swabs for isolation from the asymptomatic shedder, joint fluid from animals affected 
by arthritis, milk (mastitis), and bronchial alveolar lavage (BAL) fluid and / or pleural fluid 
(pneumonia), (Nicholas and Baker, 1998). In regards to M. bovis pneumonia, trans-tracheal wash or 
BAL samples are preferable to URT samples such as nasal swabs as isolation of M. bovis from the 
URT of pneumonic animals is not well correlated with its presence in the LRT or with clinical 
disease (Allen et al., 1991, Thomas et al., 2002b). Although nasal or conjunctival swabs are easily 
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obtained and provide information on the infection status of the herd (Sachse et al., 2010), BAL fluid 
or samples of lung tissue are probably the only reliable method to determine whether the lung of an 
individual is infected or not (Caswell et al., 2010). Lung lesions, udder and joint or pleural fluid are 
also suitable and can all be easily collected from deceased animals (Nicholas and Baker, 1998). 
However culture of BAL samples collected at necropsy may be preferable to lung tissue when the 
samples cannot be processed immediately as isolation rates from lung tissue decrease markedly 
over a few hours after collection due to the release of mycoplasmal inhibitors from disrupted tissue 
(Nicholas and Baker, 1998, Taylor-Robinson and Chen, 1983). 
Samples submitted for culture of M. bovis must be kept cool or refrigerated (about 4°C) and ideally 
delivered to a laboratory within 24 hrs of collection (Caswell and Archambault, 2007, Nicholas and 
Baker, 1998). If shipment or storage times are anticipated to exceed 24 hrs, it has been suggested by 
Caswell and Archambault (2007) that the specimen be placed in a transport medium suitable for 
mycoplasmas and / or frozen at -70°C to help prevent any loss of viability. If microbiological 
examination of the sample cannot be performed immediately on arrival at the laboratory, Nicholas 
et al. (2008) suggest storing the samples or specimens at -20°C where they may be kept for up to 
several months. 
1.7.1.2  Speciation of culturable isolates 
Traditional biochemical tests had been the mainstay for the initial speciation process of 
mycoplasma isolates obtained via culture. Five biochemical tests were of particular value for 
speciation of bovine isolates (Erno and Stipkovits, 1973). These included the catabolism of glucose 
and arginine, phosphatase activity, formation of “film and spots”, and serum digestion (Erno and 
Stipkovits, 1973). Other biochemical characteristics that were useful included the capacity to; 
hydrolyse urea and / or casein and reduce tetrazolium (Poveda, 1998). Biochemically, M. bovis is 
similar to M. agalactiae as neither ferment glucose or hydrolyse arginine, instead utilising the 
organic acids, lactate and pyruvate as their energy source for growth (Miles and Nicholas, 1998). 
Mycoplasma bovis and M. agalactiae both possess lipolytic activity, thereby producing film and 
spot reactions on solid media (Nicholas and Ayling, 2003). Mycoplasma bovis is also able to reduce 
tetrazolium under both aerobic and anaerobic conditions and shows phosphatase activity (Nicholas 
and Ayling, 2003). The main limitation of traditional biochemical tests for speciation of 
mycoplasma isolates is that they are not completely sufficient for identifying all mycoplasma 
isolates to species level. In addition, when mixed mycoplasma species are isolated via culture, 
biochemical tests do not indicate that the culture contains a mix of different mycoplasma species.  
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Other methods used for speciation of mycoplasma isolates following successful culture include 
antibody-based tests such as immuno-fluoresence, immuno-peroxidase or more commonly 
nowadays, using species specific polymerase chain reaction (PCR) tests (Subramaniam et al., 
1998). Polymerase chain reaction systems amplify a particular DNA or RNA ‘target sequence’ 
enabling rapid detection of that sequence which may be specific for a particular organism of interest 
from culture (Sachse et al., 2010). Using species specific primer pairs, this process allows the 
detection and identification of an individual mycoplasma species (Justice-Allen et al., 2011) from 
either a submitted clinical sample or a cultured isolate. The disadvantages of PCR include: (i) the 
number of mycoplasma species that are able to be speciated using PCR is limited to the availability 
of primer pairs that are specific for a particular mycoplasma species; (ii) when used, they are not 
useful for identifying cultures containing mixed species of mycoplasma and (iii) when used alone 
on clinical material (without culture), isolates for future studies are not obtained.  
A collaborative study involving five laboratories, evaluated the sensitivity (Se) and specificity (Sp) 
of four different conventional PCR systems for the speciation of M. agalactiae and three 
conventional PCR systems for speciation of M. bovis on a total of 41 strains (Bashiruddin et al., 
2005). This work found that the vast majority of PCR systems correctly identified the strains 
(97.1% of all tests) and the specificity of all seven detection systems assessed appeared to be high 
(Bashiruddin et al., 2005). This study also found that two of the five laboratories in the study using 
the primer sequences described by Subramaniam et al. (1998) and Bashiruddin et al. (2005) had 
100% compliant results for M. agalactiae; while the M. bovis PCR assays by Hotzel et al. (1996) 
and Subramaniam et al. (1998) also performed without error.  
1.7.2  Immunological methods 
Numerous immunological methods have been developed and described in the associated literature 
for the detection of M. bovis surface antigens or antibodies from milk, serum or body fluids 
(Behymer et al., 1985, Caswell et al., 2010, Cho et al., 1976, Le Grand et al., 2002, Nicholas et al., 
2000, Rosendal and Martin, 1986, Uhaa et al., 1990). All methods rely on an antigen-antibody 
interaction and are used to detect antigen or antibody in a sample thereby indicating exposure of an 
animal to the pathogen of interest. Methods such as haemagglutination inhibition, complement 
fixation, agar gel diffusion, ring precipitation and film inhibition are reported in the associated 
literature (Andrew and Carter, 1977, Caswell and Archambault, 2007, Markham and 
Noormohammadi, 2005, Nicholas et al., 2000, Robino et al., 2005). Other techniques such as 
western blotting (WB) and immunohistochemistry are generally only used for research purposes 
(Markham and Noormohammadi, 2005). Today, ELISAs have become the principal method used 
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for immunological detection of serum antibody due to the cost effectiveness and potential for 
commercial production (Caswell and Archambault, 2007). 
Few studies have assessed the Se and Sp of these immunological methods. Like culture, 
immunological methods come with limitations for their routine diagnostic use. Cross-reactions in 
serological assays between M. agalactiae and M. bovis are often a concern (Bashiruddin et al., 
2005, Subramaniam et al., 1998). The repeatability of these tests between laboratories is often 
problematic due to the absence of a ‘gold standard’, or standardised and validated M. bovis-specific 
antigen and/or antibody. While the reliability of any immunological diagnostic method is dependent 
on a thorough understanding of the antigenicity and genomic repertoire of M. bovis field strains in 
the study region. As many of the major membrane antigens of M. bovis are phase and antigenically 
variable, immunological diagnostic methods for M. bovis always carry the risk of varying Se 
(Markham and Noormohammadi, 2005, Rosengarten and Yogev, 1996). To address these issues, 
attention has been drawn to the use of individual immunodominant proteins such as the Vsps, or 
their distinct epitopes in designing immunological tests, especially ELISAs (Brank et al., 1999, Le 
Grand et al., 2002, Markham and Noormohammadi, 2005). The use of immunodominant proteins or 
their epitopes together with the advancement of recombinant protein technology, and the 
development of monoclonal antibodies has the potential to improve the Se and Sp of these systems 
and facilitate standardisation of the diagnostic antigens used (Markham and Noormohammadi, 
2005).  
1.7.2.1  Serum antibody detection methods 
Mycoplasma bovis possesses both lipid and protein surface antigens capable of eliciting a host 
antibody response following infection (Caswell et al., 2010, Nicholas and Ayling, 2003). There is 
some variation in the reported time frame in which M. bovis-specific antibody can be detected 
following infection. Sachse et al. (1993) reports the length of incubation period whereby infection 
cannot be detected using antibody detection methods is 10 – 14 days after the onset of MbAD. A 
report by Uhaa et al. (1990) found that serum antibodies specific to M. bovis were usually detected 
by indirect ELISA six (IgM) to ten days (IgG) after experimental infection. Caswell et al. (2010), 
Nicholas and Ayling (2003) and Robino et al. (2005) on the other hand all report that M. bovis-
specific antibody is often detectable two to four weeks following an invasive infection. The 
variation in the time frame for antibody detection between Uhaa et al. (1990) and Caswell et al. 
(2010), Nicholas and Ayling (2003) and Robino et al. (2005) is likely a result of different 
immunological methods and antigens used. 
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1.7.2.1.1 Enzyme-linked immunosorbent assay (ELISA) 
Enzyme-linked immunosorbent assays use direct binding assay techniques to screen herds for the 
presence of M. bovis antibody(s) or antigen(s) (Sachse et al., 1993). When a quick and inexpensive 
screening method is required, ELISAs prove invaluable (Le Grand et al., 2002). In the 1980s, 
several experimental ELISAs were developed for the detection of M. bovis antibodies. These early 
ELISAs were developed using whole cell lysates (Liberal and Boughton, 1994) and were often 
associated with misleading results due to the reactivity of sera against non-specific bacterial 
proteins (Robino et al., 2005). In addition, cattle have the potential to be infected by more 
mycoplasmal species than any other host and as a result serologic cross-reactions can reduce the Sp 
of ELISAs (Thomas et al., 1987). As discussed previously, Sp issues have been partly overcome 
through the production and use of recombinant antigens through the expression and purification of 
mycoplasma antigens in Escherichia coli (Markham and Noormohammadi, 2005). 
The main advantages of ELISAs are that prior antibiotic treatment of the animal does not affect the 
result and they are often compatible with automation (Nicholas et al., 2008, Thomas et al., 1987). In 
addition, they provide a cost effective method for screening a large number of samples, are time 
efficient and have the potential for commercialisation. However, there are a number of factors that 
complicate interpretation and the use of antibody detection ELISAs in the diagnosis of MbAD. 
Following a natural infection, individual animal titres are poorly correlated with infection or disease 
as not all diseased animals develop high titres (Le Grand et al., 2002). In addition, titres can remain 
high in some animals for months (Le Grand et al., 2002), while maternal antibody in calves can also 
produce high titres (Maunsell et al., 2011). All of these factors make interpretation of serology 
results difficult when used for individual animal diagnosis. At a group or herd level however, sero-
conversion or high titres are predictive of active M. bovis infection (Martin et al., 1990). It has 
therefore been suggested that serological detection methods for M. bovis antibody are best applied 
in surveillance or as part of a biosecurity program (Le Grand et al., 2002). 
Many ELISA methods referenced in the associated literature are in-house methods for which the 
antigen(s) are either whole-cell (Ghadersohi et al., 2005, Nicholas et al., 2002, Prysliak et al., 2011, 
Prysliak et al., 2013, Thomas et al., 1987), recombinant (Brank et al., 1999, Le Grand et al., 2002, 
Wawegama et al., 2014) or unknown (Behymer et al., 1985, Uhaa et al., 1990). In Australia, current 
commercially available M. bovis ELISAs can be sourced from Bio-X Diagnostics

 (Belgium). 
These include a sero-conversion detection BioK260 ELISA kit (Bio-X Diagnostics
®
, 2013a), and a 
monowell sero-diagnostic BioK302 ELISA kit (Bio-X Diagnostics
®
, 2013b). Both Bio-X 
Diagnostics

 ELISAs contain a recombinant M. bovis antigen expressed by E. coli. Unfortunately 
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the Se and Sp of these ELISAs has not been reported other than by Bio-X Diagnostics

 themselves 
using a very limited sample size (sera from 40 experimentally infected animals, consisting of 15 
infected and 25 control animals) (Bio-X Diagnostics
®
, 2014). The use of a recombinant antigen in 
serological detection methods such as ELISAs places the burden of proof on the investigator to 
show that the selected antigen is present in all Mycoplasma spp. of interest, and that all animals 
infected with that species produce antibody to the selected antigen (Thomas et al., 1987). With little 
known about the genetic or antigenic diversity of Australian M. bovis strains, combined with the 
fact that the recombinant antigen used in the commercial Bio-X Diagnostics

 ELISAs remains 
undisclosed, how these ELISAs perform in the Australian, or any cattle population remains to be 
determined. 
1.7.2.1.2 Western blotting 
Antigens used in WB are prepared from whole mycoplasma cell proteins or semi-purified fractions 
of cells (Markham and Noormohammadi, 2005). More recently, as for ELISAs, the use of 
recombinant antigen(s) are being used for the detection of M. bovis antibody in sera using WB. The 
use of WB as a sero-diagnostic screening tool when large numbers of samples need to be processed 
is not cost or time efficient. In addition, the process is limited to use in a laboratory setting and can 
be labour intensive.  
1.7.2.2  Mycoplasma bovis antigen detection using immunohistochemistry 
Immunohistochemical techniques are useful when the isolation of M. bovis using culture from lung 
tissue is not possible (Nicholas et al., 2008). Such situations can occur in chronically affected 
animals; animals with prior antimicrobial treatment; poor condition of the lung tissue sample or if 
gross bacterial contamination is present (Nicholas et al., 2008). Immunohistochemistry allows 
visualisation of mycoplasma antigens in a tissue sample through the use of monoclonal antibodies 
(Radaelli et al., 2008). This method proves diagnostically useful when M. bovis antigen can be 
localised to the characteristic lesions of caseonecrotic bronchopneumonia (Castillo-Alcala et al., 
2012). 
1.7.3  Molecular methods 
1.7.3.1  Polymerase chain reaction  
Polymerase chain reaction is useful for speciation of cultured isolates as outlined earlier in addition 
to the direct detection of M. bovis from clinical specimens (Maunsell et al., 2011). Because PCR 
systems amplify a particular DNA or RNA ‘target sequence’, they enable rapid detection of that 
sequence which ideally is specific for the organism of interest, viable or not, from clinical material 
(Sachse et al., 2010). As PCR systems amplify a ‘target sequence’, their application with slow 
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growing or non-culturable organisms, in addition to samples collected from animals treated with 
antimicrobials or with samples that have been stored for some time or incorrectly (Maunsell et al., 
2011, Pinnow et al., 2001). This is a definite advantage of PCR in comparison to culture as the 
detection of the organism from the sample does not require the presence of viable M. bovis cells. 
Furthermore, PCR has the ability to detect M. bovis in clinical samples before the emergence of 
clinical signs or even the development of serum antibody (Sachse et al., 2010).  
The Sp of PCR systems is highly dependent of the system being used. Early PCR systems for 
M. bovis were based on sequences from the 16S rRNA genes. These systems lacked Sp as often 
sequences derived from other mycoplasmas, most notably M. agalactiae were also amplified, 
causing false positive results (Konigsson et al., 2002, Pfutzner and Sachse, 1996). More recently 
PCR assays targeting housekeeping genes (i.e. oppD/F and uvrC) have proven to be very reliable, 
making them candidates for reference tests with improved Sp (Bashiruddin et al., 2005, 
Subramaniam et al., 1998). However, because many of the currently used PCR assays target 
different genomic regions, each PCR assay can and does perform differently (Bashiruddin et al., 
2005). Another disadvantage of conventional PCR methods is that their use in regard to diagnosis 
of disease is limited. As M. bovis is a commensal organism of the bovine in the URT, detection of 
the organism in a sample via PCR confirms the presence of the organism only, nothing more. In 
addition, the detection of the organism via PCR from clinical tissues confirms the presence of the 
organism; however no information on the level of infection, nor whether the organism was viable or 
not in the tissue is obtained from a positive PCR result. These factors limit the usefulness of PCR 
for diagnostic purposes when confirming the cause of disease. 
In addition to conventional PCR, real-time-PCR systems have also been described for the detection 
of M. bovis in clinical samples (Ben Shabat et al., 2010, Cai et al., 2005, Clothier et al., 2010, 
Sachse et al., 2010). These systems differ from conventional PCR systems by incorporating a probe 
specific to the section of DNA or RNA amplified by the primer for the organism of interest. They 
also facilitate the screening of large numbers of samples within a few hours, allow quantification of 
the amount of target DNA / RNA in the sample and require minimal volumes of template DNA 
(Sachse et al., 1993, Sachse et al., 2010). 
1.8  Disease prevention and control 
Basic on-farm biosecurity measures such as maintaining a closed herd or screening and 
quarantining purchased animals remain the best way to minimise and / or prevent M. bovis 
infections (Gonzalez et al., 1992). Additional on-farm control and prevention strategies will vary 
with the production system and should be developed with the individual enterprise in mind. 
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Recommendations for the prevention and control of MbAD in feeder cattle primarily focus on 
maximising respiratory system health and immune function rather than M. bovis-specific measures 
(Maunsell et al., 2011). Limiting the level of spread and transmission by segregating affected 
animals from new arrivals could reduce exposure of high-risk animals (Maunsell et al., 2011). 
Meanwhile using appropriate hygiene measures when handling sick cattle could reduce fomite-
mediated transmission (Maunsell et al., 2011). In some situations the strategic use of antimicrobials 
in feed of high-risk animals on arrival or during a BRD outbreak may also prove useful in reducing 
the incidence of mycoplasma associated disease in feedlots (Maunsell et al., 2011). 
The use of antimicrobials for the treatment of MbAD is often unsuccessful and unrewarding. 
Despite this, they are still widely used, sometimes correctly (to reduce secondary bacterial 
infections), but often ineffectively to treat the mycoplasma infection (Nicholas et al., 2008). 
Antimicrobials such as the beta-lactams and glycopeptides that rely on the presence of a bacterial 
cell wall are not useful for the treatment of MbAD. Those known to be effective inhibit protein or 
nucleic acid synthesis and include members of the macrolide, fluoroquinolone, tetracycline, 
lincosamide, aminoglycoside and chloramphenicol groups (Maunsell and Donovan, 2009). There 
are many studies comparing the susceptibility of M. bovis to a range of antibiotics in vitro, however, 
antimicrobials that perform well in vitro do not necessarily perform well in vivo (Nicholas et al., 
2008).  
In addition, in the past decade, in vitro susceptibility studies have shown an increased resistance to 
antimicrobials commonly used to treat infections associated with M. bovis; in particular 
oxytetracyclines, spectinomycin, tilmicosin and chlortetracycline (Francoz et al., 2005, Gerchman 
et al., 2009, Hirose et al., 2003, Rosenbusch et al., 2005, Siugzdaite et al., 2012). Infrequent or no 
resistance has been reported to enrofloxacin or florfenicol (Francoz et al., 2005, Gerchman et al., 
2009, Hirose et al., 2003, Rosenbusch et al., 2005, Siugzdaite et al., 2012). Successful treatment of 
M. bovis pneumonia and arthritis in calves using valnemulin in the milk from four days of age for 
three weeks has also been reported (Stipkovits et al., 2001). Despite the plethora of antimicrobials 
that M. bovis isolates remain susceptible to today, there are two main factors that determine 
treatment of M. bovis-associated pneumonia a failure or success; these include early recognition and 
prolonged therapy (Nicholas et al., 2008). Currin et al. (2009) recommends continuous therapeutic 
levels of antimicrobials for 10 – 14 days. Without this, relapse is likely, causing more lung damage 
and necessitating further treatment. This finding is a consequence of the alleviation of clinical signs 
in the affected animal without the eradication of the organism from the LRT (Horwood et al., 
2014).  
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With the use of antimicrobials in food producing animals an ever increasing concern to consumers 
and the public, vaccination would appear to be the ‘silver’ bullet in the control and prevention of 
MbAD. However, attempts to vaccinate cattle against MbAD to date have been unrewarding and 
produced variable results (Maunsell et al., 2011). In a controlled setting, vaccination against MbAD 
has looked promising, but those vaccines that have been critically evaluated are not protective in the 
field (Maunsell et al., 2011). An inactivated vaccine containing saponin-killed cells developed by 
Nicholas et al. (2002) was shown to be safe, highly immunogenic and protective against strong 
experimental challenge with virulent M. bovis. Reductions in lung lesions, arthritis, severity and the 
incidence of clinical disease have been reported with the use of vaccines containing inactivated 
M. bovis (Chima et al., 1980, Maunsell and Donovan, 2009, Nicholas et al., 2002). The use of 
naturally occurring low-hydrogen peroxide producing M. bovis strains or strains modified through 
in vitro passages also have the potential to be used as vaccine strains (Nicholas et al., 2008). 
However, these described prototype vaccines fail to completely protect cattle from M. bovis 
respiratory tract colonisation and are therefore not useful for control of transmission between 
animals.  
1.9  A review of studies investigating the serological prevalence of M. bovis infection 
Considerable differences exist between studies reporting the sero-prevalence of M. bovis-specific 
antibody in cattle entering feedlots. Variation in the age of animals across the studies and the use of 
different sero-diagnostic methods, often where the antigen employed is not thoroughly defined, 
make comparison of results between these studies difficult. This is confounded by the absence of a 
gold-standard sero-diagnostic test for the detection of M. bovis-specific antibody, and hinders the 
validation of in-house and commercial tests. With this in mind, there are a number of sero-
diagnostic kits for the detection of M. bovis-specific antibody from bovine serum commercially 
available. These tests combined with the increased interest and research directed at the 
epidemiology and transmission dynamics of M. bovis in recent years has enabled and increased the 
literature available on the sero-prevalence of M. bovis-specific antibody. A notable issue that 
remains, even with the availability of these commercial sero-diagnostic kits is that information on 
the M. bovis antigen(s) used in these kits is not available. This factor creates issues when 
interpreting results from these tests and makes validation of the tests in the region or study 
population they are to be used troublesome. 
There are few studies that report the sero-prevalance of M. bovis antibody at the time of feedlot 
arrival. A French study by Arcangioli et al. (2008) used a commercial (CHEKIT-M. bovis) ELISA 
and found that approximately 2% (n = 135) of two – three week old dairy breed veal calves entering 
10 veal calf feedlots were sero-positive for M. bovis-specific antibody. In this case, the authors’ 
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suggested that this sero-prevalence may reflect the sero-prevalence in the maternal population but 
further investigations were required. A US study by Hanzlicek et al. (2011) found that 
approximately 27% of male crossbred beef calves with a mean feedlot arrival weight of 183.5 kg 
purchased from livestock auctions in Georgia had M. bovis-specific serum antibody on the day of 
arrival. The sero-diagnostic test used in this study was an undefined commercially available Bio-X 
Diagnostics

 ELISA kit and although an exact age of the animals was not defined, it could be 
assumed these animals were roughly or no more than six months of age.  
Sero-prevalance data from studies performed at the herd level are more readily available in the 
associated literature. Le Grand et al. (2002) examined 824 herds of beef cattle > 1 yr of age across 
eight French countries with a total of 32,197 animals in 1997 – 1998. Using a commercial 
(CHEKIT-M. bovis) ELISA kit and found that 2 – 13% of animals / herd / country and 28 – 90% of 
herds/country were sero-positive. A polish study by Bednarek et al. (2012) examined 2,005 
clinically healthy animals from 361 herds across 16 Polish provinces. It was not defined in this 
study what proportion of the clinically healthy animals were calves and / or adults. Using a 
commercial Bio-X Diagnostics

 (BioK162) ELISA kit, the authors’ found that approximately 78% 
of the healthy cattle population had detectable M. bovis-specific serum antibodies. In Northern Italy, 
Radaelli et al. (2008) had similar findings among cattle in the 18 - 24 month old range in that 76% 
of the animals tested were sero-positive using a M. bovis whole cell antigen ELISA developed by 
Nicholas et al. (2000). The findings from these studies indicate the variability of M. bovis-specific 
antibody between countries, between regions within a country and even between herds in the same 
region. In addition, the findings also suggest that M. bovis is not present on all farms and is not 
circulating among all herds. Alternatively, it may suggest that there is significant strain variation 
between herds and the antigen used in these ELISA detection methods is not commonly expressed 
by all M. bovis strains. In this situation, it is possible that false negative results can occur in some 
herds where the M. bovis strain(s) in that herd do not express the target antigen used in the ELISA. 
Fewer studies report overall sero-conversion rates among feedlot cattle during the early feeding 
period. Despite this there is general agreement that M. bovis infection is much more widespread 
once cattle have been in the feedlot environment for approximately two weeks or longer (Arcangioli 
et al., 2008). More commonly, sero-conversion rates after feedlot entry are reported in association 
with the occurrence of BRD. Reported overall sero-conversion rates often range from 60 – 100% 
(Arcangioli et al., 2008, Hanzlicek et al., 2011, Rosendal and Martin, 1986). In Rosendal and 
Martin (1986) an overall sero-conversion rate of 60% was reported among five groups of calves 
housed at two different feedlots (three at one and two at another), 28 days post feedlot arrival using 
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an indirect haemagglutination method reported by Cho et al. (1976). The rate of sero-conversion 
among BRD cases (animals treated for respiratory disease) and controls in this study was reported 
as 74% and 50% respectively. Arcangioli et al. (2008) using a commercial (CHEKIT-M. bovis) 
ELISA found that indicator animals tested 30 – 59 days following a BRD outbreak from eight out 
of nine French feedlots had 60 – 100% sero-conversion to M. bovis. These animals were of two –
 three week old dairy breed veal calves that had a sero-prevalence at arrival of approximately 2%. 
Interestingly one feedlot in this study had no indicator animals testing sero-positive at feedlot 
arrival or when re-tested approximately 40 days after the BRD outbreak. This finding supports that 
some herds / farms / properties are in fact free of M. bovis. Finally, Hanzlicek et al. (2011) reported 
overall sero-positivity for M. bovis antibody 42 days post feedlot arrival of 98.2% using an 
undefined commercially available Bio-X Diagnostics

 ELISA kit. Of these, the author reported a 
sero-conversion (animals that had increased two or more sero-status categories as defined by the 
manufacturer) rate of approximately 60%. 
1.10  M. bovis in Australia 
Mycoplasma bovis was first isolated in Australia in 1970 (Nicholas et al., 2002), and is arguably the 
most significant bovine mycoplasma spp. in the country today. The first isolation of M. bovis in 
Australia followed the successful eradication of M. mycoides subsp. mycoides small colony 
(MmmSC), the most pathogenic bovine mycoplasma species known and the cause of contagious 
bovine pleuropneumonia in 1968 (Newton and Norris, 2000). 
Despite the significance of M. bovis in Europe, Canada and North America, little is known about 
the prevalence, risk factors associated with infection and the extent of MbAD within the Australian 
cattle population. This is surprising given the level of research this organism has attracted in 
Europe, Canada and North America, combined with its pathogenicity and association with a variety 
of clinical syndromes in cattle that are of economic significance. Explanations for the lack of 
research on M. bovis in Australia are difficult to discern. It is possible that M. bovis has been largely 
overlooked due to the relative absence of intensive calf rearing production systems in Australia in 
comparison to Europe and North America. The age of animals entering intensive beef production 
systems such as feedlots in Australia are also somewhat different to those typically seen in Europe, 
Canada and North America (Cusack et al., 2007, Hay et al., 2014, Horwood et al., 2014). For 
instance, Australian animals are often weaned before feedlot arrival, while it is calves still on milk 
diets or young animals at the time of weaning typical of those entering intensive beef production 
systems in Europe and Canada (Hay et al., 2014). Another factor that may have led to M. bovis 
being overlooked in Australia could be due to the commensal nature of M. bovis. This may have led 
to the belief that being older at the time of feedlot entry, most animals should have already been 
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exposed and possibly sub-clinically infected with M. bovis before they arrive at the feedlot. This 
belief however is not supported by the literature. Mycoplasma bovis-free herds and properties can 
exist and exposure to M. bovis itself should not be related to the rate of infection. 
Until recently the most extensive peer reviewed research conducted in Australia was in Townsville, 
Queensland by Ghadersohi et al. (1997, 2005, 1999). The author investigated the prevalence of 
M. bovis in dairy cattle by milk sample PCR (Ghadersohi et al., 1997), milk culture (Ghadersohi et 
al., 1999) and serology using a monoclonal blocking ELISA for the detection of M. bovis serum 
antibody (Ghadersohi et al., 2005). More recently interest in M. bovis in the Australian setting 
appears to be re-emerging with a number of recent publications from Australian researchers 
appearing in the literature. These include a short communication on lung lesions in calves involved 
in a M. bovis experimental infection trial (Wawegama et al., 2012), a review on M. bovis membrane 
proteins and their role in pathogenesis (Adamu et al., 2013), and a publication regarding the 
development of an ELISA for the diagnosis of M. bovis infection (Wawegama et al., 2014). 
Meanwhile, Horwood et al. (2014) published a review of M. bovis with preliminary findings 
suggestive of M. bovis being involved in the development of BRD in Australian feedlot cattle and 
highlighting the need for further research.  
Despite this current resurgence of interest in M. bovis in Australia, as indicated by Horwood et al. 
(2014) a significant gap in the literature remains. Unfortunately, these Australian studies do not 
address or provide insight into the fundamental epidemiological aspects of M. bovis in Australian 
cattle populations, nor do they provide estimations of the prevalence of infection. This information 
is necessary for interpretation of diagnostic tests and to determine the significance and potential 
impact M. bovis has on the Australian beef and dairy livestock industries. On the other hand, 
interpretation of sero-diagnostic tests requires a better understanding of the genetic and antigenic 
diversity of M. bovis strains in Australia.  
1.11  Thesis aims and objectives 
It is evident from the literature that little is known regarding the sero-prevalence, risk factors or 
epidemiology of M. bovis in the Australian feeder cattle population. In addition, Se and Sp 
information regarding commercially available ELISAs is absent. It must be noted here that 
throughout this thesis Se and Sp refer to measures in a diagnostic rather than analytical context 
unless otherwise stated. The overarching aim of this thesis was to explore the potential importance 
of M. bovis in this population and in doing so, assess the performance of the commercial M. bovis 
ELISAs currently available in Australia.  
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Objective one: Develop a recombinant M. bovis antigen and assess its use for M. bovis antibody 
detection using WB analyses (Chapter 3 and 4). 
Objective two: Characterise the Se and Sp of commercial ELISAs currently available in Australia 
(Chapter 4 and 5). 
Objective three: Determine the sero-prevalence of M. bovis in the Australian feeder cattle 
population (Chapter 5). 
Objective four: Assess and quantify risk factors that may be associated with M. bovis sero-positivity 
are feedlot arrival and those associated with sero-conversion or a sero-increase in M. bovis antibody 
during the early feeding period (Chapter 6).  
Objective five: Determine if sero-conversion or a sero-increase in M. bovis antibody during the 
early feeding period is itself a risk factor for the development of BRD (Chapter 7). 
  
26 
CHAPTER 2   General materials and methods 
2.1  Description of reference sera  
A total of 102 bovine sera were sourced as generous gifts from overseas and interstate laboratories. 
A total of 50 sera were from animals recently exposed to M. bovis (expected to be sero-positive) 
and 52 sera were from animals not exposed to M. bovis (expected to be sero-negative), (Table 2.1). 
In addition to the bovine sera, M. bovis positive (n = 11) and negative (n = 7) control samples 
supplied with commercial M. bovis ELISA kits were also included in the study (Table 2.2). 
2.1.1  Asia-Pacific Centre for Animal Health sera 
Thirty-five paired sera obtained from five negative control animals (not exposed) and 30 M. bovis 
challenged animals (exposed) were sourced from the Asia-Pacific Centre for Animal Health 
(APCAH), The University of Melbourne, Australia (Table 2.1). The sera were obtained from male 
Friesian-cross calves, approximately one month old when acquired. These animals have been 
previously described by Wawegama et al. (2014). The calves were determined to be free of 
M. bovis prior to experimental infection by culture of nasal and conjunctival swabs in addition to 
quantitative real-time PCR (Sachse et al., 2010).  
Animals (n = 30) were challenged by aerosol exposure to an overnight culture of M. bovis strain 
3683 in mycoplasma media twice on days one and three (Wawegama et al., 2014) using the method 
described in Wawegama et al. (2012). Blood samples were collected on days 0, 10, 17 and 24 
following infection (Wawegama et al., 2014), however, only sera from day 0 and day 24 were 
utilised in this study. The control calves (n = 5) were exposed to mycoplasma media only (aerosol) 
on day 0 and were kept separate until the end of the experiment. For the purposes of this study, all 
calves were considered to have no prior exposure to M. bovis with pre-infection (day 0) samples 
expected to be sero-negative for M. bovis antibodies. Calves challenged with M. bovis were 
considered to have been exposed, and their post-infection (day 24) samples were expected to be 
sero-positive for M. bovis antibody. Antibody titre units for each sample were provided by APCAH 
(Table 2.3). 
All day 0 sera (n = 35) as well as day 24 sera from control animals (n =5) were classified as 
negative for M. bovis serum antibodies, while day 24 sera from calves challenged with M. bovis 
(n = 30) were classified as being positive for M. bovis serum antibodies (Table 2.1). 
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Table 2.1: Source and sample description of bovine sera from M. bovis experimental infection trials  
Source 
No. pre-infection 
samples* 
No. post-
infection samples 
Sample description 
Asia-Pacific Centre for Animal Health 
(APCAH), Australia 
40 30 Paired pre- (day 0) and post-infection (day 24) samples from 35, one month old 
when acquired male Friesian-cross calves. There were a total of 5 negative 
control animals and 30 M. bovis challenged animals as previously described in 
Wawegama et al. (2014). 
Vaccine and Infectious Disease 
Organization International Vaccine 
Centre (VIDO-InterVac), Canada  
5 10 Paired pre- (day 0) and post-infection (day 68) samples from 5 animals, and 
5 post-infection (day 68) samples. Samples were obtained from six to eight 
month old beef calves as previously described in Prysliak et al. (2013). 
Animal Health and Veterinary 
Laboratories Agency (AHVLA), 
England 
7 10 Paired pre- (day 0) and post-infection (days 7, 14, 21 and 28) samples from two 
experimentally infected and one control animal. Calves were approximately 
seven weeks of age and of dairy-cross breed. 
Two additional samples consisted of a ‘positive control’ and a ‘cut-off control’ 
used by AHVLA for interpretation of results obtained using their own in-house 
indirect ELISA to whole M. bovis cells. 
Total 52 50  
* Pre-infection samples include sera collected from animals prior to experimental infection with M. bovis in addition to subsequent samples collected from control 
animals.  
A total of 102 bovine sera from M. bovis experimental infection trials were obtained from three mycoplasma reference laboratories. These laboratories were the 
Asia-Pacific Centre for Animal Health (APCAH), Australia (n = 70); the Vaccine and Infectious Disease Organization International Vaccine Centre (VIDO-
InterVac), Canada (n = 15); and the Animal Health and Veterinary Laboratories Agency (AHVLA), England (n = 17). For analysis purposes sera were divided into 
those collected from animals prior to experimental infection (pre-infection) and sera collected from animals following M. bovis challenge (post-infection). Sera 
collected from control animals not challenged with M. bovis on any day other than day 0 of the trial were included in the pre-infection samples.  
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Table 2.2: Bio-X Diagnostics

 ELISA kit control sera summary 
Source No. negative sera No. positive sera Description 
BioK302 3 3 Positive and negative control sera from 
3 batches of BioK302 ELISA kits 
BioK260 4 4 Positive and negative sera from 
4 batches of BioK260 ELISA kits 
BioK284 0 4 Positive sera only from 4 batches of the 
BioK284 pentavalent ELISA 
Total 7 11  
The control sera (positive and negative) obtained from two commercial M. bovis ELISA kits (BioK302 and 
BioK260) manufactured by Bio-X Diagnostics

 (Belgium). In addition, positive control sera were obtained 
from pentavalent ELISA kits for BRD pathogens (BioK284) available from the same manufacturer. A total 
of 18 sera were utilised, consisting of M. bovis negative sera (n = 7), and M. bovis positive sera (n = 11). 
Both negative and positive sera were obtained from three batches of the BioK302 and four batches of the 
BioK260, while only positive sera were obtained from four batches of the BioK284.  
 
2.1.2  Vaccine and Infectious Disease Organization International Vaccine Centre sera 
A total of 15 bovine sera were obtained from Dr Jose Perez-Casal (Bacterial Vaccine Development 
Group at the Vaccine and Infectious Disease Organization International Vaccine Centre (VIDO-
InterVac), The University of Saskatchewan, Canada). These sera were sourced from ten, 
six to eight month old beef calves from a farm in southern Saskatchewan as part of an M. bovis 
experimental infection trial as described previously by Prysliak et al. (2013). Animals were 
determined to be free of M. bovis prior to infection by negative culture of nasal secretions (Prysliak 
et al., 2013). 
The M. bovis challenge was performed intra-nasally as described by Prysliak et al. (2013) where a 
4 ml suspension containing three M. bovis isolates (Mb1, Mb160 and Mb163) at approximately the 
same concentration for each was injected directly into the nasal cavity of each animal four days 
after the animals were challenged with bovine herpesvirus-1 (BoHV-1). Sera supplied by VIDO-
InterVac consisted of samples collected prior to M. bovis challenge (day 0) from five animals 
expected to be sero-negative for M. bovis antibody and ten samples collected from animals on day 
68 after M. bovis challenge and are therefore expected to be sero-positive for M. bovis. In-house 
M. bovis ELISA antibody titres for each sample were provided by VIDO-InterVac and categorised 
as sero-negative, low antibody titre or high antibody titre (Table 2.4).   
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Table 2.3: Asia-Pacific Centre for Animal Health in-house ELISA antibody titre units for 
each animal sample collected pre- and post-experimental infection with M. bovis. 
M. bovis exposure 
group 
Animal ID 
Antibody titre units supplied by APCAH 
Day 0 Day 24 
Control  APCAH13 30.18 20.22 
 
APCAH24 38.08 50.42 
 
APCAH30 13.16 7.74 
 
APCAH43 14.28 16.85 
 
APCAH71 26.06 17.24 
    
Challenged  APCAH3 20.63 186.12 
 
APCAH5 13.83 109.24 
 
APCAH7 9.82 16.97 
 
APCAH8 4.75 52.68 
 
APCAH9 30.06 250.52 
 
APCAH10 22.46 376.80 
 
APCAH18 22.67 32.98 
 
APCAH20 9.75 93.08 
 
APCAH21 11.96 67.96 
 
APCAH22 14.32 114.19 
 
APCAH23 28.15 571.84 
 
APCAH26 6.42 1,222.20 
 
APCAH31 20.51 200.42 
 
APCAH32 39.82 986.98 
 
APCAH34 19.40 237.86 
 
APCHA35 43.43 1,222.20 
 
APCAH36 13.09 115.60 
 
APCAH45 31.58 236.67 
 
APCAH46 14.35 170.42 
 
APCAH48 22.98 571.84 
 
APCAH49 8.06 403.51 
 
APCAH51 38.73 392.33 
 
APCAH52 30.52 281.68 
 
APCAH53 20.40 301.19 
 
APCAH54 13.28 247.22 
 
APCAH57 22.84 99.06 
 
APCAH60 5.32 451.57 
 
APCAH62 26.24 103.82 
 
APCAH63 18.83 183.65 
 
APCAH64 10.77 508.45 
APACH: Asia Pacific Centre for Animal Health; ELISA: Enzyme-linked immunosorbent assay. 
Antibody titre units supplied by the APCAH using an in-house ELISA described by Wawegama et al. (2014) 
were provided for each animal sample collected at day 0 and day 24 of an M. bovis experimental challenge. 
The APCAH ELISA uses a cut-off of 65 antibody titre units, and samples returning a value above that 
threshold are defined as sero-positive for M. bovis-specific antibody.  
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Table 2.4: Vaccine and Infectious Disease Organization International Vaccine Centre in-
house ELISA antibody titre categorisation for each animal sample collected pre- and post- 
experimental M. bovis challenge. 
Animal ID Day 0 Day 68 
VIDO18 No sample High 
VIDO19 Negative Low 
VIDO20 Negative High 
VIDO21 Negative Low 
VIDO25 No sample High 
VIDO26 No sample Low 
VIDO29 No sample High 
VIDO30 Negative High 
VIDO34 No sample High 
VIDO38 Negative Low 
VIDO-InterVac categorised samples according to results obtained using an in-house, whole cell M. bovis 
ELISA developed by VIDO-InterVac into M. bovis negative, low and high antibody titre. 
 
2.1.3  Animal Health and Veterinary Laboratories Agency samples 
A total of 17 serum samples were obtained from Dr. Roger Ayling (Mycoplasma Group, Animal 
Health and Veterinary Laboratories Agency (AHVLA), England). Samples consisted of pre-
infection (day 0) and post-infection (day 7, 14, 21 and 28) samples from two experimentally 
infected and one negative control animal (Table 2.1). A ‘positive control’ and a ‘cut-off control’ 
used by AHVLA for their in-house whole cell M. bovis ELISA interpretation were also included.  
Calves were sourced from a local farm reported to be free of all BRD pathogens (viruses and 
bacteria including mycoplasma), were of dairy-cross breed and five to seven weeks of age. Calves 
were challenged with a known pathogenic strain of M. bovis (the route of infection and the strain 
used could not be disclosed by AHVLA for commercial reasons).  
Samples collected from animals prior to experimental infection (day 0) and day 7, 14, 21 and 28 
from the control animal are expected to be sero-negative for M. bovis antibodies. While samples 
collected post-infection from M. bovis challenged animals (day 7, 14, 21 and 28) were expected to 
be sero-positive for M. bovis antibodies. Both the ‘positive control’ and ‘cut-off control’ samples 
were expected to be sero-positive for M. bovis antibodies. The AHVLA in-house M. bovis ELISA 
optical density (OD) readings for all samples were provided by AHVLA and are provided in Table 
2.5.  
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Table 2.5: Animal Health and Veterinary Laboratories Agency in-house ELISA optical 
density readings for each animal sample collected pre- and post-experimental infection with 
M. bovis. 
M. bovis 
exposure group 
Animal ID 
Sample OD reading at 450 nm using AHVLA 
in-house indirect whole cell M. bovis ELISA 
Day 0 Day 7 Day 14 Day 21 Day 28 
Control  AHVLA370 0.13 0.13 0.09 0.09 0.11 
       
Challenged  AHVLA304 0.08 0.14 0.22 0.38 0.54 
AHVLA339 0.13 0.06 0.33 1.23 1.44 
       
Cut-off control 0.3 
Positive control 1.00 
AHVLA: Animal Health and Veterinary Laboratories Agency; ELISA: Enzyme-linked immunosorbent 
assay; OD: Optical density.  
Samples returning an OD reading > 0.3 using an in-house indirect ELISA to whole M. bovis cells developed 
by AHVLA are considered positive for M. bovis-specific antibody (Nicholas et al., 2000). Each of the 
samples OD readings listed above were supplied by AHVLA. 
 
2.1.4  Bio-X Diagnostics

 control sera  
A total of 18 control sera supplied with the commercially available Bio-X Diagnostics

 (Belgium) 
M. bovis ELISA kits (BioK302 and BioK260) and the pentavalent bovine respiratory pathogen 
ELISA kit (BioK284) which is used to assess antibody levels to BoHV-1 , bovine viral diarrhoea 
virus (BVDV), bovine respiratory syncytial virus (BRSV), bovine parainfluenza virus 3 (BPIV-3) 
and M. bovis. Positive and negative controls are provided with both the BioK302 and BioK260 kits, 
while only a positive control is supplied with the BioK284 pentavalent ELISA kit. Controls were 
available from three batches of the BioK302 (MYC14C04, MYC13K26, MYC13J16), and four 
batches of both the BioK260 (SMYC14C04, SMYC13K26, SMYC13J16, SMYC09I28) and 
BioK284 (IBRPM12F04, IBRPM12K08, IBRPM12F28, IBRPM09L01) ELISA kits. A summary is 
provided in Table 2.6. 
2.2  Routine culture of mycoplasma isolates 
Frozen modified Frey broth (MFB) (Appendix 1) stocks of mycoplasma isolates were thawed on 
ice. A 10 µl loop was used to streak an inoculum taken from the MFB stock onto a modified Frey 
agar (MFA) (Appendix 2) plate. Streaked plates were incubated at 37°C in a 5% CO2 atmosphere 
for three to five days or until ‘fried-egg’ colonies, typical for mycoplasma, were evident using a 
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standard 40 × stereomicroscope. The isolate was sub-cultured by sectioning a single, well isolated 
colony from the agar using a sterile Pasteur pipette. The agar plug was placed in 3 ml of MFB and 
incubated for 48 hr at 37°C. 
Table 2.6: Certificate of analysis optical density readings for Bio-X Diagnostics

 M. bovis 
ELISA kit control sera.  
ELISA batch sample ID 
Sample OD reading at 450 nm 
COA
a
 quality control reading 
Sample reading for individual 
ELISA kit validation 
BioK302   
MYC14C04 Positive 1.903 > 0.700 
MYC14C04 Negative 0.050 < 0.400 
MYC13K26 Positive 1.580 > 0.700 
MYC13K26 Negative 0.047 < 0.400 
MYC13J16 Positive 1.668 > 0.700 
MYC13J16 Negative 0.059 < 0.400 
   
BioK260   
SMYC14C04 Positive 2.132 > 0.800 
SMYC14C04 Negative 0.011 < 0.300 
SMYC13K26 Positive 1.918 > 0.800 
SMYC13K26 Negative 0.003 < 0.300 
SMYC13J16 Positive 2.132 > 0.800 
SMYC13J16 Negative 0.011 < 0.300 
SMYC09I28 Positive NA NA 
SMYC09I28 Negative NA NA 
   
BioK284 (multiplex)   
IBRPM12F04 Positive NA NA 
IBRPM12K08 Positive 0.450 > 0.200 
IBRPM12F28 Positive 0.346 > 0.200 
IBRPM09L01 Positive NA NA 
a
COA, certificate of analysis; NA, Not available (information not available from Bio-X Diagnostics

); OD: 
Optical Density. 
Values listed were obtained from quality assurance certificates supplied with each of the BioK ELISA kits. 
Certificates of analysis were not available for control samples supplied with one BioK260 ELISA kit (batch 
number SMYC09I28) and two BioK284 ELISA kits (batch numbers IBRPM12F04 and IBRPM09L01). The 
quality control reading is an optical density reading at 450 nm obtained by Bio-X Diagnostics

 for the 
sample prior to release and distribution of the BioK ELISA kit for which the control sample relates. The 
sample reading for individual ELISA kit validation refers to the optical density reading threshold at 450 nm 
that a sample must either be less than (negative control) or greater than (positive control) to validate the 
ELISA at the time of sample testing.   
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2.3  Mycoplasma cell harvest 
Whole mycoplasma cells were harvested from a 48 hr, 3 ml MFB culture inoculated with a single 
well isolated colony. The whole cells were pelleted by centrifugation at 5,525 g for 1 hr at room 
temperature. The supernatant was discarded and the pellet re-suspended with 500 µl sterile 
phosphate buffered saline (PBS) and transferred to a 1.5 ml microcentrifuge tube. Centrifugation 
was repeated at 17,000 g for 15 min and the supernatant removed. Cells were washed twice with 
500 µl sterile PBS. After the final wash, the supernatant was carefully removed and discarded. The 
PBS washed whole cell pellets were used fresh for genomic deoxyribonucleic acid (DNA) 
extraction or stored at -20°C until required. 
2.4  Genomic DNA extraction 
Genomic DNA was extracted from fresh, unfrozen, PBS washed whole cells (as described in 
Section 2.3) using the commercial DNeasy Blood and Tissue Kit (Qiagen, Australia), following the 
manufacturer’s spin-column protocol (Qiagen Pty Ltd., 2006). A spectrophotometer 
(Nanodrop

 ND-1000) was used to estimate the purity of the eluted DNA whereby a ratio of 
absorbance at 260 nm and 280 nm of   1.8 indicated that the DNA was of sufficient purity for 
further analysis. An estimation of the DNA concentration (ng/µl) for each sample was also obtained 
using the same method. Eluted DNA was labelled and stored at -20°C until required. 
2.5  Direct sequence analysis 
2.5.1  Preparation of PCR amplicons 
Amplicons generated from PCR (further details of all PCR experiments will be provided in each 
relevant Chapter) were used fresh (within one day) for direct sequence analysis. The PCR 
amplicons were initially prepared by removing annealed and residual oligonucleotide primers and 
deoxyribonucleotide triphosphates (dNTPs) using ExoSAP-IT

 (Affymertix, Santa Clara, CA, 
USA). A total of 2 µl of ExoSAP-IT

 was added to 5 µl of fresh PCR product, mixed by briefly 
vortexing and incubated at 37°C for 15 min in a thermocycler. The ExoSAP-IT

 was subsequently 
inactivated by heating the mixture to 80°C for 15 min in a thermocycler.  
2.5.2  BigDye

 Terminator sequencing reaction 
Sequencing was performed using the BigDye

 Terminator (BDT) v3.1 Cycle Sequencing kit and 
protocol (Applied Biosystems, 2002). The BDT v3.1 sequencing reaction contained 4 µl 5X 
Sequencing Buffer (Applied Biosystems

), 2 µl BDT v.3.1 Ready Reaction Mix (Applied 
Biosystems

), 20 ng PCR template DNA (Section 2.5.1), 1.6 pmol of oligonucleotide and nuclease 
free water to 20 l.  
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The cycling conditions used were an initial denaturation at 95°C for 5 min followed by 60 cycles of 
denaturation at 95°C for 30 sec, annealing at 50°C for 20 sec, and polymerisation at 60°C for 4 min, 
then held at 4°C. Tubes were briefly pulse spun prior to proceeding to purification of BDT 
extension products. 
2.5.3  Purification of BDT reaction extension products 
Extension products were purified using the ethanol / ethylenediaminetetraacetic acid (EDTA) / 
sodium acetate (NaOAc) precipitation protocol as per the BDTv3.1 protocol methods (Applied 
Biosystems, 2002). The completed BDT v3.1 sequencing reaction (20 µl) was transferred to a 
1.5 ml microcentrifuge tube and 2 µl of 125 mM EDTA, 2 µl of 3 M NaOAc pH 4.6, followed by 
50 µl of 100% ethanol were added and mixed thoroughly by vortexing before incubation at room 
temperature for 15 min. Following incubation to allow precipitation of the extension products, the 
tubes were centrifuged at 20,000 g for 15 min and the supernatant was immediately and carefully 
removed. Residual supernatant was collected by briefly pulse spinning and removing with a fine tip. 
The pellet was washed with 70 µl of 70% ethanol and allowed to air-dry in the dark for 2 hr.  
2.5.4  Preparation of purified BDT reaction products for direct sequence analysis 
Samples were re-suspended with 10 µl Hi-Di
TM
 Formamide (Life Technologies), briefly vortexed 
and pulse spun before incubating, covered at room temperature for 10 min in the dark. Samples 
were re-vortexed and pulse spun before transferring to a 96-well plate (PCR-96M2-HS-C, Axygen), 
covered with an Applied Biosystems 3130xl genetic analyzer rubber septa and centrifuged at 500 g 
for 3 min. Samples were then denatured at 95°C for 3 min in a thermocycler with the lid open, the 
96-well plate removed and immediately placed carefully in an ice bath for 2 min. The 96-well plate 
containing the samples was then centrifuged again at 500 g for 3 min to ensure the sample was at 
the bottom of the wells before they were loaded into the Applied Biosystems 3130xl genetic 
analyzer.  
Direct sequence analysis was performed using the Applied Biosystems 3130xl genetic analyzer, the 
POP-7
TM
 Polymer (Applied Biosystems

), and a standard run (module StdSeq50_POP7).  
2.5.5  Sequence alignment 
Individual nucleotide sequence traces for each DNA fragment (forward and reverse sequences) 
obtained from each PCR amplicon assessed were retrieved from the Applied Biosystems 3130xl 
genetic analyzer as an .abi file. Nucleotide sequence editing for ambiguous bases using the trace 
data and sequence alignments using multiple sequence comparison by log-expectation (MUSCLE) 
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were performed using the free molecular evolutionary genetics analysis (MEGA6) software (Build: 
6140122), version 6.0.5. 
2.6  Western blotting 
2.6.1  Nitrocellulose membrane preparation 
A 25µl aliquot of pre-prepared antigen stored at -20°C (Section 3.2.7) containing approximately 
21 µg of total protein was prepared for SDS-PAGE by combining with an equal volume of sample 
reducing buffer (SRB) [62.5 mM Tris-HCl pH 6.8, 10% glycerol, 2% (w/v) SDS, 6 mM 
dithiothreitol (DTT), 0.05% (w/v) bromophenol blue, 47.5% (v/v) double distilled water (DDW)] in 
a PCR microtube. The sample was briefly vortexed and pulse spun before being heated at 95°C for 
5 min in a thermocycler. The sample was held at 4°C and pulse spun before being loaded into a 
hand-cast 0.75 mm 10% resolving / 4% stacking polyacrylamide (Bio-Rad Laboratories Inc., 2011) 
single well gel.  
Electrophoresis was performed using the Mini-PROTEAN

 Tetra Cell Electrophoresis Module 
(Bio-Rad) at 180 V for 40 min in 1 × Run buffer [25 mM Tris, 192 mM glycine, 0.1% SDS]. The 
Precision Plus Protein
TM
 Kaliedoscope
TM
 Standard (Bio-Rad) was used as a molecular weight 
marker. Protein transfer to nitrocellulose membranes was performed using a transfer apparatus 
(Bio-Rad Laboratories) at 100 V for 60 min in 1 × transfer buffer containing 20% methanol [25 mM 
Tris, 192 mM glycine, 20% (v/v) methanol]. Following transfer, membranes were blocked for 1 hr 
at room temperature whilst shaking in 5% (w/v) skimmed milk powder (blotto) in 
tris buffered saline with Tween 20 (TBST) [20 mM Tris, 150 mM NaCl, 0.1% Tween 20]. 
Following blocking, three 5 min washes using cold TBST were performed before the membrane 
was air-dried at room temperature, and stored at -20°C until required.  
2.6.2  Routine western blot protocol 
Membranes were thawed at room temperature for 10 min then cut into 3 mm wide vertical strips. 
Strips were incubated overnight, with shaking, at 4°C in primary antibody diluted in 5% (w/v) 
blotto TBST. Exact antibody dilutions are described in further detail in each relevant Section. 
Following overnight incubation, each strip was washed three times in cold TBST, for 5 min/wash. 
Strips were then incubated for 1 hr at room temperature with shaking in secondary antibody diluted 
(further described in relevant Chapter Section) in 5% (w/v) blotto TBST. Each strip was again 
washed three times for 5 min/wash using cold TBST.  
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The immunoreactivity was visualised using chemiluminescence (Pierce ECL Plus Western Blotting 
Substrate, Thermo Scientific) following a 10 min exposure time. The exposed film was developed 
using an automatic film developer (Okamoto X3) and an image of the radiograph was digitised 
using the Molecular Imager

 Gel Doc
TM
 XR+ imaging system (Bio-Rad) with Image Lab
TM
 
software (Bio-Rad).  
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CHAPTER 3   Development of a recombinant M. bovis protein for the detection of 
M. bovis-specific serum antibody 
3.1  Introduction 
Immunological methods such as western blotting (WB) and other serological techniques enable 
screening and identification of animals that have been exposed to a particular antigen. Development 
of these methods relies on identification of an antigen specific to the organism of interest. In regards 
to the detection of antibodies directed against M. bovis, the antigen must be highly conserved 
among different isolates despite the antigenic variation that is commonly reported. Recently, 
attention has been drawn to the use of individual immunodominant proteins such as the variable 
surface proteins (Vsps), or their distinct epitopes in designing immunological tests (Brank et al., 
1999, Le Grand et al., 2002, Markham and Noormohammadi, 2005). The advancement of 
recombinant protein technology, together with the development of monoclonal antibodies and 
improvements in the sensitivity (Se) and specificity (Sp) of these systems, standardisation of the 
diagnostic antigens used has been facilitated (Markham and Noormohammadi, 2005). 
The genes encoding the Vsp antigens have been shown to spontaneously undergo non-coordinate 
phase variation between on- and off- expression states (Lysnyansky et al., 1999). This can greatly 
affect the reliability of immunological screening and diagnostic tools (Rosengarten and Yogev, 
1996). For example if a specific Vsp antigen is used the Se of the test may be reduced if it is absent 
in the M. bovis isolate to which an animal has been exposed, or if it is not the major Vsp antigen 
expressed by the M. bovis cells in that locality (Markham and Noormohammadi, 2005). Despite 
this, studies using WB have shown that Vsps were the predominant antigens recognised by the host 
humoral response during M. bovis infections (Brank et al., 1999, Burnens et al., 1999). In addition, 
Brank et al. (1999) showed that the immunoreactivity of three of the Vsps (VspA, VspB and VspC) 
with host antibodies was independent of the clinical manifestation, the geographical origin of the 
M. bovis isolate, the mode of infection, and the animal’s history. The authors implied that despite 
their clonal variability, the Vsps or at least some members of the Vsp family are persistently 
expressed by M. bovis in the bovine host during infection and that immunodominant epitopes are 
highly conserved among strains and isolates, suggesting that the Vsps could be used as target 
antigens in sero-diagnostic assays for epidemiological studies.  
Further research on VspA in particular, found that approximately 80% of the VspA amino acid 
sequence is composed of two distinct stretches of repeated sequences separated from each other by 
22 amino acids. The first block, localised at the N-terminal portion, is composed of two distinct 
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motifs, designated RA1 and RA2, while the second block, localised at the C-terminal portion, 
contains three repeated motifs, RA3, RA4.1 and RA4.2 (Brank et al., 1999), (Figure 3.1).  
Poumarat et al. (1999) reported a study investigating the presence of vsp gene homologues in field 
isolates or strains other than the M. bovis PG45 type strain. A total of 250 M. bovis field isolates 
collected in France, Germany, Italy, Spain and Switzerland were assessed. They found that all 
isolates contained DNA sequences homologous to vsp genes (Poumarat et al., 1999). They also 
found that all isolates contained multiple copies of the sequence encoding the RA1 motif (Poumarat 
et al., 1999). These findings supported the conclusions made by Brank et al. (1999) and provide 
further evidence that there are possible immunodominant epitopes that are highly conserved among 
different strains and isolates of M. bovis. It is also plausible that a region of a Vsp containing one or 
more of these immunodominant epitopes, in this case RA1, could be applied as a target antigen in 
sero-diagnostic assays for epidemiological studies. 
Brank et al. (1999) identified an epitope that was immunoreactive in both experimental and field 
environmental settings. In the current study this was used to inform the area of the VspA protein 
that would be selected and subsequently used as an M. bovis antigen in WB. The aim of this study 
was to develop a truncated version of the VspA protein encoding the N-terminal RA1 motif and 
evaluate its use as an antigen for the specific detection of M. bovis antibodies in bovine serum. In 
the absence of a “gold standard” for the detection of M. bovis antibody in serum, WB was used to 
visualise the antigen-antibody reaction. The resulting WB was then used to assign a qualitative 
measurement of immunoreactivity of the serum to the antigen. In the following Chapter 4, an 
estimation of the Se and Sp of the WB was assessed. 
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Figure 3.1: Schematic representation of the VspA protein domains and their localisation 
(Brank et al., 1999).  
The first 106 amino acid sequence of the vspA gene encodes 10 ‘Proline-Glycine-Glutamic Acid-Asparagine-
Lysine-Threonine’ (PGENKT) amino acid repeats and comprise the RA1 motif. The RA1 motif has been 
shown to have reactivity with an immunoglobulin of G1 isotype (IgG1) (Behrens et al., 1994, Brank et al., 
1999, Le Grand et al., 1996, Rosengarten and Yogev, 1996). The C-terminal region from amino acid 155 to 
amino acid 325 encodes the RA4 motif and shows reactivity to an immunoglobulin of M isotype (IgM) 
(Behrens et al., 1994, Brank et al., 1999, Rosengarten and Yogev, 1996). 
 
3.2  Materials and Methods 
3.2.1  Amplicon generation 
The M. bovis PG45 type strain was obtained as a generous gift from the Department of 
Employment, Economic Development and Innovation (DEEDI) Tropical and Aquatic Animal 
Health Laboratory (TAAHL), Townsville. Routine culture was performed from a MFB stock as 
described in Section 2.2. Whole cells were harvested as described in Section 2.3 and used fresh for 
genomic DNA extraction as described in Section 2.4. 
Conventional PCR was carried out to amplify a target DNA sequence of 342 bp encoding the 
RA1 motif of the VspA protein (Figure 3.2). A 20 µl reaction containing 25 ng DNA template, 
20 mM Tris-HCl pH 8.4, 50 mM KCl, 1.5 mM MgCl2, 0.2 mM of each dNTP, 4 µg purified bovine 
serum albumin (BSA, New England BioLabs), 1 U Platinum

 Taq DNA polymerase and 8 pmol of 
each of the oligonucleotide primers vspA-F1 (5’-GTA GCA GCT AAA TGT GGT GAG ACC-3’) 
and vspA-R2 (5’-GTC ATC ATG CGG AAT TCT TGG-3’) (Geneworks) was performed. Cycling 
conditions consisted of an initial denaturation at 94°C for 3 min, followed by 35 cycles of 
denaturation at 94°C for 10 sec, annealing at 54°C for 15 sec, polymerisation at 72°C for 30 sec; 
and a final extension for 2 min at 72°C. The DNA concentration and purity of the PCR reaction 
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product was estimated using a spectrophotometer (NanoDrop

 ND-1000) as described in 
Section 2.4. 
 
 
Figure 3.2: Schematic representation of vspA-F1 and vspA-R2 oligonucleotide primer 
locations on the M. bovis PG45 type strain vspA gene (Genbank Accession Number L81118.1). 
Using the oligonucleotide primers vspA-F1 and vspA-R2, amplification of a 342 base pair amplicon 
containing the RA1 motif occurs.  
 
3.2.1.1  Size assessment  
The size of PCR amplicon generated was assessed using agarose gel electrophoresis at 70 V for 1 hr 
in 1% (w/v) agarose gel using 1 × Tris-acetate-EDTA (TAE) buffer [40 mM Tris-HCl pH 7.6, 
20 mM acetic acid, 1 mM EDTA] and visualised by staining with 0.1 µl GelRed
TM
/ml agarose. 
3.2.1.2  Sequence analysis  
Prior to ligation into the pET SUMO plasmid vector using the Champion
TM
 pET-SUMO Protein 
Expression System (Invitrogen, 2010), sequence analysis of the 5’-vspA PCR amplicon generated in 
Section 3.2.1 was performed. A 5 µl aliquot (0.6 µg) of the PCR reaction product was used and 
prepared as PCR template as described in Section 2.5.1. A BDT sequencing reaction as described in 
Section 2.5.2 was performed using the oligonucleotide primers vspA-F1 and vspA-R2 in forward 
and reverse sequencing reactions. The methods for the purification of the BDT reaction products, 
direct sequence analysis and sequence alignment have been previously described in Sections 2.5.3, 
2.5.4 and 2.5.5, respectively. 
3.2.2  Plasmid ligation  
The 5’-vspA amplicon was cloned into the pET SUMO plasmid vector using the ChampionTM pET-
SUMO Protein Expression System (Invitrogen, 2010), following the manufacturer’s instructions. 
Two ligation reactions using the vector : insert molar ratios of 1:1 and 1:3 were performed. An 
aliquot of fresh PCR reaction products from Section 3.2.1 was diluted in an appropriate volume of 
nuclease free water to achieve a final DNA concentration of 1.54 ng/µl (1:1 ligation reaction), and 
4.5 ng/µl (1:3 ligation reaction), respectively. The ligation reactions were performed in a total 
volume of 10 µl consisting of 1 µl of 10 × Ligation buffer (Invitrogen) [60 mM Tris-HCl pH 7.5, 
60 mM MgCl2, 50 mM NaCl, 1 mg/ml BSA, 70 mM -mercaptoethanol, 1 mM adenosine 
triphosphate (ATP), 20 mM DTT, 10 mM spermidine], 50 ng pET-SUMO plasmid vector, 
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1 µl (4.0 Weiss units) T4 DNA Ligase (Invitrogen), 4 µl nuclease free water and 3 ng or 9 ng of 
fresh 5’-vspA amplicon insert for the 1:1 or 1:3 ligation reaction, respectively. The ligation reaction 
was incubated at 15°C overnight in a thermocycler.  
3.2.3  Plasmid transformation 
One vial of One Shot

 Mach1
TM
-T1
R
 chemically competent Escherichia coli cells were transformed 
with 2 µl of each ligation reaction. The One Shot

 Mach1
TM
-T1
R
 cells and ligation reactions were 
incubated on ice for 30 min before being heat shocked in a water bath at 42°C for 30 sec. Following 
heat shock, cells were immediately returned to ice and 250 µl of room temperature super-optimal 
catabolite repression (SOC) medium [2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 
10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose] was added. The cells were then incubated at 
37°C for 1 hr with shaking at 200 rpm. Two aliquots (50 µl and 150 µl) of each transformation 
reaction was plated onto pre-warmed Luria Bertani (LB) agar plates containing 50 µg/ml 
kanamycin sulfate (LB-Kan50) and incubated overnight at 37°C. 
3.2.3.1  Screening of transformant colonies 
Following overnight incubation, transformed One Shot

 Mach1
TM
-T1
R
 E. coli cells were screened 
using conventional PCR analysis of whole-cells. Cells from separate colonies on each of the LB-
Kan50 plates were gently scraped from the agar surface using a sterile 50 µl pipette tip and re-
suspended in 6 µl of nuclease free water to create a cell suspension. Screening of colonies for 
correct plasmid orientation and size was performed by directional PCR analyses. Each colony was 
screened with two PCR reactions. All reactions were performed in a total volume of 20 µl 
containing 2 µl of the cell suspension as DNA template, 20 mM Tris-HCl, pH 8.4, 50 mM KCl, 
1.5 mM MgCl2, 0.2 mM of each dNTP, 4 µg purified BSA (New England BioLabs), 1 U Platinum

 
Taq DNA polymerase and 8 pmol of each primer (Table 3.1). Primer pair vspA-R2 / SUMO forward 
were used to identify colonies with the insert in the correct orientation (Table 3.1). The primer pair 
vspA-F1 / T7 reverse identified those colonies with the PCR amplicon in the wrong orientation 
(Table 3.1). 
Cycling conditions consisted of an initial denaturation at 94°C for 3 min, followed by 35 cycles of 
denaturation at 94°C for 10 sec, annealing at 54°C for 15 sec, polymerisation at 72°C for 30 sec, 
and a final extension for 2 min at 72°C. The PCR reaction products were assessed for size using 
agarose gel electrophoresis at 70 V for 1 hr in 1% agarose using 1 × TAE buffer and visualised 
using 0.1 µl GelRed
TM
/ml.  
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Table 3.1: Oligonucleotide primer pairs used for screening of transformed E. coli colonies 
Screening Reaction Primer Pair Sequence 
Forward vspA-F1 5’-GTA GCA GCT AAA TGT GGT GAG ACC-3’ 
 T7 reverse
*
 5’-TAG TTA TTG CTC AGC GGT GG-3’ 
Reverse vspA-R2 5’-GTC ATC ATG CGG AAT TCT TGG-3’ 
 SUMO forward
*
 5’-AGA TTC TTG TAC GAC GGT ATT AG-3’ 
* 
Primers supplied with the Champion
TM
 pET SUMO Protein Expression System kit (Invitrogen, 2010).  
 
3.2.4  Sequence analysis plasmid DNA 
3.2.4.1  Plasmid DNA extraction 
Plasmid DNA was prepared from transformed One Shot

 Mach1
TM
-T1
R
 chemically competent 
E. coli cells using the QIAprep
 Spin Miniprep Kit (Qiagen) following the manufacturer’s 
instructions (Qiagen Pty Ltd., 2004). A 1.5 ml aliquot of overnight cell culture was pelleted by 
centrifugation at 6,800 g for 10 min at room temperature. The supernatant was removed and the 
pelleted E. coli cells were re-suspended in 250 µl of Buffer P1 (Qiagen) and transferred to a 
microcentrifuge tube. A 250 µl aliquot of Buffer P2 (Qiagen) was added and the solution was mixed 
thoroughly by inverting the tube until the solution became clear. A 350 µl aliquot of Buffer N3 
(Qiagen) was added and mixed immediately and thoroughly by inverting the tube four to six times. 
The solution was then centrifuged for 10 min at 17,000 g. The supernatant was collected and 
applied to the QIAprep

 spin-column and centrifuged for 60 sec and the flow through was 
discarded. The spin-column was then washed by adding 500 µl Buffer PB (Qiagen) and centrifuged 
for 60 sec and the flow through was discarded. The spin-column was washed again by adding 
750 µl Buffer PE (Qiagen), and centrifuged for 60 sec, and again the flow through was discarded. 
The spin-column was then centrifuged for an additional 60 sec to remove residual wash buffer, then 
transferred to a clean 1.5 ml microcentrifuge tube. The plasmid DNA was eluted from the spin-
column by adding a 50 µl aliquot of Buffer EB (Qiagen, 10 mM Tris-HCl, pH 8.5) to the centre of 
the spin-column. The spin-column was then allowed to stand for 1 min, before centrifuging for 
1 min and the eluted plasmid DNA was collected. The concentration and purity of the plasmid DNA 
was estimated using a spectrophotometer (NanoDrop

 ND-1000) as described in Section 2.4. 
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3.2.4.2  Plasmid DNA sequencing protocol 
Fresh eluted plasmid DNA obtained from transformed One Shot

 Mach1
TM
-T1
R
 chemically 
competent E. coli cells (Section 3.2.4.1) was used as DNA template in a 20 µl BDT v3.1 
sequencing reaction. An aliquot containing 20 ng of plasmid DNA was added to a mastermix 
containing 4 µl 5 × Sequencing Buffer (Applied Biosystems

), 2 µl BDT v3.1 Ready Reaction Mix 
(Applied Biosystems

) and 11.68 µl nuclease free water. An aliquot containing 3.2 pmol of the 
SUMO forward oligonucleotide primer (Table 3.1) was added to one sequencing reaction mix while 
an aliquot containing the same concentration of the T7 reverse oligonucleotide primer (Table 3.1) 
was added to another sequencing reaction mix.  
The BDT sequencing reaction cycling conditions have been previously described in Section 2.5.2 
and purification of the extension products was performed using the ethanol / EDTA / sodium 
acetate precipitation protocol as described in Section 2.5.3. Once the extension products had been 
purified, samples were prepared for direct sequence analysis using the Applied Biosystems 3130xl 
genetic analyzer as described in Section 2.5.4 and the individual nucleotide sequence traces for each 
plasmid DNA fragment was managed using the MEGA6 software as described in Section 2.5.5. 
3.2.4.3  Determination of pET SUMO-5’-vspA fusion protein molecular weight 
Once the sequence of the pET SUMO-5’-vspA fusion protein had been determined by direct 
sequencing (Section 3.2.4.2), the molecular weight of the resulting protein was estimated using the 
online protein molecular weight calculator which is part of ‘the sequence manipulation suite’ by 
Stothard (2000).  
3.2.5  Protein expression  
3.2.5.1  Transformation of One Shot

 BL21 (DE3) chemically competent cells  
For protein expression, DNA from the ligated pET SUMO plasmid vector was transformed into 
BL21 (DE3) One Shot

 chemically competent E. coli cells as per the pET SUMO Protein 
Expression system manufacturer’s instructions (Invitrogen, 2010). One vial (50 µl) of One Shot 
BL21 (DE3) chemically competent E. coli cells/transformation reaction was thawed on ice. Once 
thawed, 2 µl (20 ng) of plasmid DNA prepared using the QIAprep
 
Spin Miniprep Kit (Qiagen) as 
described in Section 3.2.4.1 was added to one vial of thawed chemically competent BL21 (DE3) 
One Shot

 cells. The cells were gently stirred using a pipette tip and incubated on ice for 30 min. 
Cells were then heat shocked in a water bath without shaking for 30 sec at 42°C and immediately 
returned to ice. A 250 µl aliquot of SOC medium was added and tubes incubated at 37°C with 
shaking at 200 rpm for 1 hr. A 50 µl aliquot of each transformation reaction was then plated onto 
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pre-warmed LB-Kan50 agar plates and smeared using a 10 µl loop. The plates were incubated at 
37°C overnight. 
3.2.5.2  Induction of protein expression 
Following overnight incubation, a single well-isolated colony of transformed One Shot
 
BL21 
(DE3) E. coli cells was added to a pre-warmed 5 ml LB-Kan50 broth. The broth was incubated 
overnight at 37°C with shaking at 200 rpm. The following morning, a 250 µl aliquot of overnight 
cell culture was added to a fresh pre-warmed 5 ml LB-Kan50 broth and incubated for 2 hr at 37°C 
with shaking at 200 rpm. Protein expression was induced by adding isopropylthio--galactoside 
(IPTG) to a final concentration of 1 mM. The induced cell culture was incubated at 37°C with 
shaking at 200 rpm for a further 5 hr before cells were harvested. 
Induced cells were harvested by centrifugation at 5,525 g for 10 min at 4°C. The supernatant was 
carefully removed and an aliquot saved and stored at -20°C for SDS-PAGE analysis. The harvested 
cell pellet was frozen at -20°C prior to protein extraction.  
3.2.6  Protein extraction  
The frozen cell pellet was thawed on ice and re-suspended in 5 ml of cold E. coli Lysis Buffer

 
[50 mM KH2PO4, pH 7.8, 400 mM NaCl, 100 mM KCl, 10% glycerol, 0.5% triton X-100, 10 mM 
imidazole] by gently pipetting up and down. Lysozyme to a final concentration of 0.25 mg/ml and 
benzonase nuclease to a final concentration of 5 U/ml was added and the mixture incubated at room 
temperature for 30 min with shaking at 200 rpm. Following incubation, three freeze (-80°C)/thaw 
(42°C in a water bath) cycles were performed ensuring the samples were completely frozen and 
thawed each time. The sample was then centrifuged at 5,525 g at 4°C for 10 min and the 
supernatant containing the soluble protein fraction of interest was carefully transferred to a clean 
tube. An aliquot of the soluble protein fraction was saved and stored at -20°C for SDS-PAGE 
analysis. The residual pellet containing the insoluble protein fraction was re-suspended with 2 ml 
sterile PBS and an aliquot was saved and stored at -20°C for future SDS-PAGE analysis. 
3.2.7  Protein purification 
Purification of the soluble protein fraction from the cleared soluble protein lysate was performed 
using the Ni-NTA Spin-Kit and columns (Qiagen) following the ‘protein purification under native 
conditions from E. coli lysates protocol’ (Qiagen Pty Ltd., 2008) with some modifications. A 500 µl 
aliquot of the cleared soluble protein lysate was re-suspended with 1 ml of NPI-10 Lysis buffer 
[50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0, filter sterile] and mixed by inverting 
the tube five or six times. The Ni-NTA spin-column was then equilibrated by adding 600 µl NPI-10 
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Lysis buffer to the spin-column placed in a collection tube and centrifuged for 2 min with lid open 
at 890 g. The flow through in the collection tube was discarded and 600 µl of the re-suspended 
soluble protein lysate was added to the pre-equilibrated Ni-NTA spin-column. The Ni-NTA spin-
column was centrifuged at 270 g for 5 min with lid closed to increase binding capacity. The flow 
through was collected and loading of 600 µl volumes of re-suspended soluble protein lysate was 
repeated until all of the re-suspended soluble protein lysate had been passed through the Ni-NTA 
spin-column. The flow through after each centrifugation step was collected and combined and an 
aliquot saved and stored at -20°C for future SDS-PAGE analysis.  
Once all the re-suspended soluble protein lysate had been passed through the spin-column, the spin-
column was placed into a clean collection tube and washed three times with 600 µl aliquots of  
NPI-20 Wash buffer [50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0, filter sterile], 
centrifuging at 890 g for 2 min with lid open between each wash. The flow through from each wash 
step was collected separately and aliquots saved and stored at -20°C for future SDS-PAGE analysis. 
To elute the induced protein of interest from the Ni-NTA spin-column, the Ni-NTA spin-column 
was placed in a fresh, sterile 1.5 ml Eppendorf tube and a 300 µl aliquot of NPI-500 Elution buffer 
[50 mM NaH2PO4, 300 mM NaCl, 500 mM imidazole, pH 8.0, filter sterile] was added to the Ni-
NTA spin-column. The Ni-NTA spin-column was then centrifuged for 2 min at 890 g with the lid 
open, and the first eluate collected.  
Additional eluates were collected by placing the Ni-NTA spin-column in a clean, 1.5 ml 
microcentrifuge tube adding 300 µl NPI-500 elution buffer to the Ni-NTA spin column and 
repeating the elution centrifugation step. Each eluate was collected separately and the concentration 
and purity estimated using a spectrophotometer (NanoDrop

 ND-1000). Each eluate was stored at -
20°C until required.  
3.2.8  SDS-PAGE analysis  
Protein expression was assessed using SDS-PAGE analysis. Samples were prepared by adding an 
equivalent volume of SRB (Section 2.6.1), briefly vortexed and pulse spun then heated at 95°C for 
5 min in a thermocycler. Samples were allowed to cool and pulse spun before loading into a 
10 well, 1 mm 10% resolving / 4% stacking polyacrylamide gel (Bio-Rad Laboratories Inc., 2011).  
Proteins were separated by electrophoresis at 180 V for 45 min in 1 × Run buffer, (Section 2.6.1). 
The Precision Plus Protein
TM
 Kaleidoscope
TM
 Standard (Bio-Rad) was used as a molecular weight 
marker. Protein bands were visualised using the Coomassie blue stain method where the 
polyacrylamide gel was allowed to stain for 1 hr at room temperature with agitation in Coomassie 
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blue stain [0.05% (w/v) Coomassie blue R-250, 50% (v/v) methanol, 10% (v/v) glacial acetic acid, 
40% (v/v) DDW] followed by destaining for 3 hr at room temperature with agitation in Coomassie 
blue destain [7% (v/v) glacial acetic acid, 23% (v/v) methanol, 70% (v/v) DDW].  
3.2.9  Western blotting 
Nitrocellulose membrane strips containing the Ni-NTA purified protein obtained (Section 3.2.7) 
were prepared as described in Section 2.6.1 and the general WB procedure was followed as 
described in Section 2.6.2. 
The immunoreactivity of sera from M. bovis-challenged and non-challenged animals (n = 102) 
(Table 2.1) and control sera from Bio-X Diagnostics

 M. bovis ELISA kits (n = 18,) (Table 2.2) to 
the Ni-NTA purified protein were assessed. Each serum sample was applied as the primary 
antibody to a single 3 mm wide nitrocellulose membrane strip prepared as described in Section 
2.6.1 at a 1:100 dilution in 5% (w/v) blotto TBST and incubated overnight at 4°C with agitation. 
Following three 5 min washes in cold TBST, the secondary antibody (Sigma anti-bovine IgG) at 
1:20,000 dilution in 5% (w/v) blotto TBST was applied to the membrane strip and incubated at 
room temperature with agitation for 1 hr. The membrane strips were then washed again three times 
in cold TBST, at 5 min/wash and the immunoreactivity of each reference sera tested to the purified 
protein of interest was visualised using chemiluminescence with a 10 min exposure time as 
described in Section 2.6.2. 
In addition to bovine sera and Bio-X Diagnostics

 control sera, the immunoreactivity of five mouse 
monoclonal antibodies (MAb) to the Ni-NTA purified protein were also assessed. The mouse MAbs 
were obtained as a generous gift from Prof. Konrad Sachse (The Institute of Molecular 
Pathogenesis at the Federal Research Institute for Animal Health, Jena, Germany). Each of the 
MAb have been previously described and included 1E5 (Rosengarten et al., 1994), 2A8, 4D7 and 
6E5 (Beier et al., 1998) and 9F1 (Lysnyansky et al., 2001), (Table 3.2). 
Each mouse MAb was applied to a pre-prepared 3 mm wide nitrocellulose membrane strip 
containing the Ni-NTA purified test protein and were used at a 1:100 dilution in 5% (w/v) blotto 
TBST. A sheep anti-mouse IgG peroxidase conjugate (Sigma), at a 1:2,000 dilution in 5% (w/v) 
blotto TBST was used as a secondary antibody. The immunoreactivity was visualised as described 
in Section 2.6.2. 
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Table 3.2: Summary of the mouse monoclonal antibodies with Vsp specificity 
Monoclonal antibody Specificity Reference 
1E5 VspA (63-67 kDa) 
VspB (35-46 kDa) 
VspC 
Rosengarten et al. (1994)  
2A8 VspC (75 kDa) 
VspO (40kDa) 
Beier et al. (1998)  
9F1 VspF (55 kDa) Lysnyansky et al. (2001)  
4D7 Vsp A, B & C 
(distinct from 1E5) 
Beier et al. (1998) 
6E5 VspA Beier et al. (1998)  
kDa: Kilodaltons; Vsp: Variable surface protein; MAb: Monoclonal antibody.  
The table above provides a summary of the mouse monoclonal antibodies obtained from 
Prof. Konrad Sachse (The Institute of Molecular Pathogenesis at the Federal Research Institute for Animal 
Health, Jena, Germany). The Vsp specificity for each MAb is listed along with the expected molecular 
weight, if it is known, of the Vsp protein to which the MAb has been found to react. 
3.3  Results 
3.3.1  5’-vspA vector insert amplicon  
Agarose gel electrophoresis revealed that the 5’-vspA amplicon generated using DNA from the 
TAAHL (Townsville) M. bovis PG45 type strain and conventional PCR was approximately 300 bp 
in size (Figure 3.3).  
Subsequent sequence analysis revealed that the 5’-vspA amplicon generated was 306 bp in length. 
The sequence encoded eight ‘Proline-Glycine-Glutamic Acid-Asparagine-Lysine-Threonine’ 
(PGENKT) amino acid repeats. This is in contrast to the ten PGENKT amino acid repeats encoded 
by the same region of the vspA gene for the Genbank M. bovis PG45 type strain (Accession Number 
L81118.1). The remainder of the nucleotide (and subsequent amino acid) sequence for the 5’-vspA 
amplicon generated here and the same region of the Genbank vspA gene sequence was identical, as 
shown by the sequence alignment in Figure 3.4. 
3.3.2  Screening of transformed E. coli cells containing the ligated pET SUMO plasmid  
A total of 14 well isolated single colonies from transformed One Shot

 Mach1
TM
-T1
R
 E. coli cells 
were screened using conventional PCR for the presence of the 5’-vspA insert. Four colonies from 
each of the ligation reactions (1:1 and 1:3) were selected from both LB-Kan50 plates inoculated 
with 50 µl of transformation reaction and three separate colonies from each ligation reaction were 
selected from both the LB-Kan50 plates inoculated with 150 µl of the transformation reaction 
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(Table 3.3). A total of five colonies (pvspA6 – pvspA10, lanes 7 – 11 respectively) showed 
evidence of the correct orientation of the 5’-vspA pET SUMO plasmid insert (Figure 3.5).  
Table 3.3: Summary of transformed One Shot Mach1TM-T1R E. coli colonies 
Ratio 
50 µl plate 150 µl plate 
Total colonies No. screened Total colonies No. screened 
1:1 16 4 (pvspA1-4) > 50 3 (pvspA5-7) 
1:3 23 4 (pvspA8-11) > 50 3 (pvspA12-14) 
Labels assigned to the 5’-vspA ligated pET SUMO plasmid from each transformed E. coli colony selected 
are shown in brackets. 
 
 
 
Figure 3.3: Agarose gel electrophoresis of PCR reaction product containing the 5’-vspA 
amplicon used in ligation reactions with the pET SUMO plasmid vector.  
Conventional PCR 5’-vspA amplicon generated from the Tropical and Aquatic Animal Health 
Laboratory (Townsville) M. bovis PG45 type strain and used as plasmid vector gene insert (lane 1), 
no template control (lane 2), 1 Kb+ DNA ladder (lane 3). 
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aaa         V   A   A   K   C   G   E   T   K   E   E   N   K   P   E   P   D  
PG45b  5’  GTA GCA GCT AAA TGT GGT GAG ACC AAA GAA GAA AAT AAA CCA GAG CCC GAC 
5’-vspAc 1 GTA GCA GCT AAA TGT GGT GAG ACC AAA GAA GAA AAT AAA CCA GAG CCC GAC 
                     vspA-F1 
 
            K   N   P   G   G   D   K   N   P   G   E   N   K   T   P   G   E  
           AAA AAT CCA GGT GGA GAT AAA AAC CCT GGG GAA AAT AAA ACA CCT GGC GAA 
        52 AAA AAT CCA GGT GGA GAT AAA AAC CCT GGG GAA AAT AAA ACA --- --- --- 
 
 
            N   K   T   P   G   E   N   K   T   P   G   E   N   K   T   P   G  
           AAT AAA ACA CCT GGC GAA AAT AAA ACA CCT GGC GAA AAT AAA ACA CCT GGC 
       103 --- --- --- --- --- --- --- --- --- CCT GGC GAA AAT AAA ACA CCT GGC 
 
 
            E   N   K   T   P   G   E   N   K   T   P   G   E   N   K   T   P  
           GAA AAT AAA ACA CCT GGC GAA AAT AAA ACA CCT GGG GAA AAT AAA ACA CCT 
       154 GAA AAT AAA ACA CCT GGC GAA AAT AAA ACA CCT GGG GAA AAT AAA ACA CCT 
 
 
 
            G   E   N   K   T   P   G   E   N   K   T   P   G   E   N   K   T  
           GGC GAA AAT AAA ACA CCT GGG GAA AAT AAA ACA CCT GGC GAA AAT AAA ACA 
       205 GGC GAA AAT AAA ACA CCT GGG GAA AAT AAA ACA CCT GGC GAA AAT AAA ACA 
 
 
            P   E   E   N   K   K   P   E   E   N   K   K   P   G   G   E   S  
           CCT GAG GAA AAC AAA AAA CCT GAG GAA AAT AAA AAA CCT GGG GGA GAA TCA 
       256 CCT GAG GAA AAC AAA AAA CCT GAG GAA AAT AAA AAA CCT GGG GGA GAA TCA 
 
 
            D   S   D   I   N   P   R   I   P   H   D   D  
           GAT TCA GAT ATA AAC CCA AGA ATT CCG CAT GAT GAC  3’  PG45b 
       307 GAT TCA GAT ATA AAC CCA AGA ATT CCG CAT GAT GAC  
                                         vspA-R2  
 
Figure 3.4: Sequence alignment of the TAAHL M. bovis PG45 type strain 5’-vspA amplicond 
with the same region of the Genbank M. bovis PG45 type strain vspA
b
 sequence. 
a
Genbank M. bovis PG45 type strain VspA amino acid sequence, 
b
Genbank M. bovis PG45 type strain vspA 
gene nucleotide sequence (accession number L81118.1, 
c
TAAHL M. bovis PG45 type strain 5’-vspA 
amplicon generated by PCR using the oligonucleotide primers vspA-F1 and vspA-R2. Spaces were 
introduced as indicated by a ‘-’ to facilitate sequence alignment. Each PGENKT amino acid repeat is 
highlighted by the boxed regions.  
The oligonucleotide primer (vspA-F1 and vspA-R2) binding sites are underlined. The entire 5’-vspA 
amplicon contains a total of 306 bp inclusive of the primer binding sites. When compared to the same region 
of the vspA gene for the Genbank M. bovis PG45 type strain the 5’-vspA amplicon generated here is missing 
a 12 amino acid (36 bp) section consisting of two PGENKT repeats. 
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Figure 3.5: Agarose gel electrophoresis of PCR reaction products using whole cells from transformed One Shot

 Mach1
TM
-T1
R
 E. coli colonies 
as DNA template. 
a) PCR reaction products using the oligonucleotide primer pair vspA-R2 and Sumo forward. The expected product size is 410 bp (vspA-R2 = 306 bp + 
SUMO forward = 104 bp). Colonies showing evidence of transformed plasmids correctly ligated with the 5’-vspA gene insert are indicated by the 
arrow. Lane 1, 1 Kb+ DNA ladder; Lanes 2 – 5, colonies (pvspA1, pvspA2, pvspA3, pvspA4) selected from the 1:1 ligation reaction 50 µl plate; Lanes 
6 – 8, colonies (pvspA5, pvspA6, pvspA7) selected from the 1:1 ligation reaction 150 µl plate; Lanes 9 – 12, colonies (pvspA8, pvspA9, pvspA10, 
pvspA11) selected from the 1:3 ligation reaction 50 µl plate; Lanes 13 – 15, colonies (pvspA12, pvspA13, pvspA14) selected from the 1:3 ligation 
reaction 150 µl plate. 
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Figure 3.5 cont: Agarose gel electrophoresis of PCR reaction products using whole cells from transformed One Shot

 Mach1
TM
-T1
R
 E. coli 
colonies as DNA template. 
b) PCR reaction products using the oligonucleotide primer pair vspA-F1 and T7 reverse. The expected product size is 454 bp (vspA-F1 = 306 bp + T7 
reverse = 148 bp). Colonies showing evidence of transformed plasmids correctly ligated with the 5’-vspA gene insert are indicated by the arrow. Lane 
1,1 Kb+ DNA ladder; Lanes 2 – 5, colonies (pvspA1, pvspA2, pvspA3, pvspA4) selected from the 1:1 ligation reaction 50 µl plate; Lanes 6 – 8, 
colonies (pvspA5, pvspA6, pvspA7) selected from the 1:1 ligation reaction 150 µl plate; Lanes 9 – 12, colonies (pvspA8, pvspA9, pvspA10, pvspA11) 
selected from the 1:3 ligation reaction 50 µl plate; Lanes 13 – 15, colonies (pvspA12, pvspA13, pvspA14) selected from the 1:3 ligation reaction 
150 µl plate..  
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3.3.3.  Sequence analysis of ligated pET SUMO plasmids 
Plasmid DNA obtained from two colonies of transformed One Shot Mach1TM-T1R E. coli cells 
showing evidence of correct 5’-vspA pET SUMO plasmid orientation were selected for further 
analysis using direct sequencing to ensure the 5’-vspA plasmid insert was in frame prior to 
expression of the protein. Plasmid DNA from two colonies (pvspA7, lane 8; Figure 3.5) and 
(pvspA9, lane 10; Figure 3.5) were used as template. The nucleotide sequences obtained from both 
the pvspA7 and pvspA9 ligated pET SUMO plasmid clones were aligned with the complete 
nucleotide sequence for the pET SUMO plasmid vector, and with the 5’-vspA amplicon nucleotide 
sequence obtained (Figure 3.4) was inserted at the SUMO cleavage site. The nucleotide sequences 
obtained from the pvspA7 and pvspA9 were identical and in frame with the SUMO reading frame 
of the vector. The entire pET SUMO 5’-vspA fusion protein was 675 bp in length, translating to a 
protein of 225 amino acid residues with an estimated molecular weight of 25 kDa. 
3.3.4.  Protein Expression 
The pvspA9 plasmid was selected at random and used for expression and transformed into One 
Shot
 
BL21 (DE3) chemically competent E. coli cells. The solubility and molecular weight of the 
protein of interest was assessed in both IPTG induced and un-induced cell cultures at hourly 
intervals for a total of 5 hr using SDS-PAGE analysis (Figure 3.6). The concentration of an induced 
protein was found to increase with time in the soluble fraction of the IPTG induced cell cultures and 
ran at a molecular weight of approximately 35-37 kDa (Figure 3.6). 
3.3.5  Ni - NTA purification of soluble fraction 
Purification of the induced protein revealed that the majority of the protein of interest was eluted in 
the first and second elutates (Figure 3.7). To ensure the purified protein is in fact the SUMO-vspA9 
fusion protein, WB using a His-tag mouse MAb was performed (Figure 3.8). 
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Figure 3.6: SDS-PAGE analysis of soluble and insoluble total protein fractions over a 5 hr period from IPTG induced and un-induced BL21 
(DE3) E. coli cells containing the pvspA9 pET SUMO plasmid.  
The expressed protein of interest (SUMO-vspA9) is evident by an estimated 36 kDa band of increasing intensity over time in the IPTG induced soluble 
protein fraction. Lanes 1 and 26, Molecular weight marker; Lane 2, 0 hr un-induced soluble protein fraction; Lane 3, 0 hr un-induced insoluble protein 
fraction; Lane 4, 0 hr IPTG induced soluble protein fraction; Lane 5, 0 hr IPTG induced insoluble protein fraction; Lane 6, 1 hr un-induced soluble 
protein fraction; Lane 7, 1 hr un-induced insoluble protein fraction; Lane 8, 1 hr IPTG induced soluble protein fraction; Lane 9, 1 hr IPTG induced 
insoluble protein fraction; Lane 10, 2 hr un-induced soluble protein fraction; Lane 11, 2 hr un-induced insoluble protein fraction; Lane 12, 2 hr IPTG 
induced soluble protein fraction; Lane 13, 2 hr IPTG induced insoluble protein fraction; Lane 14, 3 hr un-induced soluble protein fraction; Lane 15, 3 
hr un-induced insoluble protein fraction; Lane 16, 3 hr IPTG induced soluble protein fraction; Lane 17, 3 hr IPTG induced insoluble protein fraction; 
Lane 18, 4 hr un-induced soluble protein fraction; Lane 19, 4 hr un-induced insoluble protein fraction; Lane 20, 4 hr IPTG induced soluble protein 
fraction; Lane 21, 4 hr IPTG induced insoluble protein fraction; Lane 22, 5 hr un-induced soluble protein fraction; Lane 23, 5 hr un-induced insoluble 
protein fraction; Lane 24, 5 hr IPTG induced soluble protein fraction; Lane 25, 5 hr IPTG induced insoluble protein fraction.  
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Figure 3.7: SDS-PAGE analysis of Ni-NTA purification of the IPTG induced soluble protein fraction from BL21 (DE3) E. coli cells containing 
the pvspA9 pET-SUMO plasmid vector. 
Lane 1, Molecular weight marker; Lane 2, Ni-NTA spin column soluble protein flow through; Lanes 3 – 5, Ni-NTA spin column washes 1, 2 and 3 
respectively; Lanes 6 -10, Ni-NTA spin column eluates 1, 2, 3, 4 and 5 respectively showing the SUMO-vspA9 fusion protein of interest running at an 
estimated molecular weight of 36 kDa. 
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Figure 3.8: Immunoreactivity of the Ni-NTA purified SUMO-vspA9 fusion protein with a His-
tag mouse monoclonal antibody. 
Lane 1, approximately 10 µg of Ni-NTA purified SUMO-vspA9 protein eluate was separated by 
SDS-PAGE and transferred to a nitrocellulose membrane. A western blot was performed using the 
primary antibody (His-tag mouse MAb, Cell Signalling) diluted 1:1,000 in 5% (w/v) blotto TBST 
and visualised using chemiluminescence. Lane 2 shows a molecular weight marker. 
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3.3.6  Immunoreactivity of the SUMO-vspA9 fusion protein with mouse MAbs with Vsp 
specificity 
The immunoreactivity of the SUMO-vspA9 fusion protein was evaluated using the Vsp specific 
mouse MAbs described in Section 3.2.9 and Table 3.2. Of the MAbs with VspA specificity the 
SUMO-vspA9 fusion protein reacted with both 4D7 and 6E5, but not 1E5 (Figure 3.9). The level of 
possible cross-reactivity that may be occurring due to the SUMO portion of the fusion protein was 
assessed using a pET SUMO-chloramphenicol acetyl transferase (CAT) fusion protein produced in 
the same manner as the SUMO-vspA9 fusion protein. There was no immunoreactivity evident using 
the same mouse MAb’s against the SUMO-CAT fusion protein (Figure 3.9). 
3.3.7  Immunoreactivity of bovine sera and Bio-X Diagnostics

 control sera to the SUMO-
vspA9 fusion protein. 
The immunoreactivity of the SUMO-vspA9 fusion protein was assessed using bovine sera from 
M. bovis experimental infection trials and control sera from commercially available M. bovis 
ELISA kits as described in Section 2.1. The individual WBs for each serum sample from the four 
different sources, APCAH, VIDO-InterVac, AHVLA and Bio-X Diagnostics

 are discussed 
separately by source below. 
3.3.7.1  Qualitative classification of immunoreactivity to the SUMO-vspA9 fusion protein 
The level of immunoreactivity of each sample to the SUMO-vspA9 fusion protein was assessed 
visually by the author and qualitatively categorised into six WB categories consisting of ‘no 
reactivity’ (0), ‘very low reactivity’ (1), ‘low reactivity’ (2), ‘medium reactivity’ (3), ‘high 
reactivity’ (4), and ‘very high reactivity’ (5) (Figure 3.10).  
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Figure 3.9: Western blot analyses of five mouse monoclonal antibodies with differing Vsp specificity. 
a) Shows the immunoreactivity of the mouse MAb’s to ~25 µg of Ni-NTA purified SUMO-vspA9 fusion protein: Lane 1, 2A8; Lane 2, 1E5; Lane 3, 
9F1; Lane 4, 4D7; Lane 5, 6E5. The mouse MAb 4D7 (lane 4) has been reported as having immunoreactivity to VspsA, B and C, while 6E5 (lane 5) 
has reported immunoreactivity to VspA only. The MAb 1E5 (lane 2) has immunoreactivity to the VspsA, B and C which is distinct from that of 4D7.  
b) Shows the lack of immunoreactivity of the same mouse MAb’s to ~25 µg of Ni-NTA purified SUMO-CAT fusion protein: Lane 1, 2A8; Lane 2, 
1E5; Lane 3, 9F1; Lane 4, 4D7 and Lane 5, 6E5. 
.
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Figure 3.10: Qualitative classification of immunoreactivity with the SUMO-vspA9 fusion 
protein. 
WB: Western blot. 
Lane 1, category 0: no reactivity (AHVLA339_7); Lane 2, category 1: very low reactivity 
(AHVLA339_14); Lane 3, category 2: low reactivity (AHVLA339_21); Lane 4, category 3: 
medium reactivity (AHVLA339_28); Lane 5, category 4: high reactivity (VIDO30_High); Lane 6, 
category 5: very high reactivity (SMYC13J16 Positive). 
 
3.3.7.2  Vaccine and Infectious Disease Organization International Vaccine Centre sera 
The immunoreactivity of the VIDO-InterVac sera ranged from no reactivity to a very high reactivity 
as shown in Figure 3.11. Samples taken from animals prior to experimental infection with M. bovis 
(n = 5), showed a varied response to the SUMO-vspA9 antigen. Three of these samples showed no 
reactivity (VIDO38_Negative, lane 5; VIDO19_Negative, lane 7 and VIDO21_Negative, lane 11); 
while two of the samples (VIDO30_Negative, lane 9 and VIDO20_Negative, lane 13) respectively 
showed low and very high reactivity with the SUMO-vspA9 fusion protein. In addition, not all pre-
infection sera were qualitatively categorised as WB category 0. 
The immunoreactivity of the samples defined by VIDO-InterVac as being of low and high antibody 
levels all reacted with the SUMO-vspA9 fusion protein (Table 3.4). The level of reactivity however, 
was not always consistent with the stated antibody level (Figure 3.11). 
. 
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Figure 3.11: Western blot analyses of the VIDO-InterVac sera with the SUMO-vspA9 fusion protein 
WB: Western blot. 
Each lane represents an individual 3 mm wide nitrocellulose membrane strip that was manually aligned at the time of exposure. The qualitative WB category 
assigned to each samples reactivity to the SUMO-vspA9 fusion protein is depicted above each individual strip. The samples depicted include: Lane 1, 
VIDO26_Low; Lane 2, VIDO29_High; Lane 3, VIDO25_High; Lane 4, VIDO18_High; Lane 5, VIDO38_Negative; Lane 6, VIDO38_Low; Lane 7, 
VIDO19_Negative; Lane 8, VIDO19_Low; Lane 9, VIDO30_Negative; Lane 10, VIDO30_High; Lane 11, VIDO21_Negative; Lane 12, VIDO21_Low; Lane 13, 
VIDO20_Negative; Lane 14, VIDO20_High; Lane 15, VIDO34_High. 
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Table 3.4: Summary of the qualitative WB reactivity categorisation to the SUMO-vspA9 
fusion protein for each of the VIDO-InterVac sera  
M. bovis exposure group Animal ID WB category 
Day 0 sera VIDO19_Negative 0 
 VIDO20_Negative 5 
 VIDO21_Negative 0 
 VIDO30_Negative 2 
 VIDO38_Negative 0 
Day 68 sera VIDO19_Low 2 
 VIDO21_Low 5 
 VIDO26_Low 5 
 VIDO38_Low 2 
 VIDO18_High 5 
 VIDO20_High 5 
 VIDO25_High 5 
 VIDO29_High 5 
 VIDO30_High 4 
 VIDO34_High 5 
WB: Western blot. 
The reactivity of bovine sera from animals collected pre- and post-experimental infection with 
M. bovis. The reactivity of each sera was qualitatively categorised into six WB categories consisting 
of: no reactivity (0), ‘very low reactivity’ (1), ‘low reactivity’ (2), ‘medium reactivity’ (3), ‘high 
reactivity’ (4), and ‘very high reactivity’ (5). A sample showing any reactivity with the SUMO-
vspA fusion protein was considered to be positive for M. bovis antibodies (shaded cells). 
 
3.3.7.3  Animal Health Veterinary Laboratories Agency sera 
The immunoreactivity of the AHVLA sera from the two AHVLA animals experimentally infected 
with M. bovis increased over time, with very low reactivity evident by day 14 after M. bovis 
challenge (Figure 3.12). Very low reactivity was also evident in the cut-off control sample, while 
the positive control sample showed very strong reactivity with the SUMO-vspA9 fusion protein 
(Figure 3.12). No reactivity was seen from sera collected from the control animals at any time. A 
comparison table of the AHVLA in-house ELISA results with WB categories is provided in Table 
3.5. 
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Figure 3.12: Western blot analyses of the AHVLA sera with the SUMO-vspA9 fusion protein  
WB: Western blot, POS: Positive control, COC: Cut-off control. 
Each lane represents an individual 3 mm wide nitrocellulose membrane strip that was manually aligned at the time of exposure. The qualitative WB 
category assigned to each samples reactivity to the SUMO-vspA9 fusion protein is depicted above each individual strip. The samples depicted include: 
Lane 1, AHVLA370_0; Lane 2, AHVLA370_7; Lane 3, AHVLA370_14; Lane 4, AHVLA370_21; Lane 5, AHVLA370_28; Lane 6, AHVLA304_0; 
Lane 7, AHVLA304_7; Lane 8, AHVLA304_14; Lane 9, AHVLA304_21; Lane 10, AHVLA304_28; Lane 11, AHVLA339_0; Lane 12, 
AHVLA339_7; Lane 13, AHVLA339_14; Lane 14, AHVLA339_21; Lane 15, AHVLA339_28; Lane 16, AHVLA_positive control; Lane 17, 
AHVLA_cut-off control. 
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Table 3.5: Comparison of the AHVLA in-house M. bovis ELISA optical density reading 
results with the qualitative western blot categorisation for the reactivity to the SUMO-vspA9 
fusion protein for each of the AHVLA sera  
M. bovis exposure group Animal ID 
AHVLA in-house 
ELISA result 
WB category 
Control AHVLA370_0 0.13 0 
 AHVLA370_7 0.13 0 
 AHVLA370_14 0.09 0 
 AHVLA370_21 0.09 0 
 AHVLA370_28 0.11 0 
Challenged AHVLA304_0 0.08 0 
 AHVLA304_7 0.14 1 
 AHVLA304_14 0.22 1 
 AHVLA304_21 0.38 2 
 AHVLA304_28 0.54 2 
 AHVLA339_0 0.13 0 
 AHVLA339_7 0.06 0 
 AHVLA339_14 0.33 1 
 AHVLA339_21 1.23 2 
 AHVLA339_28 1.44 3 
AHVLA in-house ELISA 
control samples  
AHVLA_Cut-off 
control 
1 1 
AHVLA_Positive 
control 
0.3 5 
AHVLA: Animal Health and Veterinary Laboratories Agency; ELISA: Enzyme-linked immunosorbent 
assay; WB: Western blot. 
The reactivity of bovine sera from animals collected pre- and post-experimental infection with M. bovis. The 
reactivity of each sera was qualitatively categorised into six WB categories consisting of: no reactivity (0), 
‘very low reactivity’ (1), ‘low reactivity’ (2), ‘medium reactivity’ (3), ‘high reactivity’ (4), and ‘very high 
reactivity’ (5). A sample showing any reactivity with the SUMO-vspA fusion protein was considered to be 
positive for M. bovis antibodies (shaded cells). The AHVLA in-house M. bovis ELISA optical density 
readings supplied by AHVLA (Table 2.5) have been included so that a comparison of the WB category result 
can be made for each sample. An AHVLA in-house M. bovis optical density reading ≥ 0.3 is considered 
positive for M. bovis antibody.  
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3.3.7.4  Bio-X Diagnostics

M. bovis ELISA kit control sera 
The individual reactivity of control sera obtained from the three batches of the BioK302, four 
batches of the BioK260 and four batches of the pentavalent BioK284 ELISA kits to the SUMO-
vspA9 fusion protein are shown in Figure 3.13 and summarised in Table 3.6. In addition, the 
reactivity of all Bio-X Diagnostics

 sera to the SUMO-CAT fusion protein was assessed. All 
positive control sera showed reactivity SUMO-vspA9 while no reactivity was evident with any of 
the negative control sera tested. The reactivity of the pentavalent BioK284 positive control sera was 
less than the BioK302 and BioK260 positive control sera. The pentavalent BioK284 positive 
control sera were the only Bio-X Diagnostics

 sera to react with the SUMO-CAT fusion protein 
(Figure 3.14). No reactivity to the SUMO-CAT fusion protein was seen with any of the BioK302 or 
BioK260 positive or negative control sera. 
3.3.7.5  Asia-Pacific Centre for Animal Health sera 
The immunoreactivity of the APCAH sera are shown in Figure 3.15. Overall the immunoreactivity 
of the APCAH sera with the SUMO-vspA9 fusion protein was reduced in comparison to samples 
obtained from VIDO-InterVac, AHVLA and Bio-X Diagnostics

 M. bovis ELISA kits. Of the day 0 
samples from the APCAH M. bovis challenge group (n = 30); three showed reactivity with the 
SUMO-vspA9 fusion protein. When the day 24 samples were assessed, 18 showed some level of 
reactivity with the SUMO-vspA9 fusion protein. None of the APCAH M. bovis control group 
(n = 5) of animals had sera at either day 0 or day 24 that reacted with the SUMO-vspA9 fusion 
protein. There was no obvious correlation between the level of reactivity to the SUMO-vspA9 
fusion protein and the APCAH in-house M. bovis antibody titres (Table 3.7).  
A total of 16 paired APCAH sera (day 0 and day 24 from the same animal) were assessed for cross-
reactivity to the SUMO-CAT fusion protein. The WB results are shown in Figure 3.16 and a 
comparison of these results with those from the APCAH in-house M. bovis ELISA and SUMO-
vspA9 WB reactivity is provided in Table 3.7. Seven of the day 0 sera (two from the control group) 
and ten of the day 24 sera (one from the control group) showed reactivity with the SUMO-CAT 
fusion protein. The level of reactivity did not seem to be correlated with that seen using the SUMO-
vspA9 fusion protein. There were a number of sera that showed no reactivity to the SUMO-vspA9 
protein however had obvious reactivity with the SUMO-CAT fusion protein. 
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Table 3.6: Summary of the qualitative western blot categorisation for the reactivity of each 
Bio-X Diagnostics

 M. bovis ELISA kit control sera to the SUMO-vspA9 fusion protein 
Bio-X Diagnostics

 M. bovis ELISA kit control 
sera 
ELISA batch No. WB category 
Negatives 
  
BioK302 MYC14C04 0 
 MYC13K26 0 
 MYC13J16 0 
   
BioK260 SMYC14C04 0 
 SMYC13K26 0 
 SMYC13J16 0 
 SMYC09I28 0 
Positives  
 
BioK302 MYC14C04 5 
 MYC13K26 5 
 MYC13J16 5 
   
BioK260 SMYC14C04 5 
 SMYC13K26 5 
 SMYC13J16 5 
 SMYC09I28 5 
   
BioK284 (pentavalent) IBRPM12F04 3 
 IBRPM12K08 3 
 IBRPM12F28 3 
 IBRPM09L01 3 
ELISA: Enzyme-linked immunosorbent assay; WB: Western blot. 
The reactivity of control sera from commercial M. bovis ELISA kits with the SUMO-vspA9 fusion 
protein was assessed. The reactivity of each control sample was qualitatively categorised into six 
categories consisting of: no reactivity (0), ‘very low reactivity’ (1), ‘low reactivity’ (2), ‘medium 
reactivity’ (3), ‘high reactivity’ (4), and ‘very high reactivity’ (5). Sample results considered 
positive for M. bovis antibody are shaded.   
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Table 3.7: Comparison of the APCAH in-house M. bovis antibody titre, qualitative WB 
reactivity categorisation to the SUMO-vspA9 fusion protein and evidence of reactivity to the 
SUMO-CAT fusion protein for the APCAH sera  
M. bovis 
exposure 
group 
Animal ID 
APCAH in-house 
M. bovis antibody titre 
WB category 
SUMO-CAT 
reactivity 
Day 0 Day 24 Day 0 Day 24 Day 0 Day 24 
Control APCAH13 30.18 20.22 0 0 Yes Yes 
 APCAH24 38.08 50.42 0 0 Yes No 
 APCAH30 13.16 7.74 0 0 No No 
 APCAH43 14.28 16.85 0 0 NA NA 
 APCAH71 26.06 17.24 0 0 NA NA 
        
Challenged APCAH3 20.63 186.12 0 0 No No 
 APCAH5 13.83 109.24 0 1 No Yes 
 APCAH7 9.82 16.97 0 1 No No 
 APCAH8 4.75 52.68 0 2 No No 
 APCAH9 30.06 250.52 0 2 Yes Yes 
 APCAH10 22.46 376.8 0 1 Yes Yes 
 APCAH18 22.67 32.98 0 1 Yes Yes 
 APCAH20 9.75 93.08 0 1 No Yes 
 APCAH21 11.96 67.96 0 2 No Yes 
 APCAH22 14.32 114.19 0 3 No No 
 APCAH23 28.15 571.84 1 4 Yes Yes 
 APCAH26 6.42 1,222.20 0 3 Yes Yes 
 APCAH31 20.51 200.42 0 0 No Yes 
 APCAH32 39.82 986.98 1 3 NA NA 
 APCAH34 19.4 237.86 0 0 NA NA 
 APCAH35 43.43 1,222.20 0 2 NA NA 
 APCAH36 13.09 115.6 0 0 NA NA 
 APCAH45 31.58 236.67 0 0 NA NA 
 APCAH46 14.35 170.42 0 0 NA NA 
 APCAH48 22.98 571.84 2 1 NA NA 
 APCAH49 8.06 403.51 0 0 NA NA 
 APCAH51 38.73 392.33 0 0 NA NA 
 APCAH52 30.52 281.68 0 0 NA NA 
 APCAH53 20.4 301.19 0 0 NA NA 
 APCAH54 13.28 247.22 0 1 NA NA 
 APCAH57 22.84 99.06 0 2 NA NA 
 APCAH60 5.32 451.57 0 0 NA NA 
 APCAH62 26.24 103.82 0 1 NA NA 
 APCAH63 18.83 183.65 0 0 NA NA 
 APCAH64 10.77 508.45 0 1 NA NA 
APCAH: Asia Pacific Centre for Animal Health; NA: Not assessed; WB: Western blot. 
The reactivity sera collected from animals’ pre- and post-experimental infection with M. bovis with the SUMO-vspA9 
and SUMO-CAT fusion proteins were assessed. The reactivity of each sera was qualitatively categorised into six WB 
categories consisting of: no (0), ‘very low’ (1), ‘low’ (2), ‘medium’ (3), ‘high’ (4), and ‘very high’ (5)  reactivity. Sera 
considered positive for M. bovis antibody are shaded grey while sera showing reactivity to the SUMO-CAT fusion 
protein are shaded green. The APCAH considers a titre ≥ 65 to be sero-positive for M. bovis antibody.  
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Figure 3.13: Western blot analyses of the Bio-X Diagnostics

 sera to the SUMO-vspA9 fusion protein. 
WB: Western blot. 
Each lane represents an individual 3 mm wide nitrocellulose membrane strip that was manually aligned at the time of exposure. The qualitative WB 
category assigned to each samples reactivity to the SUMO-vspA9 fusion protein is depicted above each individual strip. The samples depicted include: 
Lane 1, SMYC09I28 Negative; Lane 2, SMYC09I28 Positive; Lane 3, MYC13K26 Negative; Lane 4, MYC13K26 Positive; Lane 5, SMYC13K26 
Negative; Lane 6, SMYC13K26 Positive; Lane 7, IBRPM12F04 Positive; Lane 8, IBRPM12F28 Positive; Lane 9, IBRPM09L01 Positive; Lane 10, 
IBRPM12K08 Positive; Lane 11, SMYC13J16 Negative; Lane 12, SMYC13J16 Positive; Lane 13, MYC13J16 Negative; Lane 14, MYC13J16 
Positive; Lane 15, SMYC14C04 Negative; Lane 16, SMYC14C04 Positive; Lane 17, MYC14C04 Negative; Lane 18, MYC14C04 Positive. 
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Figure 3.14: Western blot analyses of the pentavalent BioK284 sera to the SUMO-CAT fusion 
protein. 
Each lane represents an individual 3 mm wide nitrocellulose membrane strip that was manually 
aligned at the time of exposure. The positive control sera from the pentavalent BioK284 ELISA kit 
were the only Bio-X Diagnostics

 sera to show reactivity with the SUMO-CAT fusion protein: 
Lane 1, IBRPM12F04 Positive; Lane 2, IBRPM12F28 Positive; Lane 3, IBRPM09L01 Positive; 
Lane 4, IBRPM12K08 Positive.  
 
 
 
 
Figure 3.15: Western blot analyses of the APCAH samples to the SUMO-vspA9 fusion 
protein. 
WB: Western blot. 
* Indicates a day 24 sample from an M. bovis negative control animal.  
Each lane represents an individual 3 mm wide nitrocellulose membrane strip that was manually 
aligned at the time of exposure. The qualitative WB category assigned to each samples reactivity to 
the SUMO-vspA9 fusion protein is depicted above each individual strip. The samples depicted are:  
a) Lane 1, APCAH63_0; Lane 2, APCAH63_24; Lane 3, APCAH64_0; Lane 4, APCAH64_24; 
Lane 5, APCAH71_0; Lane 6, APCAH71_24*.
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Figure 3.15 cont.: Western blot analyses of the APCAH samples to the SUMO-vspA9 fusion protein. 
WB: Western blot. 
* Indicates a day 24 sample from an M. bovis negative control animal.  
Each lane represents an individual 3 mm wide nitrocellulose membrane strip that was manually aligned at the time of exposure. The qualitative WB 
category assigned to each samples reactivity to the SUMO-vspA9 fusion protein is depicted above each individual strip. The samples depicted are:  
b) Lane 1, APCAH3_0; Lane 2, APCAH3_24; Lane 3, APCAH5_0; Lane 4, APCAH5_24; Lane 5, APCAH7_0; Lane 6, APCAH7_24; Lane 7, 
APCAH8_0; Lane 8, APCAH8_24; Lane 9, APCAH9_0; Lane 10, APCAH9_24; Lane 11, APCAH10_0; Lane 12, APCAH10_24; Lane 13, 
APCAH13_0; Lane 14, APCAH13_24*; Lane 15, APCAH18_0; Lane 16, APCAH18_24; Lane 17, APCAH20_0; Lane 18, APCAH20_24; Lane 19, 
APCAH21_0; Lane 20, APCAH21_24; Lane 21, APCAH22_0; Lane 22, APCAH22_24. 
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Figure 3.15 cont.: Western blot analyses of the APCAH samples to the SUMO-vspA9 fusion protein. 
WB: Western blot. 
* Indicates a day 24 sample from an M. bovis negative control animal.  
Each lane represents an individual 3 mm wide nitrocellulose membrane strip that was manually aligned at the time of exposure. The qualitative WB 
category assigned to each samples reactivity to the SUMO-vspA9 fusion protein is depicted above each individual strip. The samples depicted include:  
c) Lane 1, APCAH23_0; Lane 2, APCAH23_24; Lane 3, APCAH24_0; Lane 4, APCAH24_24*; Lane 5, APCAH26_0; Lane 6, APCAH26_24; Lane 
7, APCAH30_0; Lane 8, APCAH30_24*; Lane 9, APCAH31_0; Lane 10, APCAH31_24; Lane 11, APCAH32_0; Lane 12, APCAH32_24; Lane13, 
APCAH34_0; Lane 14, APCAH34_24; Lane 15, APCAH35_0; Lane 16, APCAH35_24; Lane 17, APCAH36_0; Lane 18, APCAH36_24; Lane19, 
APCAH43_0; Lane 20, APCAH43_24*; Lane 21, APCAH45_0; Lane 22, APCAH46_24. 
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Figure 3.15 cont.: Western blot analysis of the APCAH samples to the SUMO-vspA9 fusion protein. 
WB: Western blot. 
Each lane represents an individual 3 mm wide nitrocellulose membrane strip that was manually aligned at the time of exposure. The qualitative WB 
category assigned to each samples reactivity to the SUMO-vspA9 fusion protein is depicted above each individual strip. The samples depicted include:  
d) Lane 1, APCAH46_0; Lane 2, APCAH45_24; Lane 3, APCAH48_0; Lane 4, APCAH48_24; Lane 5, APCAH49_0; Lane 6, APCAH49_24; Lane 7, 
APCAH51_0; Lane 8, APCAH51_24; Lane 9, APCAH52_0; Lane 10, APCAH52_24; Lane 11, APCAH53_0; Lane 12, APCAH53_24; Lane 13, 
APCAH54_0; Lane 14, APCAH54_24; Lane 15, APCAH57_0; Lane 16, APCAH57_24; Lane 17, APCAH60_0; Lane 18, APCAH62_0; Lane 19, 
APCAH60_24; Lane 20, APCAH62_24. 
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Figure 3.16: Western blot analyses of the APCAH samples to the SUMO-CAT fusion protein. 
* Indicates a day 24 sample from an M. bovis negative control animal.  
Each lane represents an individual 3 mm wide nitrocellulose membrane strip that was manually 
aligned at the time of exposure. The reactivity of day 0 (n = 16) and day 24 (n = 16) Asia-Pacific 
Centre for Animal Health bovine sera with the SUMO-CAT fusion protein is shown in the figures 
above.  
a): Lane 1, APCAH9_0; Lane 2, APCAH9_24; Lane 3, APCAH10_0; Lane 4, APCAH10_24; Lane 
5, APCAH13_0; Lane 6, APCAH13_24*; Lane 7, APCAH18_0; Lane 8, APCAH18_24; Lane 9, 
APCAH3_0; Lane 10, APCAH3_24; Lane 11, APCAH5_0; Lane 12, APCAH5_24; Lane 13, 
APCAH7_0; Lane 14, APCAH7_24; Lane 15, APCAH8_0; Lane 16, APCAH8_24. 
b): Lane 1, APCAH20_0; Lane 2, APCAH20_24; Lane 3, APCAH21_0; Lane 4, APCAH21_24; 
Lane 5, APCAH22_0; Lane 6, APCAH22_24; Lane 7, APCAH23_0; Lane 8, APCAH23_24; Lane 
9, APCAH24_0; Lane 10, APCAH24_24*; Lane 11, APCAH26_0; Lane 12, APCAH26_24; Lane 
13, APCAH30_0; Lane 14, APCAH30_24*; Lane 15, APCAH31_0; Lane 16, APCAH31_24. 
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3.4  Discussion 
In this study a recombinant M. bovis protein containing the VspA RA1 motif was expressed in 
E. coli, purified and used as antigen in WB. Using sera collected from animals of known M. bovis 
infection status and control sera obtained from commercial ELISA kits, the use of this recombinant 
M. bovis protein for the detection of M. bovis antibody in sera was assessed. Differences in the level 
of immunoreactivity were evident among the sera sourced from the APCAH in comparison to those 
sourced from VIDO-InterVac and AHVLA. Differences in the immunoreactivity of positive control 
sera from the pentavalent BioK284 in comparison to the BioK302 and BioK260 positive control 
sera were also evident in the current study. In Chapter 4 the Se and Sp of WB using the SUMO-
vspA fusion protein developed in this study will be assessed. The focus of this discussion will be on 
the development of the protein itself and its potential use in WB analyses for the detection of 
M. bovis serum antibody. 
Immunological assays applied to individuals or populations have many purposes. They aid in 
documenting freedom from disease in a country or region, preventing spread of disease through 
trade, contributing to eradication of an infection from a region or country, confirming diagnosis of 
clinical cases, estimating infection prevalence to facilitate risk analysis, identifying infected animals 
toward implementation of control measures, and classifying animals for herd health or immune 
status post-vaccination. Development of these methods requires thorough validation and 
optimisation to ensure the results obtained are reliable, repeatable and interpreted correctly for the 
intended purpose. The first step in the development process is to clearly define the purpose of the 
method. Secondly, test validation requires careful consideration of variables that can affect the 
performance of the test such as: (a) the sample being tested and host / organism interactions; (b) the 
detection method and operator-related factors that may affect the capacity of the test to detect the 
specific analyte in the sample; and (c) the test result interpretation and capacity of the test to 
accurately predict the status of the individual or population relative to the purpose for which the test 
is applied. Finally, optimisation of the test ensures the performance characteristics are best suited 
for its intended application. This process is labour-intensive but is fundamental and critical to 
achieving a reliable and predictable test performance (OIE World Organisation for Animal Health., 
2013).  
In the current study, the aim was not to develop a new serological diagnostic test but to assess the 
use of a truncated portion of the VspA protein containing the RA1 motif in WB analyses for the 
detection of M. bovis specific antibody. Western blotting is time consuming, labour intensive and 
costly and for these reasons is not ideal to use for routine diagnostic purposes, especially when large 
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numbers of samples need to be tested. However, because WB allows the visualisation of a specific 
antigen-antibody reaction, results obtained in the current study were used to compare results 
obtained using the commercially available M. bovis ELISAs described in Chapter 4. The portion of 
the VspA protein containing the RA1 motif was identified by Brank et al. (1999) and shown to have 
good immunoreactivity in both field and experimental settings. Thorough validation and 
optimisation of the protein used in this study was not performed. Had the aim been to assess the 
antigen for use in a serological method more suited for routine testing of samples, such as ELISAs, 
then the criteria for assay development and validation should have been performed (OIE World 
Organisation for Animal Health., 2013).  
The SUMO-vspA9 fusion protein developed in this study ran at an approximate molecular weight 
of 35 kDa. This was in contrast to the estimated molecular weight of 25 kDa. It has been reported in 
the associated literature that the Vsps exhibit ‘abnormal migration’ in SDS-PAGE gels (Lysnyansky 
et al., 1999). This appears to be an unusual feature displayed by the known Vsps and generates 
significant discrepancies between the molecular weights calculated from the deduced sequences and 
the molecular masses estimated for the proteins using SDS-PAGE (Lysnyansky et al., 1999). In 
addition the presence of a His-tag and highly repetitive amino acid sequences in a protein can affect 
the migration of proteins in SDS-PAGE gels (Lin et al., 2011), causing them to run at a higher 
estimated molecular weight than that deduced from the sequence. 
Cleavage from the SUMO fusion partner was attempted, however recovery of sufficient 5’-VspA 
cleaved protein for use in WB was not achieved in the current study (data not shown). When 
cleaved, the SUMO fusion partner and the recombinant 5’VspA protein portion had estimated 
molecular weights of approximately the same size of around 13 kDa. Consequently, in the current 
study visualisation of separate bands for the SUMO and 5’-VspA cleaved proteins using SDS-
PAGE was not achieved. A possible complication arising from using a non-cleaved antigen in WB 
analyses is reduced ASp due to cross-reactivity with antibodies present in the sera with residual 
E. coli proteins and or the SUMO (derived from yeast) fusion partner. The potential for cross-
reactivity was investigated using a SUMO-CAT fusion protein as antigen. The immunoreactivity of 
the Bio-X Diagnostics

 control samples and 32 (16 paired) APCAH sera were assessed. No 
reactivity of the BioK302 or BioK260 control sera (positive and negative) was visualised. However, 
reactivity of the BioK284 positive control sera to the SUMO-CAT fusion protein was seen. In fact 
the level of immunoreactivity of the four BioK284 sera with the SUMO-CAT fusion partner was 
more pronounced than that seen to the SUMO-vspA9 fusion protein. Reactivity to the SUMO-CAT 
fusion protein was also evident among some of the APCAH sera assessed, and again, reactivity was 
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more pronounced with some sera (Figure 3.15, Figure 3.16 and Table 3.7). The reactivity of the 
APCAH sera assessed against the SUMO-CAT antigen was not consistent with some sera showing 
no reactivity to the SUMO-vspA9 fusion protein but obvious reactivity with the SUMO-CAT fusion 
protein, and vise versa (Table 3.7). Because of this it is believed that these sera were cross-reacting 
with the CAT portion of the fusion protein and not the SUMO portion. The author acknowledges 
that further work is still required to completely rule out the possibility of cross-reactivity associated 
with the SUMO portion of the SUMO-vspA9 fusion protein. 
Recent publications by Wawegama et al. (2014) and Sun et al. (2014) have reported non-Vsp 
M. bovis proteins that may have potential for use in a diagnostic setting. Mycoplasma immunogenic 
lipase A (MilA), a membrane protein with lipase activity was identified and shown to be 
consistently detected in WB by antibodies in sera from calves experimentally infected with a single 
strain of M. bovis (Wawegama et al., 2014). While Sun et al. (2014) identified a number of 
immunogenic proteins of which one, pyruvate dehydrogenase E1 component beta subunit (PDHB), 
showed excellent immune reactivity and repeatability using an indirect ELISA (Sun et al., 2014). 
The identification of these proteins is promising in terms of sero-diagnosis of M. bovis 
infections,however further validation of these proteins in the test populations they are to be used in 
is necessary. 
In the current study, all Bio-X Diagnostics

 positive control sera supplied with ELISA kits for the 
detection of M. bovis antibody reacted with the SUMO-vspA9 fusion protein (Figure 3.13, Table 
3.6). Of the sera collected from animals’ post-experimental infection; reactivity to the SUMO-
vspA9 fusion protein was most evident among sera sourced from the VIDO-InterVac and AHVLA. 
All VIDO-InterVac sera collected from animals 68 days and all AHVLA sera collected from 
animals 14 or more days following experimental infection with M. bovis showed immunoreactivity 
to the SUMO-vspA9 fusion protein using WB (Figure 3.11; Table 3.4 and Figure 3.12; Table 3.5 
respectively). Meanwhile the post-experimental infection sera sourced from the APCAH appeared 
in the present study to stand out from those sourced from AHVLA and VIDO-InterVac. The 
reactivity of these sera in comparison to those sourced from AHVLA and VIDO-InterVac was 
inconsistent and reduced (Figure 3.15). These sera were collected from animals 24 days following 
experimental infection with an M. bovis strain which in theory should be sufficient time post 
exposure to detect M. bovis IgG antibody in sera. However, in contrast to the post-infection sera 
sourced from VIDO-InterVac and AHVLA, only 60% (n = 18) of the APCAH sera had evidence of 
reactivity to the SUMO-VspA9 fusion protein following M. bovis challenge. There are a number of 
possible reasons why the post-infection sera sourced from APCAH showed reduced reactivity to the 
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SUMO-vspA9 fusion protein in comparison to those sourced from AHVLA and VIDO-InterVac. 
The age of the animals could be a contributing factor, even though the AHVLA animals are of 
similar age. It has been documented that the presence of maternal antibody in young calves can lead 
to false positive serology results (Arcangioli et al., 2008). The choice of infective M. bovis strain is 
also a factor to consider. Unfortunately there is no information why the particular M. bovis strain 
3683 used by APCAH in this experimental infection trial was chosen. Nor is there any information 
in the associated literature on the pathogenicity or antigenicity of the M. bovis strain 3683. If the 
APCAH M. bovis strain 3683 lacks or does not consistently express VspA or the portion containing 
the RA1 motif, then false positive results using the SUMO-vspA9 antigen are more than likely to 
occur. This highlights the importance of the choice of antigen used in immunological detection 
methods. Ideally the antigen has to be consistently expressed across all M. bovis strains and isolates.     
None of the Bio-X Diagnostics

 negative control sera or AHVLA pre-infection / control animal 
sera showed immunoreactivity with the SUMO-vspA9 fusion protein. Of the pre-infection sera 
sourced from VIDO-InterVac and APCAH, two of the VIDO-InterVac (Table 3.4) and three of the 
APCHA presumed sero-negative sera (Table 3.6) did show reactivity with the SUMO-vspA9 fusion 
protein in WB (Figure 3.11 and Figure 3.15 respectively). Cross-reactivity with residual E. coli 
proteins or the SUMO portion of the fusion protein cannot be completely disregarded and offer 
possible explanation for the ‘false positive’ WB results. Meanwhile, in regards to the APCAH sera 
because of the age of the animals in this trial the presence of maternal antibody could explain the 
immunoreactivity seen with the SUMO-vspA9 fusion protein in this study. 
Western blotting is often regarded as a sensitive immunological method as it allows direct 
visualisation of the interaction between the antigen and antibody. Unfortunately, due to cost, time 
and labour constraints WB is not suitable for routine diagnostic purposes, especially when a large 
number of samples require testing. In this study WB was used experimentally to identify the 
presence of antibody in sera that reacted with a fusion protein containing the RA1 motif identified 
by Brank et al., (1999) and derived from the vspA gene. Bovine sera sourced from three M. bovis 
experimental infection trials in addition to sera supplied with commercial M. bovis ELISA kits were 
used to assess the immunoreactivity of the fusion protein with sera collected from animals of known 
M. bovis infection status. In Chapter 4, the Se and Sp of WB using the SUMO-VspA fusion protein 
developed here was assessed.   
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CHAPTER 4   Assessment of the performance of commercially available M. bovis 
ELISAs and western blotting 
4.1  Introduction  
The detection of antibodies using serological methods identifies the exposure status of an animal to 
M. bovis independently of clinical disease status. These methods offer a screening tool for 
researchers and clinicians, to determine whether M. bovis is circulating within a given herd or group 
of animals. There are a number of serological detection methods including enzyme-linked 
immunosorbent assays (ELISAs) that have been developed for the detection of M. bovis-specific 
antibody from bovine serum. They however, have a number of limitations which can affect the tests 
diagnostic Se and Sp and analytical Se (ASe) and analytical Sp (ASp), including:  
(i) many ELISAs are developed in-house and are not commercially available. Information on 
the diagnostic Se and Sp and ASe and ASp of these in-house ELISAs is not publically 
available making comparison of results between different methods difficult;  
(ii) some contain whole cell M. bovis antigens which can reduce ASp as cross-reactions to 
antibodies developed to other Mycoplasma spp. are possible; 
(iii) details on the M. bovis antigen(s) used in commercial ELISA kits are undisclosed. As a 
result these kits rely on the assumption that all animals are exposed (and develop antibodies) 
to M. bovis isolates that express the same M. bovis antigen used in the ELISA kit. This 
assumption unfortunately has the potential to reduce test Se as it is not known how common 
the antigen(s) used in these ELISAs are among M. bovis isolates in the population being 
tested; 
(iv) where a recombinant protein has been used and expression is facilitated by a fusion partner, 
both ASe and ASp of the test may be reduced. Non-specific cross-reactions can occur if the 
test population has been exposed to immunodeterminants that are the same or similar to 
those present in the fusion partner;  
(v) there is no parallel assay that can be used to determine the specific activity of serological 
samples to M. bovis to characterise reference sera. For example in virology, reference sera 
can be characterised using virus neutralising assays prior to use in ELISA validation; 
(vi) diagnostic Se and Sp and ASe and ASp estimates for commercially available M. bovis ELISA 
kits are not available. 
 
Consequently interpretation of serological test results is not straightforward and investigations into 
the prevalence and epidemiology of M. bovis are compromised. 
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Currently, in Australia, R-biopharm

 is the only distributor of commercially available M. bovis 
ELISA kits. These kits are manufactured by Bio-X Diagnostics

 in Belgium and contain an 
undisclosed recombinant M. bovis antigen expressed in E. coli (Bio-X Diagnostics
®
, 2013b). 
Purification and removal of residual E. coli proteins from the recombinant antigen being used in the 
test is necessary. Residual E. coli proteins have the potential to cross-react with other serum 
antibodies that may be present in the test sample if the animal has been exposed to this common 
agent. The potential consequence of this is a reduction in ASp. In addition the recombinant antigen 
needs to be immunogenic and antibodies specific to the antigen being used in the test need to be 
produced by the animal at a detectable level. If the amount of antibody produced does not exceed 
the limit of detection or the lowest antibody concentration that can be reliably distinguished from a 
truly negative sample, the ASe will be reduced (OIE World Organisation for Animal Health., 2013). 
Furthermore, the antibody needs to be produced by the animal following an evasive infection with 
M. bovis irrespective of the strain, disease condition and geographical region. If this is not the case, 
test Se will be reduced. 
The aim of the current study was to estimate the Se and Sp of WB using the SUMO-vspA9 fusion 
protein (Chapter 3) and two commercially available M. bovis ELISA kits from Bio-X Diagnostics

; 
the BioK302 and the BioK260. The Se and Sp estimates were calculated using serum collected from 
calves experimentally infected with M. bovis. Throughout this chapter, Se and Sp refer to measures 
in a diagnostic rather than analytical context unless otherwise stated. The BioK302 requires a single 
sample from an animal and is marketed as an ELISA kit to determine the immune status (sero-
positive or sero-negative) of an animal to M. bovis at the time the sample was collected (Bio-X 
Diagnostics
®
, 2013b). The BioK260 on the other hand, requires two serum samples from an 
individual animal collected two to three weeks apart and is marketed as an ELISA kit to indicate 
recent exposure of the animal to M. bovis. The manufacturer reports that the first sample must be 
collected during the acute phase of the infection. Exposure to M. bovis is considered to have 
occurred if the test result of the second sample is two categories as defined by the manufacturer 
higher than the first sample (Section 4.2.6.2) (Bio-X Diagnostics
®
, 2013a). In addition the kappa 
statistic was used to compare the performance of the BioK302 ELISA, BioK260 ELISA and WB 
methods. 
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4.2 Materials and methods 
4.2.1  Serum samples 
The serum samples used as reference sera collected from animals of known M. bovis infection 
status have been described in Section 2.1, though some samples (n = 10) were not included. There 
was insufficient volume of the VIDO38_Low sample to allow further testing. In addition, the 
samples taken from the three AHVLA animals at days 7, 14 and 21 (n = 9) were excluded as (i) 
only one pre-infection and one post-infection sample from each animal was required for analysis 
purposes, and (ii) to ensure the time interval post-infection of the samples from the experimental 
infection trials were as comparable as possible. With the exclusion of these, a total of 110 samples 
were used in the analyses for the determination of test Se and Sp. Samples tested consisted of 56 
sera considered to be from animals not exposed to M. bovis (49 from animals with no history of 
prior exposure to M. bovis and seven negative controls from Bio-X Diagnostics

 ELISA kits) and 
54 sera considered to be from animals exposed to M. bovis (43 sera from animals 24 to 68 days post 
experimental infection with M. bovis and 11 positive controls obtained from Bio-X Diagnostics

 
ELISA kits (Table 4.1). 
Table 4.1: Summary of M. bovis reference sera by source. 
Source 
No. pre-infection sera* 
(M. bovis non-exposed) 
No. post-infection sera 
(M. bovis exposed) 
Asia-Pacific Centre for Animal Health 40 30 
Vaccine and Infectious Disease 
Organization International Vaccine Centre 
5 9 
Animal Health and Veterinary Laboratories 
Agency 
4 4 
Bio-X Diagnostics
 7 11 
Total 56 54 
* Pre-infection samples include sera collected from animals prior to experimental infection with M. bovis in 
addition to subsequent samples collected from control animals. 
A total of 110 M. bovis reference sera were obtained from four sources comprising three Mycoplasma 
reference laboratories; the Asia-Pacific Centre for Animal Health, Australia; the Vaccine and Infectious 
Disease Organization International Vaccine Centre, Canada and the Animal Health and Veterinary 
Laboratories Agency, England. Control samples provided with commercial ELISA kits from Bio-X 
Diagnostics

 (Belgium), were also included. The sera were divided into two groups of M. bovis non-exposed 
and M. bovis exposed depending on the infection status of the animal from which they were derived, or the 
Bio-X Diagnostics

 control sample status.  
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Paired test sera collected prior to- and post- experimental infection with M. bovis were available 
from a total of 42 animals; 35 from APCAH, four from VIDO-InterVac and three from AHVLA 
(Table 4.2). These included six control animals that were not experimentally infected with M. bovis 
(five from APCAH and one from AHVLA). 
 
Table 4.2: Mycoplasma bovis experimental challenge paired serum samples used for the 
validation of the BioK302 and BioK260 ELISAs listed by source  
Source M. bovis exposure group No. paired sera 
Asia-Pacific Centre for Animal Health 
(APCAH), Australia 
Control 5 
Challenged 30 
 
  
Vaccine and Infectious Disease Organization 
International Vaccine Centre (VIDO-InterVac), 
Canada 
Control 0 
Challenged 4 
 
  
Animal Health and Veterinary Laboratories 
Agency (AHVLA), England 
Control 1 
Challenged 2 
Total  42 
Post-infection samples were collected from Asia-Pacific Centre for Animal Health animals 24 days; Vaccine 
and Infectious Disease Organization International Vaccine Centre animals 68 days and Animal Health and 
Veterinary Laboratories Agency animals 28 days after experimental infection with M. bovis. 
 
4.2.2  Western blotting 
Western blots for each M. bovis reference sera were obtained as described in Section 3.2.9. The 
immunoreactivity of each sample to the SUMO-vspA9 fusion protein has also been presented and 
described (Section 3.3.7), and qualitatively categorised (Section 3.3.7.1).  
For analysis purposes, the WB categories were dichotomised so that sera with no reactivity (WB 
category 0) were considered sero-negative for M. bovis. While sera showing very low (WB category 
1) through to very high (WB category 5) reactivity were considered sero-positive.  
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4.2.3  ELISA procedure 
All sera were tested using both the BioK302 and BioK260 ELISA kits as per the manufacturer’s 
instructions. Each sample was tested on both ELISA kits on the same day in parallel. Advice from 
Bio-X Diagnostics

 informed that the dilution buffer, wash buffer and stop solution supplied with 
both the BioK302 and BioK260 kits were the same (Delmont, 2013).  
All kit reagents for both ELISA kits were brought to room temperature before use. A 10 µl aliquot 
of test sample was diluted in 1 ml of dilution buffer in a dilution tube and the tube was capped. This 
was repeated for the positive and negative controls supplied with the corresponding ELISA kit. The 
capped dilution tubes were then inverted three times to homogenise the sample and dilution buffer. 
4.2.3.1  BioK302 protocol  
A total of 94 test sera could be tested on one 96-well BioK302 ELISA plate; the remaining wells 
were used for the BioK302 positive and negative control sera supplied with the kit. Aliquots 
(100 µl) of each diluted test sample and the BioK302 positive and negative controls were 
distributed across the plate placing one sample / well (Figure 4.1). The plate was then covered and 
incubated for 1 hr at room temperature on an automatic plate shaker.  
Following incubation, the well contents from the 96-well test plate were removed by flipping the 
plate sharply over clean adsorbent paper. The plate was then washed three times with the wash 
solution supplied with the kit using an automatic plate washer. Any residual wash solution was 
removed from the plate by flipping it sharply over clean adsorbent paper. 
A 100 µl aliquot of the anti-mammalian IgG peroxidase conjugate (protein G horseradish 
peroxidase-labelled) supplied with the kit was then added to each well and the plate was 
immediately covered and incubated for 1 hr on an automatic plate shaker. Following incubation 
with the conjugate, well contents were removed by flipping the plate sharply over clean adsorbent 
paper before washing the wells using the wash solution supplied and an automatic plate washer. 
Any residual well content was removed by flipping the plate sharply over clean adsorbent paper.  
A 100 µl aliquot of the BioK302 chromogen (tetramethylbenzidine; TMB) solution supplied with 
the kit was then applied to each well and the plate was incubated uncovered in the dark for 10 min 
before applying a 50 µl aliquot of the supplied stop solution to each well. The OD reading for each 
well was obtained as soon as possible after applying the stop solution (within 5 min) using a plate 
reader with a 450 nm filter (BioTeK Powerwave XS).   
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Figure 4.1: Schematic diagram of the BioK302 96-well ELISA test plate showing the layout of 
the distribution of test samples.  
Every well on the BioK302 ELISA kit plate is coated with test antigen and is regarded as a test well. A 
single 100 µl aliquot of each diluted test sample is applied a single test well on the BioK302 ELISA plate. 
 
4.2.3.2  BioK260 protocol 
A total of 46 test sera could be tested on one 96-well BioK260 ELISA plate; the remaining wells 
were used for the BioK260 positive and negative controls supplied with the kit (Figure 4.2). A fresh 
100 µl aliquot of the test sample dilution used on the BioK302 ELISA plate was applied to an 
antigen coated well and a 100 µl aliquot of the same test sample dilution was applied to a control 
well on the BioK260 ELISA plate. The procedure was repeated for the BioK260 positive and 
negative control samples. Plates were then covered and incubated at room temperature for 1 hr on 
an automatic plate shaker. 
Following incubation, the well contents were removed, the test wells were washed and residual 
wash solution was removed from the wells as described in Section 4.2.3.1 for the BioK302 ELISA. 
A 100 µl aliquot of the anti-mammalian IgG peroxidase conjugate (protein G horseradish 
peroxidase-labelled) supplied with the kit was the added to each well and the plate was immediately 
covered and incubated for 1 hr on an automatic plate shaker. Following incubation with the 
conjugate, the well contents were removed, the test wells were washed, and residual well content 
was removed as previously described for the BioK302 ELISA in Section 4.2.3.1. 
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A 100 µl aliquot of the BioK260 chromogen (TMB) solution supplied with the kit was then applied 
to each of the wells and the plate was incubated uncovered in the dark for 10 min before applying a 
50 µl aliquot of the supplied stop solution to each well. The OD reading for each well was obtained 
as soon as possible after applying the stop solution (within 5 min) using a plate reader with a 
450 nm filter (BioTeK Powerwave XS). 
 
 
Figure 4.2: Schematic diagram of the BioK260 96-well ELISA test plate showing the layout of 
the distribution of test samples 
The wells in the odd numbered columns are coated with the test antigen (test wells) while the wells in the 
even numbered columns are not coated with the antigen (control wells). A 100 µl aliquot of each diluted test 
sample is applied to both a test and a control well on the BioK260 ELISA plate.  
 
4.2.4 ELISA result data management 
The raw OD readings for each test well of each 96-well test plate were obtained from the plate OD 
reader (BioTek Powerwave XS) as a Microsoft
®
 Excel (.xls) file (one file / plate). A total of three 
BioK302 96-well test plates sourced from a single batch (MYC14C04) and four BioK260 96-well 
test plates sourced from a single batch (SMYC14C04) were used. Each 96-well test plate was 
numbered when used and the corresponding .xls file containing the raw OD readings were labelled 
to reflect the test plate number (i.e. BioK302_1, BioK302_2 etc. and BioK260_1, BioK260_2 etc.). 
Each plate .xls file was then collected into one .xls file so that the raw OD reading for each test 
sample could be assigned to its corresponding M. bovis reference sample ID (sample ID). The date 
of testing, the test kit batch number, and well number were recorded. The WB results (WB 
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category) obtained in Chapter 3 were also recorded, collated and appended to the ELISA .xls file. 
The resulting .xls file containing all BioK302 and BioK260 raw ODs as well as the WB category 
assigned to each test serum were then imported into the statistical package Stata/SE 
12.1

(Statacorp, College Station, Texas, USA). Test plate validation and calculation of the test sera 
ELISA category results using the raw OD readings were performed using Stata/SE 12.1

 
(Statacorp, College Station, Texas, USA). 
4.2.5  ELISA test plate validation 
4.2.5.1  BioK302 ELISA validation 
The BioK302 test plate validity was determined using the manufacturer’s instructions (Bio-X 
Diagnostics
®
, 2013b) whereby for each BioK302 test plate to be validated, both of the requirements 
listed below must be met:  
1. the difference in the raw OD at 10 min of the BioK302 positive control and the BioK302 
negative control must be greater than 0.7; 
2. The BioK302 negative control must give a raw OD at 10 min that is less than 0.4. 
4.2.5.2  BioK260 ELISA validation 
The BioK260 test plate validity was determined using the manufacturer’s instructions (Bio-X 
Diagnostics
®
, 2013b) whereby for each BioK260 test plate to be validated, both of the requirements 
listed below must be met: 
1. The difference in the raw OD at 10 min of BioK260 positive control in the test well with the 
BioK260 positive control raw OD reading in the control well must be greater than 0.8. 
2. The difference in the raw OD at 10 min of BioK260 negative control in the test well with the 
BioK260 negative control raw OD reading in the control well must be less than 0.3.  
4.2.6  Categorisation of BioK302 and BioK260 ELISA results 
4.2.6.1  BioK302  
The BioK302 is marketed as an ELISA kit to determine the immune status (sero-positive or sero-
negative) of the animal being tested to M. bovis (Bio-X Diagnostics
®
, 2013b). The results obtained 
were interpreted as per the manufacturer’s instructions whereby samples were determined to be 
sero-negative or sero-positive by calculating the Sample coefficient as follows: 
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Samples with a BioK302 coefficient that is ≥ 37% are considered sero-positive, while those with a 
coefficient < 37% are considered sero-negative. 
BioK302 sero-conversion  
An assessment of the proportion of animals with paired test sera sourced from AHVLA, VIDO-
InterVac and APCAH (Table 4.2) that sero-converted following experimental infection with 
M. bovis (i.e. were sero-negative prior to experimental infection and became sero-positive following 
experimental infection) using the BioK302 ELISA results was performed.  
4.2.6.2  BioK260  
The BioK260 ELISA is marketed as an ELISA kit for the sero-diagnosis of M. bovis exposure 
whereby two samples from the same animal are required. The manufacturer reports that the first 
sample must be collected during the acute phase of the infection and the second sample collected 
two to three weeks after the first. The manufacturer states that a sample must be considered positive 
if it yields a result that is greater than or equal to a one plus sign (+). The manufacturer states that 
exposure to M. bovis is considered to have occurred if the Delta Value (DV) category between the 
two test samples increases by two DV categories (i.e. from 0 to   ++; + to   +++; ++ to   ++++ 
and +++ to +++++), (Bio-X Diagnostics
®
, 2013a).  
Results obtained from the BioK260 ELISA were calculated and categorised following the 
manufacturer’s instructions whereby DV for each sample was calculated using the formula:  
 
             
                                                        
                                                                                 
      
 
Categorisation of the BioK260 DV results was performed using the cut-off values determined by 
the manufacturer. There were six BioK260 M. bovis categories which range from ‘0’ to ‘+++++’ as 
depicted in Table 4.3. For analysis purposes, the BioK260 ELISA results were dichotomised so that 
samples returning a BioK260 DV < 37% (DV category 0) were considered sero-negative for 
M. bovis; while samples returning a BioK260 DV > 37% (i.e. DV categories ≥ +), were considered 
sero-positive.  
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BioK260 sero-conversion 
As for the BioK302 ELISA, an assessment of the proportion of animals with paired test sera 
sourced from AHVLA, VIDO-InterVac and APCAH that sero-converted using results obtained with 
the BioK260 ELISA were performed. A summary of the test sera by source is provided in Table 
4.2. 
Table 4.3: Cut-off ranges for BioK260 ELISA Delta Value categories (Bio-X Diagnostics
®
, 
2013a)  
 BioK260 ELISA DV category 
 0 + ++ +++ ++++ +++++ 
Cut- off  < 37% 37 - < 60% 60 - < 83% 83 - < 106% 106 - < 129% ≥ 129% 
ELISA: Enzyme-linked immunosorbent assay; DV: Delta value. 
 
4.2.7  Statistical Methods 
All data were managed using the statistical package Stata/SE 12.1

(Statacorp, College Station, 
Texas, USA), except where otherwise stated. The level of agreement between tests was assessed 
using the kappa statistic (kap command). Estimates of test Se and Sp and associated 95% 
confidence intervals were determined using the proportion command adjusting for clustering by 
source (APCAH, VIDO-InterVac, AHVLA, Bio-X Diagnostics

). The logit transformation was 
used to compute the limits of the confidence intervals in Stata/SE 13.1

. When there was 100% 
agreement in the test result with the presumed sero-status of sera the Massey University online 
diagnostic 2by2 table calculator was used to determine confidence intervals (Massey University, 
2014). When the Massey University online calculator was used the confidence intervals obtained 
were not adjusted for clustering by source. 
An assessment of the percentage of animals that sero-converted for the BioK302 and BioK260 
ELISA kits respectively, were performed using the proportion command in Stata/SE 
12.1

(Statacorp, College Station, Texas, USA). 
Test agreement in the absence of a reference standard and test bias were assessed using the 
statistical program WinPepi Version 11.4 (Abramson, 2011). McNemar’s chi-squared test was used 
to test for bias by testing the null hypothesis that the proportion of positive responses was the same 
in two compared tests using the PAIRSetc analysis of matched observations for a ‘yes-no’ 
dichotomous variable. The percentage positive agreement (Ppos) and percentage negative 
agreement (Pneg) values were also calculated. 
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4.3  Results 
4.3.1  BioK302 and BioK260 test plate validation 
All samples were tested using ELISA kits of the same batch number for both the BioK302 and 
BioK260 (MYC14C04 and SMYC14C04, respectively). A total of three BioK302, and four 
BioK260, 96-well test plates were used. All of the BioK302 and BioK260 test plates were validated 
as per the manufacturer’s instructions.  
4.3.2  BioK302 ELISA results 
Results obtained using the BioK302 ELISA are listed by BioK302 sero-status and source in Table 
4.4. Of the 54 sera from animals exposed to M. bovis or used as a positive control, 50% (n = 27) 
tested sero-positive for M. bovis antibodies on the BioK302 ELISA. The BioK302 Se, accounting 
for clustering by source, was estimated to be 50% (95% CI: 20 - 79%), (Table 4.5). Experimental 
infection sera from animals exposed to M. bovis testing negative on the BioK302 ELISA consisted 
of: 19 / 30 APCAH samples, 2 / 4 AHVLA samples (AHVLA304_28 and Cut-off control), 2 / 9 
VIDO-InterVac samples (VIDO19_Low and VIDO21_Low) and 4 / 11 Bio-X Diagnostics
 
positive 
controls (all BioK284), (Appendix 4). 
Of the 56 sera from animals not exposed to M. bovis or used as a negative control, 54 gave a 
negative BioK302 ELISA result (Table 4.4). The BioK302 Sp, accounting for clustering by source, 
was estimated to be 96% (95% CI: 88 - 99%), (Table 4.5). The two non-exposed (pre-infection) 
samples returning a positive result were both sourced from APCAH (APCAH32_0 and 
APCAH48_0), (Appendix 4).  
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Table 4.4: Summary of BioK302 and dichotomised BioK260 and western blot M. bovis 
reference sample results by source 
Source 
BioK302 BioK260 Western blot* 
Negative Positive Negative Positive Negative Positive 
Pre-infection / control animal sera 
APCAH (n = 40) 38 2 40 0 37 3 
AHVLA (n = 4) 4 0 4 0 4 0 
VIDO-InterVac (n = 5) 5 0 5 0 3 2 
Bio-X Diagnostics

 negative control sera 
BioK302 (n = 3) 3 0 3 0 3 0 
BioK260 (n = 4) 4 0 4 0 4 0 
Sub-total 54 2 56 0 51 5 
Post-infection sera from challenged animals 
APCAH (n = 30) 19 11 26 4 12 18 
AHVLA (n = 4) 2 2 2 2 0 4 
VIDO-InterVac (n = 9) 2 7 3 6 0 9 
Bio-X Diagnostics

 positive control sera 
BioK302 (n = 3) 0 3 0 3 0 3 
BioK260 (n = 4) 0 4 0 4 0 4 
BioK284 (n = 4) 4 0 4 0 0 4 
Sub-total 27 27 35 19 12 42 
Total 81 29 91 19 63 47 
AHVLA: Animal Health and Veterinary Laboratories Agency; APCAH: Asia-Pacific Centre for Animal 
Health; VIDO-InterVac: Vaccine and Infectious Disease Organization International Vaccine Centre. 
*The western blots were performed using protein fusion protein (Chapter 3, Section 3.3.7) comprising a 
306 bp amplicon containing the RA1 motif of the M. bovis vspA gene. The fusion protein was ligated in the 
pET SUMO plasmid vector and expressed using BL21 (DE3) E. coli cells. Test sera were diluted at 1:100 in 
5% blotto and incubated at 4°C overnight with a 3 mm wide nitrocellulose strip. 
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Table 4.5: Comparative summary of sensitivity and specificity estimates for each sero-diagnostic test assessed 
Sample source removed from dataset 
(No. exposed / No. not exposed) 
Estimated sensitivity Estimated specificity 
BioK302 BioK260 WB BioK302 BioK260 WB 
None removed 
(54 / 56) 
50% 
(20 - 79%) 
35% 
(5 - 85%) 
79% 
(26 - 98%) 
96% 
(88 - 99%) 
100% 
(94 - 100%) 
89% 
(72 - 96%) 
Bio-X Diagnostics

 removed 
(43 / 49) 
47% 
(10 - 87%) 
28% 
(1 - 92%) 
74% 
(16 - 98%) 
96% 
(87 – 99%) 
100% 
(93 - 100%) 
88% 
(56 - 98%) 
APCAH removed 
(24 / 16) 
67% 
(39 - 94%) 
63% 
(48 - 76%) 
100% 
(86 - 100%) 
100% 
(81 - 100%) 
100% 
(81 - 100%) 
88% 
(64 - 97%) 
Bio-X Diagnostics

and APCAH 
removed (13 / 9) 
69% 
(42 – 100%) 
62% 
(3.4 - 99%) 
100% 
(77 - 100%) 
100% 
(70 - 100%) 
100% 
(70 - 100%) 
78% 
(45 - 94%) 
APCAH: Asia-Pacific Centre for Animal Health; WB: Western blot. 
Comparative summary of the estimated sensitivity and specificity for each diagnostic test assessed using the source samples as indicated. Confidence intervals (95%) 
are shown in parentheses. Estimates for the BioK260 enzyme-linked immunosorbent assay were obtained using dichotomised BioK260 Delta Value categories 
whereby a BioK260 Delta Value category of ‘0’ was considered sero-negative and a BioK260 Delta Value category ≥ ‘+’ were considered sero-positive for M. bovis 
antibody. Western blot immunoreactivities were qualitatively categorised into six categories. These were dichotomised for analysis purposes. A western blot 
category of ‘0’ was considered sero-negative and a western blot category ≥ ‘1’ were considered sero-positive for M. bovis antibody. 
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4.3.3  BioK260 ELISA results  
The M. bovis reference sample BioK260 DV category results are shown in Table 4.6. The 
dichotomised BioK260 DV categories are summarised in Table 4.4. Of the 54 sera from animals 
exposed to M. bovis (post-infection) or used as a positive control, 35% (n = 19) returned a DV 
result that was considered sero-positive for M. bovis antibody (DV category ‘+’ through to 
‘+++++’), (Table 4.6). Experimental infection sera from animals exposed to M. bovis that tested 
negative on the BioK260 ELISA (using the dichotomised categories) consisted of: 26 / 30 APCAH 
samples, 2 / 4 AHVLA samples (AHVLA304_28 and Cut-off control), 3 / 9 VIDO-InterVac 
samples (VIDO19_Low, VIDO21_Low and VIDO26_Low) and 4 / 11 Bio-X Diagnostics
 
(all the 
BioK284 positive controls), (Table 4.4 and Appendix 4). The BioK260 test Se, accounting for 
clustering by source, was estimated to be 35% (95% CI: 5 - 85%), (Table 4.5).  
The BioK260 ELISA test Sp, not accounting for clustering by source, was estimated to be 100% 
(95% CI: 94 - 100%), (Table 4.5), with all 56 non-exposed (pre-infection) samples returning a 
negative result (DV category 0) on the BioK260 ELISA (Table 4.6). 
Table 4.6: BioK260 ELISA Delta Value test sera results  
Animal exposure status 
BioK260 DV category 
Total 
0 + ++ +++ ++++ +++++ 
M. bovis non-exposed (n = 56) 
       Pre-infection / control animal sera  49 0 0 0 0 0 49 
Bio-X Diagnostics

 negative control 
sera 
7 0 0 0 0 0 7 
        M. bovis exposed (n = 54) 
       Post-infection sera from challenged 
animals 
31 4 2 9 2 2 50 
Bio-X Diagnostics

 positive control 
sera 
4 0 0 0 0 0 4 
Total 91 4 2 9 2 2 110 
DV: Delta value. 
Test sera results from M. bovis experimental infection trials and control sera from Bio-X Diagnostics

 enzyme-linked 
immunosorbent assay (ELISA) kits using the BioK260 ELISA. The Delta Value cut-off for each category are as follows 
< 37% = Category ‘0’; 37 - < 60% = Category ‘+’; 60 - < 83% = Category ‘++’; 83 - < 106% = Category ‘+++’, 106 - < 
129% = Category ‘++++’ and ≥ 129% = Category ‘+++++’. 
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4.3.4  Western blot results  
Of the 54 sera from animals exposed to M. bovis or used as a positive control, 42 showed reactivity 
with the SUMO-vspA9 fusion protein and were considered M. bovis sero-positive (Table 4.4). 
Table 4.7 provides more detail on the WB category results. Of the sera from animals exposed to 
M. bovis (post-infection) that had no reactivity with the SUMO-vspA9 fusion protein (n = 12), all 
were sourced from APCAH (Table 4.4). The Se, of WB accounting for clustering by source, was 
estimated to be 79% (95% CI: 26 – 98%), (Table 4.5).  
Of the 56 sera from animals not-exposed to M. bovis (pre-infection) or used as a negative control, 
51 had no reactivity with the SUMO-vspA9 fusion protein (Table 4.4). Samples collected from 
animals prior to experimental infection with M. bovis that showed reactivity with the SUMO-vspA9 
fusion protein (n = 5) were sourced from APCAH (APCAH23_0, APCAH32_0 and APCAH48_0) 
and VIDO-InterVac (VIDO21_Neg and VIDO30_Neg), (Appendix 4). The Sp of WB, accounting 
for clustering by source, was estimated to be 89% (95% CI: 72 – 96%), (Table 4.5).  
Table 4.7: Western blot category results for test sera 
Animal exposure status 
WB category 
Total 
0 1 2 3 4 5 
M. bovis non-exposed (n = 56) 
       Pre-infection / control animal sera  44 2 2 0 0 1 49 
Bio-X Diagnostics

 negative control 
sera 
7 0 0 0 0 0 7 
        M. bovis exposed (n = 54) 
       
Post-infection sera from challenged 
animals 
12 10 7 4 2 8 43 
Bio-X Diagnostics

 positive control 
sera 
0 0 0 4 0 7 11 
Total 63 12 9 8 2 16 110 
WB: Western blot. 
Western blot reactivity of the test samples was qualitatively categorised into 6 categories consisting of 0 (no reactivity), 
1 (very low reactivity), 2 (low reactivity), 3 (medium reactivity), 4 (high reactivity) and 5 (very high reactivity), 
(Section 3.3.7.1). 
 
4.3.5  Test comparison and level of agreement 
4.3.5.1  BioK302 and BioK260  
Comparison of the BioK302 and dichotomised BioK260 results revealed that all the samples that 
tested negative on the BioK302 ELISA (n = 81) also fell into the ‘0’ DV category and were 
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considered negative for M. bovis antibody using the BioK260 ELISA. Of the samples that tested 
positive on the BioK302 ELISA (n = 29), 19 (65.5%) also returned a BioK260 DV category result 
that were a ‘+’ or higher and considered positive for M. bovis serum antibody (Table 4.8).  
The McNemar’s chi-squared test for the BioK302 and dichotomised BioK260 ELISA results was 
calculated to be p = 0.002, indicating a statistical significance of difference in the BioK302 and 
BioK260 ELISA detection methods (Table 4.9). The Ppos and Pneg were calculated at 79.2% and 
94.2% respectively (Table 4.9). The observed agreement between the BioK302 and dichotomised 
BioK260 ELISA results was 90.9%, the expected agreement due to chance alone was 65.5%. The 
kappa statistic was calculated to be 0.74 (Table 4.10), indicating a substantial strength of agreement 
(Landis and Koch, 1977). 
Table 4.8: BioK302 and BioK260 test comparison results 
BioK302  
Dichotomised BioK260 BioK260 DV category 
Negative Positive 0 + ++ +++ ++++ +++++ 
Negative 81 0 81 0 0 0 0 0 
Positive 10 19 10 4 2 9 2 2 
Total 91 19 91 4 2 9 2 2 
DV: Delta value. 
Summary of the M. bovis reference sample results obtained using the BioK302 and BioK260 enzyme-linked 
immunosorbent assay (ELISA) kits. The dichotomised BioK260 Delta Value categories are shown to the left 
of the number of samples falling into each of the Delta Value categories using the BioK260 ELISA kit. 
 
4.3.5.2  BioK302 and western blot analysis  
Of the sera that tested positive for M. bovis serum antibody on the BioK302 ELISA, 27 / 29 
(93.10%) were also considered positive for M. bovis serum antibodies using the dichotomised WB 
analysis results (Table 4.11). Of the samples that tested negative on the BioK302 ELISA, 59 / 81 
(72.8%) produced no signal and were considered negative for M. bovis serum antibody using WB 
(Table 4.11).  
The McNemar’s chi-squared test for the BioK302 and dichotomised WB results was calculated to 
be p < 0.001, indicating a statistical significance of difference in the BioK302 and WB detection 
methods (Table 4.9). The Ppos and Pneg were calculated at 71.1% and 84.7% respectively (Table 
4.9). The observed agreement between the BioK302 and dichotomised WB results was 78.1%; the 
expected agreement due to chance alone was 52.6% and the kappa statistic 0.54 (Table 4.10), 
indicating a moderate strength of agreement (Landis and Koch, 1977). 
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4.3.5.3  BioK260 and western blot analysis  
Comparison of the dichotomised BioK260 ELISA results with WB was performed and a summary 
of the results is provided in Table 4.11. Of the samples that returned a negative result, or fell within 
the ‘0’ DV category on the BioK260 (n = 91), 63 (69.2%) had no reactivity when assessed using 
WB (Table 4.11). Of the test sera considered sero-positive for M. bovis antibodies using the 
BioK260 ELISA (n = 19), all showed low (‘2’) through to very high (‘5’) reactivity with the 
SUMO-vspA9 fusion protein (Table 4.11).  
The McNemar’s chi-squared test for the dichotomised BioK260 and dichotomised WB results was 
calculated to be p < 0.001, indicating a statistical significance of difference in the BioK260 and WB 
detection methods (Table 4.9). The Ppos and Pneg were calculated at 57.6% and 81.8% respectively 
(Table 4.9). The observed agreement between the dichotomised BioK260 and dichotomised WB 
results was 72.7%, the expected agreement due to chance alone was 53.6% and the kappa statistic 
0.41 (Table 4.10), indicating a moderate strength of agreement (Landis and Koch, 1977). 
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Table 4.9: Summary of McNemar’s chi-squared test and percentage agreement values for each diagnostic test comparison and each sample 
source dataset assessed. 
Sample source removed from 
dataset 
McNemar’s chi-squared test p value Percentage Positive Agreement (%) Percentage Negative Agreement (%) 
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All samples (n = 110) 0.002   < 0.001  < 0.001 79.2 71.1 57.6 94.2 84.7 81.8 
Bio-X Diagnostics

 removed  
(n = 92) 
0.002  0.001  < 0.001  70.6 69.0 50.0 93.3 85.7 82.4 
APCAH samples removed  
(n = 40) 
0.317 0.002  0.001  96.8 76.2 73.2 98.0 73.7 71.8 
Bio-X Diagnostics

 and APCAH 
samples removed (n = 22) 
0.317 0.014 0.008  94.1 75.0 69.6 96.3 70.0 66.7 
APCAH: Asia-Pacific Centre for Animal Health; WB: Western blot. 
BioK260 Delta Value category enzyme-linked immunosorbent assay and western blot analyses results used in test comparison assessment are dichotomised where 
by a BioK260 Delta Value category of ‘0’ was considered negative for M. bovis antibody categories ‘+’ through to ‘+++++’ were considered positive for M. bovis 
antibody. A western blot category of ‘0’ was considered negative for M. bovis antibody, while western blot categories 1 through to 5 were considered positive for 
M. bovis antibody. 
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Table 4.10: Summary of the observed levels of agreement and kappa statistic for each diagnostic test comparison and each sample source 
dataset assessed. 
Sample source removed from dataset 
Observed Agreement Kappa Statistic 
BioK302 / BioK260 BioK302 / WB BioK260 / WB BioK302 / BioK260 BioK302 / WB BioK260 / WB 
All samples (n = 110) 90.9% 78.2% 72.7% 0.74 0.54 0.41 
Bio-X Diagnostics

 removed  
(n = 92) 
89.1% 78.3% 71.7% 0.65 0.52 0.35 
APCAH samples removed  
(n = 40) 
97.5% 75.0% 72.5% 0.95 0.53 0.49 
Bio-X Diagnostics

 and APCAH 
samples removed (n = 22) 
95.5% 72.7% 68.2% 0.9 0.49 0.42 
APCAH: Asia-Pacific Centre for Animal Health; WB: Western blot. 
BioK260 Delta Value category enzyme-linked immunosorbent assay and western blot analyses results used in test comparison assessment are dichotomised where 
by a BioK260 Delta Value category of ‘0’ was considered negative for M. bovis antibody categories ‘+’ through to ‘+++++’ were considered positive for M. bovis 
antibody. A western blot category of ‘0’ was considered negative for M. bovis antibody, while western blot categories 1 through to 5 were considered positive for 
M. bovis antibody. The greatest level of agreement in test results was seen using the BioK302 and BioK260 ELISA kits across all serum source datasets assessed. 
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Table 4.11: Comparison of BioK302 and BioK260 ELISA with western blot analysis category results 
Test 
Dichotomised WB category WB category 
Negative Positive 0 1 2 3 4 5 
BioK302 
        
Negative 61 20 61 8 5 4 1 2 
Positive 2 27 2 4 4 4 1 14 
Total 63 47 63 12 9 8 2 16 
BioK260  
        
Negative 0 63 28 63 12 7 5 1 3 
Positive + 0 4 0 0 2 2 0 0 
++ 0 2 0 0 0 1 0 1 
+++ 0 9 0 0 0 0 1 8 
++++ 0 2 0 0 0 0 0 2 
+++++ 0 2 0 0 0 0 0 2 
Total 
 
63 47 63 12 9 8 2 16 
WB: Western blot 
A comparison summary of the M. bovis reference sample results obtained using the BioK302 ELISA kit and western blot analysis. The dichotomised western blot 
results are shown to the left of the number of samples falling into each of the western blot reactivity categories where each category represents 0 (no reactivity), 1 
(very low reactivity), 2 (low reactivity), 3 (medium reactivity), 4 (high reactivity) and 5 (very high reactivity). 
Each of the BioK260 ELISA Delta Value categories is listed to the right of the dichotomised BioK260 results. 
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4.3.6  Effect of removal of samples from the data set on test sensitivity and specificity 
estimates 
4.3.6.1  Removal of Asia-Pacific Centre for Animal Health sera 
From the results obtained, it was observed that the APCAH samples performed somewhat 
differently to the sera obtained from other sources in all the tests used. With the APCAH test sera 
being the dominant source of samples assessed comprising 60% of all “M. bovis exposed” sera, they 
were inherently very influential on the estimations calculated. As many of the post-infection 
APCAH sera from animals exposed to M. bovis returned a negative result on the BioK302, 
BioK260 and WB (Table 4.4), it was decided that these samples may be non-representative, or the 
infective M. bovis strain used by APCAH may be non-representative of the M. bovis population in 
Australian cattle. For these reasons, reassessment of Se and Sp estimates and test comparisons 
following removal of the APCAH test sera from the data set was performed. With the APCAH test 
sera removed, a total of 40 (16 non-exposed and 24 exposed) samples remained in the dataset 
(Table 4.1).  
4.3.6.1.1  BioK302 ELISA results 
Using the results obtained from the test sera following removal of the APCAH sera, the BioK302 
test Se and Sp (accounting for clustering by source and infection status) was estimated to be 67% 
(95% CI: 39 - 94%) and 100% (95% CI: 81 - 100%) respectively (Table 4.5).  
4.3.6.1.2  BioK260 ELISA results 
After removal of the APCAH test sera from the analyses the BioK260 test Se improved slightly to 
63% (95% CI: 48 - 76%) while the Sp remained at 100% (95% CI: 81 - 100%), (Table 4.5).  
4.3.6.1.3  Western blot results 
Following removal of the APCAH test sera from the dataset, the WB Se was estimated to be 100% 
(95% CI: 86 - 100%), while the Sp was estimated to be 88% (95% CI: 64 - 97%), (Table 4.5). 
4.3.6.1.4  Test comparison and level of agreement 
Reassessment of the BioK302 and BioK260 ELISA results following removal of the APCAH test 
sera revealed that all samples returning a negative result on the BioK302 also tested negative on the 
BioK260 ELISA (Table 4.12). One sample (VIDO26_Low) that tested positive on the BioK302 
produced a negative result on the BioK260 ELISA (Appendix 4).  
The McNemar’s chi-squared test for the BioK302 and dichotomised BioK260 results was calculated 
to be p = 0.32, indicating no statistical significance in the BioK302 and BioK260 ELISA detection 
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methods (Table 4.9). The Ppos and Pneg were calculated at 70.6% and 93.3% respectively (Table 
4.9). The observed agreement between the BioK302 and dichotomised BioK260 results was 97.5%, 
the expected agreement due to chance alone was 52.5% and the kappa statistic 0.95 (Table 4.10), 
indicating an almost perfect strength of agreement  between these two tests.  
Reassessment of the BioK302 and dichotomised WB results following removal of the APCAH 
samples revealed that all samples that tested positive on the BioK302 ELISA were also considered 
positive using WB (Table 4.13). Of the samples returning a negative BioK302 result, 14 / 24 
(58.3%) samples had no reactivity to the SUMO-vspA9 fusion protein (Table 4.13). The 
McNemar’s chi-squared test for the BioK302 and WB results was calculated to be p = 0.002, 
indicating a statistically significant difference in the BioK302 and WB detection methods (Table 
4.9). The Ppos and Pneg were calculated at 76.2% and 73.7% respectively (Table 4.9). The 
observed agreement between the BioK302 and dichotomised WB results was 75.0%, the expected 
agreement due to chance alone was 47.0% and the kappa statistic 0.53 (Table 4.10), indicating a 
moderate strength of agreement (Landis and Koch, 1977) between these two tests. 
Comparison of the dichotomised BioK260 and dichotomised WB results following removal of the 
APCAH samples revealed that all samples returning a positive result on the BioK260 ELISA also 
showed reactivity to the SUMO-vspA9 fusion protein, and were considered positive (Table 4.14). 
Of the samples returning a negative BioK260 ELISA result, 11 / 25 (44.0%) were considered 
positive for M. bovis serum antibody using WB (Table 4.14). The McNemar’s chi-squared test for 
the BioK260 and WB results was calculated to be p = 0.001, indicating a statistically significant 
difference in the BioK260 and WB detection methods (Table 4.9). The Ppos and Pneg were 
calculated at 73.2% and 71.8% respectively (Table 4.9). The observed agreement between the 
dichotomised BioK260 and dichotomised WB results was 72.5%, the expected agreement due to 
chance alone was 46.3% and the kappa statistic 0.49 (Table 4.10), indicating a moderate strength of 
agreement (Landis and Koch, 1977) between these two tests.  
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Table 4.12: BioK302 and BioK260 test comparison following removal of sera sourced from 
Bio-X Diagnostics

 and Asia-Pacific Centre for Animal Health. 
BioK302 
Dichotomised BioK260 BioK260 DV Category 
Negative Positive 0 + ++ +++ ++++ +++++ 
APCAH samples removed       
Negative 24 0 24 0 0 0 0 0 
Positive 1 15 1 1 1 9 2 2 
Total 25 15 25 1 1 9 2 2 
Bio-X Diagnostics

 samples removed       
Negative 70 0 70 0 0 0 0 0 
Positive 10 12 10 4 2 2 2 2 
Total 80 12 80 4 2 2 2 2 
APCAH and Bio-X Diagnostics

 removed      
Negative 13 0 13 0 0 0 0 0 
Positive 1 8 1 1 1 2 2 2 
Total 14 9 14 1 1 2 2 2 
APCAH: Asia-Pacific Centre for Animal Health; DV: Delta value. 
Comparison of ELISA results using the BioK302 and BioK260 kits. For analysis purposes, the BioK260 DV 
categories were dichotomised whereby the ‘0’ category was considered negative for M. bovis antibody and 
categories + through to +++++ were considered positive for M. bovis antibody. 
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Table 4.13: BioK302 and western blot analysis test comparison following removal of sera sourced from Bio-X Diagnostics

 and Asia-Pacific 
Centre for Animal Health. 
BioK302  
Dichotomised WB category WB category 
Negative Positive 0 1 2 3 4 5 
APCAH samples removed 
       
Negative 14 10 14 1 3 4 0 2 
Positive 0 16 0 0 0 1 1 14 
Total 14 26 14 1 3 5 1 16 
Bio-X Diagnostics

 samples removed 
       
Negative 54 16 8 5 0 1 2 70 
Positive 2 20 4 4 4 1 7 22 
Total 56 36 12 9 4 2 9 92 
APCAH and Bio-X Diagnostics

 removed 
      
Negative 7 6 7 1 3 0 0 2 
Positive 0 9 0 0 0 1 1 7 
Total 7 15 7 1 3 1 1 9 
APCAH: Asia-Pacific Centre for Animal Health; WB: Western blot. 
Each western blot category represents 0 (no reactivity), 1 (very low reactivity), 2 (low reactivity), 3 (medium reactivity), 4 (high reactivity) and 5 (very high 
reactivity). For analysis purposes, the western blot categories were dichotomised whereby the ‘0’ category was considered negative for M. bovis antibody and 
categories 1 through to 5 were considered positive for M. bovis antibody. 
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Table 4.14: BioK260 and western blot analysis test comparison following removal of sera sourced from Bio-X Diagnostics

 and Asia-Pacific 
Centre for Animal Health. 
BioK260 DV Category 
Dichotomised WB categories WB category 
Negative Positive 0 1 2 3 4 5 
APCAH samples removed        
Negative 0 14 11 14 1 3 4 0 3 
Positive + 0 1 0 0 0 1 0 0 
 ++ 0 1 0 0 0 0 0 1 
 +++ 0 9 0 0 0 0 1 8 
 ++++ 0 2 0 0 0 0 0 2 
 +++++ 0 2 0 0 0 0 0 2 
Total 14 26 14 1 3 5 1 16 
Bio-X Diagnostics

 samples removed        
Negative 0 56 24 56 12 7 1 1 3 
Positive + 0 4 0 0 2 2 0 0 
 ++ 0 2 0 0 0 1 0 1 
 +++ 0 2 0 0 0 0 1 1 
 ++++ 0 2 0 0 0 0 0 2 
 +++++ 0 2 0 0 0 0 0 2 
Total 56 36 56 12 9 4 2 9 
APCAH and Bio-X Diagnostics

 removed        
Negative 0 7 7 7 1 3 0 0 3 
Positive + 0 1 0 0 0 1 0 0 
 ++ 0 1 0 0 0 0 0 1 
 +++ 0 2 0 0 0 0 1 1 
 ++++ 0 2 0 0 0 0 0 2 
 +++++ 0 2 0 0 0 0 0 2 
Total 7 15 7 1 3 1 1 9 
APCAH: Asia-Pacific Centre for Animal Health; DV: Delta value; WB: Western blot. 
Each western blot category represents 0 (no reactivity), 1 (very low reactivity), 2 (low reactivity), 3 (medium reactivity), 4 (high reactivity) and 5 (very high reactivity). For analysis 
purposes, the western blot and BioK260 Delta Value categories were dichotomised whereby the ‘0’ category for both the western blot and BioK260 results was considered negative 
for M. bovis antibody, while western blot categories 1 through to 5 and BioK260 Delta Value categories + through to +++++ were considered positive for M. bovis antibody. 
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4.3.6.2  Removal of Bio-X Diagnostics

 control sera 
Two of the methods being assessed in the current study are supplied with the Bio-X Diagnostics

 
control sera. As these sera have been used to calculate the Se and Sp of the methods they are 
developed for, it was thought that inclusion of these sera may bias the results. For this reason, 
reassessment of the Se and Sp estimates and test comparisons following removal of the Bio-
X Diagnostics

 control sera from the data set were performed. With the Bio-X Diagnostics

 control 
sera removed, a total of 92 (49 non-exposed and 43 exposed) samples remained in the dataset 
(Table 4.1). 
4.3.6.2.1 BioK302 ELISA results 
Using the results obtained from these samples, the BioK302 test Se and Sp (accounting for 
clustering by source and infection status) was estimated to be 47% (95% CI: 10 - 87%) and 96% 
(95% CI: 87 - 99%) respectively (Table 4.5). 
4.3.6.2.2 BioK260 ELISA results 
After removal of the Bio-X Diagnostics

 samples from the analyses the BioK260 test Se was 
estimated to be 28% (95% CI: 1 - 92%) and Sp at 100% (95% CI: 93 - 100%), (Table 4.5).  
4.3.6.2.3 Western blot results 
Following removal of the Bio-X Diagnostics

 samples from the dataset, the WB Se was estimated 
to be 74% (95% CI: 16 - 98%), and Sp 88% (95% CI: 56 - 98%), (Table 4.5). 
4.3.6.2.4 Test comparison and level of agreement 
Reassessment of the BioK302 and BioK260 ELISA results following removal of the Bio-X 
Diagnostics

 samples revealed that all samples returning a negative result on the BioK302 also 
tested negative on the BioK260 ELISA (Table 4.12). However, 10 samples that tested positive on 
the BioK302 produced a negative result on the BioK260 ELISA (Table 4.12). The McNemar’s chi-
squared test for the BioK302 and dichotomised BioK260 ELISA results was calculated to be p = 
0.002, indicating a statistically significant difference in the BioK302 and BioK260 ELISA detection 
methods (Table 4.9). The Ppos and Pneg were calculated at 70.6% and 93.3% respectively (Table 
4.9). The observed agreement between the BioK302 and dichotomised BioK260 results was 89.1%, 
the expected agreement due to chance alone was 62.3% and the kappa statistic 0.65 (Table 4.10) 
indicating a substantial strength of agreement between these two tests. 
Reassessment of the BioK302 and dichotomised WB results following removal of the Bio-X 
Diagnostics

 samples revealed that 20 / 22 (90.9%) samples that tested positive on the BioK302 
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ELISA were also considered positive using WB (Table 4.13). Of the samples returning a negative 
BioK302 result, 52 / 70 (74.3%) test sera had no reactivity to the SUMO-vspA9 fusion protein. The 
McNemar’s chi-squared test for the BioK302 and WB results was calculated to be p = 0.001, 
indicating a statistically significant difference in the BioK302 and WB detection methods (Table 
4.9). The Ppos and Pneg were calculated at 69.0% and 85.7% respectively (Table 4.9). The 
observed agreement between the BioK302 and dichotomised WB results was 78.3%, the expected 
agreement due to chance alone was 54.5% and the kappa statistic 0.52 (Table 4.10) indicating a 
moderate strength of agreement (Landis and Koch, 1977) between these two tests.  
Comparison of the dichotomised BioK260 and dichotomised WB results following removal of the 
Bio-X Diagnostics

 samples revealed that all samples returning a positive result on the BioK260 
ELISA (n = 12) also showed reactivity to the SUMO-vspA9 fusion protein, and were considered 
positive (Table 4.14). Of the samples returning a negative BioK260 ELISA result, 26 / 80 (32.5%) 
were considered positive for M. bovis serum antibody using WB (Table 4.14). The McNemar’s chi-
squared test for the BioK260 and WB results was calculated to be p < 0.001, indicating a 
statistically significant difference in the BioK260 and WB detection methods (Table 4.9). The Ppos 
and Pneg were calculated at 50.0% and 82.4% respectively (Table 4.9). The observed agreement 
between the dichotomised BioK260 and dichotomised WB results was 71.7%, the expected 
agreement due to chance alone was 56.4% and the kappa statistic 0.35 (Table 4.10), indicating a fair 
strength of agreement (Landis and Koch, 1977) between these two tests.  
4.3.6.3  Removal of Asia-Pacific Centre for Animal Health and Bio-X Diagnostics

 sera 
Reassessment of Se and Sp estimates and test comparisons following removal of both the APCAH 
and Bio-X Diagnostics

 samples from the data set was performed. With these samples removed, a 
total of 22 (9 non-exposed and 13 exposed) samples remained in the dataset (Table 4.1).  
4.3.6.3.1 BioK302 ELISA results 
Using the results obtained from these samples the BioK302 test Se and Sp were estimated to be 69% 
(95% CI: 42 - 87%) and 100% (95% CI: 70 - 100%) respectively (Table 4.5).  
4.3.6.3.2 BioK260 ELISA results 
After removal of both the APCAH and Bio-X Diagnostics

 samples from the analyses the BioK260 
test Se was estimated at 62% (95% CI: 3.4 - 99%) and Sp 100% (95% CI: 70 - 100%), (Table 4.5). 
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4.3.6.3.3 Western blot results 
Following removal of both the APCAH and Bio-X Diagnostics

 samples from the dataset, the WB 
Se was estimated to be 100% (95% CI: 77 - 100%), while the Sp was estimated to be 78% (95% CI: 
45 - 94%), (Table 4.5). 
4.3.6.3.4 Test comparison and level of agreement 
Reassessment of the BioK302 and BioK260 ELISA results following removal of both the APCAH 
and Bio-X Diagnostics

 samples revealed that all samples returning a negative result on the 
BioK302 also tested negative on the BioK260 ELISA (Table 4.12). However, one (VIDO26_Low) 
sample that tested positive on the BioK302 produced a negative result on the BioK260 ELISA 
(Appendix 4). The McNemar’s chi-squared test for the BioK302 and dichotomised BioK260 ELISA 
results was calculated to be p = 0.32, indicating no statistical significance in the BioK302 and 
BioK260 ELISA detection methods (Table 4.9). The Ppos and Pneg were calculated at 94.1% and 
96.3% respectively (Table 4.9). The observed agreement between the BioK302 and dichotomised 
BioK260 results was 95.5%, the expected agreement due to chance alone was 52.5% and the kappa 
statistic 0.90 (Table 4.10), indicating an almost perfect strength of agreement  between these two 
tests. 
Reassessment of the BioK302 and dichotomised WB results following removal of both the APCAH 
and Bio-X Diagnostics

samples revealed that all samples that tested positive on the BioK302 
ELISA were also considered positive using WB (Table 4.13). Of the samples returning a negative 
BioK302 result, 7 / 13 (53.8%) samples had no reactivity to the SUMO-vspA9 fusion protein. The 
McNemar’s chi-squared test for the BioK302 and WB results was calculated to be p = 0.01, 
indicating a statistically significant difference in the BioK302 and WB detection methods (Table 
4.9). The Ppos and Pneg were calculated at 75.0% and 70.0% respectively (Table 4.9). The 
observed agreement between the BioK302 and dichotomised WB results was 72.7%, the expected 
agreement due to chance alone was 46.7% and the kappa statistic 0.49 (Table 4.10), indicating a 
moderate strength of agreement between these two tests. 
Comparison of the dichotomised BioK260 and dichotomised WB results following removal of both 
the APCAH and Bio-X Diagnostics

 samples revealed that all samples returning a positive result on 
the BioK260 ELISA (n = 8) also showed reactivity to the SUMO-vspA9 fusion protein, and were 
considered positive (Table 4.14). Of the samples returning a negative BioK260 ELISA result, 7 / 14 
(50.0%) were considered positive for M. bovis serum antibody using WB. The chi-squared test for 
the BioK260and WB results was calculated to be p = 0.01, indicating a statistically significant 
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difference BioK260 and WB detection methods (Table 4.9). The Ppos and Pneg were calculated at 
69.6% and 66.7% respectively (Table 4.9). The observed agreement between the dichotomised 
BioK260 and dichotomised WB results was 68.2%, the expected agreement due to chance alone 
was 45.0% and the kappa statistic 0.42 (Table 4.10), indicating a moderate strength of agreement 
between these two tests.  
4.3.7  Assessment of sero-conversion detection using the BioK302 and BioK260 ELISAs 
4.3.7.1  Detection of sero-conversion using the BioK302 ELISA  
Of the 42 animals with paired test sera available, 36 were experimentally infected. Thirty four of 
these had the potential to change from sero-negative to sero-positive between the two samples using 
the BioK302 ELISA results. Two APCAH animals (APCAH_32 and APCAH_48, Appendix 4) 
were considered sero-positive prior to experimental infection and were excluded. Based on the 
BioK302 ELISA results, 12 / 34 (35.3%) of the animals became sero-positive following 
experimental infection with M. bovis (Table 4.15).  
4.3.7.2  Detection of sero-conversion using the BioK260 ELISA 
Of the 36 experimentally infected animals with pre- and post-experimental infection sera, all 
returned a pre-infection test sera result that was within the ‘0’ BioK260 DV category, and had the 
potential to sero-convert following exposure to M. bovis. Of these animals, three (8.3%) returned a 
post-infection BioK260 DV result that was ≥ ‘++’ (Table 4.15). 
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Table 4.15: The number of test sera by source that sero-converted based on the BioK302 and BioK260 ELISA results following experimental 
infection with M. bovis 
Source 
BioK302 ELISA BioK260 ELISA 
No. with potential No. sero-converted No. with potential No. sero-converted 
Asia-Pacific Centre for Animal Health 
(APCAH), Australia 
28 9 (32.1%) 30 1 (3.3%) 
Vaccine and Infectious Disease 
Organization International Vaccine 
Centre (VIDO-InterVac), Canada 
4 2 (50.0%) 4 2 (50.0%) 
Animal Health and Veterinary 
Laboratories Agency (AHVLA), 
England 
2 1 (50.0%) 2 0 (0.0%) 
Total  34 12 (35.3%) 36 3 (8.3%) 
Number with potential refers to the total number of animals with paired test sera from each source that were BioK302 sero-negative or had a test sample that was 
within the ‘0’ BioK260 Delta Value category prior to experimental infection with M. bovis. For the BioK302, the number that sero-converted are based on those that 
became sero-positive following experimental infection with M. bovis. While for the BioK260 the number that sero-converted are based on those that had a pre-
infection result in the ‘0’ BioK260 Delta Value category and a post-infection result that was in a ‘++’ or higher BioK260 DV category. 
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4.4 Discussion 
In the current study it was found that none of the tests assessed performed well in terms of Se 
and Sp combined. In addition, neither the BioK302 nor the BioK260 were effective at 
detecting sero-conversion using paired serum samples collected from animals following 
experimental infection with M. bovis. It was found that the WB method used here had 
improved ASe over both the BioK302 and BioK260 ELISA kits, however, both the BioK302 
and BioK260 ELISA kits performed better in terms of ASp. The level of agreement of a test 
result with another test was greatest when the two BioK ELISA kits were compared, with a 
kappa statistic of 0.74 indicating a substantial strength of agreement.  
An understanding of a test’s performance in terms of ASe and ASp for sero-diagnosis is 
essential for interpretation of the results obtained. A test with high Se produces few false 
negative results, and as a result is useful for confirming the absence of a disease condition. A 
highly specific test gives few false positive results and is therefore most useful for confirming 
the presence of a disease. An understanding of the implications imperfect test Se and Sp can 
have on the results obtained is of utmost importance. Diagnostic methods that aim to 
determine the cause of disease in animals showing clinical signs of disease require a high Sp. 
This is because testing is limited to animals that are clinically ill and fewer samples are 
tested. The subsequent cost of the test is not as important in comparison to a test used for 
screening purposes. A screening test is typically applied to samples collected from clinically 
healthy animals with the aim of identifying unrecognised disease or infection. As screening 
tests are usually applied to a large number of animals (or samples) in a herd or from a 
population, the method must be easy to perform; relatively low in cost, preferably automated 
and most importantly, have high Se.  
In the current study, not all the pre-infection (this includes the subsequent sera collected from 
control animals) sera from animals not exposed to M. bovis were sero-negative for M. bovis 
antibody using the BioK302 or WB (Table 4.4). This affected their Sp estimates. Of the non-
exposed sera, the BioK302 returned two ‘false positive’ results while WB returned five ‘false 
positive results (Table 4.4). No ‘false positive’ results were seen using the dichotomised 
BioK260 classification. Two APCAH non-exposed sera returned ‘false positive’ results using 
both the BioK302 and WB (Appendix 4). Both the ELISAs and the antigen used in WB in the 
current study employ a recombinant M. bovis antigen, expressed by E. coli for the detection 
of M. bovis antibodies. The use of recombinant antigens in sero-diagnostic methods can be 
associated with non-specific cross-reactions between antibodies in the test sera. It is possible 
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that cross-reactivity with residual E. coli proteins is a cause of false positive ELISA and WB 
results in this study. Cross-reactivity with the SUMO fusion partner used in the production of 
the recombinant 5’-vspA antigen (Chapter 3) for WB may also reduce the Sp of WB in this 
study. Imprecision associated with qualitatively classifying WB immunoreactivies, especially 
when low categories were assigned to samples could have also reduced the Sp of the WB 
method used in this study. An immunoblot classified as a category ‘1’ by me may in fact be a 
‘0’ by someone else. There two possible solutions to this issue. The first would be to have the 
WB categorisation performed by an independent party or parties to reduce the introduction of 
potential bias by the author knowing the status of the sera. Alternatively, the use of a high 
resolution densitometry to scan the WB results may have enabled the categorisation of these 
results in a more operator independent manner with less potential bias. This equipment was 
not available to the current study.  
The presence of maternal antibodies to M. bovis has been reported to produce false positive 
ELISA results. Tschopp et al. (2001) reported that maternal antibodies were detected in 39% 
of newborn calves born to M. bovis sero-negative cows. They found that these maternal 
antibodies had a half-life of 20 days. Given the age of the APCAH animals (approximately 
six weeks when the pre-infection samples were obtained), the presence of maternal antibodies 
may be a possible explanation for the APCAH test sera returning false positive results on WB 
and the BioK302 ELISA.  
Test Se was low for all three methods assessed. A number of post-exposure sera from 
APCAH gave negative results across all three methods with approximately 63% (n = 19), 
87% (n = 26) and 40% (n = 12) returning ‘false negative’ results on the BioK302, BioK260 
and WB respectively (Table 4.4). In addition half (n = 2) of the AHVLA post-exposure sera 
returned a ‘false negative’ result on the BioK302 and BioK260 (Table 4.4). While of the 
VIDO-InterVac post-exposure samples, ‘false negative’ results were seen using the BioK302 
(n = 2) and BioK260 (n = 3) (Table 4.4).The VIDO-InterVac post-exposure sera that 
produced negative ELISA results were regarded by VIDO-InterVac as low sero-converters to 
M. bovis using their own in-house ELISA. When the BioK302 Sample coefficient and 
BioK260 Delta Value are assessed, rather than the associated category, these samples could 
be regarded similarly in the current study. With the samples collected 68 days after M. bovis 
exposure combined with a low initial antibody response in these animals, it is possible that 
the level of antibody detectable at 68 days post-infection is reduced in comparison to the 
level that may have been detectable two to three weeks after exposure. The immune response 
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of cattle following exposure to M. bovis remains poorly understood. The time frame for 
which serum IgG antibodies to M. bovis become detectable following experimental infection 
has been reported as 10 to 14 days after onset of disease (Caswell et al., 2010) and two to 
four weeks following an invasive infection (Nicholas and Ayling, 2003, Robino et al., 2005). 
It is reported that antibodies can remain detectable for months to years (Le Grand et al., 
2002). The time frame after which antibodies become undetectable, to when peak antibody 
levels may be present and then the time frame for the antibody response to wane to detectable 
levels is not known. Given the inherent variability of M. bovis in general, it can be assumed 
that each animal’s individual immune response would be different. This is somewhat 
supported by AHVLA and VIDO-InterVac who supplied animal sera that were divided into 
low and high sero-converters. Given that the initial immune response of each animal can vary 
following experimental infection where the dose, route of exposure, pathogenic strain(s) and 
the sample collection time frame following exposure is known, it can be assumed that the 
time frame for antibodies to wane would be largely dependent on the individual animal.  
An unexpected finding was the negative BioK302 and BioK260 results produced by the 
positive control sera sourced from four batches of the BioK284 ELISA kit (Bio-X-
Diagnostics

, Belgium). Given that these samples are used as a positive control for M. bovis 
on a multiplex ELISA kit manufactured by Bio-X Diagnostics

 it was unexpected that they 
did not return a positive result on these two ELISAs. This finding helped support problems 
encountered during another study that was using the BioK284 ELISA kit (unpublished data). 
In addition to information obtained from Bio-X Diagnostics

 that often the sero-positivity for 
the M. bovis component of the BioK284 positive control does not reach the cut-off 
(unpublished data). That study found that the M. bovis component of the BioK284 
pentavalent ELISA kit often did not reach the validation cut-off point using the positive 
control sera supplied with the BioK284 ELISA kit. Validation issues with the other 
components of the kit (BoHV-1, BVDV, BRSV and BPIV-3) using these positive controls 
were not seen (unpublished). It is thought that the unexpected negative results of the 
BioK284 positive controls used in this study on the BioK302 and BioK260 ELISA are a 
result of the manufacturer attempting to supply single positive control sera that has high 
antibody levels to five bovine pathogens. Trying to achieve this in a single animal is 
troublesome. A synthetic positive control could be supplied, or sera from different animals 
could be combined. However, ensuring the levels of each antibody in the control sera remains 
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high enough to give the required signal in the ELISA would require continual monitoring and 
could be a source of test kit result variation between batches.  
The implications of changing a test’s cut-off are difficult to determine when little is known 
about what the test is in fact detecting. There is some evidence here that the BioK260 ELISA 
has a higher BioK260 DV ‘0’ category cut-off at 37% than that seen with the BioK302 
ELISA. Of the APCAH samples that returned sero-positive BioK302 ELISA results post-
infection (n = 11); only four of these returned a sero-positive BioK260 ELISA result 
(BioK260 DV category of ‘+’ or higher). Of those considered BioK260 sero-negative; all 
BioK302 sero-positive animals returned BioK260 DV results that were 26.8% or higher 
(Appendix 4). In other words, if a BioK260 DV category ‘0’ had a cut-off of 26%; all post-
infection samples that tested sero-positive on the BioK302 would also be considered sero-
positive on the BioK260. This finding is in contrast to a study by Bednarek et al. (2012) who 
suggested reducing the Se of a similar M. bovis ELISA developed by Bio-X Diagnostics

 
(BioK162). The authors suggested regarding the ‘0’ and ‘+’ categories as sero-negative and 
only samples returning results ‘++’ or higher be classified as sero-positive. The exact reason 
for making this suggestion was not given, other than the mention that if they did so “the sero-
prevalence in their study was more consistent with reports from other countries” (Bednarek et 
al., 2012). It must be noted that the BioK260 and BioK162 are different Bio-X Diagnostics

 
M. bovis ELISA kits and it is not known what the cut-off for each of the BioK162 categories 
were. Regardless, the choice of cut-off is highly dependent on the relative implications 
associated with false negative or false positive test results (Dohoo et al., 2010).  
Estimates for Se and Sp were calculated for each test after removing the APCAH and / or 
Bio-X Diagnostics

 control sera results from the dataset. The Bio-X Diagnostics

 were 
removed as some of these sera were supplied with the ELISA kits and as such in some 
instances were used to validate the kit test plate(s). As such, incorporating these sera into the 
estimations for Se and Sp could potentially bias the estimates. Assessment of the test Se and 
Sp following removal of these control sera reduced the Se of methods assessed and widened 
the 95% confidence intervals for both Se and Sp across all methods. This highlighted how 
imprecise the Se and Sp estimates calculated in this study are (Table 4.5). Removal of the 
APCAH sera from the analyses improved the Se estimates for all three diagnostic tests. Sera 
sourced from the APCAH comprised the largest proportion of samples with 70 / 110 (63.6%) 
of the test sera used in this study derived from this source. In the current study, the APCAH 
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post-infection test sera performed differently to samples sourced from both AHVLA and 
VIDO-InterVac. Many of the APCAH post-infection sera (collected 24 days following 
experimental infection with one strain of M. bovis) yielded negative results across all three 
methods assessed (Table 4.4). The reason for this is not known however, a possible reason 
could be associated with the infective M. bovis strain used in this experimental infection trial. 
If the M. bovis strain 3683 (Wawegama et al., 2014) either did not or poorly expressed the 
antigen used in either of the Bio-X Diagnostics

 ELISA kits, then the use of these kits will 
result in animals being falsely classified as negative with respect to the presence of M. bovis 
antibody. It is entirely possible that these animals may have developed antibody to a different 
M. bovis antigen(s) following infection with the 3683 strain. Similarly, if the M. bovis strain 
3683 strain poorly expresses the RA1 motif associated with the M. bovis VspA protein (used 
in WB analyses in this study), as well as lacks or poorly expresses the surface proteins VspG, 
VspH and VspO (all of which contain six or more repeats of the PGENKT amino acid repeat 
and comprise the RA1 motif of VspA) (Lysnyansky et al., 1999), then antibodies that react 
with this RA1 motif will not be present in the sample. Whether these possibilities are over 
represented in the APCAH sera; or the difference in the APCAH sera is purely an effect of 
the number of samples from this source it is not known. If more sera from VIDOO-InterVac 
and AHVLA were included, it is also possible the same differences could have been seen.  
The samples used in this study were sourced from experimental infection trials from three 
different laboratories. Variation in the age of the animals from which the sera were sourced, 
the infective strain(s) and dose / route of infection used in each of the different laboratories 
experimental infection trials as well as the time frame from experimental infection to sample 
collection makes the use of these samples as ‘reference’ sera not ideal. All these factors have 
the potential to influence the animal’s immune response to infection and inflate the Se 
estimates reported in this study. In a field situation; the timing between exposure / invasive 
infection; the dose of organisms; the route of infection and the number of M. bovis strains an 
animal is subjected to is not known. How this may affect the immune response of an 
individual and the subsequent production of antibody / antibodies to M. bovis following 
natural exposure / infection in a field situation is difficult to determine. Researchers should be 
mindful when using diagnostic tests with Se and Sp estimates derived from experimentally 
infected animals that these estimates may not be transferrable to animals naturally infected in 
a field situation when many factors are not controlled for. 
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The reason for the similarity in the ELISA kit test results may be a result of them both 
detecting antibodies using the ELISA method, being manufactured by the same manufacturer 
and highly likely, though it is not known, containing the same antigen. Hence, they are 
essentially detecting the same thing. Despite some similarity, differences in the two ELISAs 
were evident. Possible explanations for the variation seen may be due to; differences in the 
amount of antigen used to coat the test wells; the amount of detectable antibody(s) in the 
ELISA kit positive and negative control sera and the choice of cut-off used to define each of 
the sero-categories for the BioK302 and BioK260 ELISAs. It is also possible that a difference 
in the TMB conjugates used has affected the timing of the ELISA end point. In this case even 
if the antigen on both the BioK302 and BioK260 ELISA kits were constant, a change in the 
conjugate can affect and produce different results for the same test sample dilution. 
The usefulness of the BioK302 and BioK260 ELISA kits for the detection of sero-conversion 
using paired samples collected from animal’s pre- and post- experimental infection with 
M. bovis was assessed. It would be expected that sero-conversion would be detected from 
samples collected from animals 24 days or more following experimental infection. This 
however, was not the finding in the current study. In the current study, sero-conversion was 
detected in 35.3% and 8.3 % of paired animal sera using the BioK302 and BioK260 ELISAs 
respectively. This finding was unexpected, especially since the BioK260 is marketed to detect 
sero-conversion. The BioK302, although not marked to detect sero-conversion, it could be 
expected that a sample collected from an animal following experimental infection should 
return a positive BioK302 result. The lack of sero-conversion in the current study is mainly 
driven by the APCAH sera with few post-infection sera exceeding the 37% cut-off assigned 
by the manufacturer to both the BioK302 and BioK260 ELISA kits. However, only two of 
the VIDO-InterVac (n = 4) and one of the AHVLA (n = 2) animals with paired sera showed 
sero-conversion post-infection. Because of this the source of samples and infective strain 
used cannot be the only explanation of these results.  
In conclusion, none of the tests assessed here, using the samples described, were both 100% 
Se and 100% Sp for the detection of M. bovis antibody. This is not surprising given the 
inherent inverse relationship that exists between Se and Sp in relation to where the tests cut-
off is assigned. Improving a tests Se, reduces the tests Sp and vise versa. Although WB had 
the highest estimates for Se and Sp combined, it is not useful as a screening test for a large 
number of samples. The BioK260 had the highest Sp estimates of the three methods assessed; 
however the 95% confidence interval of this estimate was affected when APCAH test sera 
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and Bio-X Diagnostics

 control sera were not used in the calculation. So although the point 
Sp estimate is 100%, the true Sp is likely to fall somewhere between the lower and upper 95% 
confidence intervals. The BioK302 on the other hand had the higher Se estimate of the two 
ELISA kits, but again the 95% confidence intervals are extremely wide and putting faith in 
the estimates calculated here is not advised. The overall usefulness of either of the 
commercial ELISAs assessed here as a screening tool used at the herd level lies in the 
purpose for which it is intended. If the aim is to identify M. bovis free herds, then a test that 
has a high Se and produces few false negatives is required. Based on the results of this study, 
neither the BioK302 nor the BioK260 would be useful for this purpose. If the aim is to 
identify the presence of M. bovis within a herd, then either the BioK302 or BioK260 would 
be suitable, however the results must be interpreted knowing that neither test will detect all 
positive animals in the study population, so the true prevalence of M. bovis will be 
underestimated. That said, the impact of imperfect Sp should not be overlooked because in a 
population where the true prevalence of M. bovis antibody is low, a test with imperfect Sp can 
in fact overestimate the apparent prevalence as a consequence of false positive results. 
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CHAPTER 5   Estimation of the sero-prevalence of Mycoplasma bovis-specific antibody 
in Australian feeder cattle  
5.1 Introduction 
The sero-prevalence of M. bovis-specific antibody among the beef cattle population in Australia is 
not known. As discussed in Chapter 4, there are many factors that have limited research in this area. 
Access to, and the availability of immunological detection methods which have been validated and 
for which Se and Sp information are available are arguably the main limitations. These methods also 
need to be appropriate for use as a screening tool, enabling large numbers of samples to be 
processed relatively quickly, efficiently and cost effectively. In the absence of these methods, sero-
prevalence studies are difficult to conduct. 
Currently in Australia, two ELISA kits for the detection of M. bovis antibody are available 
commercially (Chapter 4). Both these ELISA kits are produced by the same manufacturer, Bio-
X Diagnostics

 (Belgium); but are marketed for different purposes. The BioK302 requires a single 
serum sample and is marketed as an ELISA kit to determine the immune status (sero-positive or 
sero-negative) of an animal to M. bovis at the time the sample was collected (Bio-X Diagnostics
®
, 
2013b). While, the BioK260 requires two serum samples from the same animal collected two to 
three weeks apart and is marketed as an ELISA kit to indicate recent exposure of the animal to 
M. bovis (Bio-X Diagnostics
®
, 2013a). Using the BioK260 ELISA kit, exposure to M. bovis is 
considered to have occurred if the test result of the second sample is two Delta Value categories 
higher than the first sample (Chapter 4). Although these kits are commercially available, Se and Sp 
data are not available.  
The aim of this study was to estimate the sero-prevalence of M. bovis-specific antibody at the time 
of feedlot induction and at draft (approximately 42 days on feed). An additional aim was to also 
determine the level of sero-conversion or sero-increase to M. bovis that occurs between feedlot 
induction and draft. This was performed using paired serum samples collected from a subset of 
animals that were enrolled in another study that investigated risk factors associated with BRD in 
Australian feedlot cattle known as the National Bovine Respiratory Disease Initiative (NBRDI).  
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5.2  Materials and methods 
5.2.1  Study population  
Paired sera from cattle selected for serological testing were drawn from a bovine serum bank 
collected as part of the NBRDI (B_FLT_0224 V2). This project was jointly funded by Meat and 
Livestock Australia (MLA) and the Queensland Government and co-ordinated by The University of 
Queensland (UQ) and DEEDI. The project was performed under animal ethics approvals 
SVS/383/07/MLA, SVS/495/08/MLA and SVS/125/10/MLA and AEC09/027 (Barnes et al., 2014). 
A total of 14 feedlots participated in the project across Australia from July 2009 to December 2011. 
These feedlots were located in four states: New South Wales (n = 7), Queensland (n = 5), South 
Australia (n = 1) and Western Australia (n = 1) as illustrated in Figure 5.1. The two regions where 
feedlot density is highest, the Riverina and the Darling Downs, contributed the most feedlots, with 
six and five participating feedlots, respectively (Barnes et al., 2014).  
 
Figure 5.1: Distribution of accredited feedlots in Australia by size (Source FSA Consulting, 
2011) overlaid with the location of participating feedlots (white stars) (Barnes et al., 2014).  
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Managers of feedlots with a minimum capacity of 1,000 head and the necessary resources to keep 
the required records were invited to participate in the NBRDI (Barnes et al., 2014). Cattle were 
enrolled by cohort where a cohort comprised all animals in a single feedlot pen following the 
induction process (i.e. the application of an identifying ear tag, recording of the animal’s live weight 
on entry, treatment for internal and external parasites, application of a hormonal growth promotant 
(HGP) if required, and the entry of animal identifiers into an electronic feedlot system). Cohorts 
were generally selected at the convenience of the feedlot managers despite attempts to randomise 
the selection process (Hay et al., 2014). The study population had a hierarchical structure such that 
35,160 enrolled cattle were clustered within 1,077 groups defined 13 days before induction. Groups 
of animals were clustered within 170 cohorts, which were clustered within 14 feedlots (Barnes et 
al., 2014), (Table 5.1). Each animal was monitored from induction until it left the study cohort for 
any reason (i.e. removal to the hospital pen or another pen separate from the cohort, death or feedlot 
exit), (Barnes et al., 2014). A total of 35,160 animals were enrolled in the NBRDI. Five animals 
were ineligible for the NBRDI analysis dataset because they died (n = 1) or were removed from the 
feedlot pen (n = 4) before induction. A further 24 animals were lost to follow-up, leaving 35,131 
animals in the NBRDI analysis dataset.  
5.2.2 Sample collection from NBRDI enrolled animals 
At the time of induction and draft (approximately 42 days on feed), at least 5 ml of whole blood was 
collected from the caudal or jugular vein from all enrolled cattle by either a veterinarian or member 
of the feedlot personnel trained by a veterinarian (Barnes et al., 2014). Feedlots were requested by 
the NBRDI study personnel to collect the draft sample on or as close to 42 days on feed (DOF) as 
possible, however this was not always practical for the participating feedlots. Because the process 
of sample collection was co-ordinated by the participating feedlot and was dependent on the 
availability of feedlot personnel and time and / or the timing of a veterinarian visit, the timing of the 
draft sample collection was not consistent between feedlots or cohorts of animals. Timing of the 
draft sample collection from NBRDI enrolled animals selected for this study ranged from 31 DOF 
to 75 DOF, with 79.3% (1,074/1,354) recorded as having their draft sample collected between 40 
and 49 DOF (Table 5.2).  
  
 116 
 
Table 5.1: Number of cattle enrolled in each participating feedlot, date range of enrolment 
and size of cohort by feedlot (Barnes et al., 2014).  
Feedlot  
Enrolment date 
No. of animals 
No. of 
cohorts 
Cohorts 
First Last 
No. animals per cohort 
Median Min  Max 
A Dec-09 May-10 633 4 156.5 141 179 
B Sep-09 Nov-11 5,364 19 350 63 350 
C May-09 Apr-10 539 5 105 75 145 
D Sep-09 Dec-11 6,114 22 272.5 105 395 
E Mar-10 Sep-11 2,193 17 127 56 239 
F Mar-10 Sep-10 466 3 157 149 160 
G Jun-09 Dec-11 2,999 21 90 80 285 
H Aug-09 Dec-11 2,982 20 148.5 130 180 
I Feb-11 Nov-11 2,569 14 229 17 241 
J Oct-09 Dec-11 5,616 18 355 62 355 
K Mar-11 Nov-11 1,536 9 184 87 252 
L Mar-09 Jul-09 500 3 163 129 208 
M Jul-09 May-11 1,927 8 273.5 180 280 
N Oct-09 May-11 1,693 7 240 229 250 
Total Mar-09 Dec-11 35,131 170 186 17 395 
 
 
Table 5.2: Distribution of the number of days on feed at timing of draft sample collection for 
NBRDI animals selected for the M. bovis sero-prevalence study  
No. days on feed No. animals (%) 
30 < 40 128 (9.5%) 
40 < 45 736 (54.3%) 
45 < 50 338 (25.0%) 
≥ 50 152 (11.2%) 
Total 1,354 (100%) 
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After collection from the animal, samples were allowed to clot at room temperature before 
refrigerating. Samples were transported as soon as practical to the DEEDI laboratory where on 
receipt they were stored at 4°C prior to processing. At the time of processing, the samples were 
visually inspected to make an overall assessment of sample integrity. For high quality samples, 
where clear separation was observed between the serum and the blood clot, up to 2 ml of serum was 
aspirated and transferred to a 96-well 2 ml storage plate. Some samples received were sub-optimal 
with no visible serum separation following clotting. In an effort to recover a useable sample for 
subsequent analysis, these samples were centrifuged or incubated at various temperatures in an 
effort to extract serum. Plates were stored at -80°C until required. Details of the samples provided 
by feedlot personnel were recorded as the samples were processed and subsequently transferred to 
Microsoft
®
 Excel (.xls) spreadsheets. Where no sample could be recovered, this was recorded on 
the appropriate spreadsheet (Barnes et al., 2014). 
5.2.3 Animal data collection for animals enrolled in the NBRDI 
Animal data were obtained from several different sources and at different time points. Detailed 
animal-level data were recorded for each animal at the time of feedlot entry during the induction 
process and included: identification number, arrival date, induction date, first day on feed, sex, 
dentition, breed, and induction weight. This data was supplied as animal-level electronic files which 
were collated into a central NBRDI database (Barnes et al., 2014). All data used in analyses and 
pertaining to cattle selected as part of the sero-prevalence study for the detection of M. bovis-
specific antibody were obtained from the central NBRDI database. 
5.2.4 National Livestock Identification System data 
The Australian National Livestock Identification System (NLIS) requires that all cattle are 
individually identified with a unique identification string that may be applied as an ear tag or a 
rumen bolus. This unique identifier must be applied to every animal Australia wide, before they 
leave their farm of origin. Part of the unique identifier is made up of a unique Property 
Identification Code (PIC) which uniquely identifies each farm or congregation of farms provided 
they are owned and registered by the same owner and located in the same region. The NLIS relies 
on registered users electronically scanning animals every time they are moved from one PIC 
location to another ('transfers') and uploading these data to an online national electronic database. 
The database records the PIC of issue for each animal and the source and destination PIC, transfer 
date, transfer type and waybill number for all individual animal transfers. The transfer type 
distinguishes between transfers to- or from- saleyards and 'point-to-point' transfers (between two 
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PICs). Validation and correction of the NLIS data used in the NBRDI involved consolidating and 
simplifying the individual animal records to create a logical sequence from the PIC of issue to the 
feedlot. Any missing transfer dates were imputed based on common group-level transfers (Barnes et 
al., 2014).  
The NLIS data for each animal was used to define the group of animals that each animal was with 
at defined time points in relation to day 0. Day 0 was defined as the day of induction for those 
animals that are not pre-assembled, and for those that are pre-assembled, day 0 was the day the 
animals were moved into the feedlot pen (Barnes et al., 2014). Pre-assembly is a management 
practice whereby animals from different farms are assembled on pasture close to the feedlot for 
various periods of time prior to induction (Hay et al., 2014). Of the 14 participating feedlots, three 
routinely practiced pre- assembly.  
5.2.5 Sample size calculation 
The sample size was determined using an online sample size calculator named: “sample size to 
estimate a true prevalence with an imperfect test”; available at http://epitools.ausvet.com.au 
(Sergeant, 2013). Without accounting for possible clustering of samples, the input values used 
included an assumed true prevalence of 50%, a large study population, an assumed Se of 80%, an 
assumed Sp of 80%, a 95% confidence level with a desired precision of 0.05. At the time of 
performing these calculations, Se and Sp estimates for both the BioK302 and BioK260 ELISA kits 
were not yet available, as bovine sera of known sero-status had not been obtained at this time. 
Consequently, estimations used as input values were made after reviewing the available literature 
on M. bovis serological test Se and Sp and reported sero-prevalences from other countries. The 
estimated sample size required was 1,068. 
The sample size estimate was then inflated to adjust for clustering by purchase group (animals 
purchased direct from the vendor; or from a single saleyard on the same day that formed part of the 
same cohort). This required an estimate of the variance inflation factor (VIF), the factor by which 
the initial estimate needed to be inflated. This was estimated using the following equation: 
                             
(Dohoo et al., 2010) 
Where    is the average cluster size and     is the intra-class correlation coefficient (ICC). 
Mycoplasma bovis serology results obtained using a multiplex ELISA for BRD pathogens, the 
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BioK284 ELISA (Bio-X Diagnostics
®
, 2012), (Section 2.1.4) for a subset of NBRDI enrolled 
animals were used to estimate the ICC for purchase group. This subset of animals were selected as 
part of a BRD case-control study (n = 7,450) nested within the main NBRDI study. Using this 
dataset and dichotomised BioK284 ELISA results [any result in a ‘+’ category through to ‘+++++’ 
were considered sero-positive (n = 3,814); and any result in a ‘0’ category was considered sero-
negative (n = 3,517), (119 animal results were missing)]. By fitting null mixed effects logistic 
regression models using the xtlogit command in Stata/SE 12.1

 (Statacorp, College Station, Texas, 
USA) the ICC ( ) for clustering of M. bovis antibody sero-positivity at the time of induction by 
purchase group was estimated to be 0.26.  
Based on the number of purchase groups in the NBRDI and the initial sample size estimate, the 
average cluster size was estimated as two. The VIF was calculated to be 1.26. The M. bovis-specific 
antibody sero-prevalence study sample size calculated using the online sample size calculator 
(Sergeant, 2013) of 1,068 was multiplied by the VIF of 1.26 to give a final sample size estimate of 
1,346.  
5.2.6  Animal eligibility criteria for M. bovis serological testing 
Animals enrolled in the NBRDI were eligible for selection in the M. bovis-specific antibody sero-
prevalence study if records in the NBRDI database indicated an adequate serum sample was 
available for both the induction and draft time points. Of all animals in the NBRDI analysis dataset 
(n = 35,131), a total of 29,512 animals were eligible and using the statistical package Stata/SE 
12.1

(Statacorp, College Station, Texas, USA) were assigned a random number.  
5.2.7 Collation and storage of sera collated from the NBRDI serum bank 
Details of sample locations for the first 1,346 randomly assigned numbers (in sequential order) were 
extracted from the NBRDI database and comprised the primary sample selection list. Sample 
locations for an additional 15% (n = 202) of randomly assigned numbered animals (in sequential 
order) were also extracted at the same time to account for possible inadequate or missing samples. 
This list comprised the secondary sample selection list.  
Frozen 96-well 2 ml storage plates from the NBRDI serum bank were allowed to thaw whilst 
refrigerated at 4°C overnight. A 50 µl aliquot of the induction and the draft sera for each randomly 
selected animal were collated in sequential order from the primary sample selection list. If an 
induction or draft sample was not available from any of the selected animals on the primary list, 
they were substituted with samples from an animal in sequential order from the secondary sample 
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selection list. Each serum aliquot were carefully removed and transferred to a 96-well 200 µl 
storage plate (Axygen). Induction sera were placed in odd columns while the draft sera were placed 
in even columns. Induction and draft sera from the same animal were placed so that they were 
adjacent to each other in the same row. As each plate was filled, they were covered with adhesive 
foil prior to storage at 4°C until required. The 96-well 2 ml storage plates comprising the NBRDI 
serum bank of samples were returned to storage at -80°C. The details of sample location for each 
selected animal were recorded and the details later transferred to a Microsoft
®
 Excel (.xls) 
spreadsheet.  
Paired serum samples were collated until samples from a minimum of 1,346 animals had been 
obtained. In total paired sera from 1,354 animals were collated. These were obtained from 1,445 
randomly selected animals. Inadequate induction and / or draft samples were encountered for a total 
of 91 animals (Figure 5.2). Reasons for unavailability included precipitation of the sample during 
storage and the prior use of the sample in other tests conducted as part of the NBRDI. 
5.2.8  Commercial ELISA kit procedure  
All paired sera (induction and draft) were tested for the presence of M. bovis-specific antibody 
using the commercially available BioK302 and BioK260 M. bovis ELISA kits as described in 
Section 4.2.3. Testing was carried out as described in Sections 4.2.3.1 and 4.2.3.2 respectively, 
ensuring both induction and draft sera from the same animal were tested on the same ELISA kit test 
plate. Two batches of BioK302 96-well test plates (MYC13J16 and MYC14C04) and three batches 
of BioK260 96-well test plates (SMYC13J16, SMYC13K26 and SMYC14C04) were used to obtain 
ELISA results for all selected animals.  
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Figure 5.2: Flow diagram depicting the selection of animals from those enrolled in the 
National BRD Initiative and sample collation process 
 
5.2.8.1  ELISA data management 
Management of ELISA kit results has been previously described in Section 4.2.4. As described in 
Section 4.2.4, each 96-well test plate was numbered when used and the associated .xls file 
containing the raw OD readings obtained from the sera tested on that plate were labelled to reflect 
the test plate number. When all sera had been tested, .xls files for all plates were collated into one 
and the raw OD reading for each test sample assigned to the corresponding sample ID. The date of 
testing, test kit batch number and 96-well test plate number were recorded. Sample calculations 
using the raw OD readings to categorise the final ELISA result and test plate validation calculations 
were performed using Stata/SE 12.1

(Statacorp, College Station, Texas, USA). 
5.2.8.2  ELISA plate validation  
Test plates were validated according to the manufacturer’s instructions for both the BioK302 (Bio-
X Diagnostics
®
, 2013b) and BioK260 (Bio-X Diagnostics
®
, 2013a) ELISA kits as described in 
Section 4.2.5.  
Total enrolled NBRDI animals
              n = 35,160
NBRDI animals lost to follow-up
                   n = 24
NBRDI animals that died or were
removed from the cohort on day 0
                    n = 5
No. animals in NBRDI analysis dataset
                   n = 35,131
No. NBRDI animals eligible for M. bovis
       antibody sero-prevalence study
                    n = 29,512
No. animals randomly selected for inclusion in the 
      M. bovis antibody sero-prevalence study
                             n = 1,354
 
NBRDI animals with one or more serum 
     samples missing or not verified
                    n = 5,619
No. animals with induction and/or draft
  sera missing or inadequate at the time
              of collating samples             
                        n = 91
No. NBRDI aniamls not randomly 
   selected for inclusion  in the 
 M. bovis sero-prevalence study 
               n = 28,067
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5.2.8.3  Categorisation of ELISA optical density results 
Categorisation of the BioK302 and BioK260 ELISA kit results has been previously described in 
Section 4.2.6. The BioK302 ELISA is marketed to determine the immune status of the animal being 
tested to M. bovis and results obtained using this kit are classified as sero-negative (Sample 
coefficient < 37%) or sero-positive (Sample coefficient ≥ 37%), (Bio-X Diagnostics®, 2013b). For 
analysis purposes, results obtained using the BioK302 ELISA were categorised based on the 
manufacturer’s Sample coefficient cut-off of 37% into a binary variable, sero-positive or sero-
negative. The BioK260 on the other hand is not marketed for the purpose of determining the 
immune status of an animal from a single serum sample (Section 4.2.6.2), (Bio-X Diagnostics
®
, 
2013a). In addition, results are categorised into six DV categories, hindering comparison of the 
results obtained with this kit and those obtained using the BioK302. To overcome this for analysis 
purposes, the BioK260 DV categories were dichotomised (Section 4.2.6.2).  
5.2.8.3.1 Assessment of an increase in M. bovis-specific antibody levels between induction 
and draft 
Sero-conversion based on the BioK302 ELISA results was defined as an animal that returned a 
sero-negative result at induction and a sero-positive result at draft. Only animals that were sero-
negative at feedlot induction were regarded as having the potential to sero-convert using the 
BioK302 ELISA between induction and draft. Animals returning a BioK302 sero-positive result at 
feedlot induction were regarded as being initially high and not included in the BioK302 sero-
conversion analyses. 
Using the BioK260 ELISA kit results and the DV categories as defined by the manufacturer, an 
apparent increase in detectable M. bovis-specific antibody of two or more BioK260 DV categories 
between the time of induction and draft were assessed. Three BioK260 draft outcomes were 
defined. These were ‘sero-conversion’, ’re-exposure’ and ‘sero-increase’. A change from an 
induction result falling into the BioK260 DV category of ‘0’ to a draft BioK260 DV category of at 
least ‘++’ was defined as BioK260 sero-conversion. Increases from an induction category of ‘+’, 
‘++’ or ‘+++’ to a draft category of at least ‘+++’, ‘++++’ or ‘+++++’, respectively, were classified 
as a re-exposure. The sero-increase outcome included animals in the sero-conversion and re-
exposure categories. Animals returning an induction value in the ‘++++’ or ‘+++++’ categories 
were classified as being high initially and consequently did not have the potential to increase two or 
more BioK260 DV categories between induction and draft. These animals were excluded from the 
BioK260 sero-conversion, re-exposure and sero-increase calculations.  
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5.2.9  Statistical analyses 
All data were managed using the statistical package Stata/SE 12.1

(Statacorp, College Station, 
Texas, USA). The apparent prevalence and associated 95% confidence intervals were obtained 
using the (prop command) while the level of agreement between tests was assessed using the kappa 
statistic (kap command).  
5.2.9.1  Series and parallel interpretation of two screening tests 
The use of multiple tests is an often-used approach to improve the overall diagnostic ability of the 
screening (or diagnostic) process (Dohoo et al., 2010). If samples are tested on two tests, as in this 
case, the results can be interpreted in one of two ways (Dohoo et al., 2010). With series 
interpretation, only animals that test positive on both tests are considered test positive. Series 
interpretation of two tests increases Sp but decreases Se. With parallel interpretation, animals that 
are test positive on one test, the other test, or both tests are considered test positive. Parallel 
interpretation of two test results increases the Se but decreases the Sp (Dohoo et al., 2010). An 
initial review of the results obtained in this chapter revealed that the results using field samples 
obtained on the BioK302 and BioK260 appeared to differ from those obtained using experimental 
infection samples in Chapter 4. In Chapter 4 it was estimated that the BioK302 was more Se than 
the BioK260, with a greater proportion of experimental infection samples testing positive using the 
BioK302. Both ELISAs appeared to have a high specificity. An initial review of the results here 
indicated that more animals (of unknown M. bovis infection status) were returning a positive result 
using the BioK260 than the BioK302, suggesting that in this case the BioK260 may have a higher 
Se and / or the Sp of the ELISAs was lower than initially calculated and differed between the two 
ELISAs. For this reason it was decided that series and parallel interpretation of the results obtained 
from field samples would be assessed in addition to the individual results obtained using the two 
ELISA kits. 
5.2.9.2  Selection of clustering variables 
The NBRDI study data had a nested hierarchical structure with four levels: feedlot, cohort, group 
and animal. The two higher levels of clustering (feedlot and cohort) were defined by the data. 
However, there was no natural definition of the clustering relating to the grouping structure of the 
animals prior to arrival at the feedlot. The group consisted of animals in the same cohort that each 
animal was with at specified time points in relation to day 0. Because the group of animals that any 
particular animal was in could change over time before feedlot entry, the data obtained from the 
NLIS (Section 5.2.4) was used to identify animals in the same cohort that were together at the same 
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PIC at defined time points in relation to day 0. These time points were day -2, day -7, day -13, day -
28, day -91, day -365 and day -500 and the groups of animals identified to be together at these time 
points were termed group-2, group-7, group-13, group-28, group-91, group-365 and group-500, 
respectively (Barnes et al., 2014).  
5.2.9.2.1 Induction clustering variable 
Animals within the same group at any particular time point are likely to be more similar to each 
other with respect to the outcome (i.e. the presence of detectable M. bovis-specific antibody at the 
time of feedlot induction), than with animals drawn from a different group at the same time point 
(Dohoo et al., 2010). On the basis of this assumption, an allowance for clustering of the outcome is 
required. The incubation period whereby M. bovis infection cannot be detected using antibody 
detection methods has been reported as 10 -14 days (Sachse et al., 1993) and up to four weeks 
(Nicholas and Ayling, 2003, Robino et al., 2005) after the onset of M. bovis disease or following an 
invasive infection respectively. As such, it was decided that the group that an animal was in 13 days 
prior to day 0 (group-13) would provide the best balance between the timing with respect to 
possible exposure to M. bovis and the detection of antibody at the time of feedlot induction. 
5.2.9.2.2 Draft clustering variable 
At draft animals within the same cohort are likely to be more similar to each other with respect to 
the outcome (i.e. the presence of detectable M. bovis-specific antibody at 42 DOF), than with 
animals drawn from a different cohort at the same time point (Dohoo et al., 2010). Because of this, 
an allowance for clustering of the outcome is required. With the transmission and exposure to most 
respiratory pathogens among animals in the same cohort occurring early in the feeding period and 
hence the most likely cause of clustering for sero-conversion or a sero-increase in M. bovis antibody 
at draft. It was decided that adjusting for cohort would provide the best balance between the timing 
with respect to possible exposure to M. bovis and the detection of antibody at draft.  
5.2.10   Estimation of true prevalence 
True prevalence estimates were determined using an online calculator named: “true prevalence and 
sample size”; available at http://epitools.ausvet.com.au (Sergeant, 2013). The estimates and 
associated 95% confidence intervals were calculated as described by Rogan and Gladen (1978). 
True prevalence estimates that are less than zero or greater than one are not consistent with assumed 
Se and Sp values, and are indicated by '< 0' and '> 1', respectively (Rogan and Gladen, 1978). True 
sero-prevalence estimates using the BioK302 and dichotomised BioK260 ELISA results for 
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M. bovis-specific antibody at feedlot induction were calculated. Input values were the sample size 
(1,354), the number of animals testing sero-positive, a confidence level of 95% and (i) point 
estimates for Se and Sp, (ii) the lower 95% confidence interval estimate for Se and upper 95% 
confidence interval estimate for Sp and (iii) the upper 95% confidence interval estimate for Se and 
lower 95% confidence interval estimate for Sp. The Se and Sp estimates used have been reported for 
both the BioK302 ELISA and dichotomised results from the BioK260 ELISA in Chapter 4. A 
summary of the Se and Sp estimate values used as input values in this study are listed in Table 5.3. 
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Table 5.3: Test sensitivity and specificity estimates used as input values for the estimation of true prevalence 
Se and Sp estimates used were derived from 
experimental / control sera sourced from: 
Point estimate 95% CI high Se / low Sp 95% CI low Se / high Sp 
BioK302 BioK260 BioK302 BioK260 BioK302 BioK260 
Se Sp Se Sp Se Sp Se Sp Se Sp Se Sp 
APCAH, VIDO-InterVac, AHVLA and Bio-X 
Diagnostics
®
 
50% 96% 35% 100% 79% 88% 85% 94% 20% 99% 5% 100% 
VIDO-InterVac, AHVLA and Bio-X 
Diagnostics
®
 
67% 100% 63% 100% 94% 81% 76% 81% 39% 100% 48% 100% 
APCAH, VIDO-InterVac, and AHVLA  47% 96% 28% 100% 87% 87% 92% 93% 10% 99% 1% 100% 
VIDO-InterVac and AHVLA  69% 100% 62% 100% 100% 70% 99% 70% 42% 100% 3% 100% 
AHVLA: Animal Health and Veterinary Laboratories Agency; APCAH: Asia-Pacific Centre for Animal Health; CI: Confidence interval; Se: Sensitivity; Sp: 
Specificity; VIDO-InterVac; Vaccine and Infectious Disease Organization International Vaccine Centre. 
The BioK260 sensitivity and specificity estimates shown have been calculated using dichotomised BioK260 results whereby a BioK260 Delta Values category of ‘0’ 
was considered negative for M. bovis antibody, while a BioK260 Delta Value category ≥ ‘+’ was considered positive for M. bovis antibody. True prevalence 
estimates for induction and draft were calculated for induction and draft using point, and 95% confidence interval low sensitivity / high specificity and high 
sensitivity / low specificity estimates calculated using M. bovis experimental infection trial samples (Chapter 4). These estimates account for clustering of the sera by 
source. 
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5.3 Results 
5.3.1  ELISA plate validation 
5.3.1.1  BioK302  
A total of 35 BioK302 96-well test plates were used; 33 (94.3%) of these plates were validated 
while two (5.7%) were not validated as per the manufacturer’s instructions. Both non-validated test 
plates were sourced from batch number MYC13J16. The reason for non-validation was not the 
same for both plates. On one plate, the negative control serum supplied with the kit exceeded the 
minimum OD reading threshold of 0.4, giving an OD reading of 0.422. The second non-validated 
test plate failed to exceed the recommended positive control serum OD minus the negative control 
serum OD threshold of 0.7 at ten minutes, returning an OD reading of -0.052. Results from non-
validated test plates were not used in the analyses and the sera from animals that were tested on 
both of the non-validated test plates were retested. 
Final results used in the analyses for paired sera (induction and draft) were derived only from 
validated test plates. Paired sera results for 1,267 animals were derived from 28 test plates of the 
BioK302 ELISA kit batch number MYC13J16, while final results for 87 animals were derived from 
five test plates of batch number MYC14C04.  
5.3.1.2  BioK260 
A total of 68 BioK260 96-well test plates were used; 62 (91.2%) of these were validated while six 
(8.8%) were not validated as per the manufacturer’s instructions. All non-validated BioK260 
ELISA kit test plates were derived from batch number SMYC13J16 and in all cases the reason for 
non-validation was poor OD performance of the positive control serum supplied with the kit (i.e. 
the positive control serum did not exceed the 0.8 OD threshold at ten minutes). Results from non-
validated test plates were not used in the analyses and the sera from animals that were tested on the 
non-validated test plates were retested. 
Final results used in the analyses for paired sera (induction and draft) were derived only from 
validated test plates. Paired sera results for 1,236 animals were derived from 55 test plates of the 
BioK260 ELISA kit batch number SMYC13J16. Final results for paired sera from four animals 
were derived from one test plate of the BioK260 ELISA kit batch number SMYC13K26. While 
final results for paired sera from 114 animals were derived from six test plates of the BioK260 
ELISA kit batch number SMYC14C04.  
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5.3.2  Prevalence of M. bovis-specific antibody at feedlot induction 
Table 5.4 provides a comparison of results obtained at induction using the BioK302 and BioK260 
ELISA kits.  
5.3.2.1  Apparent prevalence estimates 
At the time of feedlot induction and accounting for clustering by group-13, 3.5% (95% CI: 2.0 -
 5.0%, 47/1,354) of animals were found to be sero-positive for M. bovis antibody using the 
BioK302 ELISA kit (Table 5.4 and Table 5.5). Using the dichotomised BioK260 ELISA kit results, 
5.8% (95% CI: 4.2 – 7.3%, 78/1,354) of animals were classified as sero-positive for M. bovis 
antibody (Table 5.4). The observed agreement between the BioK302 and dichotomised BioK260 
ELISA results was 95.6%; the expected agreement due to chance alone was 97.2% and the kappa 
statistic 0.51, indicating a moderate strength of agreement (Landis and Koch, 1977). 
Using series interpretation of results obtained using the two ELISAs, the apparent prevalence of 
M. bovis antibody at induction was estimated to be 2.4% (95% CI: 1.3 - 3.6%, 33/1,354). While, 
parallel interpretation of the two test results estimated the apparent sero-prevalence to be 6.8% 
(95% CI: 5.0 - 8.6%, 92/1,354), (Table 5.5). 
5.3.2.2  True prevalence estimates 
True sero-prevalence estimates for M. bovis antibody at feedlot induction were calculated using Se 
and Sp estimates listed in Table 5.3. These estimates were derived using sera sourced from M. bovis 
experimental infection trails and control sera provided with Bio-X Diagnostics

 commercial ELISA 
kits (Chapter 4). Estimates for the BioK302 and BioK260 ELISAs were calculated using the 
BioK302 and dichotomised BioK260 ELISA results. Estimates and associated 95% confidence 
intervals are provided in Table 5.6.  
The true sero-prevalence estimate at induction using the point Se and Sp estimates ranged from <0 –
 5.2% (95% CI: < 0 – 6.6%) and 5.7 – 20.6% (95% CI: 1.7 – 25.0%) using the BioK302 and 
dichotomised BioK260 ELISA results respectively (Table 5.6). These estimates encompass the 
apparent prevalence estimates described above (Section 5.3.2.1). Two of the BioK302 true 
prevalence estimates were < 0% when using point estimates obtained when APCAH sera were 
included in the Se and Sp estimate calculation (Table 5.6). The true prevalence estimate less than 
zero indicates that the result is not consistent with assumed Se and Sp estimates. 
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Table 5.4: Comparison of induction and draft sera results obtained using the BioK302 and BioK260 ELISA kits 
BioK302 Total No. 
Dichotomised BioK260 BioK260 DV category 
Negative Positive 0 + ++ +++ ++++ +++++ 
Induction samples          
Negative 1,307 1,262 45 1,262 35 4 3 2 1 
Positive 47 14 33 14 15 9 7 1 1 
Total 1,354 1,276 78 1,276 50 13 10 3 2 
Draft samples          
Negative 1,011 756 255 756 180 60 9 1 5 
Positive 343 40 303 40 93 98 70 33 9 
Total 1,354 796 558 796 273 158 79 34 14 
DV: Delta Value 
BioK302 and BioK260 ELISA kit results obtained using sera collected at the time of induction and draft from randomly selected animals (n = 1,345) enrolled in the 
National BRD Initiative. The dichotomised BioK260 Delta Value categories are shown to the left of the number of samples falling into each of the Delta Value 
categories using the BioK260 ELISA kit. 
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Table 5.5: Apparent sero-prevalence estimates for M. bovis-specific antibody at feedlot induction and draft using the BioK302 ELISA and 
dichotomised BioK260 ELISA results interpreted separately and in series and parallel. 
Apparent prevalence estimate BioK302 Dichotomised BioK260 Series interpretation Parallel interpretation 
Induction 3.5% (1.98 - 4.96%) 5.8% (4.18 – 7.34%) 2.4% (1.25 - 3.62%) 6.8% (5.01 - 8.58%) 
Draft 25.3% (21.85 - 28.81%) 41.2% (36.84 - 45.58%) 22.4% (19.05 - 25.70%) 44.2% (39.78 - 48.55%) 
Induction apparent prevalence estimates account for clustering by group-13 while draft apparent prevalence estimates account for clustering by cohort. Confidence 
intervals (95%) are shown in parentheses. 
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Table 5.6: True sero-prevalence estimates for M. bovis-specific antibody at feedlot induction and draft using the BioK302 ELISA and 
dichotomised BioK260 ELISA results 
Se and Sp estimates used 
were derived from 
experimental / control 
sera sourced from: 
True prevalence estimate 
Point Se and Sp  95% CI high Se / low Sp 95% CI low Se / high Sp 
BioK302 
Dichotomised 
BioK260 
BioK302 
Dichotomised 
BioK260 
BioK302 
Dichotomised 
BioK260 
Induction       
APCAH, VIDO-InterVac, 
AHVLA and Bio-X 
Diagnostics

 
< 0% 5.7% (1.7 - 9.7%) < 0% < 0% 13.0% (7.9 – 18.1%) > 100% 
VIDO-InterVac, AHVLA 
and Bio-X Diagnostics

 
5.2% (3.7 – 6.6%) 9.1% (7.2 - 11.1%) < 0% < 0%  8.9% (6.4 – 11.4%) 12.0% (9.4 – 14.6%) 
APCAH, VIDO-InterVac, 
and AHVLA  
< 0% 20.6% (16.1 – 25.0%) < 0% < 0% No result > 100% 
VIDO-InterVac and 
AHVLA  
5.0% (3.6 – 6.4%) 9.3% (7.3 – 11.3%) < 0% < 0% 8.3% (5.9 – 10.6%) > 100% 
        
Draft       
APCAH, VIDO-InterVac, 
AHVLA and Bio-X 
Diagnostics

 
46.4% (41.3 – 51.4%) > 100% 19.9% (16.4 – 23.4%) 44.6% (41.3 – 47.9%) > 100% > 100%  
VIDO-InterVac, AHVLA 
and Bio-X Diagnostics

 
37.8% (34.4 – 41.3%) 65.4% (61.3 – 69.6%) 8.4% (5.4 – 11.5%) 39.0% (34.4 – 43.6%) 65.0% (50.0 – 70.9%) 85.9% (80.4 – 91.3%) 
APCAH, VIDO-InterVac, 
and AHVLA  
49.6% (44.2 – 55.0%) > 100%  16.7% (13.5 – 19.8%) 40.2% (37.2 – 43.3%) No result > 100% 
VIDO-InterVac and 
AHVLA  
36.7% (33.4 – 40.1%) 66.5% (66.2 – 70.7%) < 0% 16.2% (12.4 – 20.0%) 60.3% (54.8 – 65.8%) > 100% 
AHVLA: Animal Health and Veterinary Laboratories Agency; APCAH: Asia-Pacific Centre for Animal Health; CI: Confidence interval; Se: Sensitivity; Sp: Specificity; No result: 
no result could be obtained using the online calculator; VIDO-InterVac; Vaccine and Infectious Disease Organization International Vaccine Centre. 
Confidence intervals (95%) are shown in parentheses. True prevalence estimates for induction and draft were calculated using point, low Se / high Sp and high Se / low Sp estimates 
calculated using M. bovis experimental infection trial samples (Chapter 4). True prevalence estimates < 0 and > 1 are not consistent with assumed Se and Sp values (Rogan and 
Gladen, 1978). 
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5.3.3  Prevalence of M. bovis-specific antibody at draft 
Table 5.4 provides a comparison of results obtained at draft using the BioK302 and BioK260 
ELISA kits.  
5.3.3.1  Apparent prevalence estimates 
At draft, and accounting for clustering by cohort, 25.3% (95% CI: 21.9 - 28.8%, 343 / 1,354) were 
found to be sero-positive for M. bovis antibody using the BioK302 ELISA kit (Table 5.5). Using the 
dichotomised BioK260 ELISA kit results, 41.2% (95% CI: 36.8 - 45.6%, 558 / 1,354) were 
classified as sero-positive for M. bovis antibody (Table 5.5). The observed agreement between the 
BioK302 and dichotomised BioK260 ELISA results was 78.2%; the expected agreement due to 
chance alone was 54.3% and the kappa statistic 0.52, indicating a moderate strength of agreement 
(Landis and Koch, 1977). 
Using series interpretation of results obtained using the two ELISAs, the apparent sero-prevalence 
of M. bovis antibody at draft was estimated to be 22.4% (95% CI: 19.1 - 25.7%, 303 / 1,354). 
While, parallel interpretation of the two test results estimated the apparent sero-prevalence of 
M. bovis antibody at draft to be 44.2% (95% CI: 39.8 - 48.6%, 598 / 1,354). 
5.3.3.2  True prevalence estimates 
True sero-prevalence estimates for M. bovis antibody at draft were calculated using Se and Sp 
estimates listed in Table 5.3. Estimates for the BioK302 and BioK260 ELISAs were calculated 
using the BioK302 and dichotomised BioK260 ELISA results. Estimates and associated 95% 
confidence intervals are provided in Table 5.6.  
The true sero-prevalence estimate at draft using the point Se and Sp estimates ranged from 36.7 –
 49.6% (95% CI: 33.4 – 55.0%) and 65.4 – > 100% (95% CI: 61.3 – > 100%) using the BioK302 
and dichotomised BioK260 ELISA results respectively (Table 5.6). Some true sero-prevalence 
estimates obtained were > 100% indicating that the result was not consistent with assumed Se and 
Sp estimates. Unlike the induction true prevalence estimates, the draft true prevalence estimates do 
not encompass the apparent prevalence estimates described above (Section 5.3.3.1).  
5.3.4 Assessment of an increase in M. bovis-specific antibody between induction and draft 
5.3.4.1  BioK302 ELISA  
The proportion of animals that had a detectable increase in M. bovis-specific antibody between 
feedlot induction and draft was investigated. Using the BioK302 ELISA kit, 1,307 animals were 
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sero-negative at induction and had the potential to become sero-positive (sero-convert) on the 
BioK302 at the time of draft (Table 5.7). Of these animals, 24.3% (95% CI: 20.8 - 
27.7%, 317 / 1,307) had sero-converted based on the BioK302 ELISA results at draft (Table 5.8).  
Table 5.7: Comparison of BioK302 ELISA results at induction and draft. 
BioK302 induction result 
BioK302 draft result 
Total 
Negative Positive 
Potential to sero-convert 
   
Negative 990 317 1,307 
    
Initially high 
   
Positive 21 26 47 
Total 1,011 343 1,354 
Results obtained from the BioK302 ELISA kit were interpreted as per the manufacturer’s 
instructions. A sample was classified as sero-negative if the BioK302 Sample coefficient result was 
< 37%. A sample was defined as sero-positive in the BioK302 Sample coefficient result was ≥ 37%. 
 
Table 5.8: Summary of the number of animals with a detectable increase in M. bovis antibody 
between induction and draft 
Test category Total No. No. sero-increase Percentage (95% CI) 
BioK302 sero-convert 1,307 317 24.3% (20.84 - 27.67%) 
BioK260 sero-convert 1,276 249 19.5% (6.26 - 22.77%) 
BioK260 re-exposure 73 12 16.4% (6.85 - 26.02%) 
BioK260 sero-increase 1,349 261 19.4% (16.15 – 22.55%) 
CI: Confidence interval.  
Confidence intervals (95%) are calculated adjusting for clustering by cohort.  
 
5.3.4.2  BioK260 ELISA 
A total of 1,276 animals had the potential to sero-convert based on the BioK260 DV category 
results at the time of feedlot induction (Table 5.9). Of these 19.5% (95% CI: 16.3 -
 22.8%, 249 / 1,276) of animals sero-converted to M. bovis between feedlot induction and draft. In 
regards to re-exposure, 73 animals had the potential to increase two or more BioK260 DV 
categories between feedlot induction and draft but did not have an induction sample result that fell 
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within the ‘0’ BioK260 DV category. Of these animals 16.4% (95% CI: 6.9 - 26.0%, 12 / 73) had a 
draft sample result that was two or more BioK260 DV categories higher than their induction 
sample. Combining animals in the BioK260 sero-conversion and re-exposure outcome categories; a 
total of 1,349 animals had the potential to increase two or more BioK260 DV categories between 
induction and draft, irrespective of their induction BioK260 DV result. Of these 19.4% (95% CI: 
16.2 – 22.6%, 261 / 1,349) were found to sero-increase between induction and draft.  
Table 5.9: Comparison of BioK260 ELISA results at induction and draft 
Induction BioK260 
DV category 
Draft BioK260 DV category 
Total 
0 + ++ +++ ++++ +++++ 
Potential to sero-convert 
      0 773 254 143 64 31 11 1,276 
Potential to increase  
      
+ 17 11 10 10 2 0 50 
++ 4 3 2 4 0 0 13 
+++ 2 4 2 1 1 0 10 
Initially high   
      
++++ 0 1 1 0 0 1 3 
+++++ 0 0 0 0 0 2 2 
Total 796 273 158 79 34 14 1,354 
DV: Delta Value. 
Grey shading represents animals that have sero-converted based on the BioK260 ELISA Delta Value 
category results between induction and draft. The blue shading represents those animals classified as having 
been re-exposed to M. bovis based on the BioK260 ELISA Delta Value category results between induction 
and draft. Animals classified as having sero-increased based on the BioK260 ELISA results are those in the 
sero-conversion and re-exposure categories combined. 
 
5.4 Discussion 
In the current study the apparent prevalence of M. bovis-specific antibody among cattle entering 
feedlots in Australia was low with estimates ranging from 2.4 to 6.8% (Table 5.5). In contrast the 
apparent sero-prevalence at draft was higher with estimates ranging from 22.4 to 44.2%. The 
apparent sero-prevalence of animals at feedlot induction in this study was in agreement with that 
reported for milking cows in Switzerland by Burnens et al. (1999). As the article is in French, the 
findings reported here have been obtained from the abstract only. These authors found that 6.1% (n 
= 1,816) of milking cows sampled from 118 Swedish herds were M. bovis sero-positive using a 
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commercial indirect enzyme immunoassay. In the same study, 13.4% (n = 1,354) of animals in the 
Canton du Jura region were found to be sero-positive (Burnens et al., 1999). The exact commercial 
kit used in this study was not defined in the abstract. While Arcangioli et al. (2008) reported that 
2.2% (n = 135) of two to three week old calves entering nine French feedlots were sero-positive at 
arrival using a CHEKIT-M. bovis indirect ELISA kit. Other studies report a higher sero-prevalence 
of M. bovis antibody. Bednarek et al. (2012) reported that 78.2% (n = 3,670) of clinically healthy 
cattle from 361 herds covering 16 Polish provinces were sero-positive for M. bovis using a BioK162 
M. bovis Bio-X Diagnostics

 ELISA kit. Hanzlicek et al. (2011) reported that 26.6% (n = 304) of 
male crossbred beef calves purchased from a livestock auction market in Georgia, USA were sero-
positive at feedlot arrival using a Bio-X Diagnostics

 ELISA kit (exact kit was not reported). 
Reasons for the lower sero-prevalence seen among this study population compared to many other 
studies are not clear; however the management of cattle at the farm of origin in Australia may be a 
factor to consider. It has been suggested that the intensity of the breeding and production system is 
associated with M. bovis sero-positivity (Bednarek et al., 2012). It is possible that the intensity of 
farming in Australia is less than that seen in Europe and some parts of the USA and this factor 
could provide one possible explanation for the lower apparent sero-prevalence reported here.  
Test Se and Sp is another factor that should be considered when trying to estimate a sero-
prevalence. In Chapter 4, using sera obtained from animals experimentally infected with M. bovis it 
was estimated that both the BioK302 and the BioK260 (dichotomised interpretation) ELISAs had a 
low Se (point estimates of 47% and 28% respectively), (Table 5.3). Because of the low Se, both 
tests will misclassify many truly sero-positive animals as sero-negative and as a result the true sero-
prevalence could be underestimated. In addition, the Sp of the BioK302 was not perfect (point 
estimate of 96%), (Table 5.3). A test without perfect Sp will produce false positive results so in a 
population where the true prevalence is low it is possible that the true sero-prevalence could be 
overestimated. In this study it was found that the percentage of animals testing positive using the 
more Sp BioK260 ELISA (dichotomised interpretation of results was estimated to have 100% Sp in 
Chapter 4) was in fact higher that that seen with the BioK302 ELISA (estimated to have a Sp of 
96% in Chapter 4). The results of this study suggest that the BioK260 cannot be 100% Sp as 
previously estimated. An assessment of the test Se in this study population is more difficult because 
both the BioK302 and BioK260 Se estimates in Chapter 4 were so low at 47% and 28% 
respectively. The findings of this study highlight how important knowledge of test Se and Sp is in 
addition to having an understanding how the test performs in the population it is to be used in are.  
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True sero-prevalence estimates were calculated using three Se and Sp estimate combinations for the 
BioK302 and BioK260. These consisted of point estimates for each test, the low 95% confidence 
interval for Se and high 95% confidence interval for Sp and the high 95% confidence interval for Se 
and low 95% confidence interval for Sp. These estimated were determined using sera from animals 
experimentally infected with M. bovis (Chapter 4) and are listed in Table 5.3. In this study the true 
prevalence at feedlot induction was estimated to range from < 0 – 5.2% and 5.7 – 20.6% using the 
BioK302 and dichotomised BioK260 ELISA results respectively. Two true prevalence estimates 
using the BioK302 were < 0% (Table 5.6) indicating that the result was not consistent with assumed 
Se and Sp estimates used in the calculation in this study population. Of interest here is that when 
using the point Se and Sp estimates, the two true prevalence estimates that returned the < 0% result 
occurred when using Se and Sp estimates determined using the APCAH sera. In this study there are 
three unknowns: (i) the test Se; (ii) the test Sp and (iii) the prevalence of M. bovis antibody in the 
study population. In the absence of a reasonable “gold standard”, nor a test with known Se and Sp 
characteristics for the serological detection of M. bovis antibody, determining the true prevalence of 
M. bovis antibody in any study population cannot be performed with precision. Latent class models 
can provide a means to simultaneously estimate the Se and Sp of two or more tests without any 
assumption on the true disease status of each individual animal sample (Hui and Walter, 1980). 
Latent class models in their standard and most commonly used form involve three assumptions: (i) 
the target population should consist of two or more subpopulations with different prevalences; (ii) 
the Se and Sp of the diagnostic tests should be constant across subpopulations; and (iii) the tests 
should be conditionally independent given the disease status (Enoe et al., 2000).  
Few studies report the apparent sero-prevalence of M. bovis antibody after feedlot arrival. In most 
cases, the rate of sero-conversion is reported and these will be discussed later. One study that does 
report the apparent sero-prevalence following feedlot arrival was conducted by Hanzlicek et al. 
(2011). They found that that 98.2% (n = 281) of male crossbred calves purchased from a livestock 
auction in Georgia, USA were sero-positive for M. bovis antibody using a Bio-X Diagnostics

 
ELISA at 42 DOF (the exact kit used was not defined). This estimate is much higher than the 
apparent sero-prevalence seen in this study (22.4 to 44.2%, Table 5.5). When the apparent sero-
prevalence estimates are compared to the true sero-prevalence estimates obtained using the point Se 
and Sp (Table 5.5 and Table 5.6), in most cases the true sero-prevalence estimate was between 36.7 
– 66.5% and above the apparent sero-prevalence. Here it is possible that the low test Se may be 
underestimating the true sero-prevalence, however it was seen with the induction true sero-
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prevalence results that the point Se and Sp estimates obtained using the APCAH experimental 
infection trial sera are not applicable to this study population. These findings highlight the 
importance of not only having an understanding of how a test may perform in a particular study 
population but also the importance of correctly identifying and in turn classifying sera used for 
serological test validation and for the determination of test Se and Sp.  
Comparison of the two ELISA kit test results using induction sera collected from animals naturally 
exposed and infected with M. bovis (this study population) revealed that the observed level of 
agreement was 95.6% and the kappa statistic was calculated to be 0.51. This is in contrast to those 
calculated in Chapter 4 where the level of agreement was similar at 90.9% but the kappa statistic 
was substantially higher at 0.74 (all experimental infection trial and Bio-X Diagnostics

 control 
sera) and 0.65 (using just the experimental infection trial sera). Using the draft sera from this study 
population, the observed level of agreement was decreased (78.2%), however the kappa statistic 
remained relatively unchanged at 0.52. Possible reasons for the reduced agreement seen here in this 
study population as evidenced by the kappa statistic include: the two ELISA kits contain a different 
antigen or different amounts of the same antigen; differences in the chromogen (TMB) solution 
between the two kits used could affect the raw OD reading obtained; the calculation used to obtain 
the final OD result is different for the two kits and this could affect how the Sample coefficient and 
Delta Value results are categorised for the BioK302 and BioK260 respectively. Another factor to 
consider is the level of cross-reactivity of field samples in comparison to sera collected from 
animals experimentally infected with M. bovis could be different and affect how these two tests 
perform. In addition factors that influence the kappa statistic itself that have not been accounted for 
in the current study include the prevalence of the outcome, bias and non-independent results (Sim 
and Wright, 2005). Sim and Wright (2005) also suggest caution when comparing the magnitude of 
kappas across results that are measured on different scales. This is a potential limitation here as the 
BioK302 and BioK260 ELISA kits calculate their results from the raw OD reading differently. 
These factors combined with possible inadequate sample sizes used to evaluate the level of 
agreement for the two tests limit the usefulness of comparing the kappas obtained in Chapter 4 and 
Chapter 5. Neither of these two studies were intended to or designed with the aim of comparing the 
level of agreement of the BioK302 and BioK260 against one another. 
The level of sero-conversion or a sero-increase between induction and draft was assessed. Using the 
BioK302 ELISA, 24.5% of animals were found to have sero-converted to M. bovis. Using the 
BioK260 draft outcomes, 19.5% sero-converted, 16.4% were classified as being re-exposed and 
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19.4% were considered to have sero-increased between feedlot induction and draft. These findings 
are below that reported in other studies which report M. bovis sero-conversion rates of 54.7 – 100% 
(Arcangioli et al., 2008, Hanzlicek et al., 2011, Tschopp et al., 2001). Feedlot management 
practices in Australia may differ to that seen in other countries, the age of cattle at the time of 
feedlot entry in Australia (approximately 24 months of age or older) may have some affect on LRT 
infection rates and in turn the development of antibody, or a low prevalence of the organism in the 
environment / animals actively shedding M. bovis could provide possible explanations for the lower 
sero-conversion / sero-increase rates seen in this study. 
Overall, the sero-prevalence of M. bovis antibody and sero-conversion / sero-increase rates seen in 
this study population appears to be lower than that reported in most other studies. All sero-
prevalence studies rely on an understanding of how the serological test that is to be used performs 
in the study population. Underpinning the Se and Sp of the commercially available ELISAs used 
here is the antigen used to detect M. bovis-specific antibody in the serum sample. Is there a single 
antigen used in these ELISA kits or are multiple M. bovis antigens used? What is / are the 
antigen(s)? How common is this antigen(s) among Australian M. bovis strains and do Australian 
M. bovis strains express the antigen used in these kits? These are all questions that remain 
unanswered and are essential when attempting to the interpret results obtained. If Australian field 
strains do not express the antigen used in these commercial ELISA kits then many false negative 
results will be obtained and the test Se reduced. The use of a recombinant antigen, as is the case 
with the Bio-X Diagnostics

 ELISAs, has the potential to increase test Sp by reducing the 
occurrence of false positive test results which may result due to cross-reactivity with other bovine 
Mycoplasma spp. antibody. However, regardless of what antigen(s) are used to detect antibody, an 
understanding of the population genetics of M. bovis in the study population it is being used in is 
required. The antigen(s) used to detect antibody need to be expressed by the M. bovis strains that 
persist in that study population. In Australia, the extent of M. bovis field strain variability is not 
known. It is possible that the use of a single M. bovis antigen in sero-diagnostic tests for M. bovis is 
not ideal and to achieve a test with desirable Se and Sp, more than one M. bovis antigen may be 
required.  
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CHAPTER 6   Risk factors associated with Mycoplasma bovis-specific antibody in 
Australian feeder cattle 
6.1  Introduction 
Risk factors associated with sero-positivity for M. bovis-specific antibodies or sero-conversion to 
M. bovis are poorly defined in the associated literature. A number of factors hamper serology-based 
studies such as the absence of Se and Sp information for immunological detection methods; the 
highly variable nature of the immunological response to M. bovis exposure between individual 
animals; and the highly variable nature of membrane proteins expressed by different strains of 
M. bovis itself. The latter factor further complicates serology-based studies as the antigen or 
antigens specific to M. bovis and to which animals develop an immune response are poorly 
understood. Despite this, a limited number of studies have identified particular cattle management 
practices that are often associated with an increased sero-prevalence of M. bovis-specific antibodies 
among herds. Bednarek et al. (2012) reported that sero-positivity to M. bovis was associated with 
more intensive levels of cattle breeding and production while Tschopp et al. (2001) reported that 
mixing calves from different age groups and contact of naive animals with sero-positive animals 
were associated with sero-conversion.  
Paired serum samples collected at the time of feedlot induction and at draft (approximately 
42 DOF) were derived from a subset of randomly selected animals (n = 1,354) from a larger 
Australian study, the NBDRI. The aim of this chapter was to use the serological data generated in 
Chapter 5 to assess and quantify putative risk factors associated with sero-positivity for M. bovis-
specific antibody at feedlot induction. Using the results of draft sera, putative risk factors associated 
with sero-conversion to M. bovis or a sero-increase of two or more ELISA antibody categories 
between feedlot induction and draft were also assessed.  
6.2  Materials and methods 
6.2.1  Study population  
The study population has been previously described in Chapter 5. A total of 1,354 animals were 
randomly selected and sourced from a NBRDI study population as described in Section 5.2.1. Data 
collection from NBRDI enrolled animals has been described in Section 5.2.3. Paired serum samples 
from selected NBRDI enrolled animals collected at the time of feedlot induction and at draft 
(approximately 42 DOF) as described in Section 5.2.2 were collated from the NBRDI serum bank 
as detailed in Sections 5.2.5 and 5.2.6.   
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6.2.2  Outcome variables used in analyses 
Induction and draft serum samples were tested for the presence of antibodies specific for M. bovis 
using the commercially available BioK302 and BioK260 ELISA kits as described in Section 4.2.3. 
Results obtained using these ELISA kits have been reported in Chapter 5. 
6.2.2.1  Induction outcome variables 
Induction outcome variables were derived from the two ELISA kit results based on M. bovis-
specific antibody sero-positivity at feedlot induction. Binary outcome variables (yes/no) were 
derived for both ELISA kit (BioK302 and dichotomised BioK260 ELISA) results and for series and 
parallel interpretations of the two ELISA kit results (Section 5.2.8.1). 
6.2.2.2  Draft outcome variables 
The draft outcome variables described in Section 5.2.7.3.1 (BioK302 sero-conversion, BioK260 
sero-conversion and BioK260 sero-increase) were used to assess putative risk factors associated 
with sero-conversion to M. bovis or a sero-increase in M. bovis antibodies between induction and 
draft.  
6.2.3  Derivation of exposure variables 
The NBRDI aimed to identify risk factors associated with BRD and as such, analysis variables that 
were available in the NBRDI database for each enrolled animal were derived and categorised to 
enable analyses for that purpose. Identification of putative risk factors that could be assessed for an 
association with M. bovis sero-positivity at feedlot induction (Figure 6.2) or sero-conversion or a 
sero-increase at draft (Figure 6.3), were restricted to those for which data were available in the 
NBRDI database. In addition only putative risk factors where prior hypotheses suggested an 
association with sero-positivity or sero-conversion or a sero-increase were assessed (Appendix 5). 
Many of the NBRDI variables were time-specific and described exposures prior to the animal’s 
enrolment into the NBRDI study (Barnes et al., 2014). Using data obtained from the NLIS (Section 
5.2.3.1) groups of NBRDI enrolled animals that were at the same PIC location at specified time 
points prior to day 0 and subsequently went into the same ‘cohort’ were defined (Barnes et al., 
2014). This grouping structure and the PIC location of any individual animal could vary during its 
lifetime prior to day 0. At the time of feedlot arrival, animals were assembled into cohorts (a 
collection of animals assembled at a particular feedlot during the induction period and placed on 
feed in the same feedlot pen), (Barnes et al., 2014). Once the pen was full, no further addition of 
animals to that cohort occurred. 
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6.2.4  Clustering 
6.2.4.1  Clustering of M. bovis-specific antibody sero-positivity at induction 
The extent of clustering of M. bovis sero-positivity at induction at the group and PIC levels was 
assessed by fitting null mixed effects logistic regression models using the xtmelogit command in 
Stata/SE 12.1
®
 with PIC and group as random effects. Where xtmelogit models fitted with both PIC 
and group as random effects were unstable, xtlogit models were re-fitted with group as the only 
random effect. 
As each animal’s group and PIC changed with time, separate models were fitted for the following 
time-specific groups: group-2, group-7, group-13, group-28, group-91, group-365 and group-500, 
respectively. Similarly, the PICs at the same time-points were termed PIC-2, PIC-7, PIC-13, PIC-
28, PIC-91, PIC-365 and PIC-500, respectively. The amount of variance at the PIC and group levels 
was estimated. The latent variable threshold approach, whereby the variance at the animal level was 
assumed to be π2/3 (3.29), was used to estimate the percentages of total variance that were at the 
PIC, group and animal levels (Snijders and Bosker, 2012). The intra-class correlation coefficient 
(ICC) for each time-specific group was calculated as the proportion of total variance that was at 
either the PIC or the group level: 
          
                                       
              
 
The group ICC is a measure of the correlation in M. bovis sero-positivity between any two animals 
from the same group, assuming that the correlation was the same for all pairs of animals within each 
group. These models were fitted using four induction outcome variables, the BioK302 ELISA 
result, the dichotomised BioK260 ELISA result and the series and parallel interpretations of the two 
tests.  
6.2.4.2  Clustering of sero-conversion / sero-increase in M. bovis sero-positivity at draft 
The extent of group level clustering of sero-conversion or sero-increase to M. bovis between feedlot 
induction and draft were assessed by fitting null mixed effects logistic regression models using the 
xtmelogit command in Stata/SE 12.1
®
 with feedlot, cohort and group as random effects. This was 
performed for the same groups and in the same way as outlined in Section 6.1.4.1 using the three 
draft outcome variables, BioK302 sero-conversion, BioK260 sero-conversion and BioK260 sero- 
increase.  
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6.2.5  Putative risk factors for M. bovis sero-positivity at induction 
6.2.5.1  Animal-level putative risk factors 
All animal-level putative risk factors used in both induction and draft analyses are summarised in 
Table 6.1. Further details for each of the putative risk factors assessed for M. bovis sero-positivity at 
feedlot induction are provided in the following sections. 
Table 6.1: Animal-level exposure variables and associated categories assessed as putative risk 
factors 
Putative risk factor Abbreviation  Categories Definition 
Breed NA Angus, British Cross, Hereford, 
Shorthorn, Murray Grey, 
European / European Cross, 
Tropical / Tropical Cross 
Breed category 
Induction weight Weight 190 - < 400, 400 - < 440, 440 - < 
480, ≥ 480  
Induction weight. Units in kilograms 
liveweight 
Dentition NA Milk tooth, Two tooth, Four and 
six tooth 
Number of permanent incisors present 
on day 0 
Mixing Mix pre27 Yes, No Animal was mixed with animals from a 
different PIC location 27 days or more 
prior to day 0 
Mixing summary Mix Sum No : Low, No : High, Yes : Low, 
Yes : High 
Describes mixing prior to day -27 (Mix 
pre27: Yes / No) in addition to the 
number of group-28s forming the cohort 
(Low = < 4, High = ≥ 4) 
Saleyard transfer 27 
days prior to day 0 
SY pre27 Yes, No Animal had one or more saleyard 
transfer(s) 27 or more days prior to day 
0  
Saleyard transfer 
between day -27 & day 
0 
SY 27_0 Yes, No Animal had one or more saleyard 
transfer(s) between 27 days prior to day 
0 and day 0 
Yard Weaning* Yard wean Yes, No Animal was yard weaned  
NA: Not available (no abbreviation used); PIC: property identification code. 
* Yard weaning data were restricted to a particular subset of NBRDI enrolled animals that were born on the vendor’s 
property known as the vendor questionnaire subset. 
Day 0 is defined as the day of induction or for those animals pre-assembled on pasture at or close to the feedlot it is the 
day the animal was moved to a feedlot pen.   
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6.2.5.1.1 Breed 
Breed data used by the NBRDI were obtained from participating feedlots as feedlot-specific breed 
codes. The feedlot-specific breed codes were re-coded for analysis purposes in the NBRDI to 
include all represented breeds and crosses. The final NBRDI breed variable consisted of seven 
categories: Angus, Hereford, Shorthorn, Murray Grey, British cross, European / European cross, 
and Tropical / Tropical cross. The Tropical / Tropical cross breed category included any animals 
with feedlot-specific breed codes that referred to a tropical cattle breed (e.g. Droughtmaster, Santa 
Gertrudis, Charbray, Brahford etc), the European / European cross category to any European cattle 
breed (i.e. Charolais, Gelbvieh, Limousin and Simmental) but not a tropical breed, and the British 
cross breed category referring to animals recorded by the feedlot as British breed crosses only 
(Barnes et al., 2014). 
6.2.5.1.2 Induction weight (Weight) 
Induction weight data obtained from feedlot induction files provided to the NBRDI ranged between 
196 kg and 756 kg. For NBRDI analyses, the recorded induction weights were split into four 
categories. These were 190 - < 400 kg, 400 - < 440 kg, 440 - < 480 kg and ≥ 480 kg.  
6.2.5.1.3 Dentition 
Dentition was used as a very crude estimate of age for animals in the NBRDI. Overall, the NBRDI 
reported that dentition data were completely missing for one feedlot and were not recorded at the 
animal level in another. Discussion with the feedlot manager for which dentition data were 
completely missing indicated that more than 99% of animals entering the feedlot had deciduous 
incisor teeth only. Because of this, dentition was imputed as ‘milk tooth’ (i.e. no permanent incisor 
teeth) for all animals enrolled from that feedlot. The observed low induction weight range and the 
practice of sending cattle to the feedlot soon after weaning in this region was also consistent with 
animals from this feedlot having deciduous incisor teeth only (Barnes et al., 2014). Dentition data 
for all animals were divided into three categories for analyses. These consisted of; ‘milk tooth’ 
indicating no evidence of permanent incisors, ‘two tooth’ indicating eruption or the presence of the 
medial incisor teeth and ‘four and six tooth’ indicating eruption or the presence of three or more 
permanent incisor teeth. 
6.2.5.1.4 Mixing at least 27 days prior to day 0 (Mix pre27) 
The Mix pre27 variable used in the NBRDI was a binary variable used to define if animals from 
two or more groups from an earlier time point were together in the same group at least 27 days prior 
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to day 0. Mixing referred specifically to between-PIC locations of enrolled animals only. Using this 
definition, animals that changed PIC but remained in the same group (no NBRDI study animals 
added) were not considered to have been mixed (Barnes et al., 2014). 
6.2.5.1.5 Saleyard transfer at least 27 days prior to day 0 (SY pre27) 
Using NLIS and PIC data, the NBRDI identified if an animal had prior history of a saleyard transfer 
at any point in its lifetime. A yes/no binary variable was derived for the time period at least 27 days 
prior to day 0 indicating whether or not an animal had been through a saleyard at least once in its 
lifetime (Barnes et al., 2014). This variable was designated SY pre27.  
6.2.5.1.6 Yard weaning (Yard wean) 
The process of yard weaning involves keeping calves recently removed from their dam in a yard 
environment during the process of weaning. The calves are typically fed preserved forage (hay) 
and / or grain concentrates and watered from troughs during this time. The duration of yard weaning 
is highly variable and farm or origin dependent. The yard weaning exposure variable used for 
analyses were derived from NBRDI vendor questionnaire data. This data was restricted to a 
particular subset of NBRDI enrolled animals that were born on the vendor’s property and were 
referred to as the ‘vendor questionnaire subset’, (Barnes et al., 2014). A yes/no binary variable was 
derived where animals that were recorded as being paddock weaned were classified ‘no’, and all 
animals that had been yard weaned irrespective of the duration were classified ‘yes’. 
6.2.5.2  Group-level putative risk factors 
All group-level putative risk factors used in both induction and draft (unless otherwise stated) 
analyses are summarised in Table 6.2. Further details for each of the group-level putative risk 
factors assessed for M. bovis sero-positivity at feedlot induction are provided in the following 
sections. 
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Table 6.2: Group-level exposure variables and associated categories assessed as putative risk factors  
Putative risk factor Abbreviation  Categories Definition 
Source region NA NSW / Southern Tablelands, Coastal NSW or 
QLD, Darling Downs / New England, Western 
NSW / QLD / NT, Riverina / Victoria / 
Tasmania, South Australia / Western Australia 
Region defined by the geographical coordinates of the animal’s PIC 
location 28 days prior to day 0 
Induction year* Ind year 2009, 2010, 2011 Year of induction 
Group size GroupN-13 < 50, 50 – 99, ≥ 100 For each animal within a cohort, the group size 13 days prior to 
day 0 
Move to feedlot at least 27 
days prior to day 0 
Move pre27 No, Yes Animal was moved to the feedlot 27 days prior to day 0  
NA: Not available (no abbreviation used); NSW: New South Wales; NT: Northern Territory; PIC: Property identification code; QLD: Queensland. 
Day 0 is defined as the day of induction or for those animals pre-assembled on pasture at or close to the feedlot it is the day the animal was moved to a feedlot pen. 
*
 Induction year was used as a group-level risk factor for induction analyses and a cohort-level risk factor for draft analyses. 
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6.2.5.2.1 Source region 
The source region NBRDI variable was determined for each animal using the geographical 
coordinates of its PIC 28 days prior to day 0 (PIC-28), (Barnes et al., 2014). Initially 12 categories 
were derived but these were later combined into six broad regions: New South Wales (NSW) and 
Southern Tablelands; Coastal NSW or Coastal Queensland (QLD); Darling Downs and New 
England; Western NSW, Western QLD or the Northern Territory (NT); NSW Riverina, Victoria 
and Tasmania; and South Australia and Western Australia (Figure 6.1). These regions were based 
on proximity and similarity in geography and weather patterns (Barnes et al., 2014). 
 
Figure 6.1: National bovine respiratory disease initiative source region categories  
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6.2.5.2.2 Induction year (Ind year) 
As described in Section 5.2.1, cattle were enrolled in the NBRDI from July 2009 – December 2011; 
consequently the induction year variable consisted of three categories: 2009, 2010 and 2011. 
6.2.5.2.3 Group size (GroupN-13) 
The number of animals in group-13 (GroupN-13) was a measure of group size 13 days prior to 
day 0. The NBRDI range was from 1 to 342 animals / group-13. For analyses the raw data were 
divided into three categories: < 50, 50 – 99, ≥ 100 (Barnes et al., 2014). 
6.2.6 Putative risk factors for sero-conversion or a sero-increase in M. bovis-specific 
antibody at draft 
6.2.6.1  Animal-level putative risk factors for sero-conversion / sero-increase 
Some animal-level putative risk factors used in the induction analyses were also used in draft 
analyses. These have already been described in Section 6.1.5 and included: breed, weight, dentition, 
and SY pre27. Additional animal-level putative risk factors assessed for sero-conversion or a sero-
increase of two or more BioK260 DV categories between feedlot induction and draft of M. bovis-
specific antibodies are provided below and summarised in Table 6.1. 
6.2.6.1.1 Mixing summary (Mix Sum) 
As for the mixing variable used in induction putative risk factor analyses (Section 6.2.5.1.4), mixing 
was defined as occurring within a time period when animals from two or more groups from the 
earlier time point were together in the same group at the later time point. Mixing referred 
specifically to between-PIC mixing among animals enrolled in the study. For draft putative risk 
factor analyses, a mixing summary NBRDI variable was used. This variable classified animals 
based on a combination of the binary variable used in induction risk factor analyses that described 
mixing prior to day -27 (Mix pre27) in addition to a variable describing the number of group-28s 
forming the cohort (< 4, ≥ 4). The Mix Sum variable consisted of four categories (Table 6.3). 
Table 6.3: Mixing summary (Mix Sum) categories used in draft putative risk factor analyses 
Mix Sum Category Definition 
No: Low Not mixed prior to day -27; less than 4 group-28s form cohort 
No: High Not mixed prior to day -27; 4 or more group-28s form cohort 
Yes: Low Mixed prior to day -27; less than 4 group-28s form cohort 
Yes: High Mixed prior to day -27; 4 or more group-28s form cohort 
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6.2.6.1.2 Saleyard transfer between day -27 and day 0 (SY 27_0) 
Using NLIS and PIC data, the NBRDI identified if an animal had history of a saleyard transfer for 
the time period between day -27 and day 0. A yes/no binary variable was used in analyses. 
6.2.6.2  Group-level putative risk factors for sero-conversion / sero-increase 
All group-level putative risk factors used in both induction and draft analyses are summarised Table 
6.2. Three group-level putative risk factors were used specifically for draft analyses. These included 
source region as previously described in Section 6.1.5.1.5, group size (GroupN-13, Section 
6.1.5.2.3) and the timing of the animals move to the feedlot (Move pre27). The NBRDI identified if 
an animal had been moved to (arrived at) the feedlot PIC prior to day -27 using NLIS and PIC data. 
A yes / no binary variable was used in analyses. 
6.2.6.3  Cohort-level putative risk factors for sero-conversion / sero-increase 
Most cohort-level putative risk factors used in draft analyses are summarised in Table 6.4. Induction 
year and group size are the exceptions as these were considered group-level risk factors for 
induction analyses but cohort-level risk factors for draft analyses. Details of the induction year and 
group size variables and associated categories have been previously described in Sections 6.1.5.2.2 
and 6.1.5.2.3 respectively and are summarised in Table 6.4. Further details for additional cohort-
level putative risk factors assessed for sero-conversion or a sero-increase of two or more BioK260 
DV categories between feedlot induction and draft of M. bovis-specific antibodies are provided 
below.  
6.2.6.3.1 Cohort size (CohortN) 
The NBRDI reported that the number of animals inducted into each cohort (CohortN) was highly 
clustered by feedlot. Separation of this variable into additional categories further exacerbated this 
issue. As a result only two categories of CohortN were used in analyses (17 - < 200 and ≥ 200). 
6.2.6.3.2 Number of adjoining pens (Pen join) 
The NBRDI exposure variables relating to the features of the pen relate to the pen where the cattle 
in a cohort spent most of their time during their first 50 DOF. This pen was also referred to as the 
cohort’s ‘home pen’. Details of the home pen features were provided for each cohort by the 
participating feedlot. The number of pens (one or two) adjoining the cohort’s home pen, separated 
only by a fence, was assessed as a putative risk factor for sero-conversion or a sero-increase of two 
or more BioK260 DV categories in M. bovis-specific antibodies at draft. 
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Table 6.4: Cohort-level exposure variables and associated categories assessed as putative risk factors 
Putative risk factor Abbreviation  Categories Definition 
Cohort size CohortN 17 - < 200, ≥ 200 The number of animals inducted into each cohort 
Number of adjoining pens Pen join 1, 2 The number of pens adjoining the cohort’s home pen, separated only 
by a fence 
Shared water Water No, Yes Pen water could be accessed by animals from an adjoining pen 
Pen shade Shade No, Yes The presence or absence of any shade in the home pen 
Pen density (m
2 
/SCU)  Density 11 - < 13, 13 - < 15, 15 - < 17, ≥ 17 Number of standard cattle units per square meter of pen: calculated 
from home pen area, total standard cattle units (SCU) estimated from 
the animal level induction weight and table of SCU values 
(Department of Agriculture‚ Fisheries and Forestry., 2014).  
Induction season Season Spring, Summer, Autumn, Winter Season in which the cohort was inducted based on the induction date 
BVDV PI exposure BVDV_PI Active, no PI; Active, yes PI;  
Not active, no PI 
Composite variable identifying the presence or absence of active 
infection of BVDV in the cohort and the presence of a PI in the 
group-28 
BVDV: Bovine viral diarrhoea virus; PI: Persistently infected; SCU: Standard cattle unit. 
The home pen was defined as the pen where the cattle in a cohort spent most of their time during their first 50 DOF. 
Induction year (Ind year) and group size (groupN-13) are not listed in Table 6.4 but were also assessed as cohort-level putative risk factors for sero-conversion or a 
sero-increase of two or more BioK260 DV categories in M. bovis antibodies between feedlot induction and draft. These risk factors are listed in Table 6.2 as they 
were included in group-level putative risk factor analyses for sero-positivity to M. bovis at feedlot induction.  
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6.2.6.3.3 Shared water (Water) 
The binary shared water variable indicated whether pen water in the home pen could be accessed by 
animals from an adjoining pen.  
6.2.6.3.4 Pen shade (Shade) 
Descriptions of the extent and type of shade were often unique to individual feedlots participating in 
the NBRDI. As a result a dichotomous variable indicating the presence or absence of any shade in 
the home pen was used in the final analyses. 
6.2.6.3.5 Pen density (Density) 
The NBRDI estimated stocking density (pen density) as pen area (m
2
) per standard cattle unit 
(SCU). The approximate number of SCUs in the cohort was calculated using the number of animals 
in the cohort and the appropriate conversion factor for the mean weight of animals in the cohort 
(Department of Agriculture‚ Fisheries and Forestry., 2014). The pen density was then derived by 
dividing the pen area in square meters by the number of SCUs in the cohort. An approximate pen 
density value was assigned to each cohort and these values were divided into four pen density (m
2 
/ 
SCU) categories; 11 - < 13, 13 - < 15, 15 - < 17 and ≥ 17. 
6.2.6.3.6 Induction season (Season) 
Induction dates as recorded by the participating NBRDI feedlots ranged from 31
st
 March 2009 
through to the 14
th
 December 2011. The induction dates for each cohort were divided into four 
induction season categories, spring (1
st
 September – 30th November), summer (1st December – 28th 
February), autumn (1
st
 March – 31st May) and winter (1st June – 31st August). 
6.2.6.3.7 Exposure to an animal persistently infected with bovine viral diarrhoea 
virus (BVDV_PI). 
The derivation of the NBRDI analysis variables used to investigate the presence of animals 
persistently infected (PI) with BVDV involved a number of stages and associated laboratory testing 
(Barnes et al., 2014). The NBRDI tested pooled induction and draft sera from up to 24 animals per 
pool to allow testing every animal in the cohort using the real time PCR described by Horwood and 
Mahony (2011). The results of pooled sample testing for each cohort were compared with results 
using sera collected from individual animals pulled for BRD pertaining to the same cohort. This 
allowed derivation of a binary variable to describe whether or not BVDV was active in the cohort 
(Barnes et al., 2014).  
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The NBRDI further investigated the effect of exposure to a PI animal prior to day 0. The aim was to 
identify if NBRDI enrolled animals together 28 days prior to day 0 (group-28) had been exposed to 
or contained a PI animal. Identifying whether or not a group-28 contained a PI animal required 
further testing of individual samples collected as part of the NBRDI. A repeated positive PCR test 
from the same animal least 14 days after an initial positive test was used to identify the presence of 
a PI animal (Barnes et al., 2014). Describing the full process used to identify a PI animal is beyond 
the scope of this thesis and is detailed in the NBRDI report (Barnes et al., 2014). 
In this study a pre-derived NBRDI composite variable that identified the presence or absence of 
active BVDV infection in the cohort in addition to the presence of a PI in the group-28 was used. 
This variable consisted of three categories; BVDV active in cohort, no PI in group-28 (Active, no 
PI), BVDV active in cohort, PI detected in group-28 (Active, yes PI) and BVDV not active in 
cohort and no PI detected in group-28 (Not active, no PI). 
6.2.7 Causal diagrams for putative risk factors 
6.2.7.1  Causal diagram for induction putative risk factors  
A causal diagram to describe postulated links between measured exposure variables and between 
exposure variables and M. bovis sero-positivity at feedlot induction was constructed after examining 
the evidence from the literature and the availability of data from the NBRDI. The causal diagram 
was developed with postulated interrelationships between proposed direct and indirect causes of 
M. bovis sero-positivity (Figure 6.2). Appendix 5 lists the hypotheses for causal pathways indicated 
in the causal diagram for M. bovis sero-positivity at feedlot arrival. 
Each arrow in the causal diagram depicts a hypothesised causal pathway in which one variable (the 
variable from which the arrow starts) might at least partly determine another (the variable to which 
the arrow points). Direct pathways are those where the variables are linked by an arrow that passes 
directly from one to the other. A variable with a pathway directly to M. bovis sero-positivity depicts 
a direct effect of that variable. Indirect pathways are those where a variable is linked to another via 
one or more intervening variables; depicted as a sequence of arrows so the pathway can be traced 
passing through these intervening variables by following the sequence of arrows in the correct 
direction. There may be multiple indirect pathways from any particular variable to any particular 
other variable (Barnes et al., 2014). Effects mediated in this way are known as indirect effects 
(Barnes et al., 2014). The total effect of a variable on M. bovis sero-positivity is the sum of the 
direct and all the indirect effects for that variable on M. bovis sero-positivity.  
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The causal diagram was used to inform the total and direct effects modelling processes in the same 
manner as Barnes et al. (2014). When causal diagrams are used to inform variable selection for 
analyses, failure to include a pathway is a stronger claim than including pathways that are 
potentially true (Textor, 2013). 
 
 
Figure 6.2: Causal diagram based on a priori knowledge and biologically plausible pathways 
interlinking the measured exposure variables with each other, as appropriate, and with the 
occurrence of M. bovis sero-positivity at induction. 
Yard weaning (Yard wean) was not used to determine adjustment sets for putative risk factors of 
interest as data were only available for a small subset of animals (n = 210), (Section 6.2.5.1.6). 
Appendix 5 lists the hypotheses for causal pathways indicated in the causal diagram for sero-
positivity at feedlot arrival. 
  
M. bovis sero-positive
GroupN-13
Breed
Source region 
Yard wean
Weight
Mix pre27
Dentition
Ind year
SY pre27
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6.2.7.2  Causal diagram for draft putative risk factors  
A causal diagram to describe postulated links between measured exposure variables and between 
exposure variables and sero-conversion to M. bovis at draft was constructed after examining the 
evidence from the literature and the availability of data from the NBRDI. The causal diagram was 
developed with postulated interrelationships between proposed direct and indirect causes of sero-
conversion or a change in sero-status to M. bovis (Figure 6.3). As for the induction risk factors, the 
causal diagram was used to inform the total and direct effects modelling processes. Appendix 6 lists 
the hypotheses for causal pathways indicated in the causal diagram for M. bovis sero-conversion or 
sero-increase at draft. 
 
Figure 6.3: Causal diagram based on a priori knowledge and biologically plausible pathways 
interlinking the measured exposure variables with each other, as appropriate, and with the 
occurrence of sero-conversion or an increase of two or more BioK260 DV categories between 
feedlot induction and draft 
M. bovis sero-conversion / sero-increase encompasses those animals: (i) classified as sero-negative at feedlot 
induction and sero-positive at draft based on results obtained using the BioK302 ELISA; (ii) returning a 
result that fell in the ‘0’ BioK260 DV category at induction and a draft result that was two or more BioK260 
Delta Value categories higher than their induction result; and (iii) returning an induction result that fell in the 
‘0’, ‘+’, ‘++’ or ‘+++’ BioK260 Delta Value category and a draft result that was two or more BioK260 Delta 
Value categories higher than their induction result. Appendix 6 lists the hypotheses for causal pathways 
indicated in the causal diagram for M. bovis sero-conversion or sero-increase at draft.  
M.bovis sero-conversion 
         / sero-increase
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Breed
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Mix Sum
Dentition
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Pen join
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6.2.8  Statistical modelling and data management 
6.2.8.1  Total and direct effects 
The total effect of a putative risk factor on an outcome is the best estimate of the true causal effect 
(Dohoo et al., 2010). Thus, for a change in status of a given risk factor, the total effect estimate 
measures the expected change in outcome. In contrast, the direct effect estimate measures only the 
expected change in outcome that is not mediated through specified intervening risk factor(s). It is 
only meaningful when the additional effect of a risk factor, over and above effects mediated through 
one or more indirect pathways, is of particular interest. In estimating total effects, care needs to be 
taken to adjust appropriately for confounders, including variables that become confounders through 
conditional associations (Dohoo et al., 2010). To obtain correct estimates for the total effects for a 
risk factor of interest, all confounding variables must be fitted but none of the intervening variables 
between the risk factor of interest and the outcome should be fitted. If confounders are not included, 
the estimate will be biased, and if one or more intervening risk factors are included, effects 
mediated via that indirect pathway to the outcome will be removed (Textor et al., 2011). As a result, 
only a partial rather than total effect will be estimated. Identification of which risk factors might be 
possible confounders is complicated by conditional association (see below). Therefore selection of 
which risk factors to include in any model requires close inspection of the causal diagram. 
Putative intervening risk factors can be identified from a causal diagram as they lie on a front door 
path between the risk factor of interest and the outcome. A front door path is one that goes forwards 
from the risk factor of interest to the outcome, so both direct and indirect paths are front door paths. 
For example, in Figure 6.2, considering the effect of dentition on M. bovis sero-positivity, weight is 
an intervening risk factor as it lies on a front door path from dentition on M. bovis sero-positivity 
(Figure 6.2).  
Confounding variables can be identified as those which lie on a back door path between the risk 
factor of interest and the outcome. A back door path is one that goes backwards one arrow from the 
exposure of interest (from the head towards the tail of the arrow) and then proceeds forwards to the 
outcome either directly or via one or more intervening risk factors. For example, considering the 
effect of breed on M. bovis sero-positivity, there is a back door path from breed to M. bovis sero-
positivity via source region (Figure 6.2). Each of the back door paths must be blocked by including 
a risk factor from the path in the model. Conditional association is induced if a risk factor is 
included in the model and it, in turn, is caused by two or more risk factors; conditional associations 
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would occur between these latter risk factors. If any of these conditional associations open up other 
back door pathways then these also need to be blocked (Textor and Liskiewicz, 2011).  
A set of all covariates that need to be included is known as a sufficient adjustment set (Textor and 
Liskiewicz, 2011). A minimal sufficient adjustment set is a sufficient adjustment set that would no 
longer be sufficient if any risk factor were removed (Textor and Liskiewicz, 2011). For example, 
the minimal sufficient adjustment set to estimate the total effect of weight consists of source region, 
induction year, breed and dentition as these four risk factors block all back door paths to M. bovis 
sero-positivity (Figure 6.2). If any of these risk factors (source region, induction year, breed and 
dentition) were removed, one or more back door paths would be opened.  
To obtain correct estimates for the direct effects for a risk factor of interest all confounding risk 
factors must be fitted and sufficient intervening risk factors should be fitted such that all front door 
paths other than the direct pathway to the outcome are blocked. If this process opens up additional 
back door paths, they too must be blocked (Barnes et al., 2014, Textor and Liskiewicz, 2011). To 
minimise bias in effect estimates for variables of interest, a separate model was fitted to obtain total 
effect estimates for each putative risk factor of interest (Westreich and Greenland, 2013). This 
process was repeated to obtain direct effect estimates when they were specifically required. This is 
in contrast to using a more traditional automated selection process to select one final model as the 
estimates of effects for risk factors included in such models may be total, direct or partial 
(Westreich and Greenland, 2013).  
6.2.8.2  Modelling methodology 
The DAGitty
®
 software (Textor, 2013) was used to identify minimal sufficient adjustment sets to 
assess total effects of each putative risk factor on the outcome of M. bovis sero-positivity. Where 
direct effects were of a priori interest, minimal sufficient adjustment sets were identified in a similar 
manner. The causal diagram was reproduced within the DAGitty
®
 user interface and each risk 
factor of interest was sequentially identified as the ‘exposure’ of interest. The minimal sufficient 
adjustment sets for both total and direct effects as defined by DAGitty
®
 for induction risk factors 
were noted (Table 6.5). The minimal sufficient adjustment sets for both total and direct effects as 
defined by DAGitty
®
 for draft risk factors were noted (Table 6.6). 
The statistical software package Stata/SE 12.1
®
 was used for all data management and analyses. To 
assess risk factors for sero-positivity at induction models were fitted using the xtlogit command 
with group-13 fitted as a random effect. To assess risk factors for sero-conversion or an increase of 
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two or more M. bovis BioK260 DV categories at draft, models were fitted using the xtmelogit 
command with feedlot, cohort and group-13 fitted as random effects. 
Odds ratios for direct effects were only obtained for putative risk factors of particular interest for 
M. bovis sero-positivity at induction or sero-conversion / sero-increase between induction and draft. 
For the induction putative risk factors these included SY pre27 as the effect of SY pre27 over and 
above that mediated through mixing (Mix pre27), would be estimated. In addition the direct effect 
of source region was assessed to determine the effect of source region over and above that mediated 
through Ind year, breed, weight, dentition, SY pre27, Mix pre27 and groupN-13 (Figure 6.2 and 
Table 6.5). For draft putative risk factors the direct effect of source region, breed, SY pre27, SY 
27_0, groupN-13, and cohort were assessed (Table 6.6). 
Table 6.5: Covariates indicated as minimum sufficient adjustment sets for total and direct 
effect models of induction putative risk factors as informed using DAGitty

 and the causal 
diagram 
Putative risk factor 
Minimum sufficient adjustment set to estimate: 
Total effect Direct effect 
Source region Ind year Ind year, Breed, Dentition, Weight, 
Mix pre27, GroupN-13, SY pre27 
Breed Source region Not assessed 
Weight Source region, Ind year, Breed, 
Dentition 
Not assessed 
Mix pre27 Source region, Ind year, Dentition, 
SY pre27 
Not assessed 
SY pre27 Source region Source region, Ind year, Dentition, Mix pre27 
GroupN-13 Source region, Ind year Source region, Ind year 
Dentition Ind year, breed Not assessed 
Ind Year None Not assessed 
Yard wean* Source region Not assessed 
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Table 6.6: Covariates indicated as minimum sufficient adjustment sets for total and direct effect models for sero-conversion or an increase of 
two or more BioK260 DV categories between induction and draft as informed using DAGitty

 and the causal diagram 
Putative risk factor 
Minimum sufficient adjustment set to estimate: 
Total effect Direct effect  
Source region Ind year Breed, CohortN, Dentition, GroupN-13, Ind year, Mix Sum, Move pre27, 
Season, Weight, SY pre27, SY 27_0, BVDV_PI  
Breed Source region Dentition, Ind year, Season, Source region, Weight 
Weight Source region, Ind year, Breed, Dentition, Season  Not assessed 
Mix Sum Source region, Ind year, Dentition, GroupN-13, Move pre27, SY pre27 & 
SY 27_0 
Equal to total effect model 
SY pre27 Source region Source region, Ind year, Dentition, GroupN-13, Mix Sum, Move pre27  
SY 27_0 Source region Source region, Ind year, Dentition, GroupN-13, Mix Sum, Move pre27  
GroupN-13 Source region, Ind year Source region, Ind year, Dentition, Mix Sum, Move pre27, SY pre27, 
SY 27_0  
Dentition Ind year, Breed, Season Not assessed 
Ind year None Not assessed 
Move pre27 Source region, Ind year, Dentition, Weight Not assessed 
Density CohortN Not assessed 
CohortN None Source region, Density, BDVD_PI 
BVDV_PI Source region, CohortN Equal to total effect model 
Pen join None Not assessed 
Water None Equal to total effect model 
Shade Season Equal to total effect model 
Season None Not assessed 
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6.3 Results  
6.3.1  Variance 
6.3.1.1  Induction 
Comparative results for the different group definitions and sero-positivity to M. bovis at feedlot 
induction are shown in Table 6.7 and Table 6.8. The group ICC estimates calculated account for 
clustering at the PIC for the same time point. Overall, the group ICCs for each outcome assessed 
(sero-positivity to M. bovis at feedlot induction using the BioK302 and dichotomised BioK260 
ELISA results, in addition to series and parallel interpretation of the two test results) indicate that 
sero-positivity to M. bovis are highly clustered within groups of animals defined at each of the time 
points assessed. The group ICCs also indicate that the level of clustering is higher for the smaller 
groups of animals that were together at a particular PIC 90 or more days (group-91, group-365 and 
group-500) prior to feedlot induction.  
The percentage of variance at the group level is highest for the BioK302 ELISA results while the 
percentage of variance at the PIC level is higher than that at the group level when sero-positivity at 
feedlot induction using the dichotomised BioK260 ELISA results were assessed. When the two test 
results are assessed in series and parallel the percentage of variance at the PIC and group levels 
become similar indicating that the group ICC is driven by clustering at both the group and PIC 
levels.  
6.3.1.2  Draft 
Assessment of the variance in sero-conversion / a sero-increase in M. bovis antibodies at draft 
revealed that the majority of variance is at the individual animal level, followed by cohort (Table 
6.9 and Table 6.10). The percentage of variance at the animal level across each of the defined time 
points and outcomes ranges from 59.6% (BioK302 sero-conversion, group-500) through to 77.3% 
(BioK260 sero-conversion, group-365). Variance at the cohort level ranged from 10.3% (BioK302 
sero-conversion, group-2) through to 20.4% (BioK260 sero-conversion and BioK260 sero-increase, 
group-500). The least variance was seen at the feedlot and group levels. The percentage of variance 
at the feedlot level is fairly consistent across the three outcomes assessed ranging from 6.4% 
(BioK260 sero-increase, group-91 and group-28) to 8.8% (BioK302 sero-conversion, group-500). 
The percentage of variance at the group level at each of the defined time points is not as consistent, 
being lowest for group-500 irrespective of the outcome. However, due to the important 
contributions of variance at feedlot, cohort and group levels the group ICC’s still indicate that sero-
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conversion / a sero-increase in M. bovis antibody at draft is clustered within groups of animals at 
each of the defined time points assessed. 
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Table 6.7: Distribution of variance in the BioK302 and dichotomised BioK260 ELISA results between animal, group and PIC levels for groups 
established at defined time points 
Group No. of 
observations 
No. of groups 
Mean group 
size 
Variance Percentage of variance Group 
ICC PIC Group Animal Total PIC Group Animal 
BioK302 ELISA         
Group-2 1,354 562 2.4 1.26 4.51 3.29 9.06 13.96 49.73 36.31 0.64 
Group-7 1,354 513 2.6 0.84 4.37 3.29 8.51 9.92 51.40 38.68 0.61 
Group-13 1,354 525 2.6 0.92 4.37 3.29 8.59 10.75 50.94 38.32 0.62 
Group-28 1,354 562 2.4 1.28 4.50 3.29 9.07 14.08 49.64 36.28 0.64 
Group-91* 1,341 606 2.2 - 8.73 3.29 12.02 - 72.63 27.37 0.73 
Group-365 1,340 823 1.6 3.33 3.99 3.29 10.61 31.35 37.63 31.02 0.69 
Group-500 1,340 891 1.5 3.72 5.68 3.29 12.69 29.33 44.74 25.93 0.74 
BioK260 ELISA (dichotomised results)         
Group-2 1,354 562 2.4 1.10 0.28 3.29 4.68 23.58 6.06 70.36 0.30 
Group-7 1,354 513 2.6 1.01 0.65 3.29 4.95 20.41 13.10 66.49 0.34 
Group-13 1,354 525 2.6 1.05 0.60 3.29 4.94 21.34 12.07 66.59 0.33 
Group-28 1,354 562 2.4 1.13 0.20 3.29 4.62 24.45 4.36 71.19 0.29 
Group-91 1,341 606 2.2 0.70 1.27 3.29 5.27 13.32 24.20 62.48 0.38 
Group-365 1,340 823 1.6 3.14 0.00 3.29 6.43 48.85 0.00 51.15 0.49 
Group-500 1,340 891 1.5 2.00 3.08 3.29 8.36 23.86 36.81 39.33 0.61 
ICC: Intra-class correlation coefficient; PIC: Property identification code.  
* Group-91 variance using the BioK302 enzyme-linked immunosorbent assay and the associated ICC has been determined using an xtlogit model with group as the only random 
effect. An xtmelogit model indicated that PIC and group at this time point (91 days prior to day 0) was highly unstable. Groups are defined as a collection of animals in the same 
cohort that were together at defined time points prior to day 0. Day 0 is defined as the day of induction or for those animals pre-assembled on pasture at or close to the feedlot it is the 
day the animal was moved to a feedlot pen.  
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Table 6.8: Distribution of variance using series and parallel interpretation of the BioK302 and dichotomised BioK260 ELISA results between 
animal, group and PIC levels for groups established at defined time points 
Group No. of 
observations 
No. of groups 
Mean group 
size 
Variance Percentage of variance Group 
ICC PIC Group Animal Total PIC Group Animal 
Series interpretation          
Group-2 1,354 562 2.4 1.47 1.97 3.29 6.73 21.86 29.24 48.90 0.51 
Group-7 1,354 513 2.6 1.01 2.19 3.29 6.49 15.55 33.75 50.71 0.49 
Group-13 1,354 525 2.6 1.07 2.17 3.29 6.53 16.37 33.26 50.38 0.50 
Group-28 1,354 562 2.4 1.48 1.97 3.29 6.74 21.91 29.29 48.80 0.51 
Group-91 1,341 606 2.2 0.00 6.09 3.29 9.38 0.00 64.92 35.08 0.65 
Group-365* 1,340 823 1.6 - 11.10 3.29 14.39 - 77.13 22.87 0.77 
Group-500* 1,340 891 1.5 - 14.20 3.29 17.49 - 81.19 18.81 0.81 
Parallel interpretation          
Group-2 1,354 562 2.4 0.96 1.02 3.29 5.27 18.19 19.32 62.48 0.38 
Group-7 1,354 513 2.6 0.87 1.28 3.29 5.43 15.98 23.47 60.55 0.39 
Group-13 1,354 525 2.6 0.92 1.22 3.29 5.43 16.91 22.45 60.64 0.39 
Group-28 1,354 562 2.4 0.98 0.92 3.29 5.20 18.91 17.77 63.33 0.37 
Group-91 1,341 606 2.2 0.00 2.80 3.29 6.09 0.00 45.98 54.02 0.46 
Group-365 1,340 823 1.6 0.00 3.95 3.29 7.24 0.00 54.56 45.44 0.55 
Group-500* 1,340 891 1.5 - 4.38 3.29 7.67 - 57.10 42.90 0.57 
ICC: Intra-class correlation coefficient; PIC: Property identification code.  
* Group-365 and Group-500 variance and associated ICC’s using series interpretation in addition to Group-500 variance and associated ICC using parallel interpretation has been 
determined using an xtlogit model with group as the only random effect. An xtmelogit model indicated that the PIC and groups at these time points were highly unstable. Groups are 
defined as a collection of animals in the same cohort that were together at defined time points prior to day 0. Day 0 is defined as the day of induction or for those animals pre-
assembled on pasture at or close to the feedlot it is the day the animal was moved to a feedlot pen.  
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Table 6.9: Distribution of variance in BioK302 and BioK260 sero-conversion results between animal, group, cohort and feedlot levels for 
groups established at defined time points  
Group No. of 
observations 
No. of 
groups 
Mean 
group size 
Variance Percentage of variance Group 
ICC Feedlot Cohort Group Animal Total Feedlot Cohort Group Animal 
BioK302 sero-conversion            
Group-2 1,307 562 2.7 0.37 0.47 0.40 3.29 4.52 8.16 10.32 8.81 72.71 0.27 
Group-7 1,307 509 2.6 0.38 0.49 0.32 3.29 4.48 8.41 10.93 7.22 73.44 0.27 
Group-13 1,307 520 2.5 0.38 0.48 0.40 3.29 4.54 8.33 10.58 8.69 72.39 0.28 
Group-28 1,307 552 2.4 0.37 0.50 0.36 3.29 4.52 8.25 11.12 7.86 72.77 0.27 
Group-91 1,295 595 2.2 0.37 0.52 0.18 3.29 4.36 8.41 11.99 4.09 75.51 0.24 
Group-365 1,294 799 1.6 0.37 0.54 0.08 3.29 4.28 8.72 12.61 1.76 76.91 0.23 
Group-500 1,294 865 1.5 0.37 0.54 0.06 3.29 4.26 8.77 12.62 1.31 77.29 0.23 
BioK260 sero-conversion            
Group-2 1,276 486 2.6 0.36 0.82 0.57 3.29 5.05 7.20 16.25 11.38 65.16 0.35 
Group-7 1,276 507 2.5 0.35 0.78 0.73 3.29 5.15 6.74 15.18 14.21 63.87 0.36 
Group-13 1,276 518 2.5 0.35 0.78 0.77 3.29 5.19 6.78 14.95 14.91 63.36 0.37 
Group-28 1,276 547 2.3 0.35 0.79 0.78 3.29 5.20 6.64 15.14 14.96 63.26 0.37 
Group-91 1,265 585 2.2 0.34 0.83 0.85 3.29 5.32 6.45 15.60 16.05 61.89 0.38 
Group-365 1,264 778 1.6 0.39 1.07 0.77 3.29 5.52 7.13 19.29 14.03 59.56 0.40 
Group-500 1,264 841 1.5 0.40 1.03 0.31 3.29 5.03 7.98 20.43 6.15 65.43 0.35 
ICC: Intra-class correlation coefficient.  
Groups are defined as a collection of animals in the same cohort that were together at defined time points prior today 0. Day 0 is defined as the day of induction or for those animals 
pre-assembled on pasture at or close to the feedlot it is the day the animal was moved to a feedlot pen. 
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Table 6.10: Distribution of variance in results for an increase of two or more BioK260 Delta Value categories between animal, group, cohort 
and feedlot levels for groups established at defined time points 
Group No. of 
observations 
No. of 
groups 
Mean 
group size 
Variance Percentage of variance Group 
ICC Feedlot Cohort Group Animal Total Feedlot Cohort Group Animal 
Group-2 1,349 489 2.8 0.35 0.78 0.64 3.29 5.06 6.96 15.47 12.59 64.98 0.35 
Group-7 1,349 513 2.6 0.33 0.76 0.77 3.29 5.15 6.49 14.71 14.92 63.88 0.36 
Group-13 1,349 524 2.6 0.34 0.75 0.81 3.29 5.19 6.55 14.49 15.63 63.33 0.37 
Group-28 1,349 559 2.4 0.33 0.79 0.81 3.29 5.22 6.40 15.17 15.42 63.00 0.37 
Group-91 1,336 605 2.2 0.34 0.87 0.77 3.29 5.27 6.39 16.58 14.63 62.40 0.38 
Group-365 1,335 820 1.6 0.39 1.06 0.74 3.29 5.48 7.06 19.38 13.56 60.01 0.40 
Group-500 1,335 888 1.5 0.39 1.02 0.28 3.29 4.98 7.91 20.40 5.57 66.13 0.34 
ICC: Intra-class correlation coefficient.  
Groups are defined as a collection of animals in the same cohort that were together at defined time points prior to day 0. Day 0 is defined as the day of induction or for those animals 
pre-assembled on pasture at or close to the feedlot it is the day the animal was moved to a feedlot pen. 
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6.3.2 Putative risk factor analysis results for M. bovis sero-positivity at feedlot induction 
All tables referred to in the following text are located in sequential order at the end of the results 
section. 
6.3.2.1  Animal level putative risk factor results 
6.3.2.1.1 Breed 
The most common breed was Angus comprising 56.2% (n = 761) of the study population. Tropical 
breeds and tropical crosses comprised 17.1% of the population; British crosses 12.1% and the 
remainder were of Hereford (4.3%), Shorthorn (4.1%), European / European cross (3.6%) or 
Murray Grey (2.4%) breed categories (Table 6.11).  
Overall, there was no evidence of a strong association between breed and sero-positivity to M. bovis 
when cattle were inducted at the feedlot (Table 6.12). This was consistent for both tests and for the 
series and parallel interpretations. There was some evidence to suggest that Murray Greys might be 
at increased risk, particularly based on the dichotomised BioK260 results, but the confidence 
intervals include one, so it is possible that there is no true increase in risk (OR: 2.84, 95% CI: 0.90 - 
8.99), (Table 6.12). In addition, the majority of the Murray Greys in this study were from a single 
feedlot, and any possible feedlot-level confounding has not been accounted for here.   
6.3.2.1.2 Induction weight (Weight) 
The most common induction weight category was 440 ≤ 480 kg comprising 36.8% (n = 499) of the 
study population (Table 6.11). This induction weight category was subsequently used as the 
reference category for the analysis of the total effect of induction weight model. The 190 ≤ 400 kg 
induction weight category had the highest percentage of sero-positive animals at the time of feedlot 
induction for all induction outcomes assessed (Table 6.11).  
Some association between induction weight and sero-positivity to M. bovis at induction was evident 
using the dichotomised BioK260 results and parallel interpretation of the two tests. This association 
was not significant and was not seen using results obtained from the BioK302 ELISA (Table 6.12). 
Point estimates for lighter cattle are consistently higher for sero-positivity at feedlot induction using 
all induction outcomes. Although not significant, there may be some suggestion of increased risk of 
sero-positivity at feedlot induction associated with lighter cattle.  
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6.3.2.1.3 Dentition 
The most common category was ‘milk tooth’ comprising 77.9% (n = 1,055) of the study population 
(Table 6.13). Due to the commonality of the ‘milk tooth’ dentition category in the study population, 
it was used as the reference category in the assessment of its total effect on sero-positivity to 
M. bovis at feedlot induction.  
The percentage of animals testing sero-positive in the ‘milk tooth’ category was higher using both 
test results and series and parallel interpretations (Table 6.13). Comparison of the point estimates 
for the total effect of dentition across all outcomes assessed gave some suggestion that ‘two tooth’ 
cattle were at decreased risk of being sero-positive for M. bovis at feedlot induction compared to the 
reference category (milk tooth). However this association was not significant across all four 
outcomes (Table 6.14). In addition, the point estimates for ‘four and six tooth’ cattle were 
inconsistent across the four outcomes assessed in this study. 
6.3.2.1.4 Mixing at least 27 days prior to day 0  
In the study population, 68.3% (n = 925) had been mixed while 30.8% (n = 417) had not been 
mixed with animals from another property with a different PIC at least 27 days prior to day 0 (Table 
6.13). The exact mixing history of 12 animals could not be determined from the NLIS data, and 
were categorised as missing. The number and overall percentage of animals in each mixing history 
category testing positive using each of the four outcomes assessed are shown in Table 6.13.  
The point estimates indicated that there was an increased tendency for animals with a prior history 
of mixing to be at increased risk of being sero-positive for M. bovis at feedlot induction. This 
association was significant using the dichotomised BioK260 ELISA results (OR: 2.62, 95% CI: 
1.14 – 5.98; p = 0.02), (Table 6.14). The same significant strength of association was not seen using 
the BioK302 results or series interpretation. Parallel interpretation of the results returned a p value 
of 0.07 and OR of 2.08, however the 95% confidence interval did include one, indicating there may 
be no true increase in risk. The direct effect model included the same minimum sufficient 
adjustment set as that indicated for the total effect model.  
6.3.2.1.5 Saleyard transfer at least 27 days prior to day 0  
In the study population 61.9% (n = 838) had no history of a saleyard transfer, while 37.1% 
(n = 502) had been through a saleyard at least once during their lifetime as evidenced by NLIS data, 
up until 27 days prior to day 0 (Table 6.13). The exact saleyard transfer history of 14 animals could 
not be determined from the NLIS data, and were categorised as missing. The number and overall 
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percentage of animals in each saleyard transfer history category testing positive using each of the 
four outcomes assessed are shown in Table 6.13.  
Overall the total effect model for saleyard transfer at least 27 days prior to day 0 indicated there was 
a tendency for animals that had been exposed to a saleyard environment were at increased risk of 
sero-positivity to M. bovis at feedlot induction (Table 6.14). The total effects odds ratios ranged 
from 1.97 – 2.98, 95% CI: 1.10 – 7.83; p < 0.05, across the four outcomes assessed (Table 6.14). 
The direct effect for saleyard transfer history was also assessed (Table 6.15). The increased risk 
association remained for animals with a prior history of a saleyard transfer at least 27 days prior to 
day 0, but was attenuated for most outcomes. The attenuation of the association indicates that some 
of the effect of SY pre27 is mediated through mixing (the only postulated indirect pathway) rather 
than through the direct pathway (Figure 6.2). In addition, as the confidence intervals across all 
outcomes assessed include one, it is possible there is no true increase in risk over and above that 
associated with mixing.  
6.3.2.1.6 Yard weaning 
Records of yard weaning obtained from vendor questionnaire information were available for 15.5% 
(n = 210) of the study population. Of these, 21.0% (n = 44) were paddock weaned and 79.1% 
(n = 166) were yard weaned (Table 6.16). The duration of yard weaning varied with 77 animals 
yard weaned for < seven days and 89 animals weaned for seven or more days. Of the animals that 
were not yard weaned, none had detectable M. bovis antibody at the time of feedlot induction on 
either the BioK302 or BioK260 ELISA kits (Table 6.16). As no variation was seen in the study 
population between yard weaning and sero-positivity to M. bovis at feedlot induction, further 
assessment of yard weaning as a putative risk factor was not possible. 
6.3.2.2  Group-level putative risk factor results 
6.3.2.2.1 Source region 
The most common source region category was the Darling Downs and New England category with 
28.5% (n = 386) of the study population recorded at a PIC location in this geographical region 
28 days prior to day 0. The Western NSW / QLD and the Northern Territory category contributed 
24.5% (n = 331), NSW / southern tablelands 16.2% (n = 219), and the Riverina / Victoria and 
Tasmania category 15.4% (n = 209), respectively. The South Australia / Western Australia and 
coastal NSW / coastal QLD categories contributed the remainder of the study animals (Table 6.17).  
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There was a significant overall total effect of source region across all test outcomes assessed (Table 
6.18). This appeared to be driven by the South Australia / Western Australia and Darling Downs / 
New England source region categories. Animals in the South Australia / Western Australia category 
appeared at increased risk compared to the reference group (NSW / Southern tablelands) using both 
the BioK302 (OR 3.81, 95% CI: 0.77% - 18.91%) and dichotomised BioK260 ELISA (OR 5.63, 
95% CI: 1.91% - 16.59%) results for being M. bovis sero-positive at feedlot induction. Animals in 
the Darling Downs / New England category had a decreased risk using both the BioK302 (OR 0.18, 
95% CI: 0.03% - 1.02%) and parallel interpretation (OR 0.47, 95% CI: 0.18% - 1.25%) of results 
(Table 6.18).  
The direct effect for source region was also assessed (Table 6.18). The association between source 
region and sero-positivity to M. bovis at feedlot induction remained for the Darling Downs / New 
England category (decreased risk), but was attenuated for most outcomes. This attenuation and the 
wide 95% confidence intervals seen in the direct effect model indicates that some of the effect of 
this risk factor is mediated through postulated indirect pathways (induction year, breed, dentition, 
induction weight, group size, mixing and saleyard transfer history at least 27 days prior to day 0) 
rather than through the direct pathway  
6.3.2.2.2 Induction year  
The most common induction year was 2011 comprising 54.1% (n = 733) of the study population. 
The year 2010 contributed 33.9% (n = 458) and 2009, 12.0% (n = 163) of the study population 
respectively (Table 6.17). The total effect model for induction year did not show any consistent 
association with sero-positivity for M. bovis-specific antibodies at feedlot induction (Table 6.19). 
6.3.2.2.3 Group size  
The most common group size 13 days prior to day 0 was < 50 animals with 40.1% (n = 543) of the 
study population. Animals derived from group-13 sizes of 50 - 99 animals and ≥ 100 animals 
comprised 28.4% (n = 384) and 31.5% (n = 427) of the study population respectively (Table 6.17).  
Both the total and direct effect models for group size included the same adjustment sets (source 
region and induction year). The estimated odds ratios and associated 95% confidence intervals are 
shown in Table 6.19. Animals sourced from larger groups 13 days prior to day 0 were at increased 
risk of being sero-positive for M. bovis antibody at feedlot induction compared to the reference 
category (< 50 animals). Animals sourced from a group of ≥ 100 animals had a significantly 
increased risk of sero-positivity at feedlot induction and this effect was most pronounced when 
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using the dichotomised BioK260 ELISA results and parallel interpretation; (OR 3.31, 95% CI: 1.45 
– 7.59) and (OR 3.79, 95% CI: 1.63 – 8.81) respectively (Table 6.19).  
6.3.3   Putative risk factor analysis results for sero-conversion or a sero-increase in M. bovis 
antibody between induction and draft 
As presented in Chapter 5, a total of 96.5% (n = 1,306) and 94.2% (n = 1,275) of the total study 
population (n = 1,354) had the potential to sero-convert between feedlot induction and draft using 
the BioK302 and BioK260 results respectively. Combining the BioK260 re-exposure and BioK260 
sero-conversion outcomes, a total of 99.6% (n = 1,348) of the study population had the potential to 
increase two or more BioK260 DV categories between feedlot induction and draft. Overall, 24.3% 
(317 / 1,306) and 19.5% (249 / 1,275) sero-converted using the BioK302 and BioK260 ELISA 
results respectively, while 19.4% (261 / 1,348) sero-increased between feedlot induction and draft. 
Tables referred to in the following text for each putative risk factor are located at the end of the 
results section in numerical order.  
6.3.3.1  Animal-level putative risk factor results 
6.3.3.1.1 Breed 
The percentage of animals in each breed category with the potential to sero-convert or sero-increase 
between feedlot induction and draft are shown in Table 6.20. Although a higher percentage of 
animals sero-converted based on the BioK302 ELISA results, there was no consistency in the 
proportion of animals that sero-converted or sero-increased across any of the breed categories and 
outcomes assessed. The Angus breed category was used as the reference category, comprising 
56.2% of the study population. 
The total and direct effect estimates for each breed category on the draft outcomes assessed are 
shown in Table 6.21. From the total effects model there was some indication that the risk of sero-
conversion or sero-increase was reduced if the animal was of British cross (based on the BioK260 
ELISA results), European / European cross or Tropical / Tropical cross (based on both the BioK302 
and BioK260 ELISA results) breed (Table 6.21). This effect remained when the direct effect of 
breed was assessed indicating that some of the effect breed is mediated through postulated indirect 
pathways (induction weight and dentition) rather than through the direct pathway. In addition, as the 
confidence intervals across all outcomes assessed include one, it is possible there is no true decrease 
in risk over and above that associated with the intervening variables listed.  
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6.3.3.1.2 Induction weight 
The percentage of animals in each induction weight category with the potential to sero-convert or 
sero-increase between feedlot induction and draft are shown in Table 6.22. The percentage of 
animals considered having sero-converted or sero-increased was consistent across the induction 
weight categories and the outcomes assessed. There was no indication that induction weight had an 
effect on the risk of sero-conversion or sero-increase between feedlot induction and draft (Table 
6.23). 
6.3.3.1.3 Dentition 
The percentage of animals in each dentition category with the potential to sero-convert or sero-
increase between feedlot induction and draft are shown in Table 6.22. The percentage of animals 
that sero-converted or sero-increased was lower for the ‘two tooth’ dentition category across all 
three outcomes assessed. There was no indication that dentition had an effect on the risk of sero-
conversion or sero-increase to M. bovis between feedlot induction and draft from the total effects 
model (Table 6.23). 
6.3.3.1.4 Mixing summary 
The distribution of animals in each mixing summary category and the percentage of animals with 
the potential to sero-convert or sero-increase between feedlot induction and draft are shown in 
Table 6.24. Animals that had been mixed 27 days prior to day 0 and formed a cohort with four or 
more group-28s (yes : high) comprised 47.3% of the study population and was used as the reference 
category. The percentage of animals that sero-converted or sero-increased was lower for the ‘yes, 
low’ mixing summary category across all three outcomes assessed. From the total effects model, 
there was no indication that any of the Mix Sum categories had any association with the risk of 
sero-conversion or a sero-increase of M. bovis antibody between feedlot induction and draft (Table 
6.25). 
6.3.3.1.5 Saleyard transfer at least 27 days prior to day 0 and saleyard transfer between 27 
days prior to day 0 and day 0 
The distribution and percentage of animals in each saleyard transfer history category with the 
potential to sero-convert or sero-increase are shown in Table 6.26. In the study population, 61.9% 
of animals had no history of a saleyard transfer at least 27 days prior to day 0, while 94.5% of 
animals had no saleyard transfer between 27 days prior to day 0 and day 0. The percentage of 
animals that sero-converted or sero-increased was similar for each of the saleyard transfer 
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categories and all three outcomes assessed. The total effects model for both saleyard transfer history 
putative risk factors (SY pre27 and SY 27_0) indicated that there was no strong association between 
saleyard transfer history at any time prior to day 0 and sero-conversion or a sero-increase in 
M. bovis antibody between induction and draft (Table 6.27). 
6.3.3.2  Group-level putative risk factor results 
6.3.3.2.1 Source region 
The distribution and percentage of animals in each source region category with the potential to sero-
convert or sero-increase between induction and draft are shown in Table 6.28. The percentage of 
animals that sero-converted or sero-increased was consistently lower for animals sourced from the 
Darling Downs / New England and Riverina / NSW / QLD / NT categories across all three 
outcomes assessed. Animals sourced from the South Australia / Western Australia category also had 
a lower percentage of animals that sero-converted or sero-increased based on the BioK260 results, 
but this pattern was not seen using the BioK302 ELISA results (Table 6.28).  
The total effects model for source region indicated that cattle from the Darling Downs / New 
England and Riverina / NSW / QLD / NT categories were at decreased risk of M. bovis sero-
conversion or sero-increase based on the BioK260 ELISA sero-conversion results (OR 0.35, 95% 
CI: 0.18 – 0.67), (Table 6.29). The direct effect of source region was also investigated and cattle 
sourced from the Darling Downs / New England category remained at significantly decreased risk 
of sero-conversion / sero-increase at draft across all three outcomes assessed; BioK302 sero-
conversion (OR 0.53, 95% CI: 0.31 – 0.91; p = 0.02); BioK260 sero-conversion (OR 0.40, 95% CI: 
0.21 – 0.77; p = 0.01) and BioK260 sero-increase (OR 0.43, 95% CI:0.22 – 0.83; p = 0.01), (Table 
6.29). 
6.3.3.2.2 Move to feedlot at least 27 days prior to day 0 
The distribution and percentage of animals in each move to the feedlot category with the potential 
to sero-convert or sero-increase between feedlot induction and draft are shown in Table 6.28. In the 
study population 95.9% of animals moved to the feedlot within the 27 days prior to day 0. The total 
effect point estimates for the move to feedlot risk factor were not significant across all three draft 
outcomes assessed (Table 6.30). 
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6.3.3.2.3 Group size 
The percentages of animals in each group size category with the potential to sero-convert or sero-
increase are shown in Table 6.31. Animals derived from a group size of ≥ 100 animals had the 
lowest overall percentage of sero-conversion or sero-increase between feedlot induction and draft to 
M. bovis (Table 6.31). Based on the BioK302 sero-conversion results, the point estimate of the total 
effect of group size suggested that animals sourced from a group of ≥ 100 animals 13 days prior to 
day 0 is at reduced risk of sero-conversion to M. bovis (OR: 0.53, 95% CI: 0.30 – 0.92), (Table 
6.32). The same association was seen using the BioK302 sero-conversion results in the direct effect 
model (OR: 0.59, 95% CI: 0.32 – 1.09; p = 0.09) indicating that most of the effect of group size is 
mediated through the direct pathways rather than through the postulated indirect pathways. Similar 
point estimates were seen for the BioK260 draft outcomes; however these were less precise (Table 
6.32). In addition, as the 95% confidence intervals all include one; it is possible there is no true 
decrease in risk over and above that associated with one or more of the intervening variables (Table 
6.32). 
6.3.3.3  Cohort-level putative risk factor results 
6.3.3.3.1 Induction year 
The percentage of animals in each induction year category with the potential to sero-convert or 
sero-increase between feedlot induction and draft are shown in Table 6.33. Based on the BioK260 
ELISA sero-conversion and sero-increase outcomes, the total effect model for induction year 
indicated that cattle inducted in 2011 were at increased risk (OR 2.58, 95% CI: 1.09 – 6.14 and OR 
2.55, 95% CI: 1.09 – 5.99 respectively) in comparison to cattle that were inducted in 2009 (Table 
6.34). The same effect was not seen using the BioK302 sero-conversion outcome (Table 6.34). The 
overall Wald p values for any of the draft outcomes assessed for induction year did not indicate that 
the association with induction year and M. bovis sero-conversion or sero-increase was significant. 
6.3.3.3.2 Cohort size 
The distribution and percentage of animals in each cohort size category with the potential to sero-
convert or sero-increase between feedlot induction and draft are provided in Table 6.33. The study 
population comprised 67.1% of animals that were in a cohort of ≥ 200 animals. The total effect of 
cohort size did not indicate any association of cohort size with sero-conversion or a sero-increase 
between feedlot induction and draft (Table 6.34). 
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6.3.3.3.3 Number of adjoining pens 
The distribution and percentage of animals with the potential to sero-convert or sero-increase in 
each number of adjoining pens category are provided Table 6.33. Most animals in the study 
population (67.9%) were in a pen that had two adjoining pens during their first 50 DOF. A total of 
five animals (0.4%) did not have details of the number of adjoining pens in the NBRDI database. 
The total effect model did not show any association with sero-conversion or a sero-increase to 
M. bovis between feedlot induction and draft (Table 6.34). 
6.3.3.3.4 Shared water 
The distribution and percentage of animals with the potential to sero-convert or sero-increase 
between feedlot induction and draft are shown in Table 6.35. Access to shared water was the most 
common category seen in the study population with 81.7% of animals having access to water that 
was shared with another pen of animals. Overall, animals with shared water were at increased risk 
of sero-conversion or a sero-increase in comparison to animals not having access to shared pen 
water (Table 6.36). This effect was most pronounced based on the results obtained using the 
BioK260 ELISA outcomes. Point estimates for BioK260 sero-conversion and sero-increase were 
OR 3.10, 95% CI: 1.28 – 7.35 (p = 0.01) and OR 3.32, 95% CI: 1.49 – 7.40 (p = 0.003) respectively 
(Table 6.36).  
6.3.3.3.5 Pen shade 
In the study population 69.4% of the animals had access to pen shade, while 30.6% of animals had 
no access to pen shade (Table 6.35). The distribution and percentage of animals with and without 
pen shade that had the potential to and did sero-convert or sero-increase between induction and 
draft are provided in Table 6.35. The total effect of pen shade did not show any association with the 
risk of sero-conversion or a sero-increase of M. bovis antibody between feedlot induction and draft 
(Table 6.36). 
6.3.3.3.6 Pen density 
The most common pen density categories were 13 - < 15 m
2/SCU followed by ≥ 17 m2/SCU 
comprising 38.0% and 26.2% of the study population respectively (Table 6.35). The 11 -
 < 13 m
2
/SCU and 15 - < 17 m
2
/SCU pen density categories made up the remaining 17.3% and 
18.5% of the study population respectively. The distribution and percentage of animals with the 
potential to sero-convert or sero-increase in each of the pen density categories are provided in Table 
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6.35. The total effect of pen density did not indicate any association with the risk of sero-conversion 
or a sero-increase in M. bovis antibody between feedlot induction and draft (Table 6.36). 
6.3.3.3.7 Induction season 
Animals in the study population were fairly evenly distributed across each of the induction season 
categories (Table 6.37). The point estimate for the BioK302 sero-conversion outcome in the total 
effect model suggested that cattle inducted in autumn may be at increased risk in comparison to the 
reference category (spring); (OR: 1.75, 95% CI: 1.01 – 3.02), (Table 6.38). However, this was not 
seen using the BioK260 outcomes. In addition, all 95% confidence intervals include or are very 
close to one, indicating there may be no true increase in risk (Table 6.38). 
6.3.3.3.8 Exposure to an animal persistently infected with bovine viral diarrhoea virus 
The most common BVDV_PI category in the study population was active infection in the cohort 
but no PI detected in any of the group-28s that formed the cohort (Active, no PI), (Table 6.37). The 
overall Wald p value for sero-conversion using the BioK302 ELISA results suggested that there 
may be some association with active BVDV infection in the cohort, however no other BVDV_PI 
categories for any of the outcomes were significantly different from the reference category (not 
active, no PI). In addition, the 95% confidence intervals all included one indicating there may be no 
true decrease in risk (Table 6.38). 
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Table 6.11: Distribution of the study population for breed and induction weight categories sero-positive for M. bovis antibody using four 
induction outcomes.  
Putative risk factor and 
associated categories 
No. (%) 
BioK302 Dichotomised BioK260 Series interpretation Parallel interpretation 
No. positive (%) No. positive (%) No. positive (%) No. positive (%) 
Breed      
Angus 761 (56.2%) 24 (3.2%) 33 (4.3%) 15 (2.0%) 42 (5.5%) 
British Cross 164 (12.1%) 5 (3.1%) 9 (5.5%) 4 (2.4%) 10 (6.1%) 
Hereford 58 (4.3%) 2 (3.5%) 5 (8.6%) 2 (3.5%) 5 (8.6%) 
Shorthorn 56 (4.1%) 1 (1.8%) 4 (7.1%) 1 (1.8%) 4 (7.1%) 
Murray Grey 33 (2.4%) 5 (15.2%) 8 (24.2%) 5 (15.2%) 8 (24.2%) 
European / European 
Cross 
49 (3.6%) 2 (4.1%) 5 (10.2%) 2 (4.1%) 5 (10.2%) 
Tropical / Tropical Cross 232 (17.1%) 8 (3.5%) 14 (6.0%) 4 (1.7%) 18 (7.8%) 
Missing 1 (0.1%)     
Total 1,354 (100%) 47 (3.5%) 78 (5.8%) 33 (2.4%) 92 (6.8%) 
Induction weight (kg) 
     
190 - < 400 215 (15.9%) 19 (8.8%) 26 (12.1%) 15 (7.0%) 30 (14.0%) 
400 - < 440 434 (32.1%) 13 (3.0%) 27 (6.2%) 9 (2.1%) 31 (7.1%) 
440 - < 480 499 (36.8%) 12 (2.4%) 18 (3.6%) 7 (1.4%) 23 (4.6%) 
≥ 480 206 (15.2%) 3 (1.5%) 7 (3.4%) 2 (1.0%) 8 (3.9%) 
Total 1,354 (100%) 47 (3.5%) 78 (5.8%) 33 (2.4%) 92 (6.8%) 
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Table 6.12: Estimated odds ratios for the total effect of breed and induction weight on the risk of M. bovis sero-positivity at feedlot induction 
Putative risk factor and 
associated categories  
BioK302 Dichotomised BioK260 Series interpretation Parallel interpretation 
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Breed 
 
0.95 
 
0.50 
 
0.91 
 
0.57 
Angus Reference  Reference  Reference  Reference  
British Cross 0.58 (0.16 - 2.13) 0.42 0.96 (0.40 - 2.30) 0.92 0.87 (0.24 - 3.19) 0.83 0.81 (0.34 - 1.92) 0.63 
Hereford 0.92 (0.11 - 7.48) 0.94 1.32 (0.37 - 4.75) 0.67 1.36 (0.19 - 9.78) 0.76 1.00 (0.26 - 3.83) 1.00 
Shorthorn 0.46 (0.03 - 7.79) 0.59 1.67 (0.46 - 6.13) 0.44 0.73 (0.06 - 8.90) 0.81 1.42 (0.37 - 5.49) 0.61 
Murray Grey 1.47 (0.30 - 7.28) 0.64 2.84 (0.90 - 8.99) 0.08 2.33 (0.51 - 10.68) 0.28 2.20 (0.67 - 7.20) 0.19 
European / European 
Cross 
1.43 (0.14 - 15.07) 0.77 2.49 (0.69 - 8.95) 0.16 1.78 (0.23 - 13.87) 0.58 2.34 (0.60 - 9.07) 0.22 
Tropical / Tropical Cross 1.33 (0.31 - 5.73) 0.70 1.41 (0.57 - 3.51) 0.46 0.72 (0.16 - 3.18) 0.66 1.79 (0.72 - 4.43) 0.21 
Induction weight (kg) 
 
0.41 
 
0.05 
 
0.40 
 
0.08 
190 - < 400 2.51 (0.67 – 9.36) 0.17 2.03 (0.84 - 4.88) 0.12 2.78 (0.70 – 11.00) 0.15 1.91 (0.81 - 4.49) 0.14 
400 - < 440 1.16 (0.42 – 3.23) 0.60 1.72 (0.87 - 3.39) 0.12 1.47 (0.47 - 4.54) 0.51 1.49 (0.78 – 2.86) 0.23 
440 - < 480 Reference  Reference  Reference  Reference  
≥ 480 0.76 (0.16 – 3.58) 0.73 0.89 (0.34 – 2.35) 0.81 0.68 (0.12 – 3.90) 0.66 0.86 (0.34 – 2.19) 0.76 
CI: Confidence interval; OR: Odds ratio; p: Wald p value  
Individual p values for each category are shown in the same row as the putative risk factor category while the overall Wald p value is shown in the putative risk 
factor category row (bold and italics). The total effect of breed (n = 1,353) is adjusted for source region. The total effect of induction weight (n = 1,341) is adjusted 
for source region, induction year, breed and dentition. 
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Table 6.13: Distribution of the study population for dentition, mix pre27 and SY pre27 categories sero-positive for M. bovis antibody using 
four induction outcomes. 
Putative risk factor 
and associated 
categories  
No. (%) 
BioK302 Dichotomised BioK260 Series interpretation Parallel interpretation 
No. positive (%) No. positive (%) No. positive (%) No. positive (%) 
Dentition 
     
Milk tooth 1,055 (77.9%) 40 (3.8%) 66 (6.3%) 27 (2.6%) 79 (7.5%) 
Two tooth 240 (17.7%) 5 (2.1%) 10 (4.2%) 4 (1.7%) 11 (4.6%) 
Four and six tooth 47 (3.5%) 2 (4.3%) 2 (4.3%) 2 (4.3%) 2 (4.3%) 
Missing 12 (0.9%) 
    
Total 1,354 (100%) 47 (3.5%) 78 (5.8%) 33 (2.4%) 92 (6.8%) 
Mixing at least 27 days prior to day 0 (Mix pre27) 
   
No 417 (30.8%) 11 (2.6%) 12 (2.9%) 5 (1.2%) 18 (4.3%) 
Yes 925 (68.3%) 35 (3.8%) 65 (7.0%) 27 (2.9%) 73 (7.89%) 
Missing 12 (0.9%)     
Total 1,354 (100%) 46 (3.4%) 77 (5.7%) 32 (2.4%) 91 (6.8%) 
Saleyard transfer at least 27 days prior to day 0 (SY pre27)     
No 838 (61.9%) 25 (3.0%) 39 (4.6%) 16 (1.9%) 48 (5.7%) 
Yes 502 (37.1%) 21 (4.2%) 37 (7.4%) 16 (3.2%) 42 (8.4%) 
Missing 14 (1.0%)     
Total 1,354 (100%) 46 (3.4%) 76 (5.7%) 32 (2.4%) 90 (6.7%) 
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Table 6.14: Estimated odds ratios for the total effect of dentition and mix pre27 on the risk of M. bovis sero-positivity at feedlot induction 
Putative risk factor 
and associated 
categories 
BioK302 Dichotomised BioK260 Series interpretation Parallel interpretation 
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Dentition 
 
0.43 
 
0.05 
 
0.57 
 
0.27 
Milk tooth Reference  Reference  Reference  Reference  
Two tooth 0.48 (0.15 - 1.56) 0.22 0.66 (0.31 - 1.43) 0.30 0.68 (0.20 - 2.36) 0.54 0.55 (0.26 - 1.19) 0.13 
Four and six tooth 1.28 (0.17 - 9.82) 0.81 0.70 (0.14 - 3.41) 0.66 2.04 (0.32 - 13.17) 0.45 0.53 (0.10 - 2.72) 0.44 
Mixing at least 27 days prior to day 0 0.66 
 
0.02 
 
0.33 
 
0.07 
No Reference  Reference  Reference  Reference  
Yes 1.33 (0.38 - 4.64) 0.66 2.62 (1.14 - 5.98) 0.02 1.97 (0.51 - 7.67) 0.33 2.08 (0.95 - 4.58) 0.07 
CI: Confidence interval; OR: Odds ratio; p: Wald p value. 
Individual p values for each category are shown in the same row as the putative risk factor category while the overall Wald p value is shown in the putative risk 
factor category row (bold and italics). The total effect model for dentition (n = 1,341) is adjusted for induction year and breed. The total effect model for mixing at 
least 27 days prior to day 0 (n = 1,328) included the adjustment sets: source region, induction year, dentition and saleyard transfer at least 27 days prior to day 0. Day 
0 is defined as the day of induction or for those animals pre-assembled on pasture at or close to the feedlot it is the day the animal was moved to a feedlot pen. 
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Table 6.15: Estimated odds ratios for the total and direct effect of SY pre27 on the risk of M. bovis sero-positivity at feedlot induction 
Putative risk factor 
and associated 
categories 
BioK302 Dichotomised BioK260 Series interpretation Parallel interpretation 
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p 
SY pre27 – Total effect 0.03  0.02  0.03  0.02 
No Reference  Reference  Reference  Reference  
Yes 2.92 (1.11 - 7.69) 0.03 2.05 (1.14 - 3.69) 0.02 2.98 (1.13 - 7.83) 0.03 1.97 (1.10 - 3.54) 0.02 
SY pre27 – Direct effect 0.05  0.34  0.10  0.26 
No Reference  Reference  Reference  Reference  
Yes 2.95 (0.99 – 8.73) 0.05 1.37 (0.71 – 2.63) 0.34 2.49 (0.84 – 7.36) 0.10 1.46 (0.75 – 2.81) 0.26 
CI: Confidence interval; OR: Odds ratio; p: Wald p value; SY pre27: Saleyard transfer at least 27 days prior to day 0. 
Individual p values for each category are shown in the same row as the putative risk factor category while the overall Wald p value is shown in the putative risk 
factor category row (bold and italics). The total effect model for SY pre27 (n = 1,340) included source region as the only adjustment set, while the direct effect 
model (n = 1,328) is adjusted for source region, induction year, dentition and mixing at least 27 days prior to day 0. Day 0 is defined as the day of induction or for 
those animals pre-assembled on pasture at or close to the feedlot it is the day the animal was moved to a feedlot pen. 
 
 
Table 6.16: Distribution of the study population for yard wean categories sero-positive for M. bovis antibody using four induction outcomes 
Putative risk factor 
and associated 
categories  
No. (%) 
BioK302 Dichotomised BioK260 Series interpretation Parallel interpretation 
No. positive (%) No. positive (%) No. positive (%) No. positive (%) 
No 44 (3.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Yes 166 (12.3%) 4 (2.4%) 2 (1.2%) 0 (0.0%) 6 (3.6%) 
Missing 1,144 (84.5%) 
    
Total 1,354 (100%) 4 (1.9%) 2 (0.95%) 0 (0.0%) 6 (2.9%) 
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Table 6.17: Distribution of the study population for source region, induction year and group size categories sero-positive for M. bovis antibody 
using four induction outcomes  
Putative risk factor and associated 
categories 
No. (%) 
BioK302 Dichotomised BioK260 Series interpretation Parallel interpretation 
No. positive (%) No. positive (%) No. positive (%) No. positive (%) 
Source region 
         
NSW / Southern tablelands 219 (16.2%) 11 (5.0%) 10 (4.6%) 4 (1.8%) 17 (7.8%) 
Coastal NSW or QLD 47 (3.5%) 2 (4.3%) 2 (4.3%) 2 (4.3%) 2 (4.3%) 
Darling Downs / New England 386 (28.5%) 3 (0.8%) 13 (3.4%) 3 (0.8%) 13 (3.4%) 
Western NSW / QLD / NT 331 (24.5%) 11 (3.3%) 20 (6.0%) 8 (2.4%) 23 (6.9%) 
Riverina / Victoria / Tasmania 209 (15.4%) 4 (1.9%) 8 (3.8%) 2 (1.0%) 10 (4.8%) 
South Australia / Western Australia 162 (12.0%) 16 (9.9%) 25 (15.4%) 14 (8.6%) 27 (16.7%) 
Total 1,354 (100%) 47 (3.5%) 78 (5.8%) 33 (2.4%) 92 (6.8%) 
Induction year 
         
2009 163 (12.0%) 11 (6.7%) 7 (4.3%) 5 (3.1%) 13 (8.0%) 
2010 458 (33.9%) 22 (4.8%) 29 (6.3%) 14 (3.1%) 37 (8.1%) 
2011 733 (54.1%) 14 (1.9%) 42 (5.7%) 14 (1.9%) 42 (5.7%) 
Total 1,354 (100%) 47 (3.5%) 78 (5.8%) 33 (2.4%) 92 (6.8%) 
Group size 
         
< 50 543 (40.1%) 10 (1.8%) 16 (2.9%) 9 (1.7%) 17 (3.1%) 
50 - 99 384 (28.4%) 10 (2.6%) 21 (5.5%) 4 (1.0%) 27 (7.0%) 
≥ 100 427 (31.5%) 27 (6.3%) 41 (9.6%) 20 (4.7%) 48 (11.2%) 
Total 1,354 (100%) 47 (3.5%) 78 (5.8%) 33 (2.4%) 92 (6.8%) 
NSW: New South Wales; NT: Northern Territory; QLD: Queensland.    
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Table 6.18: Estimated odds ratios for the total and direct effect of source region on the risk of M. bovis sero-positivity at feedlot induction 
Putative risk factor and 
associated categories 
BioK302 Dichotomised BioK260 Series interpretation Parallel interpretation 
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Source region – Total effect 
 
0.04 
 
0.01 
 
0.02 
 
0.01 
NSW / Southern tablelands Reference  Reference  Reference  Reference  
Coastal NSW or QLD 1.65 (0.18 - 15.31) 0.66 1.14 (0.19 - 6.78) 0.88 3.86 (0.41 - 36.20) 0.24 0.68 (0.11 - 4.09) 0.68 
Darling Downs / New England 0.18 (0.03 - 1.02) 0.05 0.84 (0.30 - 2.34) 0.74 0.55 (0.09 - 3.50) 0.53 0.47 (0.18 - 1.25) 0.13 
Western NSW / QLD / NT 1.09 (0.26 - 4.61) 0.91 1.89 (0.69 - 5.21) 0.22 2.18 (0.42 - 11.29) 0.35 1.27 (0.50 - 3.24) 0.62 
Riverina / Victoria / Tasmania 0.46 (0.08 - 2.53) 0.37 0.95 (0.30 - 2.98) 0.93 0.72 (0.09 - 5.53) 0.75 0.68 (0.23 - 1.95) 0.47 
South Australia / Western 
Australia 
3.81 (0.77 - 18.91) 0.10 5.63 (1.91 - 16.59) 0.002 7.75 (1.37 - 43.91) 0.02 3.82 (1.36 - 10.78) 0.01 
Source Region – Direct effect 0.48 
 
0.10 
 
0.32 
 
0.03 
NSW / Southern tablelands Reference  Reference  Reference  Reference  
Coastal NSW or QLD 1.73 (0.14 - 21.66) 0.67 1.47 (0.24 - 9.06) 0.68 4.55 (0.39 - 52.50) 0.23 0.86 (0.13 - 5.56) 0.87 
Darling Downs / New England 0.13 (0.02 - 0.94) 0.04 0.57 (0.19 - 1.73) 0.32 0.48 (0.06 - 3.58) 0.47 0.32 (0.11 - 0.94) 0.04 
Western NSW / QLD / NT 1.12 (0.20 - 6.25) 0.90 1.51 (0.50 - 4.58) 0.47 3.00 (0.46 - 19.40) 0.25 0.91 (0.31 - 2.64) 0.86 
Riverina / Victoria / Tasmania 0.54 (0.08 - 3.16) 0.53 1.01 (0.31 - 3.29) 0.99 0.94 (0.10 - 8.60) 0.96 0.73 (0.24 - 2.24) 0.59 
South Australia / Western 
Australia 
2.09 (0.29 - 14.89) 0.46 2.58 (0.77 - 8.64) 0.12 4.16 (0.53 - 32.79) 0.18 1.89 (0.58 - 6.15) 0.29 
CI: Confidence interval; NSW: New South Wales; NT: Northern Territory; OR: Odds ratio; p: Wald p value; QLD: Queensland. 
Individual p values for each category are shown in the same row as the putative risk factor category while the overall Wald p value is shown in the putative risk factor category row 
(bold and italics). The total effect of source region (n = 1,354) is adjusted for induction year. The direct effect of source region (n = 1,327) is adjusted for induction year, breed, 
dentition, induction weight, group size, mixing saleyard transfer history at least 27 days prior to day 0. Day 0 is defined as the day of induction or for those animals pre-assembled on 
pasture at or close to the feedlot it is the day the animal was moved to a feedlot pen   
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Table 6.19: Estimated odds ratios for the total effect of induction year and group size on the risk of M. bovis sero-positivity at feedlot induction 
Putative risk factor and 
associated categories 
BioK302 Dichotomised BioK260 Series interpretation Parallel interpretation 
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Induction year 
 
0.11 
 
0.86 
 
0.80 
 
0.61 
2009 Reference  Reference  Reference  Reference  
2010 0.50 (0.13 - 2.02) 0.33 1.29 (0.45 - 3.70) 0.64 0.66 (0.14 - 3.01) 0.59 0.91 (0.35 - 2.35) 0.84 
2011 0.25 (0.06 - 0.97) 0.04 1.33 (0.49 - 3.61) 0.58 0.62 (0.15 - 2.58) 0.51 0.69 (0.28 - 1.72) 0.43 
Group size 
 
0.06 
 
0.004 
 
0.07 
 
0.002 
< 50 Reference  Reference  Reference  Reference  
50 - 99 1.17 (0.33 - 4.18) 0.81 2.00 (0.89 - 4.47) 0.09 0.52 (0.12 - 2.17) 0.37 2.47 (1.12 - 5.44) 0.03 
≥ 100 2.95 (0.79 - 11.00) 0.11 3.31 (1.45 - 7.59) 0.01 2.19 (0.63 - 7.58) 0.22 3.79 (1.63 - 8.81) 0.002 
CI: Confidence interval; OR: Odds ratio; p: Wald p value. 
Individual p values for each category are shown in the same row as the putative risk factor category while the overall Wald p value is shown in the putative risk 
factor category row (bold and italics). The total effect model for induction year (n = 1,354) had no adjustment sets included. The total and direct effect models for 
group size (n = 1,354) included the same adjustment set (source region and induction year). 
. 
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Table 6.20: Distribution of the study population for each breed category that sero-converted or sero-increased to M. bovis between feedlot 
induction and draft 
Putative risk factor and 
associated categories 
No. (%) BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
No. with potential No. (%) No. with potential No. (%) No. with potential No. (%) 
Breed 
 
 
  
 
 
 
Angus 761 (56.2%) 737 210 (28.5%) 728 173 (23.8%) 758 178 (23.5%) 
British Cross 164 (12.1%) 159 36 (22.6%) 155 22 (14.2%) 164 22 (13.4%) 
Hereford 58 (4.3%) 56 21 (37.5%) 53 11 (10.7%) 58 13 (22.4%) 
Shorthorn 56 (4.1%) 55 16 (29.1%) 52 10 (19.2%) 56 11 (19.6%) 
Murray Grey 33 (2.4%) 28 3 (10.7%) 25 3 (12.0%) 33 3 (9.1%) 
European / European Cross 49 (3.6%) 47 5 (10.6%) 44 6 (13.6%) 48 6 (12.5%) 
Tropical / Tropical Cross 232 (17.1%) 224 26 (11.6%) 218 24 (11.0%) 231 28 (12.1%) 
Missing 1 (0.1%)       
Total  1,354 (100%) 1,306  317 (24.3%) 1,275  249 (19.5%) 1,348 261 (19.4%) 
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Table 6.21: Estimated odds ratios for the total and direct effect of breed on the risk of sero-conversion or a sero-increase to M. bovis between 
feedlot induction and draft 
Putative risk factor and 
associated categories 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Breed – Total effect 
 
0.004 
 
0.16 
 
0.06 
Angus Reference  Reference  Reference  
British Cross 0.64 (0.38 - 1.08) 0.10 0.46 (0.25 - 0.88) 0.02 0.43 (0.23 - 0.81) 0.01 
Hereford 1.77 (0.78 - 4.00) 0.17 0.97 (0.36 - 2.58) 0.94 1.13 (0.44 - 2.92) 0.80 
Shorthorn 1.23 (0.55 - 2.74) 0.61 0.94 (0.36 - 2.47) 0.90 0.95 (0.37 - 2.46) 0.92 
Murray Grey 0.25 (0.06 - 1.01) 0.05 0.48 (0.11 - 2.07) 0.32 0.40 (0.09 - 1.67) 0.21 
European / European Cross 0.22 (0.06 - 0.74) 0.02 0.36 (0.10 - 1.34) 0.13 0.27 (0.07 - 1.00) 0.05 
Tropical / Tropical Cross 0.41 (0.20 - 0.84) 0.02 0.47 (0.21 - 1.06) 0.07 0.51 (0.23 - 1.12) 0.09 
Breed – Direct effect 
 
0.001 
 
0.10 
 
0.04 
Angus Reference  Reference  Reference  
British Cross 0.61 (0.36 – 1.01) 0.06 0.43 (0.23 – 0.80) 0.01 0.40 (0.21 – 0.75) 0.004 
Hereford 1.28 (0.57 – 2.86) 0.55 0.98 (0.36 – 2.63) 0.97 1.16 (0.44 – 3.00) 0.77 
Shorthorn 1.22 (0.56 – 2.66) 0.61 0.80 (0.31 – 2.06) 0.64 0.82 (0.32 – 2.09) 0.69 
Murray Grey 0.25 (0.07 – 0.98) 0.05 0.50 (0.12 – 2.17) 0.36 0.43 (0.10 – 1.78) 0.24 
European / European Cross 0.17 (0.05 – 0.57) 0.004 0.35 (0.09 – 1.28) 0.11 0.26 (0.07 – 0.95) 0.04 
Tropical / Tropical Cross 0.34 (0.17 – 0.68) 0.002 0.46 (0.21 – 1.01) 0.05 0.50 (0.23 – 1.07) 0.07 
CI: Confidence interval; OR: Odds ratio; p: Wald p value.  
Individual p values for each category are shown in the same row as the putative risk factor category while the overall Wald p value is shown in the putative risk factor category row 
(bold and italics). The total effect model for breed is adjusted for source region. A total of 1,306, 1,275 and 1,348 animals were included in the total effect of breed model for 
BioK302 sero-conversion, BioK260 sero-conversion and BioK260 sero-increase respectively. The direct effect model adjusts for source region, induction year, induction weight, 
dentition and season. A total of 1,294, 1,263 and 1,336 animals were included in the direct effect of breed model for BioK302 sero-conversion, BioK260 sero-conversion and 
BioK260 sero-increase respectively.  
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Table 6.22: Distribution of the study population for each induction weight and dentition category that sero-converted or sero-increased to 
M. bovis between feedlot induction and draft  
Putative risk factor 
and associated 
categories 
No. (%) 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
No. with potential No. (%) No. with potential No. (%) No. with potential No. (%) 
Induction weight (kg) 
 
 
  
 
 
 
190 - ≤ 400 215 (15.9%) 196 45 (23.0%) 189 21 (11.1%) 214 24 (11.2%) 
400 - ≤ 440 434 (32.1%) 421 98 (23.3%) 407 84 (20.6%) 432 87 (20.1%) 
440 - ≤ 480 499 (36.8%) 487 126 (25.9%) 481 97 (20.2%) 497 102 (20.5%) 
≥ 480 206 (15.2%) 203 48 (23.6%) 199 47 (23.6%) 206 48 (23.3%) 
Total 1,354 (100%) 1,307 317 (24.3%) 1,276 249 (19.5%) 1,349 261 (19.4%) 
Dentition 
 
 
  
 
 
 
Milk tooth 1,055 (77.9%) 1,015 262 (25.8%) 989 205 (20.7%) 1,053 216 (20.5%) 
Two tooth 240 (17.7%) 235 44 (18.7%) 230 34 (14.8%) 237 35 (14.8%) 
Four and six tooth 47 (3.5%) 45 9 (20.0%) 45 9 (20.0%) 47 9 (19.1%) 
Missing 12 (0.9%)       
Total 1,354 (100%) 1,295 317 (24.5%) 1,264 249 (19.7%) 1,337 261 (19.5%) 
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Table 6.23: Estimated odds ratios for the total effect of induction weight and dentition on the risk of sero-conversion or a sero-increase to 
M. bovis between feedlot induction and draft 
Putative risk factor and 
associated categories 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Induction weight (kg) 
 
0.85 
 
0.16 
 
0.28 
190 - ≤ 400 1.04 (0.60 – 1.79) 0.90 0.74 (0.37 - 1.48) 0.39 0.71 (0.36 - 1.41) 0.33 
400 - ≤ 440 0.87 (0.60 - 1.25) 0.44 1.27 (0.84 - 1.92) 0.25 1.16 (0.78 - 1.75) 0.46 
440 - ≤ 480 Reference  Reference  Reference  
≥ 480 0.95 (0.60 - 1.51) 0.82 1.52 (0.92 – 2.51) 0.10 1.39 (0.84 – 2.28) 0.20 
Dentition  0.51 
 
0.45 
 
0.50 
Milk tooth Reference  Reference  Reference  
Two tooth 0.77 (0.50 - 1.20) 0.25 0.81 (0.49 - 1.34) 0.41 0.80 (0.49 - 1.32) 0.39 
Four and six tooth 0.90 (0.37 - 2.18) 0.82 1.48 (0.57 - 3.83) 0.42 1.36 (0.53 - 3.50) 0.52 
CI: Confidence interval; kg: kilograms live-weight; OR: Odds ratio; p: Wald p value.  
Individual p values for each category are shown in the same row as the putative risk factor category while the overall Wald p value is shown in the putative risk 
factor category row (bold and italics). The total effect model for induction weight is adjusted for source region, induction year and breed. A total of 1,306, 1,275 and 
1,348 animals were included in the total effect of induction weight model for BioK302 sero-conversion, BioK260 sero-conversion and BioK260 sero-increase 
respectively. The total effect model for dentition is adjusted for induction year and season. A total of 1,295; 1,264 and 1,337 animals were included in the total effect 
of dentition model for BioK302 sero-conversion, BioK260 sero-conversion and BioK260 sero-increase respectively. 
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Table 6.24: Distribution of the study population for each mixing summary category that sero-converted or sero-increased to M. bovis between 
feedlot induction and draft 
Putative risk factor 
and associated 
categories 
No. (%) 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
No. with potential No. (%) No. with potential No. (%) No. with potential No. (%) 
Mixing summary        
No : Low 58 (4.3%) 51 12 (23.5%) 55 13 (23.6%) 58 13 (22.4%) 
No : High 359 (26.5%) 355 107 (30.1%) 350 80 (22.9%) 359 82 (22.8%) 
Yes : Low 284 (21.0%) 274 47 (17.1%) 264 32 (12.1%) 283 35 (12.4%) 
Yes : High 641 (47.3%) 616 149 (24.2%) 596 123 (20.6%) 637 130 (20.4%) 
Missing 12 (0.9%)       
Total 1,354 (100%) 1,296 317 (24.5%) 1,265 249 (19.7%) 1,337 261 (19.5%) 
The mixing summary categories describe mixing at least 27days prior to day 0 (no, yes) in addition to the number of group-28’s that form the cohort (< 4 = low and 
≥ 4 = high). Day 0 is defined as the day of induction or for those animals pre-assembled on pasture at or close to the feedlot it is the day the animal was moved to a 
feedlot pen. Group-28 refers to a group of animals in a cohort that were together at the same property 28 days prior to day 0.   
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Table 6.25: Estimated odds ratios for the total effect of mixing summary on the risk of sero-conversion or a sero-increase to M. bovis between 
feedlot induction and draft 
Putative risk factor and 
associated categories 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Mixing summary  0.48 
 
0.32 
 
0.38 
No : Low 1.03 (0.35 - 3.02) 0.95 1.54 (0.50 - 4.74) 0.45 1.48 (0.49 - 4.43) 0.49 
No : High 1.42 (0.90 - 2.24) 0.13 1.27 (0.74 - 2.16) 0.39 1.29 (0.76 - 2.18) 0.35 
Yes : Low 1.09 (0.59 - 2.03) 0.79 0.62 (0.29 - 1.34) 0.23 0.67 (0.32 - 1.41) 0.29 
Yes: High Reference  Reference  Reference  
CI: Confidence interval; OR: Odds ratio; p: Wald p value.  
Individual p values for each category are shown in the same row as the putative risk factor category while the overall Wald p value is shown in the putative risk 
factor category row (bold and italics). The mixing summary categories describe mixing at least 27 days prior to day 0 (no, yes) in addition to the number of group-
28’s that form the cohort (< 4 = low and ≥ 4 = high). Day 0 is defined as the day of induction or for those animals pre-assembled on pasture at or close to the feedlot 
it is the day the animal was moved to a feedlot pen. Group-28 refers to a group of animals in a cohort that were together at the same property 28 days prior to day 0. 
The total effect model for mixing summary is adjusted for source region, induction year, group size, dentition, timing of the move to the feedlot at least 27 days prior 
to day 0, and saleyard transfer history at least 27 days prior to day 0 or between 27days prior to day 0 and day 0. A total of 1,282, 1,252 and 1,323 animals were 
included in the total effect of mixing summary model for BioK302 sero-conversion, BioK260 sero-conversion and BioK260 sero-increase respectively. 
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Table 6.26: Distribution of the study population for each saleyard transfer category that sero-converted or sero-increased to M. bovis between 
feedlot induction and draft 
Putative risk factor 
and associated 
categories 
No. (%) 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
No. with potential No. (%) No. with potential No. (%) No. with potential No. (%) 
Saleyard transfer at least 27 days prior to day 0 
  
 
 
 
No 838 (61.9%) 813 197 (24.2%) 799 151 (18.9%) 834 157 (18.8%) 
Yes 502 (37.1%) 481 118 (24.5%) 465 97 (20.9%) 501 103 (20.6%) 
Missing 14 (1.0%)       
Total 1,354 (100%) 1,294 315 (25.2%) 1,264 248 (19.6%) 1,335 260 (19.5%) 
Saleyard transfer between 27 days prior to day 0 and day 0 
 
 
 
 
No  1,279 (94.5%) 1,235 296 (24.0%) 1,206 235 (19.5%) 1,274 247 (19.4%) 
Yes 75 (5.5%) 72 21 (29.2%) 70 14 (20.0%) 75 14 (18.7%) 
Total 1,354 (100%) 1,307 317 (24.3%) 1,276 249 (19.5%) 1,349 261 (19.3%) 
Day 0 is defined as the day of induction or for those animals pre-assembled on pasture at or close to the feedlot it is the day the animal was moved to a feedlot pen.  
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Table 6.27: Estimated odds ratios for the total effect of saleyard transfer on the risk of sero-conversion or a sero-increase to M. bovis between 
feedlot induction and draft 
Putative risk factor and 
associated categories 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Saleyard transfer at least 27 days prior to day 0 0.91 
 
0.78 
 
0.71 
No Reference  Reference  Reference  
Yes 0.98 (0.70 - 1.38) 0.91 0.94 (0.63 - 1.41) 0.78 0.93 (0.62 - 1.38) 0.71 
Saleyard transfer between 27 days prior to 
day 0 and day 0 0.30  
0.41 
 
0.52 
No Reference  Reference  Reference  
Yes 1.52 (0.69 - 3.35) 0.30 1.48 (0.58 - 3.74) 0.41 1.36 (0.54 - 3.41) 0.52 
CI: Confidence interval; OR: Odds ratio; p: Wald p value. 
Individual p values for each category are shown in the same row as the putative risk factor category while the overall Wald p value is shown in the putative risk 
factor category row (bold and italics). The total effect model for both saleyard transfer history putative risk factors is adjusted for source region. A total of 1,294, 
1,264 and 1,335 animals were included in the total effect model for saleyard transfer at least 27 days prior to day 0 and BioK302 sero-conversion, BioK260 sero-
conversion and BioK260 sero-increase outcomes respectively. While a total of 1,307, 1,276 and 1,349 animals were included in the total effect of saleyard transfer 
between 27 days prior to day 0 and day 0 model for BioK302 sero-conversion, BioK260 sero-conversion and BioK260 sero-increase outcomes respectively. Day 0 is 
defined as the day of induction or for those animals pre-assembled on pasture at or close to the feedlot it is the day the animal was moved to a feedlot pen. 
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Table 6.28: Distribution of the study population for each source region and move to the feedlot category that sero-converted or sero-increased 
to M. bovis between feedlot induction and draft 
Putative risk factor and 
associated categories 
No. (%) BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
No. with potential No. (%) No. with potential No. (%) No. with potential No. (%) 
Source region 
 
 
  
 
 
 
NSW / Southern tablelands 219 (16.2%) 208 68 (32.7%) 209 63 (30.1%) 218 63 (28.9%) 
Coastal NSW or QLD 47 (3.5%) 45 17 (37.8%) 45 12 (26.7%) 47 13 (27.7%) 
Darling Downs / New England 386 (28.5%) 383 76 (19.8%) 373 63 (16.9%) 386 67 (17.4%) 
Western NSW / QLD / NT 331 (24.5%) 320 55 (17.2%) 311 40 (12.9%) 329 44 (13.4%) 
Riverina / Victoria / Tasmania 209 (15.4%) 205 65 (31.7%) 201 54 (26.9%) 208 55 (26.4%) 
South Australia / Western 
Australia 
162 (12.0%) 146 36 (24.7%) 137 17 (12.4%) 161 19 (11.8%) 
Total 1,354 (100%) 1,307 317 (24.3%) 1,276 249 (19.5%) 1,349 261 (19.3%) 
Move to feedlot at least 27 days prior to day 0  
  
 
 
 
No 1,298 (95.9%) 1,260 311 (24.7%) 1,234 245 (19.8%) 1,294 256 (19.8%) 
Yes 56 (4.1%) 47 6 (12.8%) 42 4 (9.5%) 55 5 (9.1%) 
Total 1,354 (100%) 1,307 317 (24.3%) 1,276 249 (19.5%) 1,349 261 (19.3%) 
NSW: New South Wales; NT: Northern Territory; QLD: Queensland. 
Day 0 is defined as the day of induction or for those animals pre-assembled on pasture at or close to the feedlot it is the day the animal was moved to a feedlot pen. 
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Table 6.29: Estimated odds ratios for the total and direct effect of source region on the risk of sero-conversion or a sero-increase to M. bovis 
between feedlot induction and draft 
Putative risk factor and 
associated categories 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Source region – Total effect 
 
0.13 
 
0.01 
 
0.01 
NSW / Southern tablelands Reference  Reference  Reference  
Coastal NSW or QLD 1.08 (0.45 - 2.60) 0.87 0.68 (0.26 - 1.82) 0.45 0.76 (0.29 - 2.02) 0.58 
Darling Downs / New England 0.54 (0.29 - 1.00) 0.05 0.35 (0.18 - 0.67) 0.002 0.36 (0.19 - 0.69) 0.002 
Western NSW / QLD / NT 0.70 (0.35 - 1.38) 0.30 0.36 (0.18 - 0.75) 0.01 0.39 (0.19 - 0.79) 0.01 
Riverina / Victoria / Tasmania 1.45 (0.74 - 2.85) 0.28 1.02 (0.48 - 2.17) 0.97 1.00 (0.47 - 2.14) 1.00 
South Australia / Western 
Australia 
0.98 (0.42 - 2.27) 0.96 0.35 (0.13 - 0.95) 0.04 0.35 (0.13 - 0.95) 0.04 
Source region –Direct effect 
 
0.16 
 
0.07 
 
0.09 
NSW / Southern tablelands Reference  Reference  Reference  
Coastal NSW or QLD 1.23 (0.50 - 3.05) 0.66 0.83 (0.30 - 2.34) 0.73 0.98 (0.35 - 2.75) 0.98 
Darling Downs / New England 0.53 (0.31 - 0.91) 0.02 0.40 (0.21 - 0.77) 0.01 0.43 (0.22 - 0.83) 0.01 
Western NSW / QLD / NT 0.74 (0.41 - 1.34) 0.32 0.45 (0.22 - 0.93) 0.03 0.48 (0.24 - 0.99) 0.05 
Riverina / Victoria / Tasmania 0.97 (0.48 - 1.93) 0.92 0.89 (0.40 - 1.96) 0.77 0.84 (0.38 - 1.85) 0.67 
South Australia / Western 
Australia 
0.93 (0.43 - 2.01) 0.85 0.44 (0.16 - 1.21) 0.11 0.43 (0.16 - 1.18) 0.10 
CI: Confidence interval; NSW: New South Wales; NT: Northern Territory; OR: Odds ratio; p: Wald p value; QLD: Queensland. 
Individual p values for each category are shown in the same row as the putative risk factor category while the overall Wald p value is shown in the putative risk factor category row 
(bold and italics). The total effect model for source region is adjusted for induction year. A total of 1,307, 1,276 and 1,349 animals were included in the total effect of source region 
model for BioK302 sero-conversion, BioK260 sero-conversion and BioK260 sero-increase respectively. The direct effect of source region is adjusted for induction year, cohort size, 
breed, dentition, group size, mixing summary, move to feedlot at least 27 days prior to day 0, season, induction weight, saleyard transfer history 27 days prior to day 0 or between 27 
days prior and day 0 and exposure to an animal persistently infected with bovine viral diarrhoea virus (BVDV) and/or active BVDV infection in the cohort. Day 0 is defined as the 
day of induction or for those animals pre-assembled on pasture at or close to the feedlot it is the day the animal was moved to a feedlot pen. A total of 1,281, 1,251 and 1,322 animals 
were included in the direct effect of source region model for BioK302 sero-conversion, BioK260 sero-conversion and BioK260 sero-increase respectively.  
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Table 6.30: Estimated odds ratios for the total effect of the timing of the move to the feedlot on the risk of sero-conversion or a sero-increase to 
M. bovis between feedlot induction and draft 
Putative risk factor and 
associated categories 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Move to feedlot at least 27 days prior to day 0 0.10 
 
0.73 
 
0.62 
No Reference  Reference  Reference  
Yes 0.38 (0.12 - 1.20) 0.10 0.78 (0.19 - 3.25) 0.73 0.72 (0.20 - 2.59) 0.62 
CI: Confidence interval; OR: Odds ratio; p: Wald p value. 
Individual p values for each category are shown in the same row as the putative risk factor category while the overall Wald p value is shown in the putative risk factor category row 
(bold and italics).The total effect model for move to feedlot at least 27 days prior to day 0 is adjusted for source region, induction year, induction weight and dentition. A total of 
1,295, 1,264 and 1,337 animals were included in the model for BioK302 sero-conversion, BioK260 sero-conversion and BioK260 sero-increase respectively. Day 0 is defined as the 
day of induction or for those animals pre-assembled on pasture at or close to the feedlot it is the day the animal was moved to a feedlot pen. 
 
Table 6.31: Distribution of the study population for each group size category that sero-converted or sero-increased to M. bovis between feedlot 
induction and draft 
Putative risk factor 
and associated 
categories 
No. (%) 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
No. with potential No. (%) No. with potential  No. (%) No. with potential  No. (%) 
Group size 
 
 
  
 
 
 
< 50 543 (40.1%) 533 143 (26.8%) 527 119 (22.3%) 542 121 (22.3%) 
50 - 99 384 (28.4%) 374 112 (29.9%) 363 79 (21.8%) 383 85 (22.2%) 
≥ 100 427 (31.5%) 400 62 (15.1%) 386 51 (13.2%) 424 55 (13.0%) 
Total 1,354 (100%) 1,307 317 (24.3%) 1,276 249 (19.5%) 1,349 261 (19.3%) 
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Table 6.32: Estimated odds ratios for the total and direct effect of group size on the risk of sero-conversion or a sero-increase to M. bovis 
between feedlot induction and draft 
Putative risk factor 
and associated 
categories 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Group size – Total effect 0.02 
 
0.47 
 
0.33 
< 50 Reference  Reference  Reference  
50 - 99 1.18 (0.80 - 1.74) 0.40 1.04 (0.66 - 1.63) 0.86 1.09 (0.70 - 1.71) 0.69 
≥ 100 0.53 (0.30 - 0.92) 0.02 0.69 (0.36 - 1.32) 0.26 0.67 (0.36 - 1.25) 0.21 
Group size – Direct effect 0.11 
 
0.86 
 
0.69 
< 50 Reference  Reference  Reference  
50 - 99 1.15 (0.78 - 1.70) 0.47 1.07 (0.68 - 1.70) 0.77 1.13 (0.71 - 1.77) 0.61 
≥ 100 0.59 (0.32 - 1.09) 0.09 0.89 (0.44 - 1.77) 0.73 0.85 (0.43 - 1.66) 0.63 
CI: Confidence interval; OR: Odds ratio; p: Wald p value. 
Individual p values for each category are shown in the same row as the putative risk factor category while the overall Wald p value is shown in the putative risk 
factor category row (bold and italics). The total effect model for group size is adjusted for source region and induction year. A total of 1,307, 1,276 and 1,349 
animals were included in the total effect model for BioK302 sero-conversion, BioK260 sero-conversion and BioK260 sero-increase respectively. The direct effect 
model for group size is adjusted for source region, induction year, dentition, move to feedlot at least 27 days prior to day 0, mixing summary, and saleyard transfer at 
least 27 days prior and between 27 days prior and day 0. Day 0 is defined as the day of induction or for those animals pre-assembled on pasture at or close to the 
feedlot it is the day the animal was moved to a feedlot pen. A total of 1,282, 1,252 and 1,323 animals were included in the direct effect model for BioK302 sero-
conversion, BioK260 sero-conversion and BioK260 sero-increase respectively. 
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Table 6.33: Distribution of the study population for each induction year, cohort size and number of adjoining pens category that sero-
converted or sero-increased to M. bovis between feedlot induction and draft 
Putative risk factor 
and associated 
categories 
No. (%) 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
No. with potential No. (%) No. with potential  No. (%) No. with potential  No. (%) 
Induction year 
 
 
  
 
 
 
2009 163 (12.0%) 152 44 (29.0%) 156 18 (11.5%) 163 19 (11.7%) 
2010 458 (33.9%) 436 115 (26.4%) 429 87 (20.3%) 455 90 (19.8%) 
2011 733 (54.1%) 719 158 (22.0%) 691 144 (20.8%) 731 152 (10.8%) 
Total 1,354 (100%) 1,307 317 (24.3%) 1,276 249 (19.5%) 1,349 261 (19.3%) 
Cohort size  
 
 
  
 
 
 
17  < 200 445 (32.9%) 422 100 (23.7%) 409 76 (18.6%) 444 78 (17.6%) 
≥ 200 909 (67.1%) 885 217 (24.5%) 867 173 (20.0%) 905 183 (20.2%) 
Total 1,354 (100%) 1,307 317 (24.3%) 1,276 249 (19.5%) 1,349 261 (19.3%) 
Number of adjoining pens  
  
 
 
 
1 429 (31.7%) 408 101 (24.7%) 402 89 (22.1%) 428 91 (21.3%) 
2 905 (67.9%) 895 213 (23.8%) 871 158 (18.1%) 916 168 (18.3%) 
Missing 5 (0.4%)       
Total 1,354 (100%) 1,303 314 (24.1%) 1,273 247 (19.4%) 1,344 259 (19.3%) 
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Table 6.34: Estimated odds ratios for the total effect of induction year, cohort size and number of adjoining pens on the risk of sero-
conversion or a sero-increase to M. bovis between feedlot induction and draft 
Putative risk factor and 
associated categories 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Induction year 
 
0.33 
 
0.10 
 
0.10 
2009 Reference 
 
Reference 
 
Reference 
 
2010 0.84 (0.43 - 1.64) 0.61 2.25 (0.91 - 5.54) 0.08 2.16 (0.89 - 5.26) 0.09 
2011 0.65 (0.34 - 1.25) 0.20 2.58 (1.09 - 6.14) 0.03 2.55 (1.09 - 5.99) 0.03 
Cohort size  
 
0.89 
 
0.75 
 
0.99 
17  < 200 1.04 (0.62 - 1.72) 0.89 1.10 (0.60 - 2.04) 0.75 1.00 (0.54 - 1.85) 0.99 
≥ 200 Reference 
 
Reference 
 
Reference 
 
Number of adjoining pens 
 
0.95 
 
0.38 
 
0.55 
1 Reference 
 
Reference 
 
Reference 
 
2 0.98 (0.60 - 1.62) 0.95 0.77 (0.43 - 1.38) 0.38 0.84 (0.47 - 1.50) 0.55 
CI: Confidence interval; OR: Odds ratio; p: Wald p value. 
Individual p values for each category are shown in the same row as the putative risk factor category while the overall Wald p value is shown in the putative risk 
factor category row (bold and italics). No minimum sufficient adjustment sets were indicated for inclusion in the total effect models for induction year, cohort size or 
number of adjoining pens. A total of 1,307, 1,276 and 1,349 animals were included in the total effect of induction year and cohort size models for BioK302 sero-
conversion, BioK260 sero-conversion and BioK260 sero-increase respectively. A total of 1,303, 1,273 and 1,344 animals were included in the total effect of number 
of adjoining pens model for BioK302 sero-conversion, BioK260 sero-conversion and BioK260 sero-increase respectively. 
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Table 6.35: Distribution of the study population for each shared pen water, pen shade and pen density category that sero-converted or sero-
increased to M. bovis between feedlot induction and draft 
Putative risk factor 
and associated 
categories 
No. (%) 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
No. with potential No. (%) No. with potential  No. (%) No. with potential  No. (%) 
Shared water 
 
 
  
 
 
 
No 248 (18.3%) 229 37 (16.2%) 220 21 (9.5%) 247 23 (9.3%) 
Yes 1,106 (81.7%) 1,078 280 (16.0%) 1,056 228 (21.6%) 1,102 238 (21.6%) 
Total 1,354 (100%) 1,307 317 (24.3%) 1,276 249 (19.5%) 1,349 261 (19.3%) 
Pen shade 
 
 
  
 
 
 
No 414 (30.6%) 389 92 (23.6%) 381 60 (15.7%) 411 62 (15.1%) 
Yes 940 (69.4%) 918 225 (24.5%) 895 189 (21.1%) 938 199 (21.2%) 
Total 1,354 (100%) 1,307 317 (24.3%) 1,276 249 (19.5%) 1,349 261 (19.3%) 
Pen density (m
2
/SCU)  
  
 
 
 
11 -< 13 234 (17.3%) 229 54 (23.6%) 226 50 (22.1%) 234 53 (22.6%) 
13 - < 15 515 (38.0%) 501 113 (22.5%) 482 90 (18.7%) 512 96 (18.7%) 
15 - < 17 250 (18.5%) 246 80 (32.5%) 245 65 (26.5%) 249 66 (26.5%) 
≥ 17  355 (26.2%) 331 70 (21.1%) 323 44 (13.6%) 354 46 (13.0%) 
Total  1,354 (100%) 1,307 317 (24.3%) 1,276 249 (19.5%) 1,349 261 (19.3%) 
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Table 6.36: Estimated odds ratios for the total effect of shared pen water, pen shade and pen density on the risk of sero-conversion or a sero-
increase to M. bovis between feedlot induction and draft 
Putative risk factor and 
associated categories 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Shared water 
 
0.07 
 
0.01 
 
0.003 
No Reference  Reference  Reference  
Yes 2.20 (0.94 - 5.15) 0.07 3.10 (1.28 - 7.53) 0.01 3.32 (1.49 - 7.40) 0.003 
Pen shade  0.81 
 
0.35 
 
0.31 
No Reference  Reference  Reference  
Yes 0.92 (0.48 - 1.78) 0.81 1.42 (0.68 - 2.94) 0.35 1.45 (0.71 - 2.97) 0.31 
Pen density (m
2
/SCU)  0.61 
 
0.23 
 
0.15 
11 -< 13 1.57 (0.53 - 4.63) 0.41 1.70 (0.57 - 5.07) 0.34 1.63 (0.59 - 4.49) 0.35 
13 - < 15 Reference  Reference  Reference  
15 - < 17 1.42 (0.75 - 2.70) 0.28 1.58 (0.74 - 3.36) 0.24 1.62 (0.77 - 3.40) 0.20 
≥ 17  1.11 (0.56 - 2.21) 0.76 0.76 (0.33 - 1.72) 0.50 0.69 (0.31 - 1.55) 0.37 
BioK260 sero-increase: an increase of two or more M. bovis BioK260 Delta Value categories between feedlot induction and draft; CI: Confidence interval; OR: 
Odds ratio; p: Wald p value, SCU: standard cattle unit. 
Individual p values for each category are shown in the same row as the putative risk factor category while the overall wald p value is shown in the putative risk 
factor category row (bold and italics). No minimum sufficient adjustment sets were indicated for inclusion in the total effect models for shared water. The total effect 
of pen shade was adjusted for induction season, while the total effect of pen density was adjusted for cohort size. A total of 1,307, 1,276 and 1,349 animals were 
included in the total effect of shared water, pen shade and pen density models for BioK302 sero-conversion, BioK260 sero-conversion and BioK260 sero-increase 
respectively. 
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Table 6.37: Distribution of the study population for each induction season and BVDV_PI esposure category that sero-converted or sero-
increased to M. bovis between feedlot induction and draft 
Putative risk factor and 
associated categories 
No. (%) 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
No. with potential No. (%) No. with potential No. (%) No. with potential No. (%) 
Induction season 
 
 
  
 
 
 
Spring 405 (29.9%) 395 88 (22.3%) 392 75 (19.1%) 405 77 (19.0%) 
Summer 302 (22.3%) 291 63 (21.6%) 288 47 (16.3%) 301 50 (16.6%) 
Autumn 283 (20.9%) 272 87 (32.0%) 261 72 (27.6%) 280 75 (26.8%) 
Winter 364 (26.9%) 349 79 (22.6%) 335 55 (16.4%) 363 59 (16.2%) 
Total  1,354 (100%) 1,307 317 (24.3%) 1,276 249 (19.5%) 1,349 261 (19.3%) 
BVDV PI exposure  
  
 
 
 
Active, no PI 757 (55.9%) 739 212 (28.7%) 722 164 (22.7%) 756 170 (22.5%) 
Active, PI 146 (10.8%) 137 24 (17.5%) 131 21 (16.0%) 143 22 (15.4%) 
Not active, no PI 451 (33.3%) 431 81 (18.8%) 423 64 (15.1%) 450 69 (15.3%) 
Total 1,354 (100%) 1,307 317 (24.3%) 1,276 249 (19.5%) 1,349 261 (19.3%) 
BVDV: Bovine viral diarrhoea virus; PI: Persistently infected with BDVD. 
Categories for BVDV_PI exposure indicate the presence or absence of active BVDV infection in the cohort (Active / Not active) and whether or not a PI animal was 
identified in a group-28 that formed part of the cohort (PI / no PI). 
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Table 6.38: Estimated odds ratios for the total effect of induction season and BVDV_PI exposure on the risk of sero-conversion or a sero-
increase to M. bovis between feedlot induction and draft 
Putative risk factor and 
associated categories 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Induction season  0.18 
 
0.24 
 
0.29 
Spring Reference  Reference  Reference  
Summer 1.01 (0.57 - 1.77) 0.98 0.77 (0.39 - 1.51) 0.45 0.77 (0.39 - 1.52) 0.45 
Autumn 1.75 (1.01 - 3.02) 0.05 1.51 (0.78 - 2.92) 0.22 1.44 (0.74 - 2.77) 0.28 
Winter 1.12 (0.67 - 1.89) 0.67 0.82 (0.44 - 1.55) 0.55 0.81 (0.43 - 1.52) 0.51 
BVDV PI exposure  0.05 
 
0.28 
 
0.24 
Active, no PI 1.46 (0.89 – 2.12) 0.13 1.45 (0.79 – 2.66) 0.28 1.46 (0.81 – 2.64) 0.21 
Active, PI 0.72 (0.35 – 1.47) 0.36 0.91 (0.39 – 2.11) 0.83 0.90 (0.39 – 2.06) 0.80 
Not active, no PI Reference  Reference  Reference  
BVDV: Bovine viral diarrhoea virus; CI: Confidence interval; OR: Odds ratio; p: Wald p value; PI: Persistently infected with BVDV.  
Categories for BVDV_PI exposure indicate the presence or absence of active BVDV infection in the cohort (Active / Not active) and whether or not a PI animal was 
identified in a group-28 that formed part of the cohort (PI / no PI). Individual p values for each category are shown in the same row as the putative risk factor 
category while the overall Wald p value is shown in the putative risk factor category row (bold and italics). No minimum sufficient adjustment sets were indicated 
for inclusion in the total effect model for induction season. The total effect of BVDV PI exposure was adjusted for source region and cohort size. A total of 1,307, 
1,276 and 1,349 animals were included in the total effect of induction season and BVDV PI exposure models for BioK302 sero-conversion, BioK260 sero-
conversion and BioK260 sero-increase respectively. 
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6.4  Discussion 
Serology provides a relatively inexpensive and time efficient method to assess a large number of 
samples for the presence of antibodies to a particular pathogen of interest. Serology can also 
provide a means to identify and quantify particular risk factors that may be associated with 
exposure as indicated by the development of antibodies to the pathogen of interest. In the current 
study, putative risk factors for M. bovis-specific antibody sero-positivity at feedlot induction were 
assessed and quantified. In addition, putative risk factors for sero-conversion to M. bovis or a sero-
increase of M. bovis antibody between feedlot induction and draft were also assessed.  
Null mixed effects models were fitted to evaluate the amount of variance in the outcome of interest 
at different levels. The majority of variance in the outcomes of interest assessed for both sero-
positivity at induction and sero-conversion or a sero-increase between induction and draft was seen 
at the animal level. This is not surprising given that the immune response of one animal to infection 
with M. bovis can differ to the next animal’s immune response to infection with M. bovis. Further 
variance for sero-positivity at the feedlot was seen at the group level in addition to the PIC level for 
each of the defined time points assessed. The group ICCs across the four induction outcomes and 
the seven defined time points prior to day 0 ranged from 0.29 (dichotomised BioK260 ELISA 
results, group-28) through to 0.74 (BioK302 ELISA results, group-500), (Table 6.7). The level of 
clustering of sero-positivity at feedlot induction by group seen in this study population was higher 
than expected and higher than that seen for many other infectious agents (McDermott and 
Schukken, 1994). An explanation for this finding may lie in the commensal nature of M. bovis. 
More asymptomatic carriers or sero-positive animals are likely to be present in herds where 
M. bovis is endemic. The presence of these animals in a herd can provide a constant source of 
infection for naive animals in the same herd.  
There was additional variance seen at the PIC level that was over and above that seen at the group 
level. This indicates that in the current study population, there was more similarity between groups 
from the same PIC than groups from different PICs. This finding suggests that M. bovis can persist 
on a property and that not all properties have M. bovis circulating in their herds which is in line with 
findings from other studies (Bednarek et al., 2012, Pfutzner and Sachse, 1996, Nicholas and Ayling, 
2003). 
Additional variance to that seen at the animal level for the three draft outcomes assessed (sero-
conversion or a sero-increase between feedlot induction and draft) was found to occur at the feedlot 
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and cohort levels more so than the group level. This finding suggests that factors occurring at the 
feedlot and cohort levels are more important in terms of the animal sero-converting or sero-
increasing to M. bovis between induction and draft than factors that may have occurred at the group 
level prior to feedlot induction. Although occurring at different levels, this finding is similar to that 
seen for sero-positivity at feedlot induction. For example, the feedlot (for draft outcomes) could be 
equated to the PIC (for induction outcomes). This is because once animals arrive at the feedlot, the 
feedlot basically acts as the property. Similarly, the cohort (draft outcomes) could be equated to a 
particular herd or group of animals at a particular PIC (for induction outcomes). In this context, if 
M. bovis is endemic at a particular feedlot than you could expect that cohorts at that feedlot are 
more likely to be exposed and in turn be infected with M. bovis resulting in a sero-increase or sero-
conversion in comparison to cohorts at a feedlot where M. bovis is not endemic. Again, if there is an 
asymptomatic carrier animal shedding M. bovis in a particular cohort, then animals within that 
particular cohort are more likely to be exposed and in turn infected with M. bovis resulting in a 
sero-increase or sero-conversion in comparison to cohorts where there are no animals shedding 
M. bovis. 
A number of putative risk factors for M. bovis sero-positivity at feedlot induction and sero-
conversion or a sero-increase to M. bovis between feedlot induction and draft were investigated. 
When quantifying risk factors of interest, care needs to be taken to allow for possible clustering of 
the outcome among the animals in the study population. A high level of clustering was found to 
occur at the group level for the induction outcomes and at the feedlot, cohort and group levels for 
the draft outcomes in this study population. Consequently, total (and direct where indicated) effect 
models were fitted using these levels fitted as random effects. The total effect models indicated an 
association between a number of group-level and animal-level putative risk factors and M. bovis 
sero-positivity at feedlot induction. These included source region, group size (groupN-13), mixing 
with animals from another PIC at least 27 days prior to day 0 (mix pre27), and history of a saleyard 
transfer at least 27 days prior to day 0. 
The total effect model for source region (Table 6.18) indicated that this could be a significant risk 
factor for M. bovis sero-positivity at feedlot induction. The BioK302 ELISA results indicated that 
animals from the Darling Downs / New England category (OR 0.18, 95% CI: 0.03 – 1.02) were at 
reduced risk compared to animals from NSW / Southern Tablelands, but this finding was not 
consistent across the other outcomes. Animals from South Australia / Western Australia were at 
consistently higher risk (dichotomised BioK260 ELISA results: OR 5.63, 95% CI: 1.91 – 16.59 in 
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addition to series: OR 7.75, 95% CI: 1.37 – 43.91 and parallel: OR 3.82, 95% CI: 1.36 – 10.78 
interpretations). The estimated effect of source region was attenuated using a direct effects model 
with only the point estimates obtained from cattle sourced from the Darling Downs / New England 
region using the BioK302 ELISA results (OR 0.13, 95% CI: 0.02 – 0.94) and parallel interpretation 
(OR 0.32, 95% CI: 0.11 – 0.94) remaining significant. The attenuation of the association for source 
region and sero-positivity at feedlot induction indicates that some of its effect is mediated through 
postulated indirect pathways rather than through the direct pathway. The marked attenuation of the 
estimate from direct effect model for the increased risk of sero-positivity at feedlot induction for the 
South Australia / Western Australia source region category provides an example of intervening 
variables affecting the outcome. Three feedlots sourced cattle from this region, one of which 
encompassed approximately 55% (89 / 162) of the study animals in this source region category. 
This particular feedlot practiced pre-assembly and as a consequence of this management practice 
sera collected from animals at the time of induction has occurred after the animal has been mixed 
with animals from other PICs in a less intensive environment compared to a feedlot pen. The 
induction blood samples are also collected after a period of time in which the animal has had time to 
be exposed to, be infected with and develop antibody to M. bovis (in addition to many other 
pathogens), possibly as a result of this mixing. In effect, a sample collected at the time of 
‘induction’ from a pre-assembled animal could be classified as being equivalent to a draft sample 
from animals that are not pre-assembled. In addition, the pre-assembly practice was found to 
increase the likelihood of an animal being part of a larger group 13 days prior to day 0. For 
instance, 89 animals in the South Australia / Western Australia source region category were from 
the same feedlot that practiced pre-assembly. Approximately 59% (n = 53) of these animal were in 
a group of ≥ 100 animals 13 days prior to day 0. When the intervening variables of group size and 
mixing at least 27 days prior to day 0 are accounted for in the direct effect model for source region, 
the increased risk of cattle in the South Australia / Western Australia source region category was no 
longer significant. 
The total effect models for group size 13 days prior to induction (groupN-13) suggested an 
association with M. bovis sero-positivity at feedlot induction. Animals in groups of ≥ 100, formed at 
least 13 days prior to day 0 were at increased risk of being sero-positive in comparison to animals 
derived from a group of < 50 (Table 6.19). This effect was most significant when using the 
dichotomised BioK260 ELISA result and parallel interpretation, OR 3.31, 95% CI: 1.45 – 7.59, and 
OR 3.79, 95% CI: 1.63 – 8.81, respectively.  
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There was also an indication that mixing with animals from another PIC at least 27 days prior to 
day 0 (Mix pre27) was associated with sero-positivity at feedlot induction. Even though mixing was 
not consistently significant across all the induction outcomes assessed in the total effects models of 
the current study. The dichotomised BioK260 ELISA result was significant and the odds ratio for 
animals that had been mixed at least 27 days prior to day 0 was estimated at OR: 2.62, 95% CI: 1.14 
– 5.98 (Table 6.14). What remains unknown in regards to mixing in this context is whether the 
timing of mixing at least 27 days prior to day 0 is at all relevant. For instance are animals mixed at 
least 100 days prior to day 0 still at increased risk of being sero-positive at feedlot induction as 
those that are mixed only 27 days prior to day 0? Further research in this regard may provide 
valuable information on the duration for which M. bovis antibody remains detectable. To the best of 
the author’s knowledge, information on the half-life of M. bovis antibody and the duration for 
which antibody remains detectable following natural infection is not known.  
In the current study, animals with a saleyard transfer at least 27 days prior to day 0 (SY pre27) as 
evidenced by the NLIS data were at increased risk of M. bovis sero-positivity at feedlot induction. 
This association was significant in a total effect model (adjusted for source region) across all four 
induction outcomes assessed (Table 6.15). The significance was attenuated in the direct effect 
model were the effect of the intervening variable; mixing at least 27 days prior to day 0, was 
accounted for. The direct effect estimate of animals that have had a saleyard transfer at least 27 days 
prior to day 0 was calculated using the BioK302 ELISA results giving an OR 2.95, 95% CI: 0.99 – 
8.73.  
Dentition was used as a very crude estimate for age of the animals in the current study. Results 
presented here although insignificant made some suggestion that ‘two tooth’ cattle were at 
decreased risk of M. bovis sero-positivity at feedlot induction compared to ‘milk tooth’ cattle (Table 
6.14). As the point estimates calculated across all four outcomes assessed were imprecise, it is 
possible that if a more precise and accurate measure of age were available then the effect of age 
may have been significant. In the same context, there was an insignificant suggestion that cattle of 
lighter induction weight (190 ≤ 400 kg) were at increased risk of M. bovis sero-positivity at feedlot 
induction compared to those in the 440 ≤ 480 kg weight range category using the dichotomised 
BioK260 results OR 2.03, 95% CI: 0.84 - 4.8 and parallel interpretation of the two tests OR 1.91, 
95% CI 0.81 - 4.49 (Table 6.12). Again an accurate measure of age was not available in the current 
study. Had this been available then a better understanding of age as a contributing factor into the 
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observed effect of induction weight would have been possible. As such the effect of age on the risk 
of M. bovis sero-positivity at feedlot induction certainly warrants further research. 
The assessment of putative risk factors for sero-conversion or a sero-increase to M. bovis between 
feedlot induction and draft indicated that there may be some association with breed, group size, 
shared pen water, and exposure to a BVDV PI animal. Firstly the direct effect of breed was found to 
be a significant risk factor for sero-conversion or a sero-increase between induction and draft. 
European / European Cross, Tropical / Tropical cross and British cross breeds were at markedly 
reduced risk compared to Angus. A possible explanation for the decreased risk of the Tropical / 
Tropical cross (Bos indicus) types of cattle could lie in the evolutionary origin of these types 
(Taylor et al., 2010). Being from hotter, drier climates, disease susceptibility could be expected to 
vary with geographic location and climate (Taylor et al., 2010). In relation to the development of 
BRD, an Australian study compared Bos Taurus (represented by several breeds) with Bos indicus 
(represented by Santa Gertrudis and Santa Gertrudis cross) cattle for BRD incidence and found Bos 
taurus to be at greater risk for BRD than Bos indicus (Cusack et al., 2007). In addition, hybrid vigor 
may be beneficial in terms of disease resistance and may explain the decreased risk associated with 
the European / European cross and British cross breed categories in this study. Again in relation to 
BRD, a study by Snowder et al. (2005) found that crossbred cattle had a lower incidence of BRD. 
The basis of disease resistance in crossbred animals and cattle of tropical breed descent is not fully 
understood. However, if crossbred animals are less likely to have LRT infection with M. bovis then 
they are less likely to develop antibodies that can be detected using serological methods.  
Animals sourced from the Darling Downs / New England source region category were at decreased 
risk of sero-conversion or a sero-increase between induction and draft. This was significant for all 
three outcomes assessed. Using the direct effect model, the point estimates were OR 0.53, 95% CI: 
0.31 – 0.91; OR 0.40, 95% CI: 0.21 – 0.77 and OR 0.43, 95% CI: 0.22 – 0.83 for the BioK302 sero-
conversion, BioK260 sero-conversion and BioK260 sero-increase outcomes, respectively (Table 
6.21).  
In the current study population there was an indication from the total effect model that animals from 
a group-13 of ≥ 100 animals were at decreased risk of sero-conversion based on the BioK302 
ELISA results between feedlot induction and draft (OR 0.53, 95% CI: 0.30 – 0.92), (Table 6.32). 
The significance was attenuated when the effect of group size was assessed using a direct effect 
model indicating that one or more intervening variables play a role in the effect of group size seen 
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in this study. Closer examination of the data indicated that animals that are part of a group-13 which 
is in excess of 100 animals, may potentially form part of a larger cohort or be mixed with fewer 
other group-13’s once arriving at the feedlot and warrants further research.  
Access to shared pen water was associated with a markedly increased risk of sero-conversion or 
sero-increase (Table 6.36). This effect was significant based on the BioK260 sero-conversion and 
sero-increase results. The BioK302 sero-increase results were suggestive of a strong association 
although the point estimate was not significant. Access to water which is shared with another pen of 
animals essentially increases the potential for indirect transmission of M. bovis between animals, 
not only from the pen of animals the individual is part of, but also with the pen of animals that also 
has access to that water. The same can be said for pathogens other than M. bovis that have the 
ability to persist in the environment, especially in cool, moist and potentially dark / somewhat 
protected from sunlight areas.  
The assessment of putative risk factors in this study was limited by the small sample size which was 
estimated for the determination of the sero-prevalence of M. bovis (Chapter 5), not for the 
assessment of risk factors associated with sero-positivity or sero-conversion. The group ICC 
estimates obtained here were consistently high across the four M. bovis sero-positivity outcomes 
assessed and were higher than expected ranging from 0.29 (dichotomised BioK260 ELISA results, 
group-28) through to 0.81 (series interpretation, group-500), (Table 6.7 and Table 6.8, respectively). 
The sample size was estimated using an ICC of 0.26 (Chapter 5, Section 5.2.4), and the ICC results 
reported here indicate that this was an underestimate. Consequently the power of this study to 
accurately identify and quantify risk factors of particular interest was reduced. In this context, risk 
factors assessed and found to have no association with sero-positivity to M. bovis or sero-
conversion / a sero-increase at draft cannot be completely dismissed. For example, the effect of risk 
factors with a point odds ratio estimate that is well away from one (i.e. < 0.8 or > 1.5) and have a 
wide 95% confidence interval are imprecisely estimated because of the small sample size, and the 
high level of clustering. For sero-positivity at feedlot induction these factors include; breed (Murray 
Greys, European / European Cross and Tropical / Tropical Cross breed categories may be at 
increased risk); animals of a lower induction weight may be at increased risk; and animals that have 
been mixed with animals from another PIC at least 27 days prior to day 0 may be also at increased 
risk. Imprecise estimates for an increased risk of sero-conversion or a sero-increase to M. bovis 
between induction and draft in this study were obtained for: animals with a history of a saleyard 
transfer between day 0 and 27 days prior; animals that have not been mixed at least 27 days prior to 
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day 0 and form a cohort irrespective of the number of group-28s that form that cohort (Mix Sum 
categories no, low and no, high); animals in a pen at higher stocking density; cattle inducted in 
autumn compared to those inducted in spring and active BVDV infection in the cohort combined 
with the presence of a PI animal identified in a group-28 that formed part of that cohort (BVDV_PI 
exposure category active, no PI). All these risk factors for which their effect have been imprecisely 
estimated require further investigation to determine their true effect on sero-positivity or sero-
conversion to M. bovis.  
In the current study, co-infection with respiratory pathogens as a risk factor for sero-positivity or 
sero-conversion to M. bovis was only addressed with BVDV_PI data. The opportunity to investigate 
the possible role of other viral and bacterial bovine respiratory pathogens was not possible due to 
the unavailability of data. A number of studies have reported that infection with BVDV increases 
the pathogenicity of other viral and bacterial bovine respiratory pathogens (Haines et al., 2001, 
Potgieter, 1997, Potgieter et al., 1984, Prysliak et al., 2011, Richer et al., 1988, Shahriar et al., 
2002, Stott et al., 1980). This has been attributed to the immunosuppressive effects of BVDV on the 
host which increases the susceptibility of animals with persistent and primary postnatal BVDV 
infections to secondary infection (Haines et al., 2001, Potgieter, 1997, Potgieter et al., 1984, 
Shahriar et al., 2002). In light of these studies, it is possible that an active BVDV infection would 
increase the risk of M. bovis infection and sero-increase or sero-conversion. Given the imprecise 
estimate obtained for the risk of M. bovis sero-positivity and sero-increase or sero-conversion 
associated with an active BVDV infection in the cohort combined with the presence of a PI animal 
identified in a group-28 that formed part of that cohort (BVDV_PI exposure category active, no PI), 
further investigations are warranted. 
In a study by Prysliak et al. (2011), prior exposure to BoHV-1 was associated with clinical M. bovis 
related respiratory disease. Damage caused to the URT associated with a BoHV-1 infection, like 
BVDV infection, increases the susceptibility of animals to secondary infection. It is possible that 
prior administration of the BoHV-1 vaccine, Rhinogard™ could provide animals with some 
protection against a secondary infection with M. bovis once in the feedlot environment. On the other 
hand however, it is postulated that administration of the Rhinogard™ vaccine at the time of feedlot 
induction may in fact predispose animals to infection with M. bovis. Due to the way in which 
Rhinogard™ is administered it is possible that the vaccination equipment itself may act as a fomite 
for the transmission of M. bovis between one animal and the next. It was not possible in the current 
study to investigate the association of BoHV-1 co-infection or prior Rhinogard™ vaccination with 
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the risk of M. bovis sero-positivity and or sero-conversion in the feedlot environment due to the lack 
of sufficient data.  
Another limitation of the current study was the use of two serological tests that are imperfect in 
terms of Se and Sp to assess and quantify putative risk factors for the presence of M. bovis antibody. 
Because of this the level of misclassification and the direction (false negative or false positive) of 
the misclassification of the animals in the current study is not known and as a result it could not be 
adjusted for. Greiner and Gardner (2000) report that because sero-positivity has two components 
(true- and false- positive test results), in some studies that use logistic-regression analyses it is 
possible that risk factors for false-positive results may be evaluated more so than risk factors for 
true-positive results if the test used does not have perfect Sp. In this particular study, this is less 
likely to be an issue, particularly for the sero-conversion / sero-increase analyses. Because test Sp 
estimates (presented in Chapter 4 and Chapter 5) are reasonably high and strong clustering of the 
outcome by group has been demonstrated in this study, the test-positive results obtained using these 
ELISAs are extremely unlikely to be false-positives. That is of course unless there is some unknown 
reason for false-positive test results that could also be strongly clustered by group in this study 
population. 
In conclusion, in spite of the current study’s limitations, a number of putative risk factors have been 
identified as significant risk factors for M. bovis sero-positivity at induction and sero-conversion or 
a sero-increase to M. bovis between induction and draft of feedlot cattle. For those risk factors 
where some association is indicated, future research is required to more accurately assess and 
quantify these risk factors. In addition further assessment is required for putative risk factors where 
an association was not identified but the point estimates were away from the null and the confidence 
intervals indicated the estimates were imprecise. In the current study this was an effect of the small 
sample size and greater than expected clustering by group.  
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CHAPTER 7   Mycoplasma bovis sero-status and bovine respiratory disease in 
Australian feeder cattle 
7.1  Introduction 
In recent years there has been increased interest in the involvement of M. bovis and the role it plays 
in the development of bovine respiratory disease (BRD). With improvements in the isolation and 
detection of M. bovis, it is becoming increasingly clear that M. bovis infections are major primary or 
contributory causes to the development of BRD in intensive cattle production systems (Caswell et 
al., 2010, Nicholas et al., 2008). Studies have shown that M. bovis is the most common bacterium 
identified in feedlot cattle affected by chronic pneumonia and in veal calves with fatal 
bronchopneumonia (Adegboye et al., 1995, Haines et al., 2001, Shahriar et al., 2002). Respiratory 
disease associated with M. bovis can occur in cattle of any age (Maunsell et al., 2011) however, the 
causative nature of M. bovis in cattle older than six months of age is not well understood. Evidence 
to support M. bovis as a predisposing factor in the infectious process for the development of BRD in 
cattle older than six months of age has been provided by Divers (2008), Horwood et al. (2014) and 
Poumarat et al. (2001). They suggest that the presence of M. bovis in an animal under the correct 
conditions can further compromise the animal’s immune defences, thereby enhancing the ability of 
other bacteria to invade the LRT (Divers, 2008, Gourlay and Houghton, 1985, Poumarat et al., 
2001, Rodríguez et al., 1996). 
In Australia to the best of the author’s knowledge, there has been no research relating to the 
association M. bovis infections may have on the development of BRD in the early feeding period of 
feeder cattle. The aim of the current study was to determine if sero-positivity to M. bovis at feedlot 
induction or sero-conversion to M. bovis between feedlot induction and draft were potential risk 
factors for the development of BRD within the first 50 days on feed (DOF). 
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7.2  Materials and methods 
7.2.1  Study population 
The study population has been previously described in Chapter 5 (Section 5.2.1). Paired sera 
(induction and draft) from 1,354 animals randomly selected from the NBRDI study population were 
collated for a M. bovis-specific antibody sero-prevalence study as described in Chapter 5. Serum 
samples were collated as described in Section 5.2.2 and animal data relating to the selected animals 
were sourced from the NBRDI database as outlined in Section 5.2.3. 
7.2.2 Outcome variable used in analyses 
The binary outcome variable used in this study related to whether the individual animal was 
recorded in the NBRDI database as having developed BRD (being removed from the feedlot pen by 
feedlot personnel for symptoms referrable to the respiratory system) within the first 50 DOF 
(Barnes et al., 2014).  
7.2.3  Putative risk factors used in analyses 
Induction and draft sera from 1,354 animals randomly selected from the NBRDI study population 
(Chapter 5) were tested for the presence of M. bovis-specific antibody using the commercially 
available BioK302 and BioK260 ELISA kits as described in Section 4.2.3. Results obtained have 
been reported in Chapter 5. These results were used to derive a binary exposure variable relating to 
M. bovis sero-positivity at the time of feedlot induction using the BioK302 and dichotomised 
BioK260 ELISA results (Chapter 5). In addition binary BioK302 sero-conversion, BioK260 sero-
conversion and BioK260 sero-increase exposure variables (Section 5.2.7.3.1) were used. 
7.2.4  Clustering 
The derivation and selection of clustering variables have been previously described in Chapter 6, 
Section 6.1.4. In this study all analyses were adjusted for clustering at the feedlot, cohort and group-
13 levels.  
7.2.5  Causal diagrams 
Two causal diagrams were created to describe postulated links with; (i) M. bovis sero-positivity at 
feedlot induction (Figure 7.1) and (ii) sero-conversion or a sero-increase to M. bovis between 
induction and draft; with the outcome being the development of BRD within the first 50 DOF 
(BRD50), (Figure 7.2). Risk factors that were found to be associated with M. bovis sero-positivity at 
feedlot induction in Chapter 6 were included in the causal diagram for M. bovis sero-positivity at 
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feedlot induction and BRD50 (Figure 7.1). While risk factors found to be associated with sero-
conversion or a sero-increase to M. bovis between induction and draft (Chapter 6) were included in 
the sero-conversion / sero-increase and BRD50 causal diagram (Figure 7.2). The threshold for 
inclusion was p < 0.05 on one or more of the induction or sero-conversion / sero-increase outcomes 
respectively. Some risk factors (Mix Sum, group size and BVDV PI) which did not have a p < 0.05 
for one or more of the outcomes were still included as it was believed that these associations were 
biologically plausible and the total effects may have been underestimated in Chapter 6. For 
completeness these factors were still included as failure to include a pathway in the causal diagram 
is a stronger claim that including pathways that are potentially true (Textor, 2013). The risk factors 
that were included in each of the causal diagrams are listed below and have been previously 
described in Chapter 6 (relevant section listed). The causal diagrams enabled identification of the 
minimum sufficient adjustment sets required to derive the best estimates of the total effects of (i) 
M. bovis sero-positivity at feedlot induction and (ii) sero-conversion or a sero-increase to M. bovis 
on BRD50 (Table 7.1). The minimal sufficient adjustment sets to assess total effects of M. bovis 
sero-positivity at feedlot induction and sero-conversion / a sero-increase in M. bovis antibody 
between induction and draft on BRD50 were identified using the relevant causal diagram and the 
DAGitty

 software (Textor, 2013), (Table 7.1). As there were no intervening variables, the 
minimum sufficient adjustment sets for both the total and direct effects models were the same. 
 Breed (Section 6.1.5.1.1). 
 Saleyard transfer at least 27 days prior to day 0 (SY pre27), (Section 6.1.5.1.5). 
 Saleyard transfer between 27 days prior to day 0 and day 0 (SY 27_0), (Section 6.1.6.1.2). 
 Mixing at least 27 days prior to day 0 (Mix pre27), (Section 6.1.5.1.4). 
 Mixing summary which is a composite variable that relates to mixing at least 27 days prior to 
day 0 in addition to the number of group-28s forming the cohort (Mix Sum), (Section 6.1.6.1.1) 
 Source region (Section 6.1.5.2.1). 
 Group size (GroupN-13) which relates to an individual animals group size 13 days prior to day 
0 (Section 6.1.5.2.3). 
 Access to shared pen water (water), (Section 6.1.6.3.3). 
 Exposure to an animal persistently infected (PI) with BVDV (BVDV_PI) which is a composite 
variable identifying the presence or absence of active BVDV infection in the cohort and the 
presence of a PI in the animals group-28 (Section 6.1.6.3.7).  
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Figure 7.1: Causal diagram based on results from Chapter 6 and biologically plausible 
pathways interlinking M. bovis sero-positivity at feedlot induction with the outcome of bovine 
respiratory disease within the first 50 days on feed. 
BRD50: Bovine respiratory disease in the first 50 days on feed; GroupN-13: Group size 13 days prior to day 
0; Mix pre27: Mixing at least 27 days prior to day 0; SY pre27: Saleyard transfer at least 27 days prior to day 
0; Source region: Region at which the animal was located 28 days prior to day 0. 
Day 0 is defined as the day of induction or for those animals that are pre-assembled on pasture at or close to 
the feedlot; it is the day the animal was moved to a feedlot pen.  
GroupN-13
Source region 
Mix pre27
SY pre27
M. bovis  sero-positive at induction
BRD50
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Figure 7.2: Causal diagram based results from Chapter 6 and biologically plausible pathways 
interlinking sero-conversion to or a sero-increase in M. bovis-specific antibody between 
induction and draft with the outcome of bovine respiratory disease within the first 50 days on 
feed. 
BRD50: Bovine respiratory disease in the first 50 days on feed; BVDV PI: Exposure to a persistently 
infected bovine viral diarrhoea virus animal at least 28 days prior to feedlot arrival in addition to the 
presence of active bovine viral diarrhoea virus infection in the cohort; GroupN-13: Group size 13 days prior 
to day 0; Mix pre27: Mixing at least 27 days prior to day 0; Mix Sum: Mixing at least 27 days prior to day 0 
in addition to the number of groups of animals that were together 28 days prior to day 0; SY pre27: Saleyard 
transfer at least 27 days prior to day 0; Source region: Region at which the animal was located 28 days prior 
to day 0; Water: Access to water shared with another pen of animals.  
Day 0 is defined as the day of induction or for those animals that are pre-assembled on pasture at or close to 
the feedlot; it is the day the animal was moved to a feedlot pen. 
M. bovis sero-conversion describes whether an animal sero-converts based on the BioK302 ELISA results 
(i.e. changes from sero-negative to sero-positive between induction and draft) or changes from a BioK260 
Delta Value (DV) category of '0' to ≥ '++' between induction and draft. M. bovis sero-increase related to 
those animals that change from a BioK260 DV category of '0', '+', '++', or '+++' to '++', '+++', '++++' or 
'+++++' respectively between induction and draft.  
GroupN-13
Source region 
Mix Sum
M. bovis  sero-conversion 
         / sero-increase
BRD50
Water
Breed
BVDV PI 
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Table 7.1: Covariates indicated as minimum sufficient adjustment sets for total effect models 
of M. bovis sero-positivity at feedlot induction or sero-conversion / sero-increase to M. bovis 
between induction and draft as informed using DAGitty

 and the appropriate causal diagram 
BRD50 
Minimum sufficient adjustment set to estimate total 
effect 
Sero-positivity at feedlot induction Source region, GroupN-13, Mix pre27 and SY pre27 
Sero-conversion / sero-increase  Source region, breed, GroupN-13, Mix Sum, shared 
water and BVDV PI exposure 
BRD50: Bovine respiratory disease in the first 50 days on feed; BVDV PI exposure: Exposure to a 
persistently infected bovine viral diarrhoea virus animal at least 28 days prior to feedlot arrival in addition to 
the presence of active bovine viral diarrhoea virus infection in the cohort; GroupN-13: Group size 13 days 
prior to day 0; Mix pre27: Mixing at least 27 days prior to day 0; Mix Sum: Mixing at least 27 days prior to 
day 0 in addition to the number of groups of animals that were together 28 days prior to day 0; SY per27: 
Saleyard transfer at least 27 days prior to day 0.  
Day 0 is defined as the day of induction or for those animals that are pre-assembled on pasture at or close to 
the feedlot; it is the day the animal was moved to a feedlot pen. M. bovis sero-conversion describes whether 
an animal sero-converts based on the BioK302 ELISA results (i.e. changes from sero-negative to sero-
positive between induction and draft) or changes from a BioK260 Delta Value (DV) category of '0' to ≥ '++' 
between induction and draft. M. bovis sero-increase related to those animals that change from a BioK260 DV 
category of '0', '+', '++', or '+++' to '++', '+++', '++++' or '+++++' respectively between induction and draft. 
 
7.2.6 Statistical modelling and data management 
The statistical modelling and data management used in this study were adapted from that used in 
Chapter 6 (Section 6.1.8). Odds ratios for the total effect of M. bovis sero-positivity at feedlot 
induction and sero-conversion / a sero-increase in M. bovis antibody between induction and draft on 
BRD50 were estimated using the xtmelogit command with feedlot, cohort and group-13 fitted as 
random effects. The statistical program Stata/SE 12.1

 (Statacorp, College Station, Texas, USA) 
was used for all data management and analyses.   
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7.3  Results 
7.3.1  BRD50 and M. bovis sero-positivity at feedlot induction 
In the current study it was found that 15.3% (n = 207) were classified as having developed BRD 
within the assigned time period. Of these, 1.9% (n = 4) and 2.4% (n = 7) tested positive for M. bovis 
antibody at the time of feedlot induction using the BioK302 and dichotomised BioK260 ELISA 
results respectively (Table 7.2). Using series and parallel interpretations; 1.0% (n = 2) and 4.3% 
(n = 9) were considered M. bovis sero-positive at feedlot induction. 
 
The total effect model for M. bovis sero-positivity at feedlot induction did not indicate any 
association with the development of BRD within the first 50 DOF (Table 7.3). An odds ratio for the 
total effect of M. bovis sero-positivity at feedlot induction using series interpretation of the two tests 
was not estimated as only two animals tested M. bovis sero-positive on the BioK302 and using the 
dichotomised BioK260 results. As a consequence of this, the model failed to converge. 
7.3.2  BRD50 and sero-conversion to M. bovis or a sero-increase in M. bovis antibody 
between induction and draft  
Overall 15.3% (n = 207) of the animals in the current study were classified as having developed 
BRD within the first 50 DOF. Of these, 203 had the potential to sero-convert based on the BioK302 
ELISA results; 200 had the potential to sero-convert based on the BioK260 ELISA results and 206 
had the potential to sero-increase between induction and draft irrespective of their induction result 
(Table 7.4). Of the animals with the potential to sero-convert; 43.5% (n = 88) and 32.0% (n = 64) 
developed BRD in the first 50 DOF based on the BioK302 and BioK260 ELISA results 
respectively. Of the animals with the potential to sero-increase, 32% (n = 66) developed BRD in the 
first 50 DOF (Table 7.4). 
The total effect model indicated that there was a significant association between M. bovis sero-
conversion or a sero-increase between induction and draft and the development of BRD within the 
first 50 DOF (Table 7.5). In the current study, animals showing sero-conversion or a sero-increase 
in M. bovis antibody between induction and draft were at markedly increased risk across all test 
outcomes of developing BRD in the first 50 DOF (Table 7.5).  
 
 
 215 
 
Table 7.2: Number of animals that developed BRD within the first 50 DOF and were sero-positive for M. bovis antibody at feedlot induction 
using the BioK302 or dichotomised BioK260 ELISA results including series and parallel interpretation of the two test results 
BRD50 No. (%) 
BioK302 Dichotomised BioK260 Series interpretation Parallel interpretation 
No. positive (%) No. positive (%) No. positive (%) No. positive (%) 
No 1,147 (84.7%) 43 (3.7%) 71 (6.2%) 31 (2.7%) 83 (7.2%) 
Yes 207 (15.3%) 4 (1.9%) 7 (2.4%) 2 (1.0%) 9 (4.3%) 
Total 1,354 (100%) 47 (3.5%) 78 (5.8%) 33 (2.4%) 92 (6.8%) 
BRD50: Bovine respiratory disease in the first 50 days on feed; DOF: Days on feed. 
 
Table 7.3: Estimated odds ratios for the total effect of M. bovis sero-positivity at feedlot induction on the risk of developing BRD in the first 
50 DOF 
BRD50 
BioK302 Dichotomised BioK260 Series interpretation Parallel interpretation 
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p 
  
0.87 
 
0.86 
 
NA 
 
0.53 
No Reference  Reference  Reference  Reference  
Yes 0.84 (0.10 – 6.82) 0.87 1.15 (0.19 – 6.88) 0.86 NA NA 1.61 (0.36 – 7.25) 0.53 
BRD50: Bovine respiratory disease in the first 50 days on feed; CI: Confidence interval; DOF: Days on feed; OR: Odds ratio; p: Wald p value; NA: Not assessed.  
Individual p values for each category are shown in the same row as the BRD50 outcome, while the overall Wald p value is shown above in (bold and italics). The 
total and direct effect models for BRD50 outcome are adjusted for source region, group size, mixing at least 27 days prior to day 0 and history of a saleyard transfer 
at least 27 days prior to day 0. A total of 430 animals were included in the total and direct effect models. The odds ratio for series interpretation of the two test results 
was not estimated because there were so few animals that were series test positive and of these only two developed BRD within the first 50 days on feed. 
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Table 7.4: Number of animals that developed BRD within the first 50 DOF and were regarded as having sero-converted or sero-increased to 
M. bovis between feedlot induction and draft 
BRD50 Total No. (%) 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
No. with potential No. (%) No. with potential No. (%) No. with potential No. (%) 
No 1,147 (84.7%) 1,104 229 (20.7%) 1,076 185 (17.2%) 1,143 103 (9.0%) 
Yes 207 (15.3%) 203 88 (43.5%) 200 64 (32.0%) 206 66 (32.0%) 
Total 1,354 (100%) 1,307 317 (24.3%) 1,276 249 (19.5%) 1,349 261 (19.3%) 
BRD50: Bovine respiratory disease in the first 50 days on feed; DOF: Days on feed. 
M. bovis sero-conversion describes whether an animal sero-converts based on the BioK302 ELISA results (i.e. changes from sero-negative to sero-positive between 
induction and draft) or changes from a BioK260 Delta Value (DV) category of '0' to ≥ '++' between induction and draft. M. bovis sero-increase related to those 
animals that change from a BioK260 DV category of '0', '+', '++', or '+++' to '++', '+++', '++++' or '+++++' respectively between induction and draft. 
 
Table 7.5: Estimated odds ratios for the total effect of sero-conversion to or a sero-increase in M. bovis antibody between induction and draft 
and the risk of developing BRD in the first 50 DOF 
BRD50 
BioK302 sero-convert BioK260 sero-convert BioK260 sero-increase 
OR (95% CI) p OR (95% CI) p OR (95% CI) p 
  
< 0.001 
 
0.002 
 
0.001 
No Reference  Reference  Reference  
Yes 3.08 (2.00 – 4.74) < 0.001 2.12 (1.33 – 3.38) 0.002 2.16 (1.38 – 3.39) 0.001 
BRD50: Bovine respiratory disease in the first 50 days on feed; OR: Odds ratio; CI: Confidence interval; p: Wald p value; BioK260 sero-increase: an increase of two 
or more M. bovis BioK260 Delta Value categories between feedlot induction and draft.  
Individual p values for each category are shown in the same row as the BRD50 outcome category while the overall Wald p value is shown in the BRD50 outcome 
row (bold and italics). The total and direct effect models for the BRD50 outcome are adjusted for source region, breed, group size, mixing summary, shared water 
and exposure to a persistently infected bovine viral diarrhoea virus animal. A total of 1,295, 1,264 and 1,336 animals were included in the total effect models for 
BioK302 sero-conversion, BioK260 sero-conversion and BioK260 sero-increase respectively.  
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7.4 Discussion 
In the current study, sero-positivity at feedlot induction was not found to be associated with the 
development of BRD within the first 50 DOF. This result is consistent with the findings of other 
studies (Allen et al., 1992, Booker et al., 1999, Castillo-Alcala et al., 2012). Conversely, sero-
conversion or an increase in M. bovis-specific antibody between induction and draft was found to be 
an important risk factor for the development of BRD in the first 50 DOF. In this study, animals that 
sero-converted or had a detectable sero-increase in M. bovis antibody between induction and draft 
were two to three times more likely than those that did not sero-convert or sero-increase to develop 
BRD in the first 50 DOF. 
Bovine respiratory disease is multi-factorial with many physical, physiological (Taylor et al., 2010) 
and infectious stressors combining to predispose susceptible animals to the development of clinical 
respiratory disease. There are a number of bovine viral and bacterial pathogens that are consistently 
implicated. The causal association of the these agents is based upon criteria that include isolation 
from clinical cases (Gagea et al., 2006b, Haines et al., 2001, Shahriar et al., 2002), vaccination 
trials (O'Connor et al., 2001, Wildman et al., 2008) and serological surveys (Booker et al., 1999, 
Martin et al., 1989). In Australia, M. bovis has typically been overlooked as an important pathogen 
in the development of BRD (Horwood et al., 2014). However, preliminary investigations by 
Horwood et al. (2014) demonstrated that M. bovis was present in both clinical and fatal cases of 
BRD in Australian feedlots. Horwood et al. (2014) assessed two lung and 12 tracheal samples from 
animals that had died from BRD for the presence of M. bovis using an in-house real-time PCR assay 
targeting the 16S rRNA gene. The samples were provided by seven Australian feedlots between 
April 2008 and November 2010. To differentiate between M. bovis and M. agalactiae, the PCR 
amplicons from positive samples were subjected to nucleotide sequence analyses to confirm the 
presence of M. bovis. It was reported that M. bovis was the most frequently detected pathogen in the 
tissue samples, and in most cases was detected in combination with BoHV-1 (Horwood et al., 
2014). Although preliminary in nature, this study did provide evidence for the inclusion of M. bovis 
to the list of pathogens implicated in BRD in Australia, thereby highlighting the importance of 
further research.  
In other countries the implication of M. bovis in BRD outbreaks is not novel and it is suggested that 
M. bovis plays an important role as a predisposing factor in the development of BRD (Arcangioli et 
al., 2008, Burnens et al., 1999, Le Grand et al., 2002, Tenk et al., 2004, ter Laak et al., 1992). In a 
study by Arcangioli et al. (2008) serological evidence of, and sero-conversion to M. bovis was 
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found to occur in eight out of nine feedlots during BRD outbreaks. Gourlay and Houghton (1985) 
found that experimentally induced pneumonia in gnotobiotic calves was more severe when M. bovis 
was inoculated before M. haemolytica rather than vice versa. There is substantially more literature 
on the association of M. bovis being cultured from respiratory samples (lungs, trachea) and BRD 
than serological evidence associating M. bovis with BRD. In these studies the ability to isolate / 
culture M. bovis in addition to the ability to detect M. bovis antibody from apparently healthy and 
sick animals limits an assessment of the causal association M. bovis may have with BRD (Gourlay 
and Houghton, 1985, Rodríguez et al., 1996, Tenk et al., 2004). A Hungarian study by Tenk et al. 
(2004) examined the occurrence of pneumonia, the isolation of M. bovis from lung tissue and the 
presence of M. bovis-specific antibody in cattle originating from different dairy farms. The authors 
reported that in 38.1% of the cases; lung pathology was not associated with M. bovis infection 
(culture or serology). Fulton et al. (2009), Gagea et al. (2006a) and Stipkovits et al. (2000) also 
report that co-infections involving the bacteria M. haemolytica, H. somni and P. multocida are 
extremely common in cases of M. bovis-associated pneumonia. Consequently, M. bovis is not the 
only bacteria isolated from pneumonic lung lesions, and the presence of M. bovis antibody is not 
always associated with successful culture of M. bovis. This suggests that M. bovis alone may not 
always be the cause of BRD, but in some way may predispose animals to LRT colonisation by other 
bacteria, which are also often commensals of the URT, leading to the development of BRD 
(Gourlay and Houghton, 1985, Hermeyer et al., 2012, Rodríguez et al., 1996, Tenk et al., 2004). 
Assessing causality is difficult with respect to any of the commonly implicated bacterial pathogens 
and BRD. Many are commensals of the URT of healthy animals so culture of the organism from 
nasal swabs indicates presence of the organism but nothing more. Disease results if infection of the 
LRT tissue occurs, but collecting samples for culture from the LRT is difficult in a live animal. 
Lung tissue samples collected from deceased animals usually occurs sometime after the initial onset 
of disease and often follows treatment with antimicrobials. These factors make identification of 
organisms that may have been present during the initial infectious process difficult. In addition 
antimicrobial treatment will affect the culturability of pathogens that may have been present prior to 
treatment. Serology offers a means to identify live animals that have undergone an immune 
response to a LRT infection with M. bovis. However, serology used as a tool for individual animal 
diagnosis of infection in the author’s opinion may not be ideal. There are many factors that affect an 
individual animal’s immune response to M. bovis infection and these are poorly understood. In 
addition; the presence of antibody does not always indicate clinical disease. Currently, there may 
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not be one ideal method; however studies combining culture, serology and molecular methods may 
be the best compromise for assessing the causal nature of M. bovis and BRD. 
The exact mechanism(s) by which M. bovis may predispose susceptible animals to BRD is 
unknown. Experimental infection trials conducted using calves have shown that M. bovis has both 
stimulating and suppressing effects on the bovine immune response (Hermeyer et al., 2012). The 
production of nitric oxide and tumor necrosis factor-alpha by macrophages is stimulated (Jungi et 
al., 1996); apoptosis of lymphocytes (Vanden Bush and Rosenbusch, 2002) and the production of a 
lympho-inhibitory peptide is induced (Vanden Bush and Rosenbusch, 2004); while lymphocyte 
responses to mitogens and the neutrophil oxidative burst is suppressed (Wiggins et al., 2010). 
Mycoplasma bovis also has the ability to produce hydrogen peroxide (H2O2) which has been 
suggested as an important virulence factor causing oxidative injury to lung tissue (Khan et al., 
2005b, Schott et al., 2013). Furthermore, Schott et al. (2013) speculate that the generation of 
oxygen free radicals at the sites of M. bovis infection can be detrimental to the local immune 
response and contribute to the chronicity that is typical of M. bovis infections. Any one or 
combination of these factors may lead to suppression or down regulation of the local immune 
response allowing other bacteria to invade tissue in the LRT. In addition, how the pathogenicity and 
the capability of different M. bovis field strains may affect the LRT local immune response of an 
individual animal is poorly understood and is certainly an area that warrants further research. 
In this study, samples were drawn from a bovine serum bank collated as part of a large Australian 
epidemiological study investigated risk factors associated with the development of BRD in feedlot 
cattle, the NBRDI. Part of this project involved a BRD case-control study that assessed the effect of 
sero-positivity at feedlot induction and the effect of sero-conversion at draft to BoHV-1, BVDV, 
BPIV-3 and BRSV on BRD. Their findings were that evidence of prior exposure to any of the viral 
agents investigated (indicated by sero-positivity at feedlot induction) reduced the risk of BRD in the 
first 50 DOF (Barnes et al., 2014). Meanwhile evidence of exposure early in the feeding period as 
indicated by sero-conversion at draft to any of the viral agents investigated increased the risk of 
BRD in the first DOF. Barnes et al. (2014) also reported that the effects of each individual virus 
were similar but were compounded by exposure to multiple viruses. Since the animals used in this 
particular study were derived from the NBRDI population, viral serological data were available for 
some animals; however the overlap in samples in this study was too small to allow any analyses to 
be performed. However, comparison of the strength of association of sero-conversion to BoHV-1, 
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BVDV, BPIV-3 and BRSV seen in the NBRDI case-control study to that seen with M. bovis and 
BRD in the current study is possible.  
With respect to BoHV-1, the NBRDI reported that 79% of the study population were vaccinated 
with Rhinogard
TM
 at feedlot induction and this was completely clustered by feedlot (Barnes et al., 
2014). Vaccination with Rhinogard
TM
 was associated with a markedly increased risk of BRD (OR 
5.3, 95% credible interval: 0.4 to 17.0), albeit imprecise (Barnes et al., 2014). Following on from 
this, Barnes et al. (2014) reported that sero-conversion to BoHV-1 between induction and draft was 
found to increase the risk of BRD (OR 1.3; 95% credible interval: 1.1 – 1.5). However, the same 
association, although imprecise, was not seen in the small subset of animals not given Rhinogard
TM
 
at induction (OR 0.7, 95% credible interval: 0.3 – 1.4). These findings were unexpected, however 
assuming Rhinogard™ does not cause BRD, it is almost certain that feedlots participating in the 
NBRDI with past high BRD incidences preferentially vaccinated animals with Rhinogard™ at 
induction (Barnes et al., 2014). For this reason the effects of Rhinogard™ on BRD risk could not be 
accurately determined from the NBRDI study. 
Sero-conversion to BVDV between induction and draft was associated with increased risk of BRD 
(OR 1.6, 95% credible interval: 1.2 – 2.1) as was sero-conversion to BPIV-3 (OR 1.4, 95% credible 
interval: 0.9 – 2.2) albeit imprecise probably due to the small number of sero-negative animals at 
induction (weighted BPIV-3 sero-prevalence at induction was 91%). While the odds ratio for sero-
conversion to BRSV (OR 1.5, 95% credible interval: 1.0 – 2.2) also indicated an association of 
sero-conversion with the development of BRD. In the current study, the association of sero-
conversion to M. bovis with the development of BRD is substantially higher than that seen for the 
viruses investigated by Barnes et al. (2014) ranging from an OR of 2.12 – 3.08 with 95% CI of 1.33 
– 4.74 depending on the sero-conversion / sero-increase outcome used (Table 7.5). Of highest 
priority on the Bradford Hill criteria for assessing causality is the strength of association (Hill, 
1965). The strength of association of sero-conversion / sero-increase to M. bovis and the 
development of BRD seen in this study, especially when compared to that seen with commonly 
implicated viruses, provides support for a causal association of M. bovis in the development of 
BRD.  
Finally, a limitation of this study is that the presence of other bacteria or serological evidence of 
viruses commonly implicated in BRD was not investigated in the study population. In addition, the 
sample size was not determined for an assessment of M. bovis sero-conversion with respect to BRD. 
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Consequently the precision of this association will have been reduced. However, that aside, sero-
conversion to M. bovis in this study was found to be strongly associated with the development of 
BRD in the early feeding period. The findings of this study strongly support the need for further 
research on the association M. bovis has with BRD during the early feeding period in addition to 
risk factors that are associated with sero-conversion. Identification of these factors will inform the 
development of management practices that could reduce the incidence of sero-conversion and in 
turn may provide therapeutic-free options for the control and management of BRD in feeder cattle 
during the early feeding period. 
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CHAPTER 8   General discussion  
8.1  General aims and chapter summary overview 
The aim of this thesis was to improve the understanding of the serological prevalence of M. bovis in 
the Australian feeder cattle population. In the process of addressing this objective a number of 
hurdles were encountered. Preliminary testing using the pentavalent BioK284 suggested that over 
90% of cattle were sero-positive for M. bovis antibody at the time of feedlot induction (data not 
reported in this thesis). If this prevalence were true it meant that a very large sample size would be 
required to identify and quantify risk factors associated with M. bovis based on serology. 
Conversations with experts in bovine mycoplasma research revealed differing opinions on the 
accuracy of the commercially available Bio-X Diagnostics

 ELISAs in general, which led to 
questions regarding the Se and Sp of the ELISA which was initially intended to be used in this 
study. In addition, no published information was available in the associated literature to support 
expert opinion on these ELISAs. Some experts were suggesting reduced Se, while others suggested 
the test had reduced Sp. As a result of the uncertainty surrounding the accuracy of the commercial 
ELISA, the focus of the early part of the thesis shifted to try and estimate Se and Sp. These could 
then inform sample size calculations to estimate the sero-prevalence of M. bovis and allow 
estimation of true sero-prevalence after accounting for imperfect tests.  
The current thesis was divided into five studies. Study one (Chapter 3) involved the development of 
a recombinant M. bovis protein that could be used as an antigen to detect M. bovis-specific antibody 
using WB analyses. At the time this study was conducted, the author did not have access to bovine 
serum collected from animals of known M. bovis infection status. As WB is often regarded as a 
sensitive immunological detection method, the objective was to assess the immuno-reactivity of 
bovine sera to the recombinant antigen, thereby allowing the determination of samples that are truly 
sero-negative for M. bovis-specific antibody. During the course of this study however, access to 
sera collected from animals of known M. bovis infection status sourced from three experimental 
infection trials was obtained. This in turn allowed assessment of the performance of the 
recombinant antigen in WB analyses. 
The aim of study two (Chapter 4) was to calculate Se and Sp estimates for the antigen developed in 
study one (Chapter 3) in addition to two commercial M. bovis ELISA kits. This was performed 
using the sera collected from animals of known M. bovis infection status. These estimations were in 
 223 
 
turn used to inform the sample size calculation required to estimate the sero-prevalence of M. bovis 
in Australian feedlot cattle (study three, Chapter 5). 
Chapter 5 (study three) aimed to estimate the sero-prevalence of M. bovis antibody among cattle at 
feedlot induction and at draft (approximately 42 DOF), while Chapter 6 (study 4) used the results 
obtained in Chapter 5 to assess and quantify risk factors associated with sero-positivity at feedlot 
induction and those associated with sero-conversion or a sero-increase in M. bovis antibody 
between induction and draft. Chapter 7 (study five) also used the results obtained in Chapter 5 to 
evaluate M. bovis sero-positivity at feedlot induction and sero-conversion or a sero-increase in 
M. bovis antibody between induction and draft as separate risk factors for the development of BRD 
during the first 50 DOF. 
8.2  Major findings and their limitations 
One major finding of the thesis was that neither the BioK302 nor the BioK260 M. bovis ELISA 
performed well in terms of Se and Sp combined. This is not surprising given the inverse relationship 
between Se and Sp in a test population. A trade off exists between Se and Sp which is dependent on 
where the test cut-off value for the test is defined. If the cut-off is increased to improve test Sp 
(more non-diseased animals test negative) then the test Se is reduced and vise versa. Using sera 
collected from animals of known infection status, the BioK302 had an estimated Se of 47% (95% 
CI: 10 – 87%) while using the dichotomised BioK260 results Se was estimated at 28% (95% CI: 1 – 
92%). The wide confidence intervals indicate the imprecision of these estimates. Both ELISAs 
performed better in terms of Sp than Se. Again using sera collected from animals of known 
infection status the BioK302 Sp was estimated at 96% (95% CI: 87 – 99%) and the dichotomised 
BioK260 ELISA results indicated a Sp of 100% (95% CI: 93 – 100%).  
Western blotting using the recombinant SUMO-vspA9 fusion protein as antigen developed in 
Chapter 3 did perform better in comparison to the ELISAs in regards to Se. Using experimental 
infection sera the Se of WB was estimated at 74% (95% CI: 16 – 98%). However it underperformed 
in regards to Sp, estimated at 88% (95% CI: 56 – 98%).  
When used to detect sero-conversion or a sero-increase in M. bovis antibody following experimental 
infection, again neither the BioK302 nor the BioK260 performed well. This finding was 
unexpected, especially given that the BioK260 is marketed for sero-conversion detection as a means 
to identify animals recently exposed to M. bovis. Using sera collected prior to and following 
experimental infection (range 24 – 68 days), sero-conversion to M. bovis was detected in 35.3% and 
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8.3% of the animals using the BioK302 and BioK260 ELISAs, respectively. These results were 
driven mainly by sera obtained from the APCAH, comprising 83.3% (35 / 42) of the sera used to 
assess the usefulness of these ELISAs to detect sero-conversion. A limitation associated with this is 
that these samples seemed to perform differently in comparison to sera sourced from VIDO-
InterVac and the AHVLA. This suggested that some other underlying factor was affecting the 
detection of M. bovis antibody in these samples using the commercially available ELISAs. This 
finding is not unexpected as tests inherently perform differently in different populations (Banoo et 
al., 2010, OIE World Organisation for Animal Health., 2013). Biological differences in the host 
such as age, sex and breed, differences in the pathogen they are exposed to including infection load 
and duration of infection, as well as environmental differences can all affect the host-pathogen 
interaction and therefore test outcome (Banoo et al., 2010, OIE World Organisation for Animal 
Health., 2013). 
In addition to the poor performance of the two commercial ELISA kits it was found that they each 
performed differently using sera collected from animals of known infection status in comparison to 
samples collected from animals naturally exposed to M. bovis in a field situation. This was 
evidenced by the difference in kappa statistic calculated between the BioK302 ELISA and 
dichotomised BioK260 ELISA results in Chapters 4 and 5. The kappa statistic provides an estimate 
of the ‘true’ agreement of the result of two tests that occurs beyond the agreement that occurs 
purely by chance (Sim and Wright, 2005). The kappa statistic for the two ELISA kits in Chapter 4 
using only the experimental infection trial samples was calculated at 0.65 (substantial strength of 
agreement), (Landis and Koch, 1977). This is in comparison to the kappa statistic for the 1,354 
animals randomly selected from the NBRDI study population in Chapter 5 where it was calculated 
to be 0.51 (moderate strength of agreement), (Landis and Koch, 1977). It must be pointed out 
however that the Se and Sp estimates calculated using sera from one to eight month old calves 
experimentally infected with M. bovis in Chapter 4 may not have been accurate for an older 
population such as the NBRDI animals described in Chapter 5. In the current study, factors that 
influence the kappa statistic which include the prevalence of the outcome, bias and non-independent 
results (Sim and Wright, 2005), have not been taken into consideration. Sim and Wright (2005) also 
suggest caution when comparing the magnitude of kappas across results that are measured on 
different scales which is the case here with the BioK302 and BioK260 ELISA kits calculating their 
results from the raw OD reading in different manners. These factors, combined with lack of 
precision in estimates from the experimentally infected samples in particular, due the low sample 
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size and the small number of sources, limit the usefulness of comparing the kappas obtained for the 
BioK302 and BioK260 ELISA kits. 
McNemar’s chi-squared test can be used to assist in the interpretation of kappa in the absence of a 
reference standard (Sim and Wright, 2005). In addition positive percent agreement (Ppos) and 
negative percent agreement (Pneg) may also offer an alternative to kappa statistic estimates. These 
measures of test agreement although, not commonly seen in the literature they can be used to 
determine where efforts to improve test performance should be focused (Cicchetti and Feinstein, 
1990). 
In Chapter 5, the apparent sero-prevalence of M. bovis antibody among cattle inducted at Australian 
feedlots was estimated to be 3.47% and 5.76% using the BioK302 ELISA and dichotomised 
BioK260 ELISA results. The apparent sero-prevalence was nothing like that seen in preliminary 
testing using the BioK284 ELISA and was below that determined by other researchers that have 
used a commercial ELISA in populations of cattle of similar age; reporting sero-prevalences of 
78%, 13% and 27% (Bednarek et al., 2012, Burnens et al., 1999, Hanzlicek et al., 2011) 
respectively. At draft the apparent sero-prevalence was estimated to be 25.33% and 41.21% using 
the BioK302 and dichotomised BioK260 results, respectively. Sero-conversion or a sero-increase in 
M. bovis antibody between induction and draft were also assessed. Sero-conversion was detected in 
24.5% and 19.5% of the current study population (a subset of animals randomly selected from the 
NBRDI) using the BioK302 and BioK260 ELISA, respectively. A sero-increase was detected in 
16.4% of the current study population using the BioK260 ELISA results. These findings were also 
below other reports where sero-conversion rates of 54 to 100% have been suggested (Arcangioli et 
al., 2008, Hanzlicek et al., 2011, Tschopp et al., 2001). 
Using the results obtained in Chapter 5, putative risk factors associated with either sero-positivity at 
feedlot induction or a change in sero-status (sero-conversion or a sero-increase) at draft in Chapter 
6. Prior to evaluating each risk factor, an evaluation of the variance seen at different levels in the 
study population was performed. These levels were PIC, group and animal for sero-positivity at 
feedlot induction and feedlot, cohort, group and animal for sero-conversion or a sero-increase 
between induction and draft. This process indicated that most of the variance in the study 
population used here was seen at the animal level for the sero-positivity at induction and the sero-
conversion or a sero-increase between induction and draft outcomes. Variance was also observed at 
the group level indicating that animals that were together at a defined time point are more similar 
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than another group of animals. Further variance was seen at the PIC level and this was over and 
above that seen at the group level for the induction outcome. This suggests that M. bovis can persist 
on a property and that not all properties have M. bovis circulating in their herds. It is also in 
agreement with findings from other studies (Bednarek et al., 2012, Pfutzner and Sachse, 1996, 
Nicholas and Ayling, 2003).  
Estimation of the ICC for groups at defined time points revealed that the level of clustering of the 
outcome by group was substantially higher than that typically seen for most infectious animal diseases 
(McDermott and Schukken, 1994). Because the ICC was higher than estimated using the BioK284 
ELISA (as used in the sample size calculation in Chapter 5), the power to accurately identify and 
quantify risk factors of interest was reduced. Despite this, a number of risk factors were associated with 
an increased risk of sero-positivity to M. bovis at feedlot induction in the described study population. 
History of exposure to a saleyard at least 27 days prior to induction, mixing with animals from another 
property at least 27 days prior to induction and; and the size of the group of animals an animal was 
with 13 days prior to induction were associated with an increased risk of sero-positivity at feedlot 
induction. While the region from which animals are sourced 28 days prior to induction was associated 
with a reduced risk of sero-positivity at feedlot induction. Risk factors that were found to be associated 
with a decreased risk of sero-conversion between induction and draft included; breed, source region, 
and group size. Access to water shared with another pen of animals was strongly associated with 
increased risk and to the authors’ knowledge is the first report of this association. Due to the reduced 
power of the study, risk factors with a true but weaker association with M. bovis sero-status may not 
have been identified so even if no significant association was seen here, they should not be completely 
dismissed as possible risk factors (Banoo et al., 2010) 
Sero-conversion to M. bovis between induction and draft was also found to be strongly associated 
with the development of BRD in the first 50 DOF (OR: 2.1 – 3.1, 95% CI: 1.4 – 4.7). The study 
identified that animals sero-converting or sero-increasing with respect to M. bovis antibody between 
induction and draft were two to three times more likely to develop BRD compared to animals that 
did not sero-convert or sero-increase. These findings are in line with other studies that have 
suggested M. bovis plays an important role as a predisposing factor in BRD (Gourlay and 
Houghton, 1985, Rodríguez et al., 1996). However no studies investigating the possible role of 
M. bovis in the development of BRD have been conducted in Australia. The main limitations of this 
study was the small sample size, the use of imperfect tests and the fact that an assessment of other 
viruses or bacteria involved in BRD was not performed.  
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8.3 Future directions 
These studies have improved the understanding of the epidemiology of M. bovis among feeder 
cattle in Australia. Future research is certainly required and the findings from this thesis will 
provide a baseline for which the design and development of other studies can now be more 
informed. For example, limitations associated with the commercially available ELISAs have been 
identified. The estimation of the sero-prevalence and ICC will now allow improvements to be made 
in sample size calculations so that the power to detect differences or associations will be increased. 
In addition, this study has highlighted that sero-conversion to M. bovis is a significant risk factor for 
the development of BRD in feedlot cattle. Further research is warranted to more accurately quantify 
risk factors associated with sero-conversion to M. bovis. Given the economic significance of BRD 
on feeder cattle industries worldwide, sero-conversion to not only M. bovis but in association with 
other bovine pathogens commonly implicated in the development of BRD requires further 
investigation. In conclusion, the results of this research thesis have identified areas where further 
research is required to further enhance the knowledge M. bovis epidemiology with respect to BRD. 
This in turn will assist in the identification and development of targeted control measures to help 
reduce the economic impact of BRD and M. bovis associated disease.  
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Appendix 1  Modified Frey Broth (MFB) 
Broth Base 
Mycoplasma broth base CM0403 (Oxoid)  25.5g 
10% (w/v) Thallous Acetate    2.5ml 
Milli-RO water     1000ml 
0.4% (w/v) Phenol Red    5ml 
 
Dispense in 80 ml volumes and autoclave at 121°C for 15 min and store at 4°C. The agar base has 
an approximate 1 yr fridge shelf life. 
For use, to 80 ml volume of broth base add:- 
Heat-Inactivated Equine Donor serum (Gibco)     20ml 
Herderschees Yeast Extract (HYE; Appendix 3)     1ml 
0.2% (w/v) Deoxyribonucleic acid sodium salt from calf thymus   1ml 
1% (w/v) -Nicotinamide adenine dinucleotide hydrate    1ml 
10% (w/v) D-Glucose         1ml 
2% (w/v) Vancomycin Hydrochloride Hydrate     1ml 
1.5% (w/v) Ampicillin Sodium Salt       1ml 
1.5% (w/v) Bacitracin         1ml 
 
Adjust the pH to 7.8 and filter through a 0.2 µm filter (Millipore) and dispense in 3 ml volumes in 
10 ml tissue culture tubes. Store at 4°C. Once antibiotics are added the broth has an approximate 
6 wk fridge shelf life to ensure the effectiveness of the antibiotics. 
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Appendix 2  Modified Frey Agar (MFA) 
Agar Base 
Agar Bacteriological Agar No. 1 LP0011 (Oxoid)   10g 
Mycoplasma broth base CM0403 (Oxoid)   25.5g 
10% (w/v) Thallous Acetate     2.5ml 
Milli-RO water      1000ml 
 
Melt the agar in the steamer, mix, and dispense in 80 ml volumes and autoclave at 121°C for 
15 min. Store the agar base at 4°C. The agar base has an approximate 1 yr fridge shelf life. 
For use, to 80 ml of cooled agar base add:- 
Heat-Inactivated Equine Donor serum (Gibco)    20ml 
Herderschees Yeast Extract (HYE, Appendix 3)    1ml 
1% (w/v) -Nicotinamide adenine dinucleotide hydrate   1ml 
2% (w/v) VancomycinHydrochloride Hydrate     1ml 
1.5% (w/v) AmpicillinSodium Salt      1ml 
1.5% (w/v) Bacitracin        1ml 
 
Pour in 55-60 mm diameter petri dishes and store at 4°C. Once antibiotics are added the agar has an 
approximate 6 wk shelf life to ensure the effectiveness of the antibiotics. 
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Appendix 3  Herderschees Yeast Extract (HYE) 
Mix 1 kg of freshly collected baker’s yeast (Pinnacle Yeast) with 1000 ml (1L) Milli-RO water in a 
stainless steel bucket. Heat to 80°C in a water bath or steamer stirring occasionally. Adjust the pH 
to 4.5 by adding NHCl (check using universal pH papers; acceptable range 4.0 – 5.0). Record the 
volume of acid required to adjust the pH (usually 10 -15 ml). Hold at 80°C for 20 min; allow to 
cool, then adjust the pH to 8.0 with 5N NaOH (use pH papers) and stir well. Record the volume of 
alkali required (usually 25 – 40 ml). Centrifuge at 10,000 g for 40 min. Decant the supernatant and 
filter through sterile 0.2 µm filters (Millipore). Dispense aseptically in 20 ml amounts in 
MacCartney bottles. Store at -20°C. 
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Appendix 4 BioK302 Sample coefficient, BioK260 Delta Value and qualitative western blot 
category results for all M. bovis experimental infection trial sera and Bio-X Diagnostics

 
control sera (n = 110) 
Sample ID 
BioK302 BioK260 
WB category 
Sample 
coefficient 
Sero-status Delta Value 
Dichotomised 
DV category 
Asia-Pacific Centre for Animal Health sera 
Control animal sera         
APCAH3_0 4.170 Negative 5.26 0 0 
APCAH3_24 9.57 Negative 8.26 0 0 
APCAH24_0 5.83 Negative 5.70 0 0 
APCAH24_24 4.33 Negative 4.28 0 0 
APCAH30_0 5.77 Negative 4.20 0 0 
APCAH30_24 3.90 Negative 5.12 0 0 
APCAH43_0 1.66 Negative 2.52 0 0 
APCAH43_24 10.10 Negative 12.99 0 0 
APCAH71_0 21.55 Negative 10.94 0 0 
APCAH71_24 6.38 Negative 3.78 0 0 
      
Pre-infection sera (day 0) 
    
APCAH5_0 6.31 Negative 6.67 0 0 
APCAH7_0 1.76 Negative 2.87 0 0 
APCAH8_0 3.10 Negative 2.96 0 0 
APCAH9_0 3.79 Negative 2.47 0 0 
APCAH10_0 8.18 Negative 9.28 0 0 
APCAH13_0 14.38 Negative 9.94 0 0 
APCAH18_0 23.36 Negative 28.84 0 0 
APCAH20_0 7.70 Negative 5.70 0 0 
APCAH21_0 4.22 Negative 6.54 0 0 
APCAH22_0 6.25 Negative 5.83 0 0 
APCAH23_0 7.86 Negative 6.63 0 1 
APCAH26_0 8.77 Negative 6.63 0 0 
APCAH31_0 11.49 Negative 5.74 0 0 
APCAH32_0 40.89 Positive 33.17 0 1 
APCAH34_0 10.10 Negative 7.55 0 0 
APCAH35_0 12.61 Negative 10.82 0 0 
APCAH36_0 9.67 Negative 5.52 0 0 
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Appendix 4 cont. 
Sample ID 
BioK302 BioK260 
WB category Sample 
coefficient 
Sero-status Delta Value 
Dichotomised 
DV category 
APCAH pre-infection sera (day 0) 
cont. 
    
APCAH45_0 11.70 Negative 11.53 0 0 
APCAH46_0 4.28 Negative 4.51 0 0 
APCAH48_0 38.75 Positive 16.39 0 2 
APCAH49_0 7.53 Negative 2.67 0 0 
APCAH51_0 6.38 Negative 3.60 0 0 
APCAH52_0 14.11 Negative 6.88 0 0 
APCAH53_0 6.73 Negative 2.57 0 0 
APCAH54_0 7.98 Negative 3.60 0 0 
APCAH57_0 6.08 Negative 3.35 0 0 
APCAH60_0 5.49 Negative 3.24 0 0 
APCAH62_0 12.42 Negative 2.24 0 0 
APCAH63_0 13.02 Negative 4.88 0 0 
APCAH64_0 5.64 Negative 3.49 0 0 
      
APCAH post-infection sera (day 24) 
        
APCAH5_24 42.12 Positive 29.28 0 1 
APCAH7_24 8.12 Negative 8.52 0 1 
APCAH8_24 38.27 Positive 27.08 0 2 
APCAH9_24 53.18 Positive 37.15 + 2 
APCAH10_24 14.48 Negative 15.24 0 1 
APCAH13_24 8.02 Negative 6.63 0 0 
APCAH18_24 35.60 Negative 35.42 0 1 
APCAH20_24 50.99 Positive 35.03 0 1 
APCAH21_24 22.88 Negative 19.70 0 2 
APCAH22_24 62.64 Positive 74.60 ++ 3 
APCAH23_24 33.46 Negative 30.57 0 4 
APCAH26_24 48.42 Positive 36.84 0 3 
APCAH31_24 23.57 Negative 11.75 0 0 
APCAH32_24 65.05 Positive 46.11 + 3 
APCAH34_24 12.77 Negative 9.41 0 0 
APCAH35_24 52.75 Positive 47.92 + 2 
APCAH36_24 42.33 Positive 26.81 0 0 
APCAH45_24 46.13 Positive 33.52 0 0 
APCAH46_24 4.92 Negative 4.68 0 0 
APCAH48_24 51.32 Positive 27.54 0 1 
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Appendix 4 cont. 
Sample ID 
BioK302 BioK260 
WB category Sample 
coefficient 
Sero-status Delta Value 
Dichotomised 
DV category 
APCAH post-infection sera (day 24) 
cont.     
APCAH49_24 5.29 Negative 3.17 0 0 
APCAH51_24 13.07 Negative 5.70 0 0 
APCAH52_24 12.52 Negative 6.16 0 0 
APCAH53_24 6.78 Negative 4.70 0 0 
APCAH54_24 14.76 Negative 5.42 0 1 
APCAH57_24 36.56 Negative 15.25 0 2 
APCAH60_24 25.99 Negative 12.50 0 0 
APCAH62_24 17.61 Negative 6.66 0 1 
APCAH63_24 14.91 Negative 7.59 0 0 
APCAH64_24 6.38 Negative 3.56 0 1 
 
Vaccine and Infectious Disease Organization International Vaccine Centre sera 
Pre-infection sera (day 0) 
VIDO19_Neg 3.90 Negative 5.09 0 0 
VIDO20_Neg 10.85 Negative 12.48 0 5 
VIDO21_Neg 4.76 Negative 5.60 0 0 
VIDO30_Neg 7.86 Negative 7.44 0 2 
VIDO38_Neg 6.36 Negative 6.71 0 0 
     
Post-infection sera (day 68)         
VIDO19_Low 23.30 Negative 15.38 0 2 
VIDO21_Low 25.71 Negative 26.58 0 5 
VIDO26_Low 50.67 Positive 35.17 0 5 
VIDO18_High 121.86 Positive 147.52 +++++ 5 
VIDO20_High 66.70 Positive 77.22 ++ 5 
VIDO25_High 123.68 Positive 150.51 +++++ 5 
VIDO29_High 152.22 Positive 125.98 ++++ 5 
VIDO30_High 97.38 Positive 83.89 +++ 4 
VIDO34_High 98.40 Positive 83.55 +++ 5 
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Appendix 4 cont. 
Sample ID 
BioK302 BioK260 
WB 
category Sample 
coefficient 
Sero-status Delta Value 
Dichotomised 
DV category 
Animal Health and Veterinary Laboratories Agency sera 
Pre-infection / control animal sera (day 0)         
AHVLA304_0 3.63 Negative 5.00 0 0 
AHVLA339_0 10.37 Negative 7.48 0 0 
AHVLA370_0 14.16 Negative 9.36 0 0 
AHVLA370_28 9.19 Negative 6.71 0 0 
 
   
Post-infection challenged animal sera (day 28)        
AHVLA304_28 26.83 Negative 26.50 0 2 
AHVLA339_28 51.52 Positive 43.25 + 3 
      
Control samples for AHVLA in-house ELISA     
AHVLA cut-off control 8.87 Negative 6.92 0 1 
AHVLA positive control 128.49 Positive 111.45 ++++ 5 
      
Bio-X Diagnostics

ELISA kit control sera       
BioK302           
MYC14C04 Negative 0.13 Negative 0.64 0 0 
MYC13J16 Negative -0.27 Negative 0.13 0 0 
MYC13K26 Negative -0.05 Negative 1.11 0 0 
MYC14C04 Positive 89.31 Positive 103.59 +++ 5 
MYC13J16 Positive 98.77 Positive 102.39 +++ 5 
MYC13K26 Positive 98.77 Positive 104.36 +++ 5 
      
BioK260           
SMYC14C04 Negative -0.16 Negative 0.41 0 0 
SMYC13J16 Negative -0.75 Negative 0.65 0 0 
SMYC13K26 Negative -0.11 Negative 1.50 0 0 
SMYC09I28 Negative -0.43 Negative -0.13 0 0 
SMYC14C04 Positive 99.79 Positive 90.33 +++ 5 
SMYC09I28 Positive 100.80 Positive 101.03 ++++ 5 
SMYC13J16 Positive 97.92 Positive 84.74 +++ 5 
SMYC13K26 Positive 77.77 Positive 100.94 +++ 5 
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Appendix 4 cont. 
Sample ID 
BioK302 BioK260 
WB category Sample 
coefficient 
Sero-status Delta Value 
Dichotomised 
DV category 
Bio-X Diagnostics

ELISA kit control sera 
   
BioK284           
IBRPM09L01 8.98 Negative 11.24 0 3 
IBRPM12F04 13.20 Negative 10.60 0 3 
IBRPM12F28 10.96 Negative 7.52 0 3 
IBRPM12K08 11.38 Negative 11.03 0 3 
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Appendix 5: Hypotheses for causal pathways indicated in the causal diagram for M. bovis sero-positivity at feedlot induction 
From variable  To variable  Hypothesis for causal diagram arrow 
Source region Yard wean Certain enterprises or properties are more likely to yard wean than others. Yard weaning may be location 
dependent. 
Source region GroupN-13 Larger properties are more likely to sell a larger group of animals compared to smaller properties. This may be 
location dependent. 
Source region Breed Breed differences in regions of Australia, more Bos taurus breeds located in southern regions, while Bos indicus / 
Bos indicus infused breeds are located in northern regions. 
Source region Weight Source region may also affect the animal’s nutrition and consequently affect weight. 
Source region Mix pre27 Due to property size and differences in cattle management in the north compared to the south, southerly cattle 
may be more likely to be mixed with animals from another property in comparison to northern cattle. 
Source region M. bovis sero-positivity Different regions and / or properties in different regions may be more likely to harbour M. bovis in the 
environment and / or be endemically infected with the organism. As a consequence of cattle management 
practices and biosecurity measures in place on different properties in different regions may be more likely to have 
active M. bovis infections occurring in their herds than others.  
Source region SY pre27 Certain enterprises or properties may be more likely to sell cattle through saleyards than others. This can be 
location dependent. 
Ind year M. bovis sero-positivity Weather and climate differences that may occur over different years may affect transmission of M. bovis between 
animals and the likelihood of a naive animal being exposed to a shedding or infected animal.  
Ind year GroupN-13 Weather and climate differences that may occur over different years may influence the number of animals sold. 
For example during dry years producers may sell off more animals and these animals may be sold as larger 
groups. 
  
 252 
 
Appendix 5 cont. 
From variable  To variable  Hypothesis for causal diagram arrow 
Ind year Mix pre27 Weather and climate differences that may occur over different years may have an effect on the likelihood of an 
animal being mixed with other animals from a different property.  
Ind year Weight Weather and climate differences that may occur over different years can affect the availability and nutritional 
quality of pasture / feed and hence have an effect on the weight of the animal. 
Ind year Source region Weather and climate differences that may occur over different years can be region based and hence influence the 
availability of animals sourced from different regions. 
Ind year Dentition Weather and climate differences that may occur over different years can affect turn off age of animals and hence 
dentition. 
GroupN-13 M. bovis sero-positivity The size of the group an animal is / was part of can affect the level of mixing and hence the chance of exposure to 
a sero-positive animal or an animal actively shedding / infected with M. bovis. 
Mix pre27 M. bovis sero-positivity Mixing with animals from another property is likely to increase chance of a naive animal being exposed to an 
animal shedding M. bovis or an asymptomatic carrier animal.  
Breed Dentition Bos indicus breeds of cattle mature later in comparison to Bos taurus breeds and their crosses. 
Breed Weight Bos indicus cattle are generally lighter framed and are lighter on a weight-for-age basis in comparison to 
Bos taurus breeds and their crosses. 
Breed M. bovis sero-positivity Breed may have an effect on the immune response to M. bovis exposure. Basis of this is poorly defined but 
Bos indicus breeds and their crosses and cross bred animals are in general more resistant to disease. 
Weight M. bovis sero-positivity The underlying effects of nutrition can affect the weight of an animal and in turn affect the immuno-competence 
of the animal and its ability to mount an immune response following M. bovis exposure.  
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Appendix 5 cont. 
From variable  To variable  Hypothesis for causal diagram arrow 
Dentition Mix pre27 Older animals have had more time to have been mixed. 
Dentition Weight Dentition is affected by age which in turn can affect the animal’s weight.  
Dentition M. bovis sero-positivity Dentition is affected by age which in turn can affect the immuno-competence of the animal and its ability to 
mount an immune response following M. bovis exposure.  
SY pre27 M. bovis sero-positivity Transfer through a saleyard increases the likelihood of exposure to new pathogens and animals shedding 
pathogens. 
SY pre27 Mix pre27 Transfer through a saleyard inherently increases the likelihood of being mixed with animals from another 
property. 
Yard wean M. bovis sero-positivity Yard weaning could increase the chance of a naive animal coming into contact with shedding / carrier animal. 
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Appendix 6. Hypotheses for causal pathways indicated in the causal diagram for sero-conversion or a sero-increase in M. bovis antibody 
between induction and draft 
From variable  To variable  Hypothesis for causal diagram arrow 
GroupN-13 M. bovis sero-conversion The size of the group an animal is / was part of prior to feedlot induction can affect the number of other 
groups forming the cohort and therefore the chance of exposure to a sero-positive animal or an animal 
actively shedding / infected with M. bovis.  
GroupN-13 Mix Sum The size of the group an animal is / was part of prior to feedlot could affect the level of mixing that occurs 
once at the feedlot. Animals in large groups are more likely to be mixed with fewer animals / a smaller 
number of groups to make up a cohort once at the feedlot. The level of mixing with animals from other 
groups and properties will subsequently affect the level of exposure to new pathogens during the early 
feeding period.  
Source region GroupN-13 Refer to the Source region to GroupN-13 hypothesis given in Appendix 5 
Source region M. bovis sero-conversion Different regions and / or properties in different regions may be more likely to harbour M. bovis in the 
environment and / or be endemically infected with the organism. As a consequence of this properties in 
different regions may be more likely to have active M. bovis infections occurring in their herds than 
others.  
Source region  BVDV PI  Different regions / properties in different regions may be more likely to have a BVDV PI animal than 
others. 
Source region SY pre27 Refer to the Source region to SY pre27 hypothesis given in Appendix 5 
Source region SY 27_0 Refer to Source region to SY pre27 hypothesis given in Appendix 5 
Source region Weight Refer to the Source region to Weight hypothesis given in Appendix 5 
Source region Breed Refer to the Source region to Breed hypothesis given in Appendix 5 
Source region Mix Sum Due to property size and differences in cattle management in the north compared to the south, southerly 
cattle may be more likely to be mixed with animals from another property in comparison to northern 
cattle. 
  
 255 
 
Appendix 6 cont. 
From variable  To variable  Hypothesis for causal diagram arrow 
Source region Move pre27 Animals in locations closer to feedlots are less likely to move to the feedlot 27 or more days prior to day 0 / 
induction. 
Ind year M. bovis sero-conversion Weather and climate differences that may occur over different years may affect transmission of M. bovis 
between animals and the likelihood of a naive animal being exposed to a shedding or infected animal.  
Ind year Source region Refer to the Ind year to Source region hypothesis given in Appendix 5 
Ind year GroupN-13 Refer to the Ind year to GroupN-13 hypothesis given in Appendix 5 
Ind year Mix Sum Refer to the Ind year to Mix pre27 hypothesis given in Appendix 5 
Ind year Dentition Refer to Ind year to Dentition hypothesis given in Appendix 5 
Ind year Weight Refer to the Ind year to Weight hypothesis given in Appendix 5 
Ind year Move pre27 The year of induction may affect the timing of the animals move to the feedlot (i.e. During drought animals 
may be moved to the feedlot sooner and fed in a paddock environment until space in the feedlot opens up or 
the animal reached the required entry weight). 
Move pre27 Mix Sum The timing of the move to the feedlot may affect the mixing summary of the animals. For example, animals 
acquired earlier by the feedlot (27 or more days prior to day 0) may be mixed more during that time, but 
mixed less in the pre 27 day to day 0 time period. Animals acquired during the pre 27 day to day 0 time 
period may be mixed less in the time period prior to pre 27 days but more in the pre 27 to day 0 time period. 
Move pre27 M. bovis sero-conversion Animals moved to the feedlot earlier may have been mixed with animals from other properties, and hence 
exposed to more pathogens sooner, in comparison to animals moved to the feedlot closer to day 0. Prior 
exposure to pathogens at an earlier time period prior to day 0 will affect wether animals have the potential to 
sero-convert or not. In addition, if there is less mixing as a result of a cohort being formed at the feedlot in a 
paddock situation (pre-assembly) at a point in time prior to day, animals in that cohort will not be mixed 
with other animals on day 0 and hence not be exposed to new pathogens in the early feeding period. 
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Appendix 6 cont. 
From variable  To variable  Hypothesis for causal diagram arrow 
Dentition M. bovis sero-conversion Dentition is affected by age which in turn can affect the immuno-competence of the animal and its ability 
to mount an immune response following M. bovis exposure. In addition, older animals may be more 
likely to have already been exposed to M. bovis and hence already have antibodies and are therefore less 
likely to sero-convert. 
Dentition Weight Refer to the Dentition to Weight hypothesis given in Appendix 5 
Dentition Mix Sum Dentition is affected by age which in turn could affect the likelihood of mixing with animals from 
another property. The older an animal is the more time it has had to have potentially been mixed with 
animals from another property. 
Dentition Move pre27 Dentition is affected by age which in turn could affect the timing of when animals are moved to the 
feedlot in relation to day 0. Young animals (fewer teeth) purchased may not reach feedlot entry weight 
and may be put out into a paddock situation rather than going straight onto feed in a feedlot pen. If the 
animal is put out into the paddock then in relation to its day 0 it would have been moved to the feedlot 
sooner than animals arriving at the feedlot and going straight onto feed. 
SY pre27 M. bovi  sero-conversion  Transfer through a saleyard increases the likelihood of exposure to new pathogens and animals shedding 
pathogens. This could in turn affect whether an animal has the potential to sero-convert once at the 
feedlot. 
SY pre27 Mix Sum  Transfer through a saleyard inherently increases the likelihood of being mixed with animals from another 
property. 
SY 27_0 M. bovis sero-conversion Refer to the SY pre27 to M. bovis sero-conversion hypothesis in Appendix 5 
SY 27_0 Mix Sum Refer to the SY pre27 to Mix Sum hypothesis in Appendix 5 
Season Shade The season of induction may affect whether an animal / cohort of animals are placed in a pen with shade 
or not. 
  
 257 
 
Appendix 6 cont. 
From variable  To variable  Hypothesis for causal diagram arrow 
Season Dentition The season of induction may have an effect on dentition (dependent on when the animals were born). More 
calves born in spring / summer hence animals inducted in spring or summer the following year that were 
born in spring or summer will be older in comparison to those born in autumn or winter. 
Season Weight The season of induction could affect entry / induction weight as a consequence of the nutritional quality and 
pasture availability variation that occurs during different seasons. 
Season M. bovis sero-conversion The season of induction may have an effect on the environmental load of M. bovis in the feedlot 
environment; this in turn will affect exposure rates in the early feeding period and hence sero-conversion 
rates. 
Weight  M. bovis sero-conversion The underlying effects of age and nutrition can affect the weight of an animal and in turn affect the 
immuno-competence of the animal, its ability to mount an immune response following M. bovis exposure, 
and whether or not it has the potential to sero-convert during the early feeding period. 
Weight Move pre27 Refer to the Dentition to Move pre27 hypothesis in Appendix 6 
Breed M. bovis sero-conversion Breed may have an effect on the immune response to M. bovis exposure. Basis of this is poorly defined but 
Bos indicus breeds and their crosses and cross bred animals are in general more resistant to disease. 
Breed Weight Refer to the Breed to Weight hypothesis given in Appendix 5 
Breed Dentition Refer to the Breed to Dentition hypothesis given in Appendix 5 
Mix Sum M. bovis sero-conversion Mixing with animals from another property is likely to increase chance of a naive animal being exposed to 
an animal shedding M. bovis or an asymptomatic carrier animal. This in turn will affect whether an animal 
has the potential to sero-convert or not. In addition, the timing of this mixing could affect whether sero-
conversion is detected. 
Water M. bovis sero-conversion Access to water that is shared with animals from another pen could increase the level of exposure to 
pathogens such as M. bovis. It also effectively increases the level of mixing / indirect method of pathogen 
transmission. 
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Appendix 6 cont. 
From variable  To variable  Hypothesis for causal diagram arrow 
Density M. bovis sero-conversion Pen density may have an effect on transmission rates between naive and asymptomatically infected / shedding 
animals. The higher the density of animals the more likely it will be for direct transmission of pathogens to 
occur. 
CohortN Density The number of animals in a cohort may have an effect on the density of animals in the feedlot pen. 
CohortN M. bovis sero-conversion The number of animals in a cohort may have an effect on the level of mixing, especially if a large number of 
smaller groups of animals are combined to form the cohort. This in turn will affect the level of exposure to new 
pathogens during the early feeding period and hence may affect the level of sero-conversion. 
CohortN BVDV PI  The more animals in a cohort the more likely it is that one will be a PI and hence the likelihood of exposure to a 
PI animal is increased in larger cohorts of animals.  
BVDV PI  M. bovis sero-conversion Exposure of BVDV naive animals to a PI during the early feeding period can affect the immuno-competence of 
the animal. This could in turn affect the likelihood of sero-conversion to M. bovis. 
 
 
